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ABSTRACT 
 
The Ireland-Claisen rearrangement is a powerful synthetic technique allowing 
predictable diastereocontrol and chirality transfer within the synthesis of γ,δ-
unsaturated carboxylic acids. The Carbery group has recently disclosed a novel 
enamido-Ireland-Claisen rearrangement (EICR) allowing access to β2,3-amino acid 
precursors, where a strong dependency between diastereoselectivity and the substrate 
acyl moiety was noted. Development of this seminal work in terms of mechanistic 
rationale and synthetic utility subsequently ensued. 
 
Initial focus, covered in Chapter 2, began with a thorough optimisation of 
rearrangement conditions and resulted in a desire to probe the electronic dependency 
of the diastereoselective phenylacetate EICR. With this in mind, rearrangement of a 
range of electronically differentiated arylacetates demonstrated that diastereoselectivity 
is profoundly susceptible to electronic perturbation as shown by a non-linear Hammett 
type plot involving that of para-substituents.  
 
In order to evaluate the origins of this free energy relationship, Chapter 3 covers the in-
situ 1H- and 13C-NMR mechanistic studies undertaken, involving model silyl ketene 
acetal (SKA) formation and EICR monitoring. These studies demonstrated that poor 
E/Z-SKA generation and rearrangement through a chair transition state may be 
operative in the case of electron rich aryl substitution; however selective formation of 
the E-SKA and subsequent rearrangement via competing chair and boat transition 
states may be operative for electron poor aryl substitution. A useful synthetic 
transformation brought about by these mechanistic studies was seen to be the isolation 
of phenylacetate derived SKAs in excellent yield and far superior E-geometric control 
to that currently published.  
 
Finally, Chapter 4 involves investigations into improving the diastereoselectivity of the 
non-α-arylacetates and results in the rearrangement of alkyl- and arylacetate-N-
allylsulfonamides in high diastereoselectivity and utilisation of an optically enriched 
substrate demonstrated good chirality transfer (>88% e.e.). Utilisation of these 
products has been shown within the synthesis of β-proline analogues.  
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1. Introduction 
 
1.1. β−Amino Acids 
 
An amino acid is a compound that contains both an amine and a carboxylic acid 
functional group. β-amino acids differ from the more common proteinogenic α-amino 
acids in that a two carbon chain separates these functional groups as opposed to a one 
carbon link. In order to distinguish positional isomers of β-substituted amino acids, 
Seebach has proposed the terms β2- and β3-amino acid, where the superscripts indicate 
the α− or β−substitution with respect to the carboxyl group.1 Seebach’s notation shall 
be used throughout this report. 
 
 
 
Fig. 1.  α- & β-Amino Acids. 
 
There are three general types of β-amino acids: 
 
1) Acyclic – Where substitution takes place at the carbon bearing the carboxyl 
group (β2-amino acid) e.g. (R)-β2-homovaline 1, the carbon bearing the amino portion 
(β3-amino acid) e.g. iturnic acid 2, or at both positions (β2,3-amino acid) e.g. Amha (3) 
an important precursor to the Adda fragment in cytotoxic microcystins and nodularins. 
2-3 
2) Carbocyclic – Where the β2,3-amino acid substitution is presented in a 
carbocyclic ring, for example the antifungal antibiotic cispentacin 4.4 
3) Heterocyclic – Where the amino group is incorporated in a heterocyclic ring, 
for example methylphenidate (Ritalin®) 5, which is used in the treatment of attention 
deficit hyperactivity disorder (ADHD) and narcolepsy.5 
Chapter 1  Introduction
   
2 
 
 
Fig. 2. General Types of β-Amino Acids. 
 
To date there are eight natural occurring β-amino acids that are directly derived from 
the corresponding proteinogenic α-amino acids, either in free form, or as part of a 
larger molecule. These are: β-alanine 6, β-leucine 7, β-lysine 8, β-glutamate 9, β-
glutamine 10, β-arginine 11, β-phenylalanine 12 and β-tyrosine 13. Other β-amino 
acids that are not related to proteinogenic α-amino acids are classified as unusual β-
amino acids. There are several classes of unusual β-amino acids, these being aliphatic, 
aliphatic hydroxyl, aliphatic with oxo groups, amino, alicyclic and heterocyclic. 
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CO2H
(R)- -Leucine
CO2H
(R)- -Lysine
CO2H
-Glutamine
NH2 NH2
NH2
Me
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H2N
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N
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H2N
NH
CO2H
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H2NOCHO2C
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Fig. 3. Natural β-Amino Acids. 
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In general β-amino acids occur in all five kingdoms of living organisms, which are 
animals, plants, fungi, bacteria and protista.6 Contrary to all other β-amino acids, β-
alanine and β-aminoisobutyric acid are present in all living organisms since they are 
directly involved in primary metabolism. To date it is thought that animals are not able 
to synthesise any β-amino acids except β-alanine 6 and β-aminoisobutyric acid 14.7 
 
 
 
Fig. 4. Naturally Occuring  β-Amino Acid. 
 
Contrary to proteinogenic α-amino acids which are constituents of all enzymes 
controlling the metabolism in living matter and  hence an essential prerequisite for life, 
most β-amino acids occur as constituents of distinct natural products, such as peptides, 
alkaloids or terpenoids.8 Bacteria, cyanobacteria, fungi and plants often incorporate β-
amino acids into secondary metabolites that serve as tools to secure their survival in 
competition with other organisms.9-10 Therefore these compounds are often 
characterised by potent biological and physiological activities that are often crucially 
based on their β-amino acid substructures.11 Moreover, the incorporation of β-amino 
acids into peptides as opposed to α−amino acids increases their stability against 
degradation by mammalian peptidases, caused by a lack of enzymes which allow 
cleavage of peptidic bonds between α-amino acids and β-amino acids.12  Therefore β-
amino acids are an important tool in the development of drugs capable of withstanding 
hydrolytic degradation for prolonged periods of time.  
 
As a consequence, many natural products with a β-amino acid moiety are potential lead 
structures for the development of pharmaceutical and agro-chemicals and this still 
remains an area of extensive research. For instance, the disease lathyrism characterised 
by crippling of the bones is caused by consumption of seeds derived from plants such 
as the grass pea (Lathyrus sativus) that contain 3N-oxalyl-2,3-diamino propanoic acid 
(L-β-ODAP) 15.13 On the other hand, the outstanding cytotoxic effects of the 
cryptophycins 16 or the nodularins 19 might result in the development of new 
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anticancer drugs. Taxol® 17 and the derivative taxotere® 18 have already become 
important anticancer drugs, whereas penicillins such as 20 and related β-lactams have 
served for decades as prominent antibiotics.14-19 
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Fig. 5. β-Amino Acid Moiety in Natural Products. 
 
In recent years β-peptide foldamers constructed from constrained carbocyclic β-amino 
acids like trans-2-aminocyclopentanecarboxylic acid (ACPC) 21 and trans-3-
aminopyrrolidine-4-carboxylic acid (APC) 22 have gained significant interest as they 
adopt a robust helical conformation in aqueous solution with as few as six residues. 
This property makes these oligomers attractive scaffolds and antimicrobial activity 
paralleling that of host-defense peptides have been reported for a 12-helical β-peptide 
composed of ACPC and APC.20-21 
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Fig. 6. Carbocyclic β-Amino Acids used in β-Peptide Foldamers. 
 
1.2. Preparation of Enantiopure β-Amino Acids 
 
1.2.1 Homologation of α-Amino Acids 
 
Historically α-amino acids have been shown as excellent starting materials for the 
preparation of β-amino acids. This is not only due to the fact that there are a plethora of 
methods available for their synthesis, but also that there is a stereogenic centre present 
in these compounds that can be transferred to the homologated β-amino acid without 
significant racemisation.22 There are two classical methods used for the homologation 
of α-amino acids to β-amino acids and these are- 
 
1) Arndt-Eistert Homologation 
In the late 1920’s a method for the homologation of carboxylic acids was developed by 
Arndt, Eistert and Partale.6 This procedure includes activation of the parent α-amino 
acid to either the acid chloride or the mixed anhydride, followed by treatment with 
diazomethane to give the diazoketone. Subsequent photolysis, thermolysis or treatment 
with catalytic amounts of silver salts in the presence of protic nucleophiles leads to a 
Wolff rearrangement resulting in loss of nitrogen and homologation of the starting 
substrate.23,24 The original Arndt-Eistert homologation was subsequently adapted by 
Balenovic in 1947, allowing the formation of β-amino acids.25 Initially, activation of 
the carboxylic acid was pursued with thionyl chloride, but later developments allowed 
milder activation methods utilising more suitable protecting groups for the amino 
function. α-Amino acids protected as carbamates 23 can be used as starting materials 
producing β3 amino acids 24 in good yields (Scheme 1).26-27 
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Scheme 1. Arndt-Eistert Homologation of α-Amino Acids. 
 
2) Homologation of Amino Acids Using Cyanohydrins 
Although the Wolff rearrangement is the most popular approach for the homologation 
of α-amino acids, another approach involves the transformation of amino acids 25 to 
β
2-hydroxy-amino acid derivatives 28, via amino aldehydes 26, which are converted to 
cyanohydrins 27 and subsequently hydrolysed. A major disadvantage with this 
approach are selectivities in cyanide addition are usually poor, resulting in mixtures of 
diastereoisomers (Scheme 2).28,29 
 
 
 
Scheme 2. Homologation of Amino Acids Using Cyanohydrins. 
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1.2.2. Hydrogenation of β-Amino Acrylates 
 
Noyori was the first to publish an enantioselective route to β3-amino acids via an 
asymmetric hydrogenation of N-acyl-β-(amino)acrylates utilising ruthenium complexes 
and (R)-BINAP, producing e.e.’s of >90%.30 Since this intial report there have been 
countless publications based on improving yield and enantioselectivities with 
ruthenium and rhodium catalysed homogenous hydrogenations. An important 
breakthrough was presented by Hsiao in the realisation that chiral-ferrocenylphosphine 
ligand 30 could be used in the hydrogenation of unprotected (Z)-enamine esters 29 to 
yield the corresponding β3-amino esters 31 with excellent yields and 
enantioselectivities.31 
 
NH2
CO2Me
[Rh(COD)Cl]2 (cat.)
30 (cat.)
TFE or MeOH
6.2-6.9 bar H2
NH2
CO2Me
29 3031
9 examples
R1 = Arom, Bn, 3-Pyr
Yield = 74-98%
e.e. 82-97%
R1
R1 Fe
PPh2
PtBu2
Me
 
 
Scheme 3. Hydrogenation of β-Amino Acrylates using Hsiao’s Protocol. 
 
Holz has subsequently shown that MalPhos 32 is an effective ligand in the asymmetric 
hydrogenation of (E)- and (Z)-β-amino acrylates 31 providing β2-amino acids 33 with 
enantioselectivities up to 99% and 90% respectively.32 
 
R1
R1
NH2
CO2Me
Rh(COD)2BF4 (cat.)
32 (cat.)
THF or MeOH
1 bar H2
NH2
CO2Me
31 3233
11 examples
R1 = Alkyl, Arom
Conversion = 100%
(E) e.e. 79-99%
(Z) e.e. 57-90%
O OO
PP
 
 
Scheme 4. Hydrogenation of β-amino Acrylates using Holz’s Protocol. 
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Although the synthesis of multisubstituted β-amino acids by ruthenium or rhodium 
catalysis has yet to be accomplished, Zhang has reported the use of (S)-C3-TunaPhos 
34 in the ruthenium catalysed synthesis of the β2,3 carbocyclic amino acid derivative 35 
of cispentacin 4.33 
 
 
 
Scheme 5. Hydrogenation of β-Amino Acrylates using Zhang’s Protocol. 
 
1.2.3. Conjugate Addition  
 
When applied to the synthesis of β-amino acids the catalytic asymmetric conjugate 
addition can be achieved by either the addition of carbon based nucleophiles, such as 
organometallics, cyanide and Michael donors, or by the addition of nitrogen 
nucleophiles such as amines, hydroxylamines and carbamates.34 
 
The conjugate addition of carbon nucleophiles to a variety of α,β-unsaturated acceptors 
is an important C-C bond forming reaction, and in the context of synthesising β-amino 
acids, nitroolefins are versatile acceptors. Wendisch has shown the copper catalysed 
conjugate additions of organozinc species to nitropropenoates 36 utilising 
phosphoramidite 37 proceeds with excellent regio- and stereo-selectivities.35 These β2-
amino acid precursors 38 can then be subjected to hydrogenation and saponification 
conditions to yield the required β2-amino acids 39. 
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 Scheme 6. Wendisch’s Route to β2-Aliphatic Amino Acids. 
 
Jacobsen has utilised the aluminium salen catalyst 41 for the conjugate addition of 
cyanide to α,β-unsaturated imides 40.36 The imide of the hydrocyanation adducts 42 
are hydrolysed and subsequent Curtius rearrangement of acid 43 yields N-Boc 
protected cyano amides 44. Subsequent hydrolysis of the nitrile in hydrochloric acid 
affords the β2-amino acid 45, with only a small degree of racemisation (Scheme 7). 
 
 
 
Scheme 7. Jacobsen Route to β2-Aliphatic Amino Acids. 
 
Fillion has recently shown that Meldrum’s acid derivatives 46 can be utilised with 
phosphoramidite 37 in synthesising β3,3-amino precursors 48, post deprotection of 
adduct 47 and followed by a Curtius rearrangement.37 
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Scheme 8. Fillion’s  Route to β3,3-Aliphatic Amino Acids. 
 
Jacobsen has also reported the use of the salen catalyst 41 in the catalytic 
enantioselective conjugate addition of hydrazoic acid to α,β-unsaturated imides 49, 
yielding the corresponding azides 50.38 Conversion to the corresponding β-amino acid 
was performed by a one pot azide hydrogenolysis/N-Boc protection sequence followed 
by regioselective cleavage of the imide group, allowing access to β3-aliphatic amino 
acids 51 with excellent yields and enantioselectivities.39 
 
 
 
Scheme 9. Jacobsen Route to β3-Amino Acids. 
 
1.2.4. Catalytic Mannich Reactions 
 
Asymmetric Mannich reactions provide useful direct routes for the synthesis of 
optically active β-amino acids. Two key features that render the Mannich reaction and 
its products very attractive, are that the reaction tolerates a large diversity of 
functionality and in cases where β-amino carbonyl products are formed, these can be 
Chapter 1  Introduction
   
11 
readily transformed into β-amino acids. Catalytic Mannich reactions rely on the 
utilisation of various Lewis and Brønsted acid catalysts. 
 
Kobayashi has shown that Mannich reactions of imines 52 and silyl ketene acetals 
53/54 in the presence of zirconium-based Lewis acid 55, allows the synthesis of syn- 56 
and anti-β2,3-disubstituted-amino acids precursors 57, in excellent yields, 
diastereoselectivities and enantioselectivities.40,41 Full deprotection has been shown to 
yield the syn-β2,3- amino acid 58 as the hydrochloride salt. 
 
 
 
Scheme 10. Kobayashi’s Route to syn- and anti-β2,3-Amino Acids. 
 
Hoveyda has shown the use of silver catalysed asymmetric additions of silyl ketene 
acetals 59 to alkynyl imines 60 in the presence of a Schiff base 61, allows the synthesis 
of β3-alkynyl amino esters 62, in good yields and enantioselectivities.42 
 
 
 
Scheme 11.  Hoveyda’s Route to β3-Alkynyl Amino Acids. 
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The use of chiral Brønsted acids is ubiquitous in organocatalytic Mannich reactions  
and also allows a direct entry to the β-amino carbonyl moiety.34 There are two general 
types of Brønsted acid, these being thiourea or (L)-proline derivatives, and stronger 
Brønsted acids such as binol or phosphoric acid derivatives. The mode of 
organocatalytic reaction follows a generic protocol, in which the electrophile becomes 
activated by hydrogen bond formation to the organocatalyst and a transition state 
ordering occurs prior to nucleophilic attack in a stereocontrolled fashion.43-44 
 
Jacobsen has shown that access to β3-aryl-amino acids 66 is possible via an asymmetric 
Mannich reaction of silyl ketene acetals 64 and imines 63, catalysed by thiourea 
derivative 65.45 
 
 
 
Scheme 12. Jacobsen’s  Route to β3-Aryl-Amino Acids. 
 
Barbas and Hayashi have shown that syn-β2,3-aminoaldehydes 69 can be synthesised 
using the classical organocatalyst (L)-proline 68.46-47 This organocatalyst reacts with 
aldehyde 67 to form chiral nucleophilic enamines in-situ, which then react with 
electrophiles, such as aldimines and ketimines in a stereocontrolled manner. 
Advantages associated with this reaction are that it is atom economical, utilises 
relatively inexpensive readily available starting materials and preactivation of 
aldehydes (for example as silyl enol ethers) or preformation of enamines are not 
required. Higher yields, diastereoselectivities (syn selective) and enantioselectivities are 
often obtained when a three component reaction using aldehyde donors is utilised.  
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Scheme 13.Barbas & Hayashi Route to syn-β2,3-Amino Acids. 
 
Barbas has subsequently shown that all carbon quaternary stereocentres can be 
synthesised utilising the (L)-proline catalyst 68 and α,α−disubstituted aldehydes 70, 
yielding β-formyl substituted α-amino acid derivatives 71 in excellent yield, 
diastereoselectivities and enantioselectivities.48 Synthesis of spiro lactam 72 was 
accomplished by oxidation of the corresponding precursor 71 followed by a simple acid 
and base treatment. 
 
 
 
Scheme 14. Barbas’s Route to syn-β2,2,3-Lactam. 
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The mechanism for the direct asymmetric (L)-proline catalysed Mannich reaction has 
been extensively investigated by Houk.49 The proposed transition state 73 explains the 
preferential formation of the syn-diastereomer, where (L)-proline directs the reaction 
between the Si face of the (E)-enamine of aldehyde and the Si face of the (E)-PMP-
imine. The carboxylic acid proton is completely transferred to the imine and it is 
hypothesised that the interaction between the newly formed iminium and the 
carboxylate anion is retained even when water is present.  
 
 
 
Fig. 7. (L)-Proline Catalysed Transition State. 
 
Akiyama has shown that Taddol-derived phosphoric acid 76 can be used to catalyse the 
addition of silyl ketene acetals 75 to aromatic aldimines 74, yielding  β2,2,3-amino acids 
77 with good yields and excellent enantioselectivities.50 Unfortunately, this chemistry 
was limited to the use of symmetric isobutyric derived silyl ketene acetals. 
 
 
 
Scheme 15.  Akiyama’s Route to β2,2,3Amino Acids 
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1.2.5. Organocatalytic Conjugate Addition 
 
The synthesis of β-amino acids via organocatalytic C-N bond forming conjugate 
additions are a relatively recent development within the synthetic community and 
represent a fast and atom economic entry.  
 
MacMillan’s use of his second generation imidazolinone catalyst 80  with α,β-
unsaturated aldehydes 78, allows conjugate addition of his purpose designed nitrogen 
nucleophile 79, to the in-situ formed α,β-unsaturated imminium ion.51 The β2-amino 
aldehyde products 81 were obtained in high yields and enantioselectivities, and were 
subsequently oxidised to N-protected amino acids 82. 
 
 
 
Scheme 16. Macmillan’s Route to β3-Amino Acids. 
 
Córdova has subsequently followed a similar approach to synthesising analogous 
compounds to MacMillan, utilising a prolinol catalyst, producing the corresponding β3-
amino acids in lower yields but similar enantioselectivities.52 These current results 
demonstrate that further optimization of the organocatalytic conjugate addition of 
nitrogen nucleophiles to α,β-unsaturated carbonyl compounds is required. 
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1.2.6. Enolate Addition to N-
t
Butylsulfinyl Imines 
 
Davis has shown the synthesis of β3,3-amino acids 84 are possible by the addition of 
acetate ester enolates to a limited set of N-p-toluenesulfinyl imines 83 with good yields 
and excellent enantioselectivities.53-55 
 
 
 
Scheme 17. Davis’s Route to β3,3-Amino Acids. 
 
Prompted by this methodology, Ellman has extended this protocol to the more suitable 
N-tbutylsulfinyl imines 85.56-57 The additions of titanium enolates to various 
substituted-N-tbutanesulfinyl aldimines and ketimines were shown to proceed in good 
to excellent yields allowing access to N-tbutanesulfinyl-protected β3, β2,3, β3,3, β2,2,3, 
β
2,3,3 and β2,2,3,3-amino esters 86 with diastereoselectivities of anti:syn between 9:1 and 
99:1 with excellent enantioselectivities. 
 
 
 
Scheme 18. Enolate Additions to N-tButylsulfinyl Imines. 
 
The observed diastereoselectivity in the syntheses of these β-amino esters, regardless of 
substitution pattern, can be explained through a six-membered transition state 87, 
where enolate addition occurs from the least hindered face of the imine. 
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Scheme 19. Reaction Transition State. 
 
In addition to the N-tbutylsulfinyl protecting group directing the reaction, it also serves 
as a versatile protecting group that parallels the reactivity of the Boc group. It is stable 
to basic conditions and is easily cleaved with one equivalent of HCl.  
 
1.3. Pericylic reactions 
 
Pericyclic reactions are a distinct class of reactions which possess cyclic transition 
structures, and in which all bond making and breaking occurs with a concerted 
movement of electrons, lacking formation of intermediates. There are four distinct 
subclasses of pericyclic reactions and these are: 
 
Cycloadditions- 
Cycloadditions are ring forming reactions between two conjugated pi-systems and are 
classified by the net formation or loss (in the case of a retro-cycloaddition) of two σ-
bonds. Diels–Alder reactions are ubiquitous in organic chemistry and the 6 pi electron 
dimerization of cyclopentadiene via a [4+2]-cycloaddition is a common example, 
however the inherent reversibility is demonstrated by heating the dimer to afford the 
retro-cycloaddition products. 
 
 
 
Scheme 20. Diels-Alder Cycloaddition Reaction. 
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Electrocyclic Reactions- 
Electrocyclic reactions are invariably unimolecular ring forming reactions, derived 
from an open chain conjugated pi-system. Electrocyclisations are classified by the net 
formation of a new σ-bond and the loss of 2pi-orbitals or vice-versa in the case of an 
electrocyclic ring opening. 
 
 
Scheme 21. Electrocyclic Ring Formation & Ring Opening. 
  
Group Transfer Reactions- 
Group transfer reactions are bimolecular reactions between an allylic group (ene) and a 
pi-bond (enophile), and are classified by the formation of a new σ-bond with the 
migration of a hydrogen atom.  
 
 
 
Scheme 22. Ene Reaction. 
 
Sigmatropic Reactions- 
Sigmatropic reactions are unimolecular reactions which involve the formation and 
simultaneous loss of a σ-bond, exemplified by the [3,3]-Cope rearrangement, where the 
[x,n] nomenclature refers to the number of carbon atoms on each fragment that the σ-
bond migrates. 
 
 
 
Scheme 23. Cope [3,3]-Rearrangement. 
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1.4. The Claisen Rearrangement 
 
The Claisen [3,3] rearrangement was the first example of a sigmatropic rearrangement 
and was published in 1912 by Ludwig Claisen.58 Historically the Claisen rearrangement 
is the thermal rearrangement of aliphatic 88 and aromatic allyl vinyl ethers 90 which 
occur through a suprafacial pericyclic process via a chair like transition state, to 
produce γ,δ-unsaturated aldehydes 89 and substituted phenols 91 (post rearomatisation) 
respectively.59 
 
 
 
Scheme 24. Historical Claisen Rearrangements. 
 
 
Since its introduction to the synthetic community the Claisen rearrangement has been 
utilised within the synthesis of a magnitude of carbon skeletons, for instance in the total 
synthesis of (-)-furodysinin, where a tandem Claisen rearrangement and an 
intramolecular ene reaction affords the bicyclic alcohol 92 in excellent yield and 
enantioselectivity.60 
  
Me
O
Me Me
Me O Me
H
H
OH
Claisen Ene
Neat Neat
Yield = 74%
e.e. >99%
92
 
 
Scheme 25. Utilisation of Claisen Rearrangement in Natural Product Synthesis. 
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1.5. The Ireland–Claisen Rearrangement 
 
The Ireland–Claisen [3,3]-sigmatropic rearrangement is the Ireland variant of the 
Claisen rearrangement and was first introduced to the synthetic community in 1972.61 
The reaction proceeds via the low temperature deprotonation of an allylic ester 93 by 
treatment with a lithium dialkylamide base in the presence of a silylating agent. The 
silyl ketene acetal 94 formed in-situ undergoes the [3,3]-sigmatropic rearrangement via 
a chair transition state 95 to generate the γ,δ-unsaturated carboxylic acid 96 in excellent 
yield, after acidic workup. Although the rearrangement was presumed to be 
diastereoselective, the diastereoselectivity was not reported in Ireland’s seminal paper. 
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Scheme 26. The Ireland–Claisen Rearrangement. Relative Stereochemistry not Initally Reported. 
 
Although Ireland reported the first successful rearrangement of allylic ester reactants, 
Wang reported the very first ester enolate Claisen rearrangement in 1937.62 This 
protocol produced pent-4-enoic acid 98 in low yield, upon attempted acetoacetic ester 
97 condensation using sodium metal. 
 
 
 
Scheme 27. First Ester Enolate Rearrangement. 
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There were subsequent scattered reports of ester enolate Claisen rearrangements that 
employed sodium metal, sodium hydride, mesityl-magnesium bromide and 
diethylamine magnesium bromide up to the point of Ireland’s first publication, however 
these reactions all suffered low yields and high reaction temperatures.63 Ireland’s major 
contribution to this chemistry was the discovery that silylation of the ester enolate 
suppressed any side reactions, such as decomposition via the ketene pathway and 
Claisen type condensations. 
 
Since Ireland’s seminal work the Ireland-Claisen rearrangement has been incorporated 
into a wide variety of target-orientated syntheses and Ireland first exemplified his own 
chemistry within the synthesis of dihydrojasmone 99.61 
 
 
 
Scheme 28. Ireland–Claisen Rearrangement in the Synthesis of Dihydrojasmone. 
 
Other examples of the inclusion of the Ireland-Claisen rearrangement have been seen 
within Angle’s synthesis of the Pharoah’ ant food trail pheromone (+)-monomorine I 
100, and within Zakarian’s synthesis of the E-ring 101 of a spirolide C 102, a marine 
toxin.64,65 
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Scheme 29. Ireland-Claisen Rearrangement in Target Orientated Synthesis. 
 
 
1.5.1. Stereochemical Aspects of the Ireland Claisen Rearrangement 
 
An attractive feature of the Ireland-Claisen rearrangement lies in the ability to reliably 
transfer stereochemistry from appropriately substituted allyl silyl ketene acetals to 
either of the newly formed sp3 stereocenters and the alkene, leading to the formation of 
syn or anti pentenoic acids. The stereochemical outcome of the reaction is determined 
by two features: (1) the geometry of the silyl ketene acetal and the allylic alkene, and 
(2) whether the rearrangement proceeds via a chair-like or boat like transition state.  
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Enolate and Silyl Ketene Acetal Geometry- 
In 1975 Ireland reported ester enolates of propionates and related esters 103 could be 
stereoselectively generated to give either the (E)- 104 or the (Z)-silyl ketene acetal 105, 
once trapped with TBSCl. When THF was used as the solvent, the (E)-silyl ketene 
acetal 104 predominates and selectivities were high, with the exception of the phenyl 
acetates, however when 23% HMPA/THF was used, (Z)-silyl ketene acetal 105 
predominates.66  
 
 
Entry R1 R2 
(E)-104:(Z)-105 
THF 
(E)-104:(Z)-105 
23 vol% HMPA,THF 
1 Et Me 91:9 16:84 
2 tBu Me 97:3 9:91 
3 Et tBu 95:5 23:77 
4 Ph Me 29:71 5:95 
  
Table 1. Silyl Ketene Acetal Geometries 
 
Acyclic Allyl Silyl Ketene Acetals- 
Ireland demonstrated that relative diastereocontrol could be imparted into the synthesis 
of anti-2,3-dimethyl pentenoic acid 109 by rearrangement of the (E)-silyl ketene acetal 
107 of (E)-crotyl propionate 106 or with the (Z)-silyl ketene acetal 111 of the (Z)-crotyl 
propionate 113 at comparable levels of diastereoselectivity.61, 67-69 The analogous 
results for the syn-pentenoic acid 110 could be obtained using the (Z)-silyl ketene acetal 
108 of (E)-crotyl propionate 106, or with the (E)-silyl ketene acetal 112 with (Z)-crotyl 
propionate 113, with diastereoselectivities varying from 5:1 to 8:1. 
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Scheme 30. Acyclic Allyl Silyl Ketene Acetals. 
 
The stereochemical outcome of these rearrangements are consistent with preferential 
rearrangement via a chair like transition state, and computational analysis has 
confirmed that chair like transition states are favoured over the boat by 2-3 kcal/mol.70 
 
Cyclic Allyl Silyl Ketene Acetals- 
Ireland and others have shown that the rearrangement of cyclic substrates can 
preferentially rearrange via chair or boat transition states, however this is highly 
dependant on ring size, ring constitution and ring substituent stereochemistry.71-72 
Bartlett has also shown that the treatment of cyclohexenyl propionates under conditions 
for generation of (E)- or (Z)-silyl ketene acetals results in the formation of the same 
diastereoisomer 115 (Scheme 31).73-74 It was subsequently concluded that the (E)-silyl 
ketene acetal 114 rearranges preferentially via a chair transition state, whereas the (Z)-
silyl ketene acetal 116 rearranges via a boat transition state, a conclusion that was later 
supported by computational analysis.70 
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Scheme 31. Cyclic Allyl Silyl Ketene Acetals. 
 
However, in the case of dihydropyran- and dihydrofuran-derived allylic esters the boat 
transition state is favoured, irrespective of the silyl ketene acetal geometry. Ireland has 
subsequently provided a pertinent explanation for this observation and this is based on 
the effect of the pyran/furan oxygen, which increases the level of C-O bond cleavage 
leading to a transition state that has more product like geometry.71-72  This shift in the 
transition state relative to carbocyclic systems, leads to a more polarized transition state 
structure, which is better stabilised by the overlap of the two allyl moieties, hence 
rearrangement via a boat transition state is favoured (Scheme 32), however this 
postulation has yet to be computationally supported. 
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Scheme 32. Geometries of Dihydropyran Allylic Silyl Ketene Acetals. 
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Alkene Stereochemistry- 
The rearrangement of allylic esters derived from primary alcohols affords terminal 
alkenes, however if the allylic ester is derived from secondary or tertiary alcohols, then 
the formation of geometrical alkene isomers may be an issue with the rearrangement. 
As acyclic systems possess a strong preference for chair-like transition states, the 
stereochemistry of the product alkene is highly predictable in the case of secondary 
carbinol derived esters. This is because the substituent is placed in a pseudo-equatorial 
position. This is exemplified in the synthesis of the butterfly pheromone 118, in which 
the (E)-alkene 117 is selectively formed during the rearrangement.75  
 
 
 
Scheme 33. Predictability of Alkene Geometry in Ireland-Claisen Rearrangement. 
 
Allylic Esters Possessing One Stereocentre: Absolute Control- 
Absolute stereocontrol in the Ireland-Claisen rearrangement can be accomplished 
through incorporating an enantiopure secondary carbinol derived allylic ester, which 
will allow transfer of chirality to the newly formed stereocenter(s) at the α− and/or 
β−postion of the pentenoic acid product. Ireland first demonstrated this by use of a 
bulky TBS crotyl propionate 119.76 
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Scheme 34. Absolute Control in the Ireland-Claisen Rearrangement. 
 
 
1.6. Other Variants of the Claisen Rearrangement 
 
There are many other variations of the Claisen rearrangement, all of which have sub-
classes of their own present in the literature. The most popular examples are: 
 
Meerwein–Eschenmoser-Claisen Rearrangement- 
This rearrangement involves the conversion of allylic,77-79 benzylic, propargylic and 
allenyl carbinol systems to a ketene N,O-acetal, by treatment with dimethylacetamide 
dimethyl acetal under refluxing conditions, followed by a rapid [3,3]-sigmatropic 
rearrangement forming γ,δ-unsaturated amides (Scheme 35).77-80 
 
 
 
Scheme 35. Meerwein–Eschenmoser–Claisen Rearrangement. 
 
Compared to the Ireland–Claisen, the Meerwein-Eschenmoser version is often found to 
proceed with higher yields and the neutral conditions required allows the use of 
sensitive substrates, provided they are not thermally labile.  
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The Johnson–Claisen Rearrangement- 
This rearrangement proceeds via condensation of an ortho-ester and an allylic or 
propargylic alcohol, producing a mixed ortho-ester, which forms a ketene acetal by 
elimination of a low boiling alcohol.81-82 The ketene acetal intermediate then rearranges 
via a [3,3]-sigmatropic process to produce γ,δ-unsaturated esters (Scheme 36).  
 
 
 
Scheme 36. The Johnson–Claisen Rearrangement. 
 
 The Overman Rearrangement- 
This rearrangement involves the thermal or mercuric or palladium catalysed 
rearrangement of allylic trichloroacetimidates to afford the corresponding 
trichloroacetamides via a [3,3]-sigmatropic rearrangement.83-84 The allylic 
trichloroacetimidates are easily prepared from reacting allylic alcohols with 
trichloroacetonitrile in the presence of catalytic amounts of base. Good levels of 
enantioselectivity have been accomplished through utilisation of chiral palladium 
sources (Scheme 37). 
 
 
 
Scheme 37. The Overman Rearrangment. 
 
 The Carroll Rearrangement- 
This involves the thermal or anionic [3,3]-sigmatropic rearrangement of β−keto-allylic 
esters to β-keto acids, which upon decarboxylation provides the corresponding γ,δ-
unsaturated ketones. The overall transformation is equivalent to a Claisen 
rearrangement, but at the ketone oxidation state (Scheme 38).67, 85 
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Scheme 38. The Carroll Rearrangement. 
  
Craig has also reported a variant of the Carroll rearrangement, in which α-tosyl silyl 
ketene acetals formed from allylic tosylacetates or malonates, by bis(trimethylsilyl) 
acetamide (BSA) and catalytic potassium acetate undergo a [3,3]-sigmatropic 
rearrangemement.86-87 Subsequent acetate-induced desilylation-decarboxylation 
provides homoallylic sulfones or α-tosyl-γ,δ-unsaturated esters (Scheme 39). 
 
 
 
Scheme 39. The Craig Variant of the Carroll Rearrangement. 
 
 Aza–Claisen Rearrangement- 
This sees the replacement of the oxygen atom in a simple Claisen rearrangement by a 
nitrogen atom. The rearrangement is a thermal process and incorporates the use of 
aliphatic and aromatic substrates, however product distributions may arise involving a 
subsequent Cope rearrangement on the aza–Claisen product (Scheme 40).88 
 
 
 
Scheme 40. Aza-Claisen Rearrangement. 
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A disadvantage of the aza-Claisen rearrangement is the high reaction temperatures that 
are required. However, introduction of zwitterionic Aza-Claisen rearrangements allows 
the reduction of these reaction temperatures to a more amenable range, through charge-
accelerated ammonium or amide enolates (Scheme 41).89-90 
 
 
 
Scheme 41. The Zwitterionic Aza-Claisen Rearrangment 
 
 Thio–Claisen Rearrangement- 
This sees the replacement of the oxygen atom in a simple Claisen rearrangement by a 
sulfur atom. The rearrangement is a thermal process and incorporates the use of 
aliphatic and aromatic substrates, but historically has been plagued by low yields due to 
product distributions and product instability. Considering the rearrangement of allyl 
phenyl sulfide, product distributions are seen to arise from the desired [3,3]-sigmatropic 
rearrangement, followed by prototropy and subsequent cyclization in 5-exo-trig 6-
endo-trig fashion to yield 5 and 6 membered heterocycles (Scheme 42).91 
 
 
 
Scheme 42. The Thio–Claisen Rearrangement. 
 
 Bellus–Claisen Rearrangement- 
The Bellus–Claisen rearrangement sees the reaction of allylic ethers, amines and 
thioethers with ketenes, which form a zwitterionic intermediate that subsequently 
undergoes a [3,3]-sigmatropic rearrangement, allowing the synthesis of γ,δ-unsaturated 
esters, amides and thioesters, after zinc dechlorination (Scheme 43).92-93 
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Scheme 43. The Bellus-Claisen Rearrangement. 
 
 Enamido–Claisen Rearrangement- 
Recently Clive has published an enamido Claisen rearrangement in the synthesis of the 
marine alkaloid halichlorine 122, where the distal terminus of the allylic double bond 
carries a protected Cbz-nitrogen fragment.94 The rearrangement proceeds in one pot 
from the secondary cyclic alcohol 120 and butyl vinyl ether under mercuric catalysis to 
generate the β-amino-γ,δ-unsaturated aldehyde 121. 
 
 
 
 Scheme 44. The Enamido-Claisen Rearrangement. 
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1.7. Enamides 
 
Enamides are tempered enamines which display significant chemical stability and 
nucleophilic reactivity, and are controlled by the electron withdrawing functionality 
upon the nitrogen centre. These molecules often react akin to simple olefins and allow 
N-functionality to be incorporated into complex systems. There are several classes of 
enamide 123 and an increasing level of interest in using these compounds has 
developed over the past decade, possibly due to the plethora of syntheses available 
offering substrate versatility and E/Z control.95 
 
 
 
Fig. 8. Classes of Enamide. 
 
There are a plethora of reactions involving the use of enamides within the literature, 
however some examples of each reaction type include: 
 
Enamides as Nucleophiles- 
As enamides can be viewed as tempered enamines, their nucleophilic properties are no 
surprise. The first enantioselective use of enamides as nucleophiles with aldimines 
using copper catalysis was reported by Kobayashi.96  This use of enamides allows the 
synthesis of interesting α-amino acid precursor building blocks in excellent yield and 
enantioselectivities (Scheme 45). 
 
 
 
Scheme 45. Enamides Acting as Nucleophiles. 
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Gong has reported the H8-BINOL derived phosphoric acid 124 catalysed alkylation of 
enamides with indolyl alcohols, allowing synthesis of β-aryl 3-(3-indolyl)propanones 
in excellent yields and enantioselectivities (Scheme 46).97 
 
 
 
Scheme 46. Gong’s Use of Enamides as Nucleophiles. 
 
Enamides as Electrophiles- 
The Tareda and Zhou groups have independently reported that chiral Brønsted acids 
125 can promote the conversion of enamides to chiral iminium ion electrophiles, which 
can subsequently undergo Friedel-Crafts reactions (Scheme 47).98,99 
 
 
 
Scheme 47.Tareda & Zhou’s Use of  Enamides as Electrophiles. 
 
Tsogoeva has shown that the BINOL phosphoric acid 126 can catalyse the formation of 
a quaternary carbon centre bearing a nitrogen atom, through the self coupling of 
enamides.100 The β-amino ketone products are subsequently isolated in good yield and 
enantioselectivity (Scheme 48). 
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Scheme 48. Tsogoeva’s Use of Enamides as a Simultaneous Electrophile & Nucleophile. 
 
Enamides in Organocatalytic Reductions- 
Carbery has reported the first use of a bridged flavinium organocatalyst 128 in the 
diimide reduction of enamide 127 with excellent conversion.101 
 
 
 
Scheme 49. Enamides in Organocatalytic Hydrogenation Reactions. 
 
Antilla has also reported the highly enantioselective reduction of enamides catalysed by 
a dual chiral-achiral acid system.  This sees catalytic amounts of chiral phosphoric acid 
129 and acetic acid providing excellent yields and enantioselectivities of the reduction 
product.102 
 
 
 
Scheme 50. Enamides in Organocatalytic Reductions. 
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Enamides in Transition Metal Catalysed Reactions- 
Enamides can be viewed as attractive substrates in a number of transition metal 
mediated alkene transformations. The one reaction that is well developed for enamide 
substrates is alkene hydrogenation.95 In contexts where incorporation of nitrogen 
functionality is important, ring closing metathesis has been utilised allowing the 
synthesis of cyclic enamides (Scheme 51).103 
 
 
 
Scheme 51. Enamides in Transition Metal Catalysed Reactions. 
 
Enamides in Pericyclic Reactions- 
The use of enamide substrates in pericyclic reactions, such as cycloadditions, 
electrocyclisations and sigmatropic rearrangements has increased over the past several 
years.95 For instance a highly efficient and stereoselective Diels-Alder reaction using a 
conjugated enamide 130 as the reactive diene has been reported, in the presence of 
chromium-salen catalyst 131 (Scheme 52).104 
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Scheme 52. Enamide in a Cycloaddition. 
 
Funk has demonstrated the use of an enamide in the electrocyclisation of 2,3-pyrroline 
132, to yield the 6pi-electrocyclic ring closure product 133 in good yield, allowing 
access to indole framework seen within trikentrin alkaloids (Scheme 53).105 
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Scheme 53. Enamides in Electrocyclic Reactions. 
 
Meyer has reported the first use of an enamide 134 in a sigmatropic rearrangement, that 
sees formation of amino alcohols 135 in excellent yield and diastereoselectivity, via a 
[2,3]-Wittig rearrangement.106 
 
 
 
Scheme 54. Enamides in Sigmatropic Rearrangements. 
 
 
Enamides in Radical Reactions- 
The synthetic value of enamide substrates has recently been shown through the total 
synthesis of Lennoxamine 137, as enamide 136 is observed to undergo a regioselective 
7-endo cyclisation followed by subsequent homolytic aromatic substitution (Scheme 
55).107 
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Scheme 55. Enamides in Radical Reactions. 
 
Enamides in Heterocycle Synthesis- 
Movassaghi has demonstrated a new synthesis of pyridines, whereby enamides are 
converted to N-vinyl iminium triflates via treatment with triflic anhydride, subsequently 
reacting with electron rich heterosubstituted alkynes or alkenes to form pyridines 
(Scheme 56).108 
 
 
 
Scheme 56. Enamides in Heterocycle Synthesis. 
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2. The Enamido-Ireland-Claisen Rearrangement 
 
2.1. Background 
 
In spite of high demand for their availability, synthetic access to enantiopure β-amino 
acids relies on a variety of methods which are unique to the type and position of 
substitution required. Currently there is no single synthetic protocol allowing the 
synthesis of β-amino acids ranging from β- to β2,2,3,3-amino acids. It was therefore 
envisaged that an Enamido-Ireland-Claisen rearrangement (EICR) could pose a 
versatile route, if the synthetic properties of the related Ireland-Claisen rearrangement 
(ICR) could be transposed. This EICR would allow the required substitution and 
stereochemical outcome of the β-amino acid be decided pre-reaction.  
 
 
 
Scheme 57. Proposed [3,3]-Rearrangement of Enamides. 
 
The key factors in making the EICR a useful transformation lie in: 
 
1) A rapid preparation of enamido allylic ester substrates. 
2) The potential to control the silyl ketene acetal (SKA) geometry and hence 
control relative stereochemistry in the product. 
3) The potential for chirality transfer from the allylic stereocentre to the newly 
formed stereocenters in the product. 
4) Alkene geometry of the allyl group can be built into synthesis of the substrate. 
5) The rearrangements usually proceed at colder temperatures compared to the 
related Claisen rearrangement, hence allowing kinetic control to be achieved. 
6) The predictability between chair and boat transition states. 
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The Carbery group has recently published a direct and novel route to complex β2,3-
amino acid precursors.109 This new methodology was based upon the use of enamido 
allylic esters 138 for use in an EICR and has been shown to proceed under similar 
conditions to the generic ICR. From the several examples published moderate to good 
yields and poor diastereoselectivities were observed for the rearrangement of alkyl 
derived enamido ester substrates. However the phenyl substrate displayed a good yield 
and excellent diastereoselectivity of rearranged β-amino ester precursor 144.  
 
 
Entry R Product 
Yield 
(%) 
d.r. 
(anti:syn) 
1 Me 139 55 2:1 
2 H 140 Trace na 
3 iPr 141 48 3:2 
4 Allyl 142 79 3:2 
5 OBn 143 62 2:1 
6 Phenyl 144 69 >95:5 
 
Table 2. The EICR. 
 
At the time of publication, relative stereochemistry was tentatively assigned based on 
the observed coupling constants of the allylic methine signal, within 1H-NMR 
experiments. This proton was observed in both anti- and syn-diastereoisomers as a 
doublet of doublets, with the major diastereoisomer offering a larger coupling constant 
consistent with an anti-periplanar open chain of the product β-amino acid precursors 
and therefore assigned as the anti-diastereoisomer (Fig. 9.). 
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Fig. 9. Newman Projections of Syn- and Anti- Diastereoisomers. 
 
Whilst the diastereoselectivity in the alkyl examples was disappointing it was also 
noticeably lower than many Ireland-Claisen reactions of propionates, where 
diastereomeric ratios of the order of 85:15 or better are often observed.66 Several 
factors may be responsible for these observed reductions, including poor E/Z enolate 
geometry control, the enamide moiety affecting the preference of chair versus boat 
transition states and post-rearrangement enolisation all having deleterious effects.110-111 
 
 
2.2. Initial Aim 
 
The high diastereoselection observed with the phenylacetate was indeed intriguing. 
Following on from these initial results it was decided to first look at optimising the 
EICR of the phenylacetate, prior to probing the diastereoselection of the EICR through 
perturbing the electronic nature of the acyl fragment. Any differences in the observed 
diastereoselectivity may then offer insight into the stability of enolates, SKAs and 
conformational considerations of chair/boat transition states. Secondly, the use of 
enantiopure secondary carbinol derived enamido allylic esters may also provide useful 
information on the effect of electronic perturbations, as traditional Ireland-Claisen 
rearrangements have been shown to rearrange enantiopure starting materials to >95% 
e.e.112  
 
 
2.3. Retrosynthesis 
 
Two key requirements were identified for the synthesis of the desired enamido allylic 
ester substrates. Firstly, a cheap and simple synthesis that allows incorporation of the 
acyl moiety at late stage would be desirable, allowing multigram quantities of a key 
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intermediate to be synthesised. Secondly, investigations based on secondary allylic 
esters would offer potential for asymmetric control with enantiopure substrates during 
later studies. Retrosynthetic analysis (RSA) on enamido allylic ester 138, provides a 
key oxazolidinone derived enamide 145 via ester C-O bond cleavage (Scheme 58). 
 
 
 
Scheme 58. RSA of Generic Oxazolidinone Enamido Substrate. 
 
Access to key intermediate 145 could then be based on a racemic and an 
enantiomerically pure basis, in which: 
 
1) Racemic 145 could be accessed from vinylogous amide 146 under reduction 
conditions, subsequently produced from a conjugate addition of 2-
oxazolidinone 147 to ynone 148 generated from alcohol 149. 
 
 
 
Scheme 59. RSA of Key Vinylogous Hemiaminal 145. 
 
2) Enantiomerically pure (R)-150 could be accessed via a selective reduction of 
ynamide (R)-151, synthesised via an Ullmann type coupling of 2-oxazolidinone 
147 and bromoalkyne (R)-152. Bromoalkyne (R)-152 could be synthesised 
from enantiomerically pure but-3-yn-2-ol (R)-153 via O-protection and 
bromination (Scheme 60). 
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Scheme 60. RSA of Key Enantiomerically Pure Vinylogous Hemiaminal. 
 
 
2.4. Synthesis of Racemic Enamido Allylic Esters  
 
The synthetic route undertaken to racemic alcohol 145 followed a procedure reported 
by Carbery and Janey.109,113 After further optimisation, the developed substrate 
synthesis is outlined in Scheme 61. Vinylogous amide 146 was synthesised in a 
markedly improved 58% yield, to that published.109 This was accomplished by a two 
step procedure involving Jones oxidation of 149, followed by the immediate conjugate 
addition of 2-oxazolidinone 147 in the presence of catalytic amounts of DABCO.114 
Subsequent sodium borohydride reduction cleanly and chemoselectively reduced the 
ketone moiety to form the key intermediate 145,  in quantitative yields and without the 
need for further purification.115 
 
 
 
Scheme 61. Route to Key Racemic Intermediate. 
 
Esterification of alcohol 145 was performed via the carbodiimide coupling reagent 
EDCi, and it is noted that significantly improved yields of phenylacetate 154 were 
observed to that published.109 
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Scheme 62. EDCi Coupling. 
 
The use of EDCi has been found to be optimal, as all by-products of the reaction can 
be easily removed during a weak acid-base extraction cycle, with the product isolable 
without need for further purification. The use of other esterification protocols which 
are reliant on or generate acidic conditions in-situ, such as the hydrochloric acid 
(generated from methanol/acetyl chloride) catalysed esterification of alcohol 145 and 
phenylacetic acid, or esterification of alcohol 145 with phenylacetyl chloride even in 
the presence of triethylamine, show complete degradation of 145 with no signs of 
product formation. Access to 154 via DCC was promising, however removal of the 
urea by-products by silica or alumina column chromatography was deleterious and 
degradation resulted. The degradation pathway for acid mediated esterification 
conditions can be envisaged to occur via dehydration of alcohol 145, and that seen 
within chromatographic purification of phenyl acetate 154 could be envisaged to occur 
via elimination of phenylacetic acid facilitated by activation of the ester and ejection 
by the enamide. Both degradation pathways yield the same common iminium ion 
intermediate 155, producing quantitative yields of 2-oxazolidinone 147 and phenyl 
acetic acid 156 after aqueous work up. Crotonaldehyde 157 has not been isolated post 
chromatographic separation, but its generation is based on 1H NMR analysis of crude 
reaction mixtures for esterifications and by treatment of phenyl acetate 154 to 2M 
hydrochloric acid, followed by organic extraction. 
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Scheme 63. Sensitivity of Key Alcohol 145 & Substrate 154. 
 
2.5. Optimisation of Phenylacetate EICR 
 
Before investigation into the electronically differentiated phenylacetates, it was 
decided that optimisation of the EICR of the parent phenylacetate substrate 154 was 
required. This optimisation was envisaged to encompass all variables associated with 
this reaction and to compliment the published results.109 These variables included the 
type and equivalents of base, solvent, reaction temperature, order of addition, quench 
and workup conditions. From the outset, the methylation of the β2,3-amino acid 
precursors was accomplished by rapid treatment with diazomethane, as opposed to a 
published methanolic TMS diazomethane approach.109 This approach was based on a 
thorough mechanistic elucidation made by Lloyd-Jones into the TMS diazomethane 
methylation of carboxylic acids.116 This report highlighted product distributions seen 
using this protocol and exemplified the issues through the methylation of phenylacetic 
acid 156, whereby methylated acid 158 and unwanted TMS-methyl acetate 159 were 
generated. Reductions in 159 were seen through increasing the methanol concentration 
and by the addition of a Brønsted acid. 
 
156 158
TMSCHN2
MeOH (0.5 M)
PhMe
CO2H CO2Me CO2CH2TMS
159
+
No Catalyst
2 mol % HBF4
4 1
> 40 < 1  
 
Scheme 64. Issues Observed with TMS Diazomethane Methylations. 
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Although there is certain dogma based on the use of diazomethane, such as its toxicity 
and explosive properties, its generation under a controlled environment allows a quick, 
easy and relatively safe methylation protocol, in absence of any other complications 
potentially seen with TMS diazomethane.117 
 
 
Entry Base Eq. Eq. TMSCl Yield  144 / % (d.r.)a Yield 158 / % 
1 LiHMDS 1.1 1.1 74 (16:1)bfj 14 
2 LiHMDS 1.3 1.3 80 (16:1)bfj 11 
3 LiHMDS 1.5 1.5 85 (9:1)bfj 9 
4 LiHMDS 1.3 1.3 72 (44:1)cgj 16 
5 LiHMDS 1.3 1.3 80 (32:1)chj 14 
6 LiHMDS 1.5 1.5 66 (32:1)cgj 21 
7 LiHMDS 1.3 1.3 65 (32:1)bgj 26 
8 NaHMDS 1.3 1.3 34 (2:1)cgj 26 
9 KHMDS 1.3 1.3 na (na)cgj na 
10 LDA 1.3 1.3 na (na)cgj na 
11 LiHMDS 1.3 1.3 na(32:1)cdgj na 
12 LiHMDS 1.3 1.3 59 (32:1)cegj 21 
13 LiHMDS 1.3 1.3 71 (41:1)cgk 14 
14 LiHMDS 1.3 1.3 53 (32:1)cgl 27 
15 LiHMDS 1.3 1.3 82 (32:1)cij 12 
ad.r. measured by extended acquisition of crude on 500 MHz 1H NMR bReaction initiated at -78 ˚C 
cReaction initiated at -95 ˚C dReaction quenched by 10% citric acid (aq) eReaction performed in toluene 
fHand addition of substrate to base, TMSCl and THF  gAddition of substrate at 4 ml/h to base and 
TMSCl and THF  hAddition of substrate at 2 ml/h to base and TMSCl iAddition of base at 4 ml/h to 
substrate, TMSCl and THF    jWarm  to  RT over 1 h   kReaction allowed to stir for 2 h  lWarm  to  0 ˚C 
over 1 h. 
 
Table 3. Results from Optimisation of Phenylacetate EICR. 
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This optimisation has demonstrated that higher yields and diastereoselectivities are 
accomplished when reaction initiation was performed by slow addition of substrate to 
base and TMSCl (Entry 2, Table 3) and even better at the lower temperature of -95 °C 
(Entry 4, Table 3). The rearrangement displayed a striking dependence on the nature of 
the base used, where NaHMDS significantly reduced diastereocontrol (Entry 8, Table 
3) and both KHMDS and LDA yielded intractable mixture of products (Entry 9 and 
10, Table 3). The reaction was relatively insensitive to the choice of solvent, working 
well in toluene (Entry 12, Table 3). Furthermore, the manner of reaction quench was 
found to be important (Entry 11, Table 3), as methylation of residual citric acid present 
post work up was seen to co-elute with product during column chromatography 
leading to impure product. An inverse addition protocol was observed to have 
marginal reductions in diastereocontrol (Entry 15, Table 3). 
 
To allow structural verification of the major diastereomer, 144 was successfully 
recrystallised allowing an X-ray structure be acquired (Figure 10). To ensure that the 
major diastereomer was correctly analysed, the single crystal and powder diffractions 
of bulk sample were compared (see appendix), verifying that the anti-relationship of 
these β2,3-amino acid precursors predominates. 
                      
 
 
Fig. 10. ORTEP Plot of Phenylacetate 144 (Ellipsoids Shown at 30% Probability). 
 
A general observation from these rearrangements was seen to be the recovery of 
variable amounts of methylated phenylacetic acid 158 in addition to the desired β2,3-
amino acid precursor, allowing near quantitative mass balance be accounted for. As the 
consumption of starting material can not be monitored by TLC, due to its inherent 
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sensitivity to acidic media, it was thought that the reaction may not be complete after 
60 minutes and the acidic quench may play a deleterious effect by hydrolysing the 
unreacted enamido ester starting material. However, this was not considered to be a 
factor, as when the reaction time was increased (Entry 13, Table 3) comparable yields 
and diastereoselectivities were obtained. Other hypotheses for the generation of 158 
are based on two possible degradation pathways involving the initial formation of the 
enolate 160, from the enamido allylic ester starting material. It is postulated that either 
degradation occurs via a ketene type pathway in which the enolate 160 ejects the 
alkoxide 161 (Pathway A, Scheme 65), or alternatively through an enamide facilitated 
pathway, involving ejection of a doubly deprotonated carboxylic acid (Iwanov reagent) 
162 and yielding iminium ion 155. These intermediate degradation products would 
then yield the observed by-product 156, post protic quench via either degradation 
pathway prior to methylation.  
 
 
Scheme 65. Possible Degradation Pathways for Enolate 160. 
 
Observation analytically and/or isolation physically of the enamido alcohol 145 from 
the reaction mixtures has not been acheived, perhaps an aspect of its strong sensitivity 
to protic environments such as the reaction quench. However, potential indications of 
the presence of aldehydic signals in the 1H NMR spectra of crude reaction mixtures 
may allude to the presence of crotonaldehyde 157. This observation, however, does not 
prove either degradation pathway, as separate treatment of alcohol 145 with 1M 
HCl:brine solution yields a complex reaction profile alluding to the formation of 2-
oxazolidinone 147 and crotonaldehyde 157. 
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2.6.  Rearrangement of Electronically Differentiated 
Arylacetates 
 
With improved rearrangement conditions in hand for the parent phenylacetate enamido 
ester, the level of diastereoselectivity relative to the electronic nature of the acyl 
moiety could now be investigated. A range of phenylacetates were prepared with 
electronically differentiated substituents, namely the electron rich methoxy, the 
electron poor nitro and the relatively electron neutral methyl group, each placed 
sequentially at the ortho-, meta- and para-positions. These substrates were synthesised 
utilising the now standard EDCi coupling conditions in excellent yields (Table 4). 
 
 
Entry R Product 
Yield  
(%) 
1 o-OMe 163 94 
2 m-OMe 164 76 
3 p-OMe 165 91 
4 o-Me 166 71 
5 m-Me 167 74 
6 p-Me 168 88 
7 o-NO2 169 85 
8 m-NO2 170 92 
9 p-NO2 171 85 
 
Table 4. Yields for EDCi Couplings. 
 
Rearrangement and esterification of these substrates was then pursued using the newly 
optimised conditions, yielding the corresponding methyl esters in good yields and poor 
to excellent diastereoselectivities. 
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Entry R Product 
Yield 
(%) 
d.r.a,b 
(anti:syn) 
By-Product 
Yield 
(%)c 
1 o-OMe 172 79 22:1 181 13 
2 m-OMe 173 73 19:1 182 15 
3 p-OMe 174 77 24:1 183 13 
4 o-Me 175 71 19:1 184 16 
5 m-Me 176 74 43:1 185 14 
6 p-Me 177 70 54:1 186 21 
7 o-NO2 178 73 5:1 187 17 
8 m-NO2 179 75 16:1 188 14 
9 p-NO2 180 76 9:1 189 13 
ad.r. measured by extended acquisition of crude on 500 MHz 1H NMR bTriplicates have been performed 
in each case. Measured d.r. is reproducible and reported as an average cYield based on amount of EICR 
product that degradation product corresponds to. 
 
Table 5. Results for Arylacetate EICR. 
 
In all ortho-substituted systems a deterioration in diastereoselectivity was observed 
compared to the parent phenylacetate 144, with a significant reduction seen for the o-
NO2 (Entry 9, Table 5). Consistent reductions in diastereoselectivity were seen for the 
meta-substituted analogues, however, the most interesting range of 
diastereoselectivities were observed for the para-substituted systems. Significant 
reductions in the diastereoselectivity were observed for the electron donating methoxy  
(Entry 3, Table 5) and the electron withdrawing nitro group (Entry 9, Table 5), but an 
increase in diastereoselectivity was observed for the relatively electron neutral methyl 
group (Entry 6, Table 5), compared to the parent phenylacetate 144.  
 
With the ortho-variants, the diminished diastereoselectivity observed can be attributed 
to dual steric and electronic effects within the rearrangement transition state. However, 
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the para-variants can be viewed on deconvoluted steric and electronic effects, as these 
groups are structurally remote from the site of reaction. Within these EICR reactions 
there are several possibilities that could lead to the diminished diastereoselectivity 
observed. These are- 
 
1) Non-Selective Enolisation 
It is well known within the Ireland-Claisen rearrangement that the enolisation by 
lithium amide bases occurs under kinetic control, yielding formation of the more 
favourable Z-enolate.66-67 Therefore deprotonation of enamido allylic phenylacetate 
144 would be expected to occur with a similar outcome through an analogous six-
membered transition state, where 1,3-diaxial interactions predominate and a pseudo-
equatorial positioning of  the phenyl ring is favoured generating Z-enolate 160. 
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Scheme 66.  Enolisation Transition States. 
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However, certainly in the presence of any ortho-arylsubstituents 190, a 1,2-
transannular effect may play a significant role, counteracting the strong 1,3-diaxial 
effect (Scheme 67).  
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Scheme 67. Enolisation Transition States. 
 
If this were the case, then poor E/Z-enolate control may be responsible for the poor 
diastereoselectivity seen, assuming that the rearrangement occurs, post silyation, 
through a reliable chair transition state. This argument is exemplified by the ortho- and 
para-methyl systems (175 & 177), as a notable reduction in diastereoselectivity is seen 
with the ortho-methyl variant, yet high diastereocontrol is observed with the para-
methyl variant. However, the near identical reductions in diastereocontrol seen with 
the ortho- and para-nitro (178 & 180) and methoxy (172 & 174) systems respectively, 
may allude to the presence of an alternative stronger effect outweighing steric issues in 
these cases. 
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2) Enolate Isomerisation 
An alternative to poor E/Z-enolate control via initial deprotonation could be seen 
through a post-enolisation isomerisation. This effect, perhaps most suited by the 
presence of a conjugated electron withdrawing or donating group, could mesomerically 
remove enolate character by either withdrawing electron density out of, or inserting 
electron density into the pi-system. This mechanism, exemplified by the para-nitro 191 
and methoxy 192 variants (Scheme 68), could subsequently erode any geometrical 
control of enolisation, as the enolate could isomerise prior to silylation and subsequent 
rearrangement.  
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Scheme 68. Possible Explanation for Low d.r. with para-Nitro- and para-Methoxy-Substrates. 
 
This argument may be more suited to electron withdrawing groups which can act as a 
resonance stabilised electron sink, exemplified in the above case through nitronate 191.  
 
3) Silyl Ketene Acetal Isomerisation 
Providing that formation of the E-silyl ketene acetal is kinetically favoured, another 
variable that could result in poor diastereocontrol may be presented by silyl ketene 
acetal isomerisation. Dauben has computationally supported observed experimental 
results on E/Z silyl ketene acetal ratios of propionate derived systems, however 
inconsistencies are observed between the calculated E/Z ratios of phenylacetate 
Chapter 2  Results & Discussion
   
53 
derived silyl ketene acetals to that observed experimentally.118 The E/Z silyl ketene 
acetal ratios for the parent phenylacetate were calculated to be kinetically favoured and 
are in stark contrast to the observed ratio of 29:71  (E:Z) seen by Ireland.66,67,68 Corset 
and Tanaka have both separately shown that Dauben’s calculation for the selective 
formation of the E-silyl ketene acetal was correct.119,120 The predominant formation of 
the Z-geometrical isomer is the result of a thermodynamic equilibration between the E- 
and Z-silyl ketene acetals under the reaction conditions and/or work up procedures, 
implying that silylation may be a poor technique for maintaining high E/Z ester enolate 
ratios. With these considerations in mind the thermodynamic isomerisation of the silyl 
ketene acetal may be responsible for the poor diastereoselectivity observed within the 
electron donating and withdrawing variants of the EICR. 
 
 
 
Scheme 69. Possible Thermodynamic Isomerisation of SKA. 
 
 
4) Competition Amongst Alternative Transition States 
Another consideration which may result in the observed diastereoselectivity could be 
energetically similar chair and boat transition states prior to rearangement.3 This factor 
combined with any thermodynamic aspects of SKA isomerisation could lead to a very 
complex situation where four diastereomeric transition states may coexist (Figure 
11).119,120 The formation of the anti-diastereomer is then not only consistent with an E-
SKA rearranging via chair transition state 193, but also a Z-SKA rearranging via boat 
transition state 194. Simultaneously the syn-diastereomer could be accesed through 
rearrangement of a Z-SKA via chair transition state 196 or an E-SKA through boat 
transition state 195. 
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Scheme 70. Possible Transition States for the EICR. 
 
5) Non-Concerted Character 
The potential for pericyclic reactions to possess chameleonic transition states, where 
the mechanism skirts between a concerted intramolecular and a non-concerted  
intermolecular reaction, have proved an area of much discussion within the physical 
organic community.121-123 A possible explanation for the observed trends in 
diastereoselectivity within the EICR may be presented by such a change in mechanism. 
A truly concerted, selective, one step mechanism may exist for the highly 
diastereoselective phenyl- 144 and tolylacetates 177; however a non-concerted, non-
selective, two step mechanism may result for the nitro- 180 and methoxyacetates 174. 
The formation of intimate ion pairs could be facilitated by the enamide, causing 
cleavage of the C-Oσ ester bond and yielding iminium ion intermediate 155 in both 
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electron withdrawing nitro- and electron donating methoxy-cases. The recombination 
of these ion pairs could then occur via the nitronate 197, or by the Iwanov reagent 198, 
producing aldol type selectivity. 
 
 
Scheme 71. Possible Non-Concerted Character of EICR. 
 
 
6) Post Rearrangement Epimerisation 
Post rearrangement enolisation was first reported in Ireland’s seminal paper, where it 
was noted that 6% of C-silylated pentenoic acid 199 was isolated in addition to the 
desired product 96.61 
 
 
 
Scheme 72. C-Silyation in Ireland-Claisen Rearrangement. 
 
The issue surrounding post rearrangement enolisation relies on the retention of a second 
enolisable proton within the pentenoic acid product. McIntosh has subsequently 
reported deleterious effects seen with post rearrangement epimerisation, in that, albeit 
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no C-silyation was noted, anomously low yields and variable diastereoselectivities were 
observed in the formation of 200 as a function of time.110 These issues were 
circumvented via a cold quench with acetic acid, halting post rearrangement enolisation. 
 
 
 
Scheme 73. McIntosh’s Solution to Post Rearrangement Epimerisation. 
 
Post rearrangement epimerisation may therefore be reponsible for the low 
diastereoselectivities seen within the EICR and in order to discount this variable a 
number of test reactions were performed. In order to test whether epimerisation of the 
product silyl ester was an issue, the rearrangement of 154 was monitored over 24 hours 
by extracting aliquots after 1, 3, 5, 11 and 24 hours. After treatment by diazomethane, 
the observed diastereoselectivity from these aliquots was seen to remain identical, 
subsequently demonstrating that erosions in diastereoselectivity are independent of 
reaction time. Also, the treatment of the isolated methyl ester 144 with LiHMDS and 
TMSCl lead to quantitative return of diene 201 via E1cB elimination of 2-oxazolidinone 
147. 
 
 
Scheme 74. Time Study on EICR of Phenylacetate 154. 
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During the course of the EICR, the formation of by-products such as 
hexamethyldisilazane (HMDS) from enolisation, or lithium chloride from silyation of 
the enolate may prove important.  
 
 
 
Scheme 75. By-Product Considerations. 
 
These by-products may be reponsible for the low diastereoselectivity seen with the 
nitro-arylacetate silyl ester products, as these would be envisaged to be more susceptible 
to soft enolisation by the secondary amine HMDS in the presence of the Lewis acid, 
lithium chloride. In order to test this hypothesis, syn-180 and anti-180 were separately 
treated with HMDS and LiCl in THF at room temperature over 24 hours, no erosion of 
diastereomeric purity was observed in this experiment. 
 
 
 
Scheme 76. Soft Enolisation Considerations. 
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2.7.  Further Investigation into the Electronic Nature of 
para-Substitution 
 
The striking range of diastereoselectivity observed with the para-nitro, methoxy and 
tolylarylacetates, strongly suggest that stereoelectronic effects play an important role in 
determining the diastereochemical outcome of the EICR. The sharp reductions in 
diastereoselectivity observed for the strongly electron withdrawing 180 and donating 
analogues 174, compared to the relatively electron neutral tolyl 177 system, indicate 
that a fine balance between stereoelectronics and diastereoselectivity may exist. In 
order to probe this relationship a more comprehensive investigation into the nature of 
para-substitution was pursued, based on varying levels of electron withdrawing and 
donating capabilities. With this in mind seven other para-substituted arylacetate 
substrates were synthesised in high yields 202-208. Additionally, the synthesis of the 
electron rich 2,4-dimethoxy arylacetate 209 was also accomplished in a high yield. 
Other substrates synthesised in high yields included the styryl 210, 3-methylindolyl 
211 and dioxolane 212 arylacetates, with the intention of probing electronics of 
substitution indirectly. 
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Entry Ar Product 
Yield 
(%) 
Entry Ar Product 
Yield 
(%) 
1 
Me2N  
202 92 7 
 
208 83 
2 
 
203 79 8 
 
209 79 
3 
 
204 77 9 
 
210 91 
4 
Cl  
205 93 10 
 
211 74a 
5 
 
206 86 11 
 
212 85 
6 
NC  
207 73     
aYield over 2 steps involving N-methylation of indole-3-acetic acid and subsequent esterification with 
145. 
 
Table 6. Yields for EDCi Couplings. 
 
With these eleven other aryl acetates in hand, the rearrangement under optimised 
conditions provided the corresponding β2,3-amino acid precursors in high yields and a 
range of diastereoselectivities. 
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Entry R Product 
Yield 
(%) 
d.r.a,b 
(anti:syn) 
By-Product 
Yieldc 
(%) 
1 
Me2N  
213
d
 58 6:1 224 24 
2 
 
214 77 60:1 225 14 
3 
 
215 73 23:1 226 17 
4 
Cl  
216 72 46:1 227 19 
5 
 
217 71 21:1 228 21 
6 
NC  
218 63 17:1 229 0f 
7 
 
219
e 67 >25:1 230 16 
8 
 
220 57 6:1 231 29 
9 
 
221 68 >25:1 232 19 
10 
 
222 50 10:1 233 29 
11 
 
223 58 32:1 234 27 
ad.r. measured by extended acquisition of crude on 500 MHz 1H NMR NMR bTriplicates have been 
performed in each case. Measured dr is reproducible and reported as an average cYield based on amount 
of EICR product that degradation product corresponds to. dLiHMDS added to a solution of substrate and 
TMSCl. eSubstrate added as a solution in THF at 20 mg/mL, as opposed to standard 100 mg/mL. fClean 
isolation not accomplished. 
 
Table 7. Results for Substituted Arylacetate Substrate Rearrangements. 
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Over all eleven examples of para-substituted arylacetate rearrangements, capricious 
levels of diastereochemical control are observed varying from 6:1 for the electron rich 
para-dimethylamino 213, to 60:1 for the para-iodo 214 and finally 9:1 for the para-
nitro 180. Whilst all para-arylacetate rearrangements seemed to fit into a scale of 
diastereoselectivity based on electron donating/withdrawing capability, it is worth while 
noting that the para-dimethylamino 213 and para-sulfone 219 could not be rearranged 
via the optimised protocol and thus cannot reliably be included in any discussions based 
around mechanistic evaluations. Issues surrounding injecting a solution of the para-
dimethylamino substrate 202 to LiHMDS and TMSCl in THF were problematic, based 
on the substrate blocking the injection needle. This problem was circumvented by an 
inverse rearrangement protocol, in which a solution of LiHMDS was added to a solution 
of 202 and TMSCl in THF. Issues with the para-sulfone 208 were seen to be a general 
insolubility of the substrate. Following a modified procedure the rearrangement was 
accomplished via addition of sulfone 208 as a solution in THF at 20 mg/ml, as opposed 
to the standard 100 mg/ml, subsequently yielding an unexpectedly high 
diastereoselectivity based on its electron withdrawing capability. Rearrangement of the 
2,4-dimethoxy arylacetate 220 was seen to occur with reduced diastereocontrol to that 
of even the ortho- 172 and para-methoxy arylacetate 174, presumably a combination of 
increased electron density and the presence of ortho-substitution. The rearrangement of 
the vinylogous phenylacetate, to give styryl product 221 and also the incorporation of 
electron donating groups in the form of the dioxolane rearrangement 223 were seen to 
proceed with excellent levels of diastereocontrol. Marginal increase in diastereocontrol 
was noted for the rearrangement of the electron rich 3-methyl indole 222. Again, nearly 
complete mass balance was recovered with the corresponding methylated arylacetates 
retrieved during column chromatography. 
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2.8. Hammett Relationship 
 
The Hammett relationship and its extended forms have been one of the most widely 
used means for the study and interpretation of organic reaction mechanisms.124 The 
relationship was developed by Hammett empirically, from the ionization equilibria of 
meta- and para-substituted benzoic acids in water at 25 ˚C.125-128 
 
OH
O
R
O
O
R
R = Range of Electron Donating to
Electron Withdrawing Substituents
+ H2O + H3O
 
Scheme 77. Ionization of para-Substituted Benzoic Acids. 
 
These values led Hammett to note the existence of a linear free energy relationship 
between the acidities of substituted benzoic acid derivatives and the rates of many 
chemical reactions through a simple formula-129,130 
log =
k
k0
log
K
K0
=
 
 
   Equation 1. Hammett Equation. 
 
From this, k and K refer to the rate constant and equilibrium constant respectively for a 
substituted reactant, k0 and K0 are the corresponding quantity for the unsubstituted 
reactant. The substituent constant, σ, is a value unique to the type of substituent and is a 
reflection on how electron-donating (-σ) or electron-withdrawing (+σ) that substituent 
is relative to hydrogen. The substituent constant σ, represents the sum of the total 
electrical effects of resonance R and field F, considerations of a substituent. The 
reaction constant, ρ,  is dependant upon the reaction type but not on the substituent used 
and measures the susceptibility of the reaction to electronic effects. Graphical 
representation of the Hammett relationship allows clear indication of ρ, where a build 
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up of electrons towards (+ρ) or removal of electrons away from the aromatic ring (-ρ) 
may occur with in the rate determining step of the reaction.  
 
 
 
 
 
  Fig. 11. Typical Hammett Plot. 
Reactions that generate a positive ρ value typically involve nucleophilic attack on a 
carbonyl group, such as in the case of the alkaline hydrolysis of a variety of meta- and 
para-substituted ethyl benzoates where ρ = +2.5.129 This value indicates that the 
reaction responds to substituent effects in the same way as the ionization of the 
corresponding benzoic acids, but is enhanced by a factor of 2.5. When ρ is positive the 
overall rate of reaction reduces with electron donating substituents. Reactions that 
generate a negative ρ value typically involve loss of electron density from the aryl ring 
and the overall rate of reaction decreases by the presence of electron withdrawing 
substituents. The SN2 alkylation of meta- and para-substituted phenoxides with ethyl 
iodide leads to a ρ value of -1.0.129  
In addition to linear Hammett plots, non-linear Hammett plots can also provide 
information about the mode of reaction through curvature of the plot. Generally a 
‘‘concave-up’’ curve alludes to a change in the mechanism or transition state of the 
Log k / k0 
0 
∞ 
ρ = Negative 
ρ = Positive 
σ 
σ = Negative 
Electron Donating Groups 
σ = Positive 
Electron Withdrawing Groups 
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reaction, however, the ‘‘concave-down’’ curve alludes to a single mechanism with a 
change in the rate determining step.131 
 
 
 
 
 
  Fig. 12. Typical Non-Linear Hammett Plot. 
 
Examples of a concave up Hammett plot include that of displacement reactions, 
involving a change between SN1 and SN2 for tertiary amine substitutions of para-
substituted benzylhalides.132  
 
 
Scheme 78. Change in Mechanism between SN1 and SN2 Displacements, Concave Up Hammett Plots. 
 
 
0 
Log k 
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Examples of a concave down Hammett plot have been observed in the intramolecular 
Friedel-Crafts alkylation of 2-phenyltriarylcarbinols 235. Here, formation of 
carbocation 236 is observed to be the rate determining step for electron withdrawing 
para-substitution and Friedel-Crafts alkylation is observed to be the rate determining 
step for electron donating para-substitution.133 
 
 
Scheme 79. Change in Rate Determining Step, Concave Down Hammett Plots. 
 
 
 Modifications to the Hammett Equation- 
Hammett noted that deviations from his equation were seen for certain substituents 
within reactions producing a large value of ρ.125,129,130 Notably, the para-nitro 
substituent was the most troublesome when combined with a reaction centre or group 
having a much stronger tendency than the carboxylate ion to supply electrons, such as 
aniline and phenol derivatives. It was noted that a unique σ value could not be used for 
this substituent and this led to the development of modified σ values for this, and other 
substituents that can enter into direct resonance with the reaction site in the transition 
state. From this two new sets of parameters were devised namely σ −, developed by 
Hammett and σ + values developed by Brown.125,129,130,134-135 For cases where an 
electron withdrawing group interacts with a developing negative charge in the transition 
state, the σ –  value would be best suited, and for cases where an electron donating group 
interacts with a developing positive charge in the transition state, the σ +  value would 
suffice.  
 
There have been a variety of further modifications to the Hammett equation, however 
the most pertinent are the Taft, Yukawa-Tsuno and the Swain-Lupton equations.136-141 
The Taft equation correlates field effects in the absence of resonance effects and was 
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generated from the assumption that steric and resonance effects were equal within the 
hydrolysis of propionate esters, catalysed by acid or base conditions.136-138 This 
assumption led to the conclusion that rate differences would only be caused by the field 
effects of substitution of a propionate derived ester and the nature of the corresponding 
alcohol it is derived from. The field effects of substituents could therefore be 
determined by measuring the rates of acid- and base-catalysed hydrolysis of a series of 
propionate derived esters, providing the alcohol constituent remains constant. The 
observed rate constants lead to a new form of the Hammett equation based on a 
redefinition of σ as σl. Here (k/k0)B is the rate constant for basic hydrolysis of the 
substituted propionate ester, divided by the unsubstituted propionate ester and (k/k0)A is 
the rate constant for acidic hydrolysis of the substituted propionate ester divided by the 
unsubstituted propionate ester. 
 
 
 
   Equation 2. The Taft Equation. 
 
The major disadvantage of the Taft equation, even though it considers propionate 
esters in addition to the benzoic systems, are that steric and resonance effects (if 
possible) are not considered and if these are present then the equation fails. Taft has 
subsequently been able to isolate steric effects, Es, but again only in cases where 
resonance interactions are absent, leading to a value that is proportional to the size of 
substituent. The modified Taft equation is – 
 
 
 
Equation 3. Modified Taft Equation. 
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The Yukawa-Tsuno modification incorporates an enhanced resonance parameter r, that 
provides a measure of resonance stabilisation for positive or negative charge build up 
within the transition state structure.141 The Yukawa-Tsuno equation independently 
utilises both σ+ and σ- values, depending on which substituent constant is under 
consideration. 
 
 
 
   Equation 4. Yukawa-Tsuno Modified Hammett Equation. 
The enhanced resonance parameter r, is determined via the ρ value for a given reaction. 
Calculation of r then allows the resonance considerations of a particular reaction be 
inferred. When r = 0 there are no resonance differences seen compared to that of the 
unsubstituted compound, however when r > 0 the reaction is more sensitive to 
resonance effects and when r < 0 the reaction is less sensitive to resonance effects than 
the unsubstituted compound. 
The Swain-Lupton equation retains the idea of a practical distinction between the field, 
F and resonance, R contributions.139-140 The substituent constant is therefore a 
combination of a numerical constant, F and R, which are independent of reaction, 
solvent and temperature. 
 
 
 
   Equation 5. Swain-Lupton Modified Hammett Equation. 
Further modifications to the resonance parameter have been made in order to fully 
account for instances where strong resonance interaction occurs between reaction centre 
and substituent, of which R has been further optimised into R+ and R-, to coincide with 
σ
+ and σ- constants. 
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2.9. Hammett Relationship & EICR 
The Hammett relationship is an important tool that allows information about the mode 
and transition state structure of individual types of reactions be inferred. In order to 
explain the varied diastereoselectivity observed in the EICR of the electronically 
differentiated para-substituted arylacetates, we turned to the Hammett relationship. As 
rate constants for the EICR were lacking, utilisation of the observed 
diastereoselectivities were pursued in order to perform a Hammett type analysis. 
Although the use of diastereoselectivity is not purely Hammett based, its use has seen 
success within various types of reactions, including radical reactions, 
aminohydroxylations and Diels-Alder reactions.142,143,144 It is important to note that 
log(d.r.) is under conditions of kinetic control and is proportional to the free energy 
difference between the two alternative transition states for formation of anti- and syn-
diastereomers and is therefore considered a ratio of rate constants. Taking this in to 
account the Hammett equation takes the following form- 
log =
anti
syn
anti - syn)d.r.
 
 
   Equation 6. Hammett Equation in Terms of d.r. 
 
 
In order to examine any Hammett type relationships present, the log(d.r.) for all para-
substituted rearrangements, except the para-dimethylamino 213 and the para-sulfone 
219 were plotted against substituent constants σ, σ+ and σ− (see appendix). As these 
plots revealed no visible correlation, further investigation into the nature of the 
substituent constant σ, led us to probe the resonance R parameters, based on the 
Swain-Lupton modification.124 Again poor correlations were observed with R and R+ 
(see appendix), however utilisation of R- demonstrated excellent correlation (Graph 1). 
Perhaps this result demonstrates that the diastereoselectivity of the EICR is purely 
dependant on the electron withdrawing resonance effects of substitution, independent 
of field effects, hence why poor correlations were observed for previous plots.  
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Graph 1. Log(d.r.) vs Resonance Parameter R−. 
 
The significance behind a non-linear Hammett plot arises when the mechanism of a 
reaction changes or when the measured rate constant is a combined quantity depending 
on the rate and equilibrium constant of several reaction steps. In the case of the varying 
diastereocontrol observed within the EICR, the non-linear relationship arises from the 
relative rates of reaction producing both the syn- and anti- diastereomers. This however, 
may arise from either a change in rate-determining step or a change in mechanism 
occurring for a particular diastereomer. Several viable scenarios are available to explain 
this break in Hammett type plot (Fig 13-17).  
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Fig. 13. No change in RDS or mechanism occurs for the reaction 
producing the anti-diastereomer across the range of substituents 
considered; a change in mechanism occurs for electron withdrawing 
groups in the reaction producing the syn-diastereomer. 
 
Fig. 14. Change in mechanism occurs for reactions producing both syn- 
and anti-diastereomers. 
 
Fig. 15. Change in RDS occurs for the mechanism producing the anti-
diastereomer across the range of substituents considered; no change in 
RDS or mechanism occurs for the reaction producing the syn-
diastereomer. 
Fig. 16. Change in RDS occurs for reactions producing both syn- and 
anti-diastereomers 
 
 
Fig. 17. Change in RDS occurs for the reaction producing the anti-
diastereomer; change in mechanism occurs for the reaction producing 
the syn-diastereomer. 
 
 
 
Perhaps the least likely scenarios are that resulting in figures 13, 15 and 17, as these 
require that diastereomeric transition states respond in fundamentally different fashions 
to electronic perturbations. Consequently we suppose that either a dual change in either 
the reaction mechanism (Fig. 14) or the rate-determining step (Fig. 16) for both 
diastereomeric transition states occurs. Assuming that we thus exclude scenarios 
resulting in figure 13, 15 and 17 from consideration then, in principle, we may 
distinguish between scenarios in figure 14 and 16 on the basis of absolute rate studies. 
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It is seen from the Hammett type plot (Graph 6.), that the overall preference of 
formation of the anti- over the syn-diastereomer decreases with increasing electron 
withdrawing substituents and is consistent with an observation made by Houk in 
studying similar effects in the related Claisen rearrangement.145 If the absolute rates of 
reaction tended toward an increase with increasing electron withdrawing substituents on 
the aryl group, a change from a concerted mechanism to one involving the formation of 
an intimate ion pair may represent the change in mechanism giving rise to figure 14. 
However, it has been shown that electron withdrawing aryl groups in the related Claisen 
rearrangement retard the reaction, therefore the scenario in figure 16 may be best suited, 
reconfirming that a change in rate determining step of the EICR occurs.85, 146-148 
 
2.10. Conclusions 
 
From the experimental observations, the Enamido-Ireland-Claisen-Rearrangement of a 
range of electronically differentiated arylacetate enamido esters has proven intruiging. 
The conspicuous range of diastereoselectivities observed, certainly in the case of the 
para-substituents, has been postulated to be caused by a variety of factors, including 
issues surrounding initial enolisation, isomerisation of the enolate once formed, 
isomerisation of the silyl ketene acetal, chair/boat considerations of transition state 
structure, non-concerted character and post-rearrangement epimerization issues. The 
issues surrounding post-rearrangement epimerization have subsequently been 
discounted based on a range of control experiments performed. On consolidation of the 
residual factors which may be respnsible for the observed diastereoselectivity, this may 
be seen by thermodynamic issues of E/Z-silyl ketene acetal control, thus causing the 
observed diastereoselectivity assuming that the rearrangement occurs via a predictable 
chair transition state. A more complicated possibility may also involve contributions 
from all four diastereomic transition states (Scheme 70). In addition, the caveat 
observed by the concave down Hammett plot may be the result of a change in 
mechanism or a change in rate determining step. A change in mechanism may involve 
that of a concerted one-step mechanism for electron donating susbtituents and a non-
concerted two-step mechanism for electron withdrawing substituents, whereas a change 
in the rate determining step may be due to either SKA formation or a diastereoselective 
rearrangement. Discussions  surrounding the mechanistic evaluation of the EICR are to 
be focussed in Chapter 3. 
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3. Mechanistic Insight into the EICR of Arylacetates 
 
With the intriguing range of diastereoselection observed for the electronically 
differentiated arylacetates, a range of mechanistic studies were performed in order to 
determine the origin of diastereoselection.  
 
 
Scheme. 80. para-Substituted Substrates & Associated Diastereoselectivities from EICR. 
 
These mechanistic studies were focussed on determining whether diastereoselection is 
an aspect of: 
1) Initial formation of variable isomeric E- and Z-SKA mixtures, which rearrange 
through a chair transition state, or, 
2) Rearrangement through competing chair and boat transition states, assuming 
selective E-SKA formation. 
 
To probe these considerations, in-situ NMR studies were conducted. Initially, these 
studies involved the generation and E/Z monitoring of electronically differentiated 
model SKA’s, designed to mimic the enamido ester substrate. Further studies then 
involved in-situ rearrangement monitoring of strongly electron deficient, electron rich 
and electron neutral enamido arylacetate substrates. It was envisaged that rearrangement 
monitoring would allow E/Z-SKA and anti/syn product distributions to be observed 
throughout the course of reaction and provide a rationale for the varied 
diastereoselectivities observed. 
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Other studies have included an in-house computational collaboration where-by the full 
range of electronically differentiated arylacetates have been modelled within the EICR, 
to examine the theoretical origins of diastereoselectivity. 
 
3.1. Model SKA Studies 
 
Silylketene acetals (SKAs) are themselves valuable nucleophiles and find widespread 
use within a broad range of C-C bond forming synthetic chemistry. In addition to use in 
the Ireland-Claisen rearrangement, they are frequently seen in a range of other reactions 
including the Mannich and aldol reactions, of which their geometric purity can affect 
the diastereo- and/or enantioselectivity obtained within the reaction (Scheme 81).149-150  
 
 
Scheme. 81. Stereoselective &Enantioselective Reactions Involving SKAs. 
 
Recently, the Leighton group has demonstrated the use of an enantio- and 
diastereoselective Mannich reaction involving phenylacetate derived SKA 237. This 
protocol allows synthesis of the β-amino acid precursor 238 in good yield with excellent 
enantio- and diastereoselectivity.151 
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Scheme. 82. Enantio- & Diastereoselective Mannich Reaction. 
 
To examine the issue of E/Z control during formation of arylacetate SKAs within 
our enamide substrates, efforts were focussed on the in-situ monitoring of model 
SKAs. Initial attempts were based on utilisation of the commercially available 
isopropyl phenylacetate 239, as the EICR of the corresponding phenylacetate 154 
was shown to produce high levels of diastereoselectivity and presumably generate 
high E/Z-SKA purity. Also, the secondary ester motif was chosen to mimic the 
secondary carbinol-derived center within enamido ester substrate.  
 
 
 
Scheme 83. Initial Model Substrate for SKA Investigation. 
In order to follow the in-situ generation of SKAs by 1H-NMR spectroscopy, it was 
important that this experimental protocol mirrored the standard laboratory procedure 
for the EICR as closely as possible. Initiation of these in-situ experiments therefore 
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relied on the use of an oven dried Young’s tap NMR tube with the dropwise addition 
of a solution of substrate to LiHMDS and TMSCl at -95 ˚C, under 1 atmosphere of 
nitrogen. Once the NMR tube was sealed, it was then transferred to the 400 MHz 
spectrometer, precooled to -95 ˚C, prior to NMR experimentation.  
 
As the consumption of 239 and formation of E/Z-SKA’s were the main aim of this 
experiment, a range of temperatures for data acquisition were decided. As data were 
to be recorded at the intiation temperature (-95 °C) and room temperature (25 °C), 
an intermediary temperature was also required. Ideally, this intermediate 
temperature would represent the onset of rearrangement within the EICR and 
correspond to the stage where a ratio of generated E/Z-SKA’s will be transferred to 
the observed diastereoselectivity in the product. In order to determine this 
temperature, several experiments were performed to estimate the onset of 
rearrangement of phenylacetate 154. This was achieved by intiation of several 
phenylacetate EICR’s prior to warming to a variety of temperatures over 1 hour. 
Quenching at these cryogenic temperatures was accomplished by methanol.  
 
 
Entry 
Temperature 
(°C) 
Yield 
(%) 
d.r.a 
(Anti:Syn) 
1 -95 12 n.d.b 
2 -80 27 n.d.b 
3 -60 40 41:1 
4 -50 54 42:1 
5 -40 56 39:1 
6 -20 59 40:1 
ad.r. measured by extended acquisition of crude on 500 MHz 1H NMR bd.r. not determined due to broad 
spectra and low conversion to 144. 
Table 8. Temperature Investigation into EICR of 154. 
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These results suggest that rearrangement is even observed at initiation temperature 
with diastereoselectivity relatively invariable across the quench temperatures tested 
(excluding Entries 1 & 2, Table 8). From the variety of temperatures tested, -50 °C 
was chosen for data acquisition, as this demonstrated an adequate temperature  
where >50% of EICR product 144 was isolated. 
 
With the range of temperatures for data recordal set, utilisation of isopropyl 
phenylacetate 239 was pursued. Initial experiments monitoring the consumption of 
239 and formation of E/Z-SKA’s 240 at -95 °C , -50 °C and 25 °C were shown to be 
entirely feasible. Furthermore, standard H8-THF could be used within NMR 
experimentation. However, clean quantification of the minor Z-SKA became 
difficult due to its coincidence with the isopropyl methine signal as demonstrated in 
Scheme 84.  
 
 
 
Scheme 84. Initial Attempts at SKA Reaction Monitoring. 
 
It is noted that an increase in the loading of LiHMDS and TMSCl was required, as 
40% of phenylacetate 239 remained when applying the standard 1.3 equivalents of 
base and silylating agent. Although an increase in the stoichiometry of reagents 
within the model SKA studies is in direct contravention to EICR conditions, the 
retrieval of methylated arylacetate degradation products post rearrangement 
(Chapter 2) may derive from an incomplete SKA formation and substrate hydrolysis 
on protic quench. 
 
To counteract the problem of coincident 1H resonances, it was decided to examine the 
use of 2H1-isopropyl phenylacetate 
2
H1-239 instead, which was synthesised in good 
yield. 
 
Chapter 3  Results & Discussion
   
77 
 
 
Scheme 85. Synthesis of 2H1-Isopropyl Phenylacetate 
2
H1-239. 
 
With 2H1-239 in hand, in-situ SKA formation was pursued. The 
2H1 modification 
allowed succesful monitoring of E- and Z-SKA, with formation of Li-enolate not 
detected using this NMR analysis. The data obtained from this experiment 
demonstrated that a single E-SKA is observed at -95 °C, however on warming to -50 
°C and 25 °C erosion of the E/Z purity occurs (E/Z = 61:1 and 30:1, Figure. 18). 
 
. 
 
 
Figure 18. Variable Temperature 1H-NMR study of E/Z-SKA Formation of Phenylacetate 2H1-239. 
 
As complete formation of SKA was only observed at 25 °C, an investigation into the 
formation and time dependance of the E/Z ratio was pursued at -50 °C. Interestingly, 
an initial fast, yet partial consumption of 2H1-239 was observed, associated with an 
intriguing inflexion, with 2H1-239 accumulating within the reaction mixture prior to 
its further consumption (Graph 2).  
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Graph 2. Time Dependence of 2H1-239 Present in the Formation of SKA 
2
H1-240   at -50 °C.            
Initial & Final Data Point Refer to Monitoring at -95 °C & 25 °C. 
During this reaction, high levels of E/Z-SKA purity are observed and a plateau is 
evident at -50 °C. On warming to room temperature a drastic reduction in E/Z ratio 
results and is attributed to thermodynamic E/Z-SKA generation. 
 
E/Z-SKA
2
H1-240 vs.  Time/min
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 80 100 120 140 160 180 200
Time/min
E
/Z
 S
K
A
 2
H
1
-2
4
0
 
Graph 3. Time Dependence of E/Z-Purity in the Formation of (E)-2H1-240   at -50 °C.                       
Initial & Final Data Point Refer to Monitoring at -95 °C & 25 °C. 
Chapter 3  Results & Discussion
   
79 
These in-situ observations concerning the high levels of E/Z-SKA purity obtained from 
phenylacetate 2H1-239, are in stark contrast to that previously reported in the literature. 
Attempts involving phenylacetate 239 with LDA and an external TMSCl quench 30 
minutes after initiation at -78 °C and that involving 158 with LiHMDS and an internal 
TMSCl quench, generate isolated E/Z-SKAs of no greater than 4:1.119-120, 152  
 
 
 
Scheme 86. Previous Attempts at Isolating Phenylacetate SKAs. 
 
Subsequent studies have demonstrated that enolisation under kinetic conditions 
selectively forms the Z-enolate, however, difficulties in enolate trapping results in the 
generation of SKAs with poor E/Z control.119-120, 152-155  
 
This dogma presented in the literature is intriguing, as our in-situ NMR experiments 
have clearly shown that SKA generation is accomplished with high E/Z purity. In order 
to discerne the key factors associated with generating high levels of E-SKA purity, a 
number of variables involving the type of amide base, stoichiometry of TMSCl and the 
nature of enolate quench were investigated (Table 9). 
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2
H1-240 (E/Z)
a 
Entry M R (equiv) 
 -95 °C  -50 °C 25 °C 
1 Li Me (1.7) >100:1 61:1 30:1 
2b Li Me (1.7) 71:1 42:1 16:1 
3 Li Me (6) >100:1 >100:1 64:1 
4c Li Me (6) >100:1 >100:1d 56:1 
5 Li Me (1.7)e >100:1 8:1 5:1 
6 Li Me (1.1) >100:1 >100:1 33:1 
7 Na Me (6) - 8:1 6:1 
8 Li iPr (6) >100:1 10:1 4:1 
9 Li Et (6) >100:1 >100:1 22:1 
10 -f Me (6) 4:1 4:1 4:1 
aE/Z Ratio Measured by 1H-NMR Integration of Appropriate SKA Signals. bInitiated at -78 °C cObserved 
at -65 °C for 60 mins. dObserved at -25 °C. eExternal Quench: TMSCl Added to Reaction Mixture 30 
Minutes After Initiation of Enolate Generation  fLDA Used as Base. 
 
Table 9. Control Experiments 
 
These results clearly demonstrate that the manner of reaction initiation, temperature 
control and enolate lifetime are key parameters in accessing high levels of E/Z-SKA 
purity. Reduced E/Z control was observed with intiation at higher temperatures (entry 
2), the use of an external quench (entry 5) and lower loadings of TMSCl (entry 6). 
However, increasing the levels of TMSCl led to a more rapid silylation and reduced E/Z 
interconversion (entries 4 & 5) and it is noted that complete silylation was observed 
after 20 minutes at -50 °C. Other drastic reductions in E/Z purity were seen to occur 
when the use of bulkier silylating agents (entries 8 & 9) and alternative amide bases 
including NaHMDS and LDA (entries 7 & 10) were used. The generation of high E/Z-
SKA purity (entry 3) was even observed to retain a significant excess of the  E-
geometrical isomer at room temperature (10:1) 48 hours after its formation. 
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The successful observations associated with E/Z-SKA formation and 
interconversions prompted us to return to the primary aim of this model SKA study, 
associated with examining SKA formation for a range of electronically 
differentiated para-substituted arylacetates. As these studies were designed to mimic 
formation of the SKA during EICR, it was hoped that indications into whether 
similar or varied E/Z-selectivities would be generated and potentially allude to 
whether diastereoselection in our rearrangement is a function of generated E/Z-SKA 
ratio. With this in mind, synthesis of a variety of model para-substituted arylacetates 
was acheived in excellent yield, via the familiar EDCi coupling conditions and 
monitoring SKA formation by in-situ NMR methods was subsequently pursued.  
 
 
E/Z 
Entry Ester R SKA 
 -95 °C -50 °C 25 °C 
d.r. 
from EICR 
(anti:syn) 
1 2H1-239 H 
2
H1-240 >100:1 61:1 30:1 44:1 
2 2H1-241 OMe 
2
H1-245 >100:1 >100:1 21:1 24:1 
3 2H1-242 Me 
2
H1-246 >100:1 >100:1 39:1 54:1 
4 2H1-243 CF3 
2
H1-247 >100:1 >100:1 34:1 21:1 
5 2H1-244 NO2 
2
H1-248 >100:1 44:1 11:1 9:1 
a Ester Added to TMSCl (1.7 eq.) and LiHMDS (1.7 eq.) in THF at -95 °C & Subsequent Transferral to the 
Cooled 400 MHz Spectrometer. bE/Z Ratio Measured by 1H NMR Integration of Appropriate Signals. E/Z 
Geometrical Isomers Proven by 1D NOE Experiments on para-Tolyl 2H1-246 (See Appendix). 
 
Table 10. Synthesis of para-Electronically Differentiated Ester Substrates  
and In-Situ Formation of Corresponding SKAs. 
 
At the initiation temperature all substrates demonstrated selective formation of the 
E-SKA. On warming to -50 °C similar selectivities were observed, however a 
significant drop in geometric purity was noted for the nitro-substituted substrate 
(entry 5). Subsequent warming to 25 °C demonstrates a global erosion of E/Z-SKA 
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purities, all with varying levels. From these results it is obvious that the degree of 
E/Z-SKA purity generated depends strongly on the electronic nature of substitution. 
When comparing these in-situ SKA ratios to that of the diastereochemical outcome 
of the EICR for the same substituent, a similar ratio is observed, particularly so for 
the OMe and NO2 substituents (entries 2 and 5). These results strongly suggest that 
E/Z-SKA formation may strongly influence the observed diastereomeric outcome of 
the associated EICR. 
 
To further probe this electronic dependance of E/Z-SKA control we wanted to 
observe whether primary and teritiary derived arylacetates exhibited similar effects. 
With this in mind synthesis of a small range of model substrates based on electron 
withdrawing (-NO2), electron donating (-OMe) and electron neutral (-Me) para-
substitution was undertaken and subjection of these to in-situ SKA monitoring was 
pursued (Table 11). Interestingly, the range of methyl esters were seen to 
demonstrate similar dependancies to the isopropyl phenylacetates (entries 1-3). 
However, diminshed E/Z purity was observed for the tertiary arylacetates (entries 4-
6), with the p-NO2 substrate offering no selectivity at room temperature (entry 6). 
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E/Z 
Entry Ester R1 R2 SKA 
-95 °C -50 °C 25 °C 
1 249 Me OMe 255 >100:1 >100:1 25:1 
2 250 Me Me 256 >100:1 >100:1 26:1 
3 251 Me NO2 257 >100:1 91:1 23:1 
4 252 CMe3 OMe 258 >100:1 14:1 8:1 
5 253 CMe3 Me 259 39:1 28:1 18:1 
6 254 CMe3 NO2 260 >100:1 32:1 1:1 
a Ester Added to TMSCl (1.7 eq.) and LiHMDS (1.7 eq.) in THF at -95 °C & Subsequent Transferral to the 
Cooled 400 MHz Spectrometer. bE/Z Ratio Measured by 1H NMR Integration of Appropriate Signals. E/Z 
Geometrical Isomers Proven by 1D NOE Experiments on p-Tolyl 256 & 259 (See Appendix). 
 
Table 11. Synthesis of para-Electronically Differentiated Methyl & tButyl Ester Substrates  
and In-Situ Formation of Corresponding SKAs. 
 
Considering the results from the primary, secondary and tertiary derived arylacetate 
SKAs, the influence of the aromatic substituent is clear. Although initial E/Z-SKA 
selectivity is high, the presence of strongly electron withdrawing or donating 
substituents appears to enhance the magnitude of geometrical isomerisation as the 
reaction warms to room temperature. In the case of the electron withdrawing nitro 
substituent, erosion of geometric purity could be facilitated by a reduction in C=C 
bond character via mesomeric withdrawal of electrons out of the SKA. In the case of 
the electron donating methoxy substituent it may be conceivable that electron 
donation into the SKA may occur, subsequently reducing C=C bond order. 
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Scheme 87.  Postulation for Reduced E/Z-SKA Purity in para-Nitro & para-Methoxy Substitution. 
 
However, although significant reduction in E/Z-SKA geometric purity are observed for 
para-nitro and para-methoxy variants, their in-situ preparation has still been shown to 
be significantly higher than currently published results.149, 156-159 As the utilisation of 
arylacetate SKA’s are hindered by their isolation with low E/Z purity (≤4:1), the ability 
to isolate these compounds with the high levels of E/Z-control observed in our in-situ 
studies may be synthetically beneficial. With this in mind, utilisation of phenylacetate 
2
H1-239 was further investigated (Table 14). 
 
 
Entry Methoda X eq. (E/Z)b Yield %c 
1 (A) 1.7 68:1 81 
2 (B) 1.7 17:1 88 
3 (C) 6 >100:1 82 
aMethods: (A): Ester added to base and TMSCl via syringe pump before warming to room temperature. 
(B): Ester added to base and TMSCl by hand before warming to room temperature (C): Ester added to 
base and TMSCl, holding at -95 °C for 30 minutes before warming to room temperature via syringe 
pump. bE/Z ratio measured by 1H-NMR integration of appropriate SKA signals. cIsolated yield. 
 
Table 12. Isolation of 2H1-Phenylacetate-Derived SKA’s. 
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To demonstrate that slow addition of a solution of 2H1-239 to LiHMDS and TMSCl was 
imperative for the generation of high E/Z-SKA selectivity, initiation by syringe pump 
and rapid injection was investigated. Isolation of the SKAs was achieved by rapid 
vacuum concentration of the reaction mixture and trituration with CDCl3 subsequent to 
1H-NMR spectroscopy. In both cases excellent yields were obtained, however as 
expected, a reduced E/Z-SKA purity was obtained for the rapid injection protocol (entry 
2) than the controlled addition by syringe pump (Entry 1). This observation corresponds 
well to the optimisation of the phenylacetate EICR (Chapter 2, Table 3), where the 
difference in diastereoselection for rapid injection compared to syringe pump addition 
was 16:1 to 44:1. The final initiation method relied on utilising the increased 
stoichiometry of TMSCl, as this demonstrated the highest E/Z-SKA purity in-situ 
(Chapter 3, Table 9, Entry 3). Employing this method within the generation and 
isolation of 2H1-240 demonstrated an excellent yield and by far the best E/Z-SKA 
selectivity (Entry 3).  
 
With the successful isolation of the secondary phenylacetate ester SKA, isolation of 
primary and tertiary derived phenylacetate SKA’s were also pursued. The synthesis of 
158 and 261 were accomplished in good to excellent yields via similar carbodiimide 
coupling conditions and isolation of the corresponding SKA’s were pursued utilising the 
increased stoichiometry of TMSCl (Table 13). In both instances, excellent yields were 
obtained, with excellent E/Z purity observed for the primary SKA (Entry 1) and good 
E/Z purity observed for the tertiary variant (Entry 2).  
 
 
Entry Ester R Product (E/Z)a 
Yield 
(%)b 
1 158 Me 262 67:1 80 
2 261 C(Me)3 263 25:1 76 
aE/Z ratio measured by 1H-NMR integration of appropriate silylketene acetal signals. bIsolated yield. 
 
Table 13. Synthesis of para-Substituted Arylacetates 158 & 261 and Isolation  of Corresponding SKA’s. 
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The isolation of these primary, secondary and tertiary derived SKAs in excellent yields 
and E/Z geometrical purities far surpasses any current syntheses.160 The success 
observed with an increased loading of TMSCl are not to be ignored and would be 
expected to have a direct effect on increasing the rate of silyation, as viewed by in-situ 
1H-NMR studies. This subsequently allows generation and isolation of SKA’s with 
enhanced E/Z purities, even compared to the high levels obtained by equimolar 1.7 
equivalents of LiHMDS/TMSCl. With this in mind, the ability to improve the 
diastereomeric ratio of some EICR reactions may be possible. Indeed, subjection of the 
para-nitro and para-methoxy enamide substrates to rearrangement conditions involving 
6 equivalents of TMSCl does significantly improve the diastereochemical outcome of 
the rearrangement reaction. 
 
 
Entry R 
TMSCl 
(X eq.) 
Product 
Yield 
(%) 
d.r.a 
(anti:syn) 
By-Product 
Yield 
(%)b 
1 1.3 77 24:1 13 
2 
OMe 
6 
174 
67 82:1 
183 
11 
3 1.3 76 9:1 13 
4 
NO2 
6 
180 
66 16:1 
189 
13 
ad.r. measured by extended acquisition of crude on 500 MHz 1H-NMR  bYield based on amount of EICR 
product that degradation product corresponds to. 
 
Table 14. Results for Improved Arylacetate EICR 
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3.2. In-Situ EICR Reaction Monitoring 
 
The results generated from the model SKA studies have been informative, as they 
allude to the presence of a relationship between E/Z-SKA ratio and diastereoselection 
based upon electronic perturbation within the EICR. However, in order to prove any 
such relationship we require the ability to monitor the complete rearrangement, 
including consumption of substrate, generation of E/Z-SKAs and the in-situ formation 
of anti- and syn-β-amino silylesters. With this in mind, target substrates for 
investigation include phenylacetate 154, the strongly electron donating para-methoxy 
arylacetate 165 and the strongly electron withdrawing para-nitro arylacetate 171. 
 
 
Scheme. 88. EICR Reaction Monitoring; Following the α-H. 
 
Reaction monitoring of the EICR by 1H-NMR spectroscopic analysis would prove 
logical, based on the successful model SKA studies and could be achieved by similiar 
monitoring of the α-H in substrate, SKA and rearranged product. However, as a 2H1-
modification was required for the model SKA substrates, the added structural 
complexity of the enamide substrates would also make tracking the α-H difficult due 
to coincident 1H-NMR resonances. This consideration is highlighted in Figure 19, 
exemplifying the key spectral regions associated with phenylacetate 154, model 
phenylacetate SKA 2H1-240 and β-amino ester 144.  
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Fig. 19. Overlapping Resonances in EICR Reaction Monitoring. 
 
With this issue in mind, three viable classes of bespoke enamide substrate were 
conceived, to allow in-situ reaction monitoring by 1H-, 2H- and 13C-NMR spectroscopic 
analysis. 
 
 
Fig. 20. Modified Enamido Substrates for EICR Reaction Monitoring. 
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3.2.1. EICR Reaction Monitoring by 
1
H-NMR Spectroscopy 
 
To overcome the issues associated with coincident 1H-NMR resonances, access to 
correctly deuterium-labelled substrates were pursued, based on the synthesis of 
deuterated alcohol 2H3-145. 
 
 
 
Scheme 89. Deuterium Labelled Enamido Substrate and Key Intermediate 2H3-145. 
 
From the outset, synthesis of 2H3-145 focussed on developing the familiar conditions 
for the non-deuterated analogue 145. As formation of ketone 146 relies on a DABCO 
catalysed addition of 2-oxazolidinone 147 and ketone 148, it was envisaged that the 
synthesis of deuterated ketone 2H2-146 could be achieved from deuterated ketone 
2
H1-
148 and N-deuterated 2-oxazolidinone 2H1-147.  
 
 
 
Scheme 90. Route to Deutero Ketone 2H2-146. 
 
Access to deuterated ketone 2H2-148 required synthesis of deuterated alcohol 
2
H1-149 
prior to Jones oxidation. Attempted synthesis of 2H1-149 involved lithiation of 
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protected alcohol 264 and also double lithiation of alcohol 149, both followed by 
deuterium oxide quench. However, variable and unpredictable levels of deuterium 
incorporation were observed.  
 
 
 
Scheme 91. Attempted Route to Deuterated Acetylenic Alcohol. 
 
With facile acetylenic H/D exchange an issue, synthesis of deuterated ketone 2H1-146 
was pursued directly from ketone 148, by exchanging the solvent of the DABCO 
catalysed conjugate addition reaction for deuterium oxide. Analysis of the reaction by 
TLC demonstrated a complex reaction mixture, however careful column 
chromatography and recrystallisation allowed access to the required deuterated ketone 
2
H2-146, but in poor yield. 
 
 
 
Scheme 92. Route to Deutero Ketone 2H2-146. 
 
Subsequent reduction of 2H2-146 was accomplished by NaBD4 to yield the key 
deuterated alcohol 2H3-145 in excellent yield and synthesis of phenylacetate 
2
H3-154 
was achieved under familiar EDCi coupling conditions, again in excellent yield. 
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Scheme 93. Synthesis of Deuterated Phenylacetate 2H3-154. 
 
With 2H3-154 in hand, rearrangement was pursued under the normal laboratory 
protocol prior to in-situ 1H-NMR studies and was observed to produce comparable 
yields and diastereoselectivities to that observed for the non-deuterated phenylacetate 
analogue. 
 
1) LiHMDS (1.3 Eq),
TMSCl (1.3 Eq),
THF, - 95 °C to RT
2) CH2N2, Ether
0 °C
N O
Me O
Ph
O
O D
D
D
2H3-154
2H3-144
Yield = 62%
d.r. = 50:1
+ CO2MePh
158
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Me
CO2Me
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N
OO
H
D
D
D
(144 Yield = 72%
d.r. = 44:1)  
 
Scheme 94. EICR of 2H3-154 Under Normal Laboratory Conditions. 
 
With successful rearrangement of 2H3-154 observed, subjection to reaction monitoring 
was pursued. Initiation of the rearrangement was performed under a similar protocol to 
the model SKA studies; however, the reaction was monitored at -50 ˚C over three 
hours prior to warming to 25 ˚C.   
 
 
 
Scheme 95. In-Situ Attempt at Monitoring EICR of 2H3-154. 
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Unfortunately, observation of substrate consumption through monitoring the 
disappearance of the α-H’s were masked by THF and formation of E/Z-SKAs were not 
cleanly observed due to signal broadening and coalescence. However, it is noted that 
an initial build-up of SKA was observed, which was rapidly consumed within the first 
20 minutes of the experiment. Also, determination of the in-situ diastereoselectivity 
during EICR was not achievable as the 1H-NMR resonances used in the silylester 
product, namely the vinylic methyl group and the α-H were masked by low field silyl 
by-products and THF respectively.  
 
LiHMDS (1.3 eq),
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to - 50 °C for 180 min
to RT
N O
Me O
Ph
O
O D
D
D
Me
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N
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H
D
D
DN O
Me OTMS
O
O D
D
D
Ph
H
H H
-H Masked by THF E/Z-SKA Signals Broad
Product Signals Masked
by THF & Silyl By-Prods  
 
Scheme 96. Reaction Monitoring Issues of 2H3-154. 
 
However, quenching and esterification of the in-situ reaction mixture yielded 
comparable diastereoselectivity to that observed with EICR of 154 however in a lower 
yield and clean isolation of methyl phenylacetate was not accomplished. 
 
Although EICR reaction monitoring by 1H-NMR spectroscopy has not been 
successful, it has at least verified the feasibility of studying this reaction by NMR. This 
is demonstrated by the similarities in the diastereomeric ratio and yield between the 
generic laboratory-based protocol and that conducted in an NMR tube.  
 
3.2.2. EICR Reaction Monitoring by 
2
H-NMR Spectroscopy 
 
As subjection of phenylacetate 2H3-154  to in-situ 
1H-NMR studies was flawed by the 
inability to monitor the key α-H resonance in the substrate, E/Z-SKAs and the 
rearranged silylester, a solution to these issues may be found in 2H-NMR analysis. As 
the spectral width of 2H-NMR is identical to that of 1H-NMR, similar chemical shifts 
would be anticipated for an α-D incorporated substrate, SKA and silylester product, as 
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compared to the α-H analogue.161 As the chemical shifts of these three key signals are 
differentiated by at least 1 ppm, clean and distinguishable observation of these signals 
should be anticipated by 2H-NMR spectroscopy.  
 
With this in mind, it was envisaged that synthesis of α,α-2H2-substrates via 
esterification of α,α-2H2-carboxylic acids and key intermediate 145, may provide a 
perfect solution to this issue, may also allow evaluation of alkylacetates. Initial focus 
therefore concentrated on utilisation of the commercially available α,α-2H2-
phenylacetic- and α,α-2H2-propionic acids. 
 
 
 
Scheme 97. Access to α,α-
2H2-Aryl- & Alkylacetates. 
 
Attempted synthesis of α,α-2H2-phenylacetate 
2
H2-154 proved problematic as 
substantial and unpredictable amounts of H/D exchange resulted. Efforts at limiting this 
exchange involved preparation of 2H1-145 utilisation of the free base of EDCi, 
performing the reaction in CD2Cl2 and also performing reaction workup with D2O 
solutions of brine, citric acid and sodium bicarbonate, however to no avail. 
 
 
 
Scheme 98. Attempted Synthesis of α,α-
2H2-Phenylacetate 2H2-154. 
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With the unfavourable H/D exchange observed for synthesis of the α,α-2H2-
phenylacetate, synthesis of α,α-2H2-propionate 
2
H2-265 was accomplished in excellent 
yield and isolated with complete deuterium incorporation. 
 
 
 
Scheme 99. Synthesis of Deuterated Propionate 2H2-265. 
 
With 2H2-265 hand, rearrangement under normal laboratory protocols was attempted, 
however no reaction was observed and complete mass return of substrate resulted. 
 
 
 
Scheme 100. EICR of 2H2-265 Under Normal Laboratory Conditions. 
 
The stability of 2H2-265 to de-deuteration was demonstrated by an in-situ attempt at 
reaction monitoring of which the substrate remained intact in the reaction medium in 
excess of 40 days. This observed result is clearly an aspect of the kinetic isotope effect 
and it is unfortunate that the stability it confers on the substrate renders futile reaction 
monitoring by 2H-NMR.  
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3.2.3. EICR Reaction Monitoring by 
13
C-NMR Spectroscopy 
 
With the unsuccessful monitoring of the EICR by both 1H- and 2H-NMR spectroscopy, 
monitoring by 13C-NMR was subsequently pursued. Initial investigations focussed on 
synthesis of ipso,alpha(ι,α)-enriched phenylacetate 13C2-154, accomplished in excellent 
yield under the familiar EDCi coupling conditions.  
 
 
 
Scheme 101. Synthesis of 13C Enriched Phenylacetate Substrate 13C2-154. 
 
Utilisation of a doubly 13C enriched substrate possessing chemically and magnetically 
inequivalent carbon atoms, was envisaged to provide successful observation of E- and 
Z-SKA’s and also anti- and syn-diastereomers during the in-situ rearrangement studies. 
With 13C2-154 in hand, rearrangement under optimised conditions (Chapter 2), prior to 
in-situ studies, demonstrated that β-amino ester 13C2-144 was obtained in similar yield 
and diastereoselectivity to that of the non-enriched analogue. 
 
 
Scheme. 102. EICR of 13C Enriched Phenylacetate 13C2-154 under Standard Laboratory Conditions. 
 
With the successful rearrangement of 13C2-154 observed, subjection to in-situ reaction 
monitoring was pursued. The reaction was initiated in the reported fashion, injected into 
a pre-cooled 400 MHz NMR spectrometer at -95 ˚C and subsequently warmed to -65 ˚C 
where it was monitored in excess of 800 minutes prior to warming to 25 ˚C.  
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Scheme 103. In-Situ EICR Monitoring of 13C2-154; Equimolar 1.3 eq. LiHMDS & TMSCl. 
 
During the reaction monitoring, consumption of 13C2-154, formation and consumption 
of E/Z-SKAs and formation of silylester product 13C2-266 were observed. The 
intermediary temperature of -65 ˚C was chosen, as the ability to clearly monitor SKAs 
at -50 ˚C was troublesome due to facile rearrangement at this temperature. 
Unfortunately, resolution of the anti- and syn-diastereomers of the silyl ester product 
were not observed, as the ipso-(ι-) and alpha-(α-)carbon resonances are coincidental in 
THF. However comparable diastereoselectivity was observed post reaction quench and 
esterification to that observed with the laboratory protocol. Plotting relative 
concentrations of species consumed and formed versus time demonstrates the progress 
of this in-situ reaction. 
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Graph 4. Consumption of 13C2-154 & Formation of E/Z-SKA & Product 
13
C2-266/% vs. Time/min at       
-65 ˚C (Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl). 
Chapter 3  Results & Discussion
   
97 
These intriguing results display certain resemblances to the model phenylacetate SKA 
studies (Graph 2).  These include an initial return of starting material (SM) 13C2-154 
prior to its further consumption, an initial fast, yet partial formation and subsequent 
consumption of the E-SKA and a constant low level concentration of the Z-SKA. This 
reaction also clearly demonstrates 2 key time regions. At t < 180 minutes, trends in the 
observed rates of phenylacetate 13C2-154 consumption (after 60 minutes) and product 
13
C2-266 formation are greater than when t > 180 minutes. This initial higher rate of 
product 13C2-266 formation is presumably based on consumption of the built-up E-SKA 
over this time period. It is noted that 50% consumption/formation of phenylacetate 13C2-
154/silylester 13C2-266 was observed after 900 minutes. As a mechanistic tool used to 
evaluate the origins of diastereoselection throughout the course of the EICR, the 
inability to monitor the formation of anti- and syn-silylesters 13C2-266 is unfortunate. 
However, the formation of high levels of E-SKA and subsequent consumption of the E-
SKA strongly allude to this geometrical isomer rearranging, inferring the anti-
diastereoselectivity observed in the rearrangement.  
 
To further investigate the effects of reagent stoichiometry on the rearrangement of 13C2-
154, treatment with equimolar 1.7 equivalents of LiHMDS/TMSCl, and 1.3 equivalents 
LiHMDS and 6 equivalents of TMSCl was pursued. These conditions were chosen to 
compliment the findings from the earlier model phenylacetate SKA studies using 2H1-
239.  
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Condition 2 – Equimolar 1.7 Equivalents of LiHMDS/TMSCl- 
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Graph 5. Consumption of 13C2-154 & Formation of E/Z-SKA & Product 
13
C2-266/% vs. Time/min at       
-65 ˚C (Condition 2 - 1.7 eq. LiHMDS & 1.7 eq. TMSCl). 
 
On subjecting 13C2-154 to equimolar 1.7 equivalents of LiHMDS and TMSCl it is noted 
that familiar trends are again observed, in that a similar inflection of SM 13C2-154 is 
seen and observation of the E-SKA is not detected post 180 minutes. There are 3 
distinct time regions to consider, at t < 180 minutes the rate of formation of silylester 
13
C2-266 is highest, in concordance with consumption of E-SKA. Then reductions in the 
observed rate of 13C2-154 consumption and silylester 
13
C2-266 formation are seen to 
occur at 180 < t < 320 minutes and at t > 320 minutes. It is noted that 50% 
consumption/formation of phenylacetate 13C2-154/silylester 
13
C2-266 is quicker, 
occurring under 230 minutes.  
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Condition 3 – 1.3 Equivalents of LiHMDS & 6 Equivalents TMSCl- 
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Graph 6. Consumption of 13C2-154 & Formation of E/Z-SKA & Product 
13
C2-154/% vs. Time/min at 
 -65 ˚C (Condition 3 - 1.3 eq. LiHMDS & 6 eq. TMSCl). 
 
Interestingly, no inflection in the relative concentration of substrate 13C2-154 is 
observed in this instance. The time taken for 50% 13C2-154 consumption/silylester 
13
C2-
266 formation is reduced relative to Condition 1, occurring after 190 minutes. The E-
SKA is detected up to 280 minutes, after which trends in the observed relative rates of 
consumption 13C2-154/formation 
13
C2-266 are again reduced. 
 
As the model SKA studies had demonstrated that equimolar loadings of LiHMDS and 
TMSCl (1.3 equivalents) would not facilitate complete conversion of phenylacetate to 
SKA, these results demonstrate that higher concentrations of the silylester product 13C2-
266 can be achieved by varying the stoichiometry of TMSCl. Although full conversion 
to the SKA has not been observed from the outset of these in-situ reactions, it was 
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decided to ascertain whether complete SKA formation would lead to full conversion to 
silylester 13C2-266. As the results from Condition 1 demonstrated an initial formation of 
ca. 25% E-SKA, it was postulated that equimolar 5.2 equivalents LiHMDS/TMSCl may 
provide complete SKA formation and was thus pursued. 
 
Condition 4 – Equimolar 5.2 Equivalents of LiHMDS/TMSCl- 
 
Relative Concentration SM 
13
C2-154 , E-  & Z-SKA & Product 
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C2-266/% vs.  Time/min
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Graph 7. Consumption of 13C2-154 & Formation of E/Z-SKA & Product 
13
C2-266/% vs. Time/min at  
-65 ˚C (Condition 4 - 5.2 eq. LiHMDS & 5.2 eq. TMSCl). 
 
The results from this experiment are perhaps the most intriguing. As predicted, 
increasing the amount of LiHMDS and TMSCl leads to a higher initial concentration of 
the E-SKA which is consumed over a similar time period to the other experiments 
discussed (t = 220 minutes). Although full conversion to SKA is still not observed, a 
more rapid formation of silylester 13C2-266 results with 50% formation seen after 60 
minutes and plateauing noted after 100 minutes. Curiously a reduction in 13C2-266 and 
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increase in 13C2-154 is noted at t = 250 minutes. Although E1cB elimination of 
13
C2-266 
would not account for the sharp increase in 13C2-154 observed, another explanation may 
be a retro [3,3]-rearrangement. Unlike the other studied conditions, the trend in 
consumption of 13C2-154 was unexpected, as a prolonged inflection was observed 
throughout the course of reaction. It is also noted that recovery of β-amino ester 13C2-
144 is markedly reduced as compared to previous in-situ experiments; this observation 
is in accordance with the results from the initial phenylacetate optimisation discussed in 
Chapter 2 (Table 3). 
 
All though each reaction profile is different all are observed to possess the same generic 
trends- 
Phenylacetate 
13
C2-154 Consumption- 
SM 
13
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Graph 8. Consumption of 13C2-154 vs. Time/min at -65 ˚C. 
 
With the exception of Condition 3, an inflection in the plot of 13C2-154 is observed prior 
to subsequent consumption, however all reactions tend toward a plateau at late stage 
indicating that the reaction is stalling. Although an inflection is observed for condition 2 
and no inflection is observed for Condition 3, similar end-point conversions are 
observed. Condition 1 is observed to produce the lowest conversion, however Condition 
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4 demonstrates that increases in the stoichiometry of base and silylating agent does not 
ensure higher conversions. 
 
E-SKA Formation/Consumption- 
E -SKA/% vs . Time/min
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Graph 9. Consumption of E-SKA vs. Time/min at -65 ˚C. 
 
From the outset of each reaction there is a high relative concentration of the E-SKA, 
with a markedly high initial concentration seen with Condition 4. Furthermore, it is 
noted that consumption of E-SKA occurs at 180 < t < 280 minutes, irrespective of the 
initial conditions. 
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Z-SKA Formation/Consumption- 
Z -SKA/% vs . Time/min
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Graph 10. Consumption of Z-SKA vs. Time/min at -65 ˚C. 
 
There remains a low yet steady relative concentration of the Z-SKA for condition 1 and 
3, with an initial observation up to 140 minutes for Condition 4. However, it is noted 
that no Z-SKA is observed with condition 2. 
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Product Silylester 
13
C2-266 Formation- 
Product 
13
C2-266  Formation/% vs . Time/min
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Graph 11. Formation of 13C2-266 vs. Time/min at -65 ˚C. 
 
There are two key regions in the observed relative rates of product formation and 
involves a steep initial rise which tends towards plateau once the available E-SKA 
present has been consumed. For the first stage of reaction it is noted that the relative rate 
of product formation is by far the greatest for condition 4, where 50% is observed after 
60 minutes. Curiously, Condition 3 appears to bear resemblance from the initial stage of 
Condition 1 and that of the late stage of condition 3. Here it is seen that the initial 
observed rate of product formation matches that of Condition 1, however although the 
reaction for Condition 2 appears slower, the end-point conversion is similar to that of 
Condition 3. 
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These observations are indeed intriguing and allude to important mechanistic 
ramifications. Although full consumption of 13C2-154 and formation of 
13
C2-266 is not 
obtained under any condition, the observed inflection of 13C2-154 and the formation of 
silyl derived by-products may not only provide an answer as to why complete 
conversion is not seen, but also the observed diastereoselectivity. 
Inflection in Phenylacetate 
13
C2-154- 
It has been known from the beginning of the Li-amide era, that the secondary amine 
generated from the enolisation of a carbonyl compound has an effect upon the reactivity 
of the newly formed enolate.162 This maverick enolate reactivity in the presence of in-
situ generated secondary amines, is highlighted by the addition of a deuterating reagent 
(MeOD) to the LDA generated enolate 267.163 From this, it is shown that the desired α-
deutero ester 268 is recovered in minimal amounts, with the majority being that of 
diisopropylamine mediated re-protonated ester. In order to circumvent this scenario of 
‘Internal Proton Return (IPR)’, it has been shown that addition of nbutyllithium prior to 
addition of the electrophile allows isolation of the desired deuterated species in high 
yield.  
 
 
 
Scheme 104. Internal Proton Return (IPR) in LDA Mediated Enolisations. 
 
With this in mind it was reasoned that the observed return of phenylacetate 13C2-154 
may be due to HMDS mediated IPR to the enolate, the SKA or perhaps both. As 
detection of enolate is not observed during these NMR experiments, possibly an aspect 
of rapid silylation, it was felt that monitoring enolate formation would be highly 
desirable in order to distinguish the origins of IPR. Subjection of 13C2-154 to EICR 
conditions, excluding TMSCl did in fact allow us to observe the formation of enolate 
13
C2-160, of which an initial inflection in the amount of phenylacetate 
13
C2-154 was 
detected.119 On warming the reaction mixture to room temperature, complete 
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degradation of unreacted phenylacetate 13C2-154 and enolate 
13
C2-160 occurred, with no 
signs of Li-enolate [3,3]-rearrangement occurring.  
 
LiHMDS (1.3 eq.),
THF, - 95 °C
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Graph 12. Consumption of 13C2-154 & Formation of Enolate 
13
C2-160 /% vs. Time/min at -65 ˚C  
(1.3 eq. LiHMDS). 
 
It is noted that due to peak broadness, resolution of the E- and Z-enolate was not 
observed and evidence for enolate aggregates including monomeric and dimeric species 
were also detected, based on the reported monomeric 269 and dimeric 270 enolate 
species (Figure 21).119 
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Fig. 21. Reported Monomeric/Dimeric Enolate Species & ι,α-C observed of Enolate 13C2-160. 
 
Although IPR to the SKA cannot be ruled out, this study demonstrates that initial IPR to 
the enolate by HMDS may be responsible for the inflections associated with the 
observed return of phenylacetate 13C2-154. This consideration is demonstrated with 
dimeric enolate species in Scheme 105.162 
 
 
Scheme 105. Internal Proton Return (IPR) to Enolate by in-Situ Generated HMDS. 
 
However, as no plateau is observed during late stage of enolate formation, reaction 
retardation within the in-situ EICR studies may be an aspect of deleterious effects 
associated with the formation of silyl by-products. 
 
 
 
7580859095100105110115120125130135140145150155160 ppm
ι-C 13C2-160 α-C 13C2-160 
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Silyl By-Products- 
During the course of the EICR the expected by-products include HMDS and LiCl from 
enolisation and subsequent silylation. A re-examination of the in-situ reaction studies 
has allowed an insight into the formation of various silicon based species, by virtue of 
their α-silicon 13C resonances, including TMSCl, HMDS, SKA and silylester product. It 
is noted that the TMS signals of E- and Z-SKA’s appear coincidental as do the syn- and 
anti-silylester products. More importantly, observation of LiHMDS was not detected, 
however the formation of silanamine 271 is noted during these rearrangements. 
 
 
Scheme. 106. Silanamine. 
 
This re-evaluation of the 13C-NMR data in the context of mapping the distribution of 
silicon within these reactions, has allowed additional understanding of components not 
in the initial remit. To exemplify the silicon distribution in a typical reaction, it is shown 
from Condition 1 that product 13C2-266 only constitutes around 19% of total silicon. It 
is also demonstrated that there is a slight reduction of TMSCl during the course of 
reaction, presumably an aspect of SKA and silanamine formation; however the relative 
concentration of HMDS appears to remain constant.  Although silanamine formation is 
only small its formation is deemed to be important. 
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Relative Concentration Silanamine, TMSCl, HMDS, SKA & Prod/% vs.   Time/min
(Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl)
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Graph 13. Silicon Distribution/% vs. Time/min at -65 ˚C  
(Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl). 
 
Although different stoichiometries of LiHMDS/TMSCl are used within the other three 
reactions, similar trends in silicon distribution are undoubtedly observed. TMSCl is 
observed to be the major component followed by HMDS and although initial relative 
concentrations of product silylester and silanamine are different, these tend toward 
similar relative concentrations toward the end of reaction. 
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Relative Concentration Silanamine, TMSCl, HMDS, SKA & Prod/% vs.  Time/min
(Condition 2 - 1.7 eq. LiHMDS & 1.7 eq. TMSCl)
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Graph 14. Silicon Distribution/% vs. Time/min at -65 ˚C  
(Condition 2 - 1.7 eq. LiHMDS & 1.7 eq. TMSCl). 
 
Relative Concentration Silanamine, TMSCl, HMDS, SKA & Prod/% vs. Time/min
(Condition 3 - 1.3 eq. LiHMDS & 6 eq. TMSCl)
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Graph 15. Silicon Distribution/% vs. Time/min at -65 ˚C  
(Condition 3 - 1.3 eq. LiHMDS & 6 eq. TMSCl). 
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Relative Concentration Silanamine, TMSCl, HMDS, SKA & Prod/% vs.  Time/min
(Condition 4 - 5.2 eq. LiHMDS & 5.2 eq. TMSCl)
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 Graph 16. Silicon Distribution/% vs. Time/min at -65 ˚C  
(Condition 4 - 5.2 eq. LiHMDS & 5.2 eq. TMSCl). 
 
 
On further consideration of the relative concentration of TMSCl, HMDS and silanamine 
within these 4 reactions, it is seen from- 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  Results & Discussion
   
112 
TMSCl- A small degree of TMSCl consumption is observed (ca. 10%), which is 
more pronounced for condition 2 (ca. 20%). It is noted for condition 4 that an initial 
return of TMSCl is noted at t < 250 minutes, before its apparent consumption. 
 
Relative Concentration TMSCl/% vs.  Time/min
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Graph 17. Relative Concentration of TMSCl vs. Time/min at -65 ˚C. 
 
HMDS- The relative concentration of HMDS is observed to remain constant 
throughout each reaction, however a small negative inflection is observed for 
condition 2 (time < 50 minutes) with an elongated shallow inflection observed for 
condition 4. These negative inflections correspond to the time intervals associated 
with the inflections previously discussed with phenylacetate 13C2-154. 
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Relative Concentration HMDS/% vs.  Time/min
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Graph 18. Relative Concentration of HMDS vs. Time/min at -65 ˚C. 
 
This observed removal of HMDS from the system is proposed to be due to IPR 
to the SKA. As the largest degree of phenylacetate 13C2-154 return is observed 
for rearrangement under condition 4, deviations in the large relative 
concentrations of silyl species are easier to observe. It is noted that IPR to the 
SKA may also be facilitated by LiCl, as judged by coincidental TMSCl 
regeneration as HMDS is consumed during condition 4. 
 
 
 
Scheme 106. Internal Proton Return (IPR) to SKA, Facilitated by LiCl & HMDS. 
 
Silanamine- The changes in the observed trends of silanamine formation 
throughout each reaction are observed to vary the most. In most cases, detection of 
silanamine occurs after t = 100 minutes and once E-SKA is no longer detected, 
however in Condition 4 a sharp initial formation is observed which plateaus after t = 
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100 minutes. Interestingly the highest relative concentration of silanamine formation 
is observed with Condition 2 and the lowest is observed with Condition 3. 
 
Relative Concentration Silanamine 271/% vs.  Time/min
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Graph 19. Relative Concentration of Silanamine 271 vs. Time/min at -65 ˚C. 
 
The formation of silanamine is indeed intriguing and may originate from compatibility 
issues between HMDS and TMSCl, or between LiHMDS and TMSCl. As silanamine 
formation has no effect on the relative concentration of HMDS, its formation via this 
by-product is not thought to occur. However, Lipshutz has demonstrated that premixes 
of LDA and TMSCl at -78 ˚C generate silylated amine 272 and LiCl quantitatively.164 
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Scheme. 107. LDA & TMSCl Compatibility. 
 
In order to test Lipshutz’s observation, control experiments conducted with LiHMDS 
and TMSCl have subsequently demonstrated complete formation of silanamine 271 in-
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situ; and it was also shown that combinations of HMDS and TMSCl yielded no 
reaction. 
 
 
Scheme. 108. LiHMDS- & HMDS-TMSCl Compatibility. 
 
The added benefit of being able to track the silicon content in addition to the pre-
planned ι,α-13C of phenylacetate 13C2-154, E/Z-SKA and silylester product 
13
C2-266 
has been mechanistically beneficial, as a more thorough insight into the EICR has been 
gained. One major draw back to this study has been the inability to observe formation of 
both the syn- and anti-diastereomers via the 13C labels or the TMS signals. However, in 
order to rationalise this data in the context of examining the origins of 
diastereoselectivity within the EICR a number of key mechanistic observations can be 
made- 
 
1) Throughout each reaction a large relative concentration of the E-SKA and 
rearranged product is observed from the outset of reaction monitoring. This 
observation alludes to a large initial formation of the E-SKA between initiation 
temperature (-95 ˚C) and whence reaction monitoring occurs (-65 ˚C), with 
rearrangement also being facile. Isolation of the in-situ rearranged products as 
the methyl esters yield similar diastereoselectivities to the standard laboratory 
based protocol and this initial high formation of the E-SKA may be responsible 
for the high diastereoselectivity observed. 
2) Once the E-SKA is no longer detected, the trends in the observed relative rates 
of product 13C2-266 formation are much reduced and all tend toward plateau, 
indicating that phenylacetate 13C2-154 consumption and product 
13
C2-266 
formation are stalling. It is noted throughout each reaction low concentrations of 
Z-SKA are present and are attributed to the observed diastereochemical outcome 
of the rearrangement, post quench and methylation. 
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3) Although detection of the Li-enolate 13C2-160 has not been observed during in-
situ studies, it has been shown that IPR plays a role within the initial stages of 
enolate formation (Graph 12). As an inflection in phenylacetate 13C2-154 is 
observed for all rearrangements, bar Condition 3, IPR to the SKA is envisaged 
to be facilitated by LiCl and HMDS.  
 
Although the formation of LiCl has not been followed experimentally, the in-situ 
generation of this salt is thought to exert strong underlying effects within the EICR. As 
the reaction proceeds, increases in the relative concentration of LiCl are expected due to 
SKA formation and silanamine formation. The presence of LiCl is known to exhibit an 
auto-catalytic effect within lithium amide enolisations and the pure LDA dimer 273 has 
been shown to form the more reactive mixed aggregate 274 upon exposure to LiCl.165  
 
 
Scheme. 109. Origins of LiCl Auto-Catalysis. 
 
Although formation of more reactive LiCl mixed aggregates can be advantageous in 
speeding up enolisations, the efficiency of Li-amide mediated reactions are known to be 
highly sensitive to varying concentrations of in-situ generated LiCl. It is known that 
E/Z-enolate selectivities are improved up to the addition of 0.3 equivalents of LiCl but 
are subsequently reduced with larger amounts.165-168 It has also been shown that the 
presence of mixed halogen aggregates brings about facile N-alkylation of Li-amide 
bases, which becomes more favourable with increasing concentrations of Li-halide salt 
present.17 
 
As there are 2 separate mechanisms allowing for LiCl production within the EICR, 
auto-catalysis may account for the observed inflection of phenylacetate 13C2-154. From 
this concept it is reasoned that the apparent return of 13C2-154 is an aspect of an 
induction period allowing LiHMDS/LiCl mixed aggregates to form, in which time IPR 
Chapter 3  Results & Discussion
   
117 
to the SKA is a faster process. The subsequent consumption of 13C2-154 is then 
observed once the relative rate of SKA formation begins to outweigh the relative rate of 
IPR. As silanamine formation is generally observed after observation of the E-SKA, the 
apparent stalling of phenylacetate 13C2-154 consumption/product 
13
C2-266 formation is 
attributed to a more favourable LiCl catalysed silanation of LiHMDS. 
 
With these considerations in mind it is then possible to construct a reaction scheme 
considering the effects of by-products within the enamido Ireland-Claisen 
rearrangement (Scheme 110). Within this scheme there are three key mechanistic stages 
that would purport to the observed general trends observed with 13C2-154 consumption 
and 13C2-266 formation- 
 
Stage 1 - The first pathway gives rise to the inflection in 13C2-154 concentration, in 
that enolisation by pure LiHMDS dimer 275 is expected to produce enolate 13C2-
160. As various aggregation states were observed in the enolisation studies (Graph 
12), attempts at classifying the structure of enolate will not be pursued and a generic 
enolate shall be drawn. From the enolate IPR by HMDS may then regenerate 13C2-
154. However if enolate 13C2-160 is trapped as SKA 
13
C2-277, it is envisaged that 
consumption is either by LiCl/HMDS facilitated IPR or rearrangement to product 
13
C2-266. 
 
Stage 2- The onset of a new stage within the reaction is thought to occur when 13C2-
154 consumption resumes. This is attributed to the start of LiCl autocatalysis, in that 
formation of mixed LiHMDS dimer 276 occurs, sequestering the use of LiCl within 
IPR and allowing rearrangement to occur. As formation of product 13C2-266 is still 
observed after E-SKA is no longer observable, enolisation via pure LiHMDS 275 or 
mixed aggregate 276 may occur, but it is thought that as the reaction proceeds 
increases in LiCl concentration will cause an increase in formation of mixed 
aggregate 276. As Collum has demonstrated enolisation selectivities are 
compromised post 0.3 equivalents LiCl, reduction in diastereocontrol may result in 
rearrangement from the Z-SKA.  
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Stage 3- The third stage of the reaction is seen to occur by the onset of silanamine 
formation and reduction in the observed rates of phenylacetate 13C2-154 
consumption/product 13C2-266 formation. 
 
 
 
Scheme. 110. Three Postulated Stages within the EICR. 
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Synthesis & In-Situ Studies of Electronically Perturbed Phenylacetates-  
As the main aim of the in-situ studies was to investigate the dependency of electronic 
perturbation on diastereoselectivity, efforts were redirected on synthesising a 13C-
incorporated electron donating (-methoxy) and withdrawing (-nitro) para-substituted 
enamido arylacetate. However, due to the lack of commercial availability for the 
corresponding 13C enriched arylacetic acids, synthesis of these intermediate 
compounds was therefore required.  
 
 
 
Scheme 111. Required 13C Enriched para-Substituted Arylacetates. 
 
Access to both para-methoxy and -nitro phenylacetic acids were based on the use of a 
common 13C labelled starting material. Utilisation of α-bromo ester 278 in procedures 
reported by Gooßen and also by Hartwig has demonstrated a route to both methoxy- 
280 and nitro-substituted 281 phenylacetates.169-170 It was therefore envisaged that 
utilisation of an appropriately 13C labelled α-bromo ester would allow similar access, 
generating the required α-labelled carboxylic acids post saponification. It is noted that 
mono-labelled 13C1-278 was used due to commercial availability. 
 
 
 
Scheme 112. Required 13C Enriched para-Substituted Arylacetates. 
 
Prior to using 13C1-278, all initial reactions involved that of the non-labelled 278. 
Initial attempts at synthesising methoxy-280 were met with complex reaction mixtures 
with crude 1H-NMR alluding to the formation of homocoupled 279. However, after a 
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short optimisation synthesis of 13C-para-methoxy phenylacetic acid 13C1-282 was 
accomplished in moderate yield over two steps and subsequent EDCi coupling allowed 
access to 13C1-para-methoxy phenylacetate 
13
C1-165 in excellent yield. 
 
 
 
Scheme 113. Synthesis of 13C Enriched para-Methoxy Phenylacetate Substrate 13C1-165. 
 
With para-methoxy phenylacetate 13C1-165 in hand synthesis of the electron 
withdrawn para-nitrophenylacetate 13C1-281 was pursued. However, attempts at 
following Hartwig’s Reformatsky protocol were unsuccessful affording quantitative 
return of unreacted starting materials. 
 
 
 
Scheme 114. Attempt at Hartwig’s Route to para-Nitro Phenylacetate. 
 
Other routes to 13C1-281, involved utilisation of Gooßen’s Suzuki protocol and after 
several attempts involving the required boronic acid and trifluororborate salt, no 
coupling was subsequently observed. As synthesis of para-nitrophenylacetate 13C1-281 
was problematic, the nature of the electron withdrawing substituent was reconsidered. 
Subsequently, studies involving the trifluoromethyl substituent were envisaged to 
create a better mechanistic compliment to the methoxy variant, based on similar 
diastereoselectivities (p-OMe d.r. = 24:1, p-CF3 d.r. = 21:1). With this in mind 
synthesis of 13C1-283 was accomplished in moderate yield over two steps and 
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subsequent EDCi coupling allowed synthesis of the labelled p-
trifluoromethylphenylacetate 13C1-206 in excellent yield. 
 
 
 
Scheme 115. Synthesis of 13C Enriched para-Trifluoromethyl Phenylacetate 13C1-206. 
 
With only a limited amount of para-methoxy 13C1-165 and para-trifluoromethyl 
phenylacetate 13C1-206 available, subjection to in-situ rearrangement was subsequently 
pursued. 
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In-Situ Rearrangement of para-Methoxy Phenylacetate 
13
C1-165 - 
LiHMDS (1.3 eq.),
TMSCl (1.3 eq.),
THF, - 95 °C
to -65 °C (17 h)
to 25 °C
13C1-165
13C1-174
Yield = 52%
d.r. = 25:1
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Graph 20. In-Situ EICR of 13C1-165; Equimolar 1.3 eq. LiHMDS & TMSCl. 
Consumption of 13C1-165 & Formation of E/Z-SKA & Product 
13
C1-284/% vs. Time/min at -65 ˚C. 
 
From this study it is shown that- 
1) A large inflection of para-methoxy 13C1-165 occurs. 
2) There is a large initial concentration of SKA, of which it is noted that the E/Z 
geometric purity is reduced compared to the phenylacetate 13C2-154 studies. 
3) Throughout the experiment there remains a significant proportion of detectable 
E- and Z-SKA, unlike the in situ phenylacetate 13C2-154 studies. 
4) There are 3 distinct regions of product 13C1-284 formation. Similar to the 
previous studies there is a fast initial relative rate of product formation which is 
mirrored by E-SKA consumption (t < 50 minutes). A plateau is later observed 
at 50 < t < 500 minutes prior to its subsequent production at t > 500 minutes. 
5) At 50 < t < 500 minutes consumption of SKA is solely attributed to IPR. 
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In-Situ Rearrangement of para-Trifluoromethyl Phenylacetate 
13
C1-206- 
LiHMDS (1.3 eq.),
TMSCl (1.3 eq.),
THF, - 95 °C
to -65 °C (17 h)
to 25 °C
13C1-206
13C1-217
Yield = 48%
d.r. = >25:1
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Graph 21. In-Situ EICR of 13C1-206; Equimolar 1.3 eq. LiHMDS & TMSCl. 
Consumption of 13C1-206 & Formation of E/Z-SKA & Product 
13
C1-285/% vs. Time/min at -65 ˚C. 
 
From this study it is shown that – 
1) There is a shallow elongated inflection of para-trifluoromethyl 13C1-206 return. 
2) Similar to the phenylacetate 13C2-154 studies there is a large initial formation of 
the E-SKA which is consumed either through IPR or via rearrangement. 
3) There is a low steady relative concentration of the Z-SKA throughout and is 
similar to the in-situ phenylacetate 13C2-154 studies. 
4) The observed relative rate of product formation is initially high followed by a 
plateau, mirroring E-SKA consumption at t < 100 minutes. 
5) The reaction appears to stall after E-SKA is no longer detected. 
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Unfortunately, the ability to monitor the formation of the syn- and anti-diastereomers 
within the rearrangement of para-methoxy 13C1-165 and para-trifluoromethyl 
13
C1-206 
are again plagued by coincident resonances. Also due to an electrical fault within the 
NMR, analysis of the silyl by-products during these reactions was not achievable. 
However, in order to rationalise the acquired data in the context of explaining our 
structure-diastereoselectivity trend, significant insights into the mechanism have been 
gained. Comparisons of SM, SKA and product concentrations for the EICR of 
phenylacetate 13C2-154, para-methoxy 
13
C1-165 and para-trifluoromethyl 
13
C1-206 
allude to the electronic dependencies responsible for varied diastereoselection- 
 
SM (Ph-
13
C2-154/p-MeO-
13
C1-165/p-CF3-
13
C1-206) Consumption- 
It is seen that the greatest consumption of SM is observed for the para-methoxy 
substrate, with the lowest levels observed with the para-trifluoromethyl system. An 
inflection in SM return is observed for all substrates; however these are more extreme 
for p-OMe and p-CF3 insinuating that IPR is a major issue in the EICR of these 
substrates. 
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Graph 22. Consumption of 13C2-154, 
13
C1-165 & 
13
C1-206 /% vs. Time/min at -65 ˚C  
(Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl). 
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From the outset of the reaction, most starting material consumption is seen for para-
methoxy 13C1-165 which also demonstrates the largest inflection. It is rationalised that 
IPR to the SKA may be more facile as electron density on the α-carbon will be further 
enhanced by the electron donating substituent and the larger, longer inflection is the 
result of a fierce competition of SKA consumption via IPR and rearrangement. 
Intriguingly a shallow, longer inflection with the least SM consumption is observed for 
the para-trifluoromethyl 13C1-206. At first consideration this appears counterintuitive as 
a greater degree of enolisation would be anticipated for systems which possess lower 
pKa values. However, although enolisation isn’t a consideration in the associated 
Claisen rearrangement, mechanistic studies have demonstrated that electron 
withdrawing groups retard substrate consumption, whilst electron donating groups 
speed it up.85, 146-148 
E-SKA Formation/Consumption (Ph-/MeO-/CF3-)- 
A large presence of the E-SKA is observed from the outset of each reaction, of which 
similarities in relative concentrations and consumption times are present for 
phenylacetate and para-trifluoromethyl. Intriguingly a marked increase for the initial 
concentration of para-methoxy is noted where its consumption is rapid at t < 70 minutes 
and gradual consumption of the residual E-SKA is observed until t < 750 minutes. 
E -SKA (Ph-/MeO-/CF3-)/% vs. Time/min
(Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl)
0
5
10
15
20
25
30
35
40
0 100 200 300 400 500 600 700 800
Time/min
R
e
la
ti
v
e
 C
o
n
c
e
n
tr
a
ti
o
n
 E
-
S
K
A
(P
h
-/
M
e
O
-/
C
F
3
-)
/%
 
Ph OMe CF3
 
Graph 23. Consumption of E-SKA from 13C2-154, 
13
C1-165 & 
13
C1-206/% vs. Time/min at -65 ˚C  
(Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl). 
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Z-SKAFormation/Consumption (Ph-/MeO-/CF3-)- 
Again similarities are present for phenylacetate and para-trifluoromethyl in that a low 
steady concentration of Z-SKA is observed. However a marked increase is observed for 
the para-methoxy.  
Z -SKA (Ph-/MeO-/CF3-)/% vs. Time/min
(Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl)
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Graph 24. Consumption of Z-SKA from 13C2-154, 
13
C1-165 & 
13
C1-206/% vs. Time/min at -65 ˚C  
(Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl). 
 
These results concerning SKA formation may pertain to the origins of diastereoselection 
within the EICR and explain the change in rate determining step as alluded to by the 
Hammett type plot (Chapter 2). As phenylacetate 13C2-154 and para-trifluoromethyl 
13
C1-206 display similar trends in SKA formation/consumption and the para-methoxy 
13
C1-165 demonstrates a significantly different profile, perhaps this change in rate 
determining step between electron donating and withdrawing substitution is based on – 
 
1) A reduced geometric selectivity of E/Z-SKA generation for electron donating 
substitution, which subsequently rearranges through a chair transition state. 
2) A selective formation of the E-SKA for electron withdrawing substitution, 
which subsequently rearranges through chair and boat transition states. 
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Product (Ph-
13
C2-266/p-MeO-
13
C1-284/p-CF3-
13
C1-285) Formation- 
Similarities are yet again present between phenylacetate and para-trifluoromethyl in 
that a sharp initial formation is followed by a plateau, in which higher concentrations 
are ultimately observed for phenylacetate over para-trifluoromethyl. The para-methoxy 
displays the most intriguing behaviour in that the highest relative rate of formation is 
observed (t < 50 minutes) before the reaction appears to stall (50 < t < 500 minutes) and 
product formation resumes (t > 500 minutes). This curious behaviour associated with 
the mid plateau in formation of para-methoxy 13C2-284 is attributed to the selective IPR 
to the SKA, as observed through the extreme inflection in para-methoxy 13C2-165 
return.  
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Graph 25. Product Formation from 13C2-266, 
13
C1-284 & 
13
C1-285/% vs. Time/min at -65 ˚C  
(Condition 1 - 1.3 eq. LiHMDS & 1.3 eq. TMSCl). 
 
It is shown that the relative concentrations of product formation are observed to be 
higher for para-methoxy with the lowest obtained for para-trifluoromethyl. This 
observation corresponds well to computational studies involving the related Claisen 
rearrangement, as product formation is reduced with electron withdrawing substitution 
on the terminal vinyl position of allyl vinyl ether reactants.85, 146-148 
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3.4. Conclusions 
 
These mechanistic studies have allowed an in-depth insight into the electronic dependance 
of aryl substitution upon diastereoselection within the enamido-Ireland-Claisen 
rearrangement. Initial studies focussed on the in-situ formation and monitoring of E/Z-SKA 
selectivity derieved from electronically perturbed phenylacetate esters. Their formation was 
found to be highly E-selective but geometrical interconversion was facile under duress of 
remote electronic effects and the nature of the ester alkoxy moiety. These model SKA 
studies demonstrated that E/Z-SKA geometry may be responsible for diastereoselectivity 
within the associated EICR. In addition it has been shown that isolation of phenyl derieved 
SKA’s are now obtainable with high levels of E-geometric purity and eclipse all current 
methodologies for their synthesis. 
 
With a greater understanding of phenylacetate SKA’s, the in-situ monitoring of the EICR 
by 13C-NMR was pursued and involved the prior synthesis of 13C-labelled phenylacetate 
13
C2-154, para-methoxy 
13
C1-165 and para-trifluoromethyl 
13
C1-206 substrates. Although 
these in-situ studies have allowed a significant understanding into the EICR based on data 
associated with the 13C label and also the silyl by-products, all reactions were plagued by 
the inability to monitor the formation of the anti- and syn-diastereomers of the silyester 
products as they are formed. However, diastereoselection within the in-situ rearrangements 
was found to correspond to the non-labelled analogues, post quench and methylation of the 
reaction mixture. These studies have demonstrated the complexity of the EICR through 
complications involving internal proton return to the enolate and SKA, and also 
interferences from other by-products including LiCl auto-catalysis and silanamine 
formation. The studies involving para-methoxy 13C1-165 and para-trifluoromethyl 
13
C1-
206 substrates have aided the understanding of the varied diastereoselectivity based upon 
electronic perturbation. It is thought that the Hammett plot alludes to, the occurrence of a 
single mechanism with a change in rate determining step and it is postulated that reductions 
in diastereoselectivity observed for – 
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1) Electron donating substitution, are brought about via generation of poor E/Z-SKA 
geometric purity which subsequently rearranges through a chair transition state, and 
2) Electron withdrawing susbtitution, are brought about via competing chair and boat 
transition states from the selectively formed E-SKA.  
 
In addition to the NMR studies a computational collaboration has been initiated in-
house, in order to corroborate the origins of diastereoselection. These in-silico studies 
have involved modelling the rearrangement for the 9 para-substituted substrates, 
assuming that they proceed from either the E- or Z-SKA or if a rapid interconversion of 
the E/Z-SKA’s occurs. Initial results from this study have indicated that correspondence 
to experimental results are best suited to the occurrence of an E/Z-SKA interconversion 
and rate studies have alluded to faster rates of rearrangement for electron rich 
substitution.  
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4. Alternative N-Protection in the EICR 
 
As thorough investigations into the EICR of arylacetate enamides have been 
conducted, attention was now redirected towards alkylacetate substrates, as previous 
results have shown that their rearrangement occurs with poor diastereoselectivity.109  
 
 
4.1. Propionate EICR 
 
Initial investigation focussed on the EICR of the propionate 265, synthesised in good 
yield via the standard EDCi coupling of 145 with propionic acid. 
 
 
 
Scheme 116. Synthesis of Propionate 265. 
 
Initial investigations with propionate 265 focussed on utilising the optimised 
conditions developed for the phenylacetate EICR (Chapter 2) and that involving the 
increased loading of TMSCl (Chapter 3). Utilisation of these conditions produced 139 
with an improved yield, however no improvement in diastereocontrol was observed 
(Entry 1 and 2, Table 15). Recovery of mass balance through isolation of methylated 
propionic acid 286 was not accomplished due to volatility, however 1H-NMR analysis 
of crude reaction mixtures alludes to its presence. 
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Entry 
TMSCl 
(n eq.) 
Yield 139 
(%) 
d.r.b 
(anti:syn) 
1 1.3 72 2:1 
2 6 70 2:1 
ad.r. measured by 1H NMR 
 
Table 15. EICR of 265 under Optimised Conditions. 
 
Further investigations involved probing the effect of amide base used, where utilisation 
of NaHMDS resulted in a quantitative return of alcohol 145, however KHMDS, 
Mg(HMDS)2 and LDA all yielded intractable mixtures of products. 
 
 
 
Scheme 117. Subjection of 265 to NaHMDS Mediated EICR. 
 
Alternative investigations have involved the use of soft enolisation conditions as that 
reported by Angle in the synthesis of ∆4,5-pipecolic esters, which saw the Ireland-
Claisen rearrangement of lactone 287 by triethylamine and triisopropylsilyl triflate.171 
 
 
 
Scheme 118. Angle’s Soft Enolisation Conditions. 
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Unfortunately, subjection of propionate 265 to these reaction conditions resulted in the 
formation of intractable mixtures of products.  
 
 
 
Scheme 119. Application of Angle’s Soft Enolisation Conditions. 
 
Other alternatives have included investigations into alternative enolate trapping agents. 
Funk reported the use of diethoxyphosphinyl chloride, allowing generation of enol 
phosphates 288 after LDA deprotonation.172 Subsequent rearrangement of 288 
generates the mixed carboxylic diethoxyphosphoric anhydrides 289, which have been 
shown to be useful acylating agents allowing generation of esters and Weinreb 
reagents 290. Funk noted that the diastereoselection obtained matched that of the 
traditional Ireland-Claisen protocol. 
 
 
 
Scheme 120. Funk’s Alternative Trapping Reagent. 
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Unfortunately, treatment of propionate 265 yielded intractable mixtures of products. 
 
 
 
Scheme 121. Attempt at Funk’s Alternative Trapping Conditions. 
 
Although Funk’s protocol proved to have detrimental effects on the rearrangement of 
265, the use of HMPA in this context was intriguing. It is well known that the 
geometrical outcome of SKA generation via traditional Ireland-Claisen protocols can 
be controlled by the presence or absence of certain additives and HMPA is classically 
used to allow selective formation of the Li-(E)-enolate and subsequently the Z-SKA.66 
The mechanism in which the E-enolate is formed relies on premixing the lithium base 
and HMPA, allowing the Lewis basic HMPA to co-ordinate to lithium subsequently 
reducing its Lewis acidity, prior to addition of substrate. The reduction in the 
electrophilicity of lithium yields a looser six-membered transition state for enolisation, 
of which 1,2-transannular effects become more important than 1,3-diaxial effects, 
resulting in the E-enolate. This aspect of enolate control is highlighted by Ireland-
Claisen rearrangement of 119 in Scheme 122.76 
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Scheme 122. Mechanistic Considerations for syn-Selective Ireland–Claisen Rearrangement. 
 
As the selective formation of either E- or Z-SKA’s offers diastereocontrol, this 
prompted us to ascertain whether the syn-diastereomer could be formed using the 
EICR protocol. Subjection of propionate 265 to rearrangement conditions containing 
23 vol% HMPA/THF yielded an intractable mixture of products. However repeating 
the reaction and replacing the hydrochloric acid quench with methanol, allowed the 
quantitative isolation of the alcohol 145. Isolation of 145 by this modified quench 
protocol insinuates that the presence of HMPA may favour decomposition of the 
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enolate formed, possibly resulting in a degradation via a ketene pathway (Chapter 2, 
Scheme 65).  
 
 
 
Scheme 123. Attempt at syn-Selective EICR 
 
Whilst studies concerning 265 where ongoing, Collum reported the first example of a 
TMSCl-free, LiHMDS-mediated Ireland-Claisen rearrangement.173 The key to the 
success of this reaction was replacement of the Lewis basic solvent, THF, for a 
toluene/triethylamine solvent mixture. Collum reported that the 
LiHMDS/triethylamine mediated enolisation of 291 affords 292 rapidly and 
selectively, with subsequent rearrangement producing 293 in excellent yield, 
diastereoselectivity and was also twenty times faster than the corresponding reaction 
conducted in THF. 
 
 
 
Scheme 124. Collum’s LiHMDS/TEA Ireland-Claisen Rearrangement Protocol. 
 
Unfortunately, mechanistic studies involving the nature of LiHMDS/triethylamine 
ester enolisation and subsequent Ireland–Claisen rearrangement are reported to be 
published in due course. However, Collum has currently proposed an explanation for 
the rapid and selective enolisation observed, through analytical techniques such as 
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React-IR and 6Li- and 15N-NMR spectroscopic studies involving enolisation of ketone 
294.173 
 
 
Scheme 125. Ketone Used for Collum’s Enolisation Mechanistic Studies. 
    
Primarily the reaction proceeds under kinetic control, however, the analytical 
observations revealed some interesting subtleties (Scheme 126). Notably the 
toluene/triethylamine mediated enolisation occurs via a dimer based mechanism 298 in 
contrast to a monomer based mechanism associated with THF 299.174,175 Subjection of 
ketone 294 to LiHMDS/triethylamine (3:30 equivalents) revealed the lithium enolate-
LiHMDS mixed dimer 300 with an E/Z selectivity of 100:1. However, when the 
equivalents of LiHMDS are lowered (<2) significant reductions in E/Z-enolate purity 
are observed, resulting from a facile equilibration and consequent formation of mixed 
E/Z-300 dimers. When LiHMDS loading is lowered to 1 equivalent, enolisation is not 
observed and the substrate autoinhibits the reaction, leading to the formation of the 
unreactive bis-complexed dimer 297.  
 
 
 
Scheme 126.  Solvation Structures of Reactant, Transition Structures & Enolates. 
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The excellent geometric selectivity associated with the triethylamine mediated 
enolisation, stems from the selective stabilisation of the rate-limiting transition 
structures, relative to the reactants. Therefore solvents which display little or no 
affinity for the reactants and a high affinity for the transition structure maximise 
reaction rates. It has been shown that triethylamine mediated enolisations are typically 
150 times faster than when performed in neat THF.174 This rate acceleration derives 
from the destabilising steric affects associated with solvation of the LiHMDS dimer 
295, producing 296. Alleviation of these unfavourable steric interactions is 
subsequently accomplished through generation of dimeric transition structure 298 
allowing enolisation. With this exciting protocol reported by Collum in hand, 
rearrangement of propionate 265 was attempted using this procedure. 
 
 
  
Scheme 126. EICR Using Collum’s Protocol. 
 
Encouragingly, the isolation of 139 in moderate yield and excellent diastereoselectivity 
is in stark contrast to previous attempts. However, accounting for mass balance of this 
reaction became difficult. Analysis of the crude reaction mixture by 1H-NMR pre-
methylation, alluded to the selective formation of the anti-diastereomer 301 and 302, 
presumably generated by an E1cB type elimination of the rearranged lithium 
carboxylate.176 Methylation of the crude reaction mixture was pursued and although 
isolation of 139 was accomplished, isolation of 303 was not. Attempts at isolating 302 
was subsequently attempted by column chromatography and recrystallisation post 
rearrangement, however co-elution and recrystallisation with 301 resulted in both 
cases. 
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Scheme 127. By-product Observation. 
 
To rationalise the generation of 302, it was reasoned its formation may occur via post-
rearrangement enolisation of Li-carboxylate 304 by either the presence of excess 
LiHMDS and/or the 1N NaOH reaction quench. 
 
 
 
Scheme 128. Possible Degradation of Rearranged Li-Carboxylate via E1cB Elimination. 
 
Quenching the rearrangement with the non-nucleophilic NaHCO3 resulted in identical 
product distributions to that seen with the 1N NaOH quench. The generation of 302 
was subsequently attributed to the large excess of LiHMDS required with Collum’s 
protocol and is in conjunction with observations previously reported (Chapter 2). 
 
The use of LiHMDS/triethylamine (3 eq./30 eq.) has been found to be optimal for 
enolisations of esters and ketones. However, in order to ascertain whether Collum’s 
protocol can be adapted to the EICR, optimisation of this procedure was pursued. In 
order to counteract the issue of excess LiHMDS within the reaction protocol, any 
attempts at reducing the amount of LiHMDS and triethylamine resulted in complex 
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intractable reaction mixtures, with limited if any signs of product or by-product 
formation by 1H-NMR. Unsurprisingly, increasing the amount of LiHMDS (4 eq.) led 
to a reduced yield of 301 with an increase in 302.  
 
 
 
Scheme 129. Increasing LiHMDS in Propionate EICR. 
 
Investigations into solvent exchange demonstrated the importance of a non-Lewis 
basic media. Hexane displayed analogous results to toluene; however the use of THF 
and tbutylmethylether displayed complex and intractable reaction mixtures, with no 
product 301 or by-product 302 observed.  
 
 
 
Scheme 130. Solvent Exchange in Propionate EICR. 
 
Investigations into alternative bases including NaHMDS and KHMDS yielded varying 
amounts of unreacted starting propionate 265 (Entries 1 & 2, Table 16) with no signs 
of any rearrangement occurring. 
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Entry M 
Yield  265 
(%) 
1 Na 67 
2 K 51 
 
Table 16. Amide Base Exchange in Propionate EICR. 
 
In order to improve the reaction efficiency, the addition of TMSCl was pursued, 
following in-situ (Entry 1, Table 17) and ex-situ (Entry 2, Table 17) quench protocols. 
Incorporation of this additive demonstrated near complete formation of the E1cB by-
product 302, with trace amounts of product 301 being observed. Presumably this 
enhanced degradation arises from generation of the Lewis acid, LiCl within the 
reaction mixture. 
 
 
Entry Addition of TMSCl 
Yield  301  
(%) 
Yield 302a  
(%) 
1 In-situ 2 80 
2 Ex-situ 3 80 
aBased on 1H-NMR Conversion. 
 
Table 17. Additive Effects in Propionate EICR. 
 
As these initial optimisation attempts were shown to be unfavourable, attention was 
now turned to product 301 and by-product 302 distributions. A notable observation 
was that formation of 301 was never acheived in a yield >45%, with mass balance 
being accounted for by formation of 302. Further to this, the addition of TMSCl (Table 
20) yielded near quantitative formation of 302, presumably caused by the formation of 
the familiar Lewis acid, LiCl (as discussed in Chapter 3). In relation to our enamido 
Chapter 4  Results & Discussion
   
141 
ICR, the in-situ formation of LiCl could either allow E1cB degradation to occur on a 
diastereoselective or a non-diastereoselective rearrangement product. It was 
subsequently realised that a non-diastereoselective rearrangement may be occurring 
under Collum’s protocol and the formation of a single diastereomer in 45% yield may 
be the result of a pseudo-kinetic resolution of one diastereomer (syn-) compared to the 
other (anti-). In order to determine if this is the case, quenching the reaction prior to 
the onset of E1cB elimination would be advantageous. It is noted that during warming 
of the reaction a colour change was noted at 0 ˚C and was ascribed to the possible 
onset of E1cB elimination. With this in mind the reaction was repeated and an arbitrary 
temperature of -10 ˚C was chosen to warm the reaction to, where it was subsequently 
quenched after an identical reaction time. Analysis of the crude reaction mixture by 
1H-NMR alluded to no formation of 302 with 139 generated in a non-
diastereoselective fashion. Although the yield for this reaction was low the majority of 
the mass balance was obtained by re-isolation of the starting propionate 265.  
 
 
 
Scheme 131. Investigating Diastereoselectivity of EICR. 
 
To demonstrate that the syn-diastereomer is more susceptible to E1cB type elimination 
than the anti-diastereomer, subjection of carboxylic acid 301 (d.r. = 2:1) to LiHMDS 
(3 eq.) and triethylamine (30 eq.) was pursued. The subjection of 301 to standard 
Collum protocols was envisaged to mirror post rearrangement concentrations of 
LiHMDS and triethylamine, as one equivalent of LiHMDS would generate a lithium 
carboxylate. This study demonstrated the selective elimination of syn- over the anti-
diastereomer and it is noted that conversion to anti-301 in 59% is marginally lower 
than that expected for a 2:1 mix of diastereomers, where 66% would be the theoretical 
maximum yield. It is therefore suggested that elimination of syn-301 is more facile, but 
this does not mean that anti-301 is completely unsusceptible. 
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Scheme 132. Investigating the Selectivity of the E1cB Type Elimination. 
 
The utilisation of the Collum protocol in the EICR of propionate 265 allows clean 
access to a single anti-diastereomer in 45% yield. This contrasts favourably with our 
previous report.109 However the inherent issues associated with the unselective reaction 
and the reliance of a pseudo-kinetic resolution to generate high anti-
diastereoselectivities are not ideal and led us to pursue alternative enamide nitrogen 
protection. 
 
4.2. Investigation into Alternative N-Protection 
 
The successful EICR of propionate and arylacetate enamido allylic esters in generating 
β-amino acid precursors would allow access to a wide variety of natural and non-
natural targets. Such targets could involve the prescribed stimulant methylphenidate 
(Ritalin®) 5 and the antimicrobial β-peptide unit key to β-foldamers, such as trans-2-
aminocyclpentanecarboxylic acid (ACPC) 21 and derivatives thereof.5, 20-21 Other 
larger targets could involve that of the cytotoxic motuporin 19.14 
 
 
 
Scheme 133. RSA of Potential Target Molecules 
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Access to any target molecule using the EICR strategy relies on the use of a suitable 
enamide with reliable protecting groups. In an attempt to enhance the utility of the 
EICR, alternative enamides were investigated to probe any structure-reactivity trends. 
A number of potential enamides were identified based on the ability to modulate the 
electron donating capability of the enamine nitrogen but also to serve as readily 
cleavable protecting groups. The use of p-tolylsulfonamide (cleaved by Mg/MeOH) 
the use of N-Boc (cleaved by trifluoroacetic acid) and N-phthalimide (cleaved by 
hydrazine) were chosen for investigation.177-179 Other orthogonal components, in 
addition to the required electron withdrawing group, could be satisfied by use of N-
alkyl derivatives such as the allyl group (cleaved by Wilkinson’s catalyst) or the 
benzyl group (cleaved by hydrogenolysis).180-181 With these protecting groups in mind 
several, target EICR substrates were identified, subsequently allowing synthesis of a 
variety of protected β-amino acid precursors, including the phthalimide 305, diBoc 
306, allylBoc 307, benzylsulfonamide 308 and the allylsulfonamide 309.  
 
 
 
 
Scheme 134. Enamide Substrates for Evaluation. 
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4.2.1. Enecarbamates 
 
Initial investigations surrounding the use of N-Phth and N-Boc protection proved 
problematic. Access to racemic N-Phth and N-Boc enamido secondary alcohols were 
attempted by the standard protocol, involving Jones oxidation of 149 and subsequent 
addition of the appropriate nitrogen nucleophile in good yields.  
 
 
 
Scheme 134. Route to Alternative N-Protected Enamides. 
 
Subsequent chemoselective reduction of the ketone proved to be problematic for the N-
phthalimide 310, as competition between reduction of the imide functionality was seen 
in addition to reduction of the ketone. Reduction of 310 with 1 equivalent of NaBH4 
offered no advantage, with intractable mixtures of products resulting.  
 
 
 
Scheme 135. Route to N-Phth Protected Enamides. 
 
Reduction of the N-Boc systems 311 and 312 also appeared challenging as the alcohols 
313 and 314 proved more facile to dehydration and observation of crotonaldehyde 157 
and parent N-Boc amine 315 signals by 1H-NMR spectroscopy resulted. 
 
 
 
Scheme 136. Route to N-Boc Protected Enamides. 
Chapter 4  Results & Discussion
   
145 
4.2.2. Enesulfonamides 
 
With unsuccessful access to N-Boc and N-Phth secondary alcohols, attention was 
turned to the stereoselective synthesis of secondary sulfonamide alcohols adapted from 
a procedure reported by Meyer.106, 182 This approach was initially shown to allow 
selective access to primary propargylic E- and Z-enesulfonamides, via copper-
catalysed coupling between sulfonamide 316 and bromoalkyne 317. Alkyne, 319 was 
then reduced with geometrical control to produce the E-322 or Z-321 isomer. Meyer 
has subsequently demonstrated that the synthesis can also be applied to generating the 
secondary N-benzylsulfonamide alcohol 323 in high yield. 
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Scheme 137. Meyer’s Synthesis of N-Protected Vinylogous Alcohols. 
 
The added benefit of utilising Meyer’s protocol is that the synthesis can offer access to 
enantiomerically pure secondary enesulfonamide alcohols. This synthetic route should 
then allow chirality transfer within the EICR, providing rearrangement of the 
sulfonamide allylic ester substrates occurs efficiently. Therefore a unique entry into 
carbocyclic and heterocyclic β-amino acids, such as ACPC 21 and β-proline 324 or 
iminosugar analogues 325 should be possible. 
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Scheme 138. RSA of Potential Target Molecules. 
 
To allow rapid investigation into the EICR of these enesulfonamides, the synthetic 
route undertaken again relied on the reported procedure by Carbery and Janey.109,113 
The synthesis of racemic 329 and 323 involved the two step procedure involving Jones 
oxidation of 149, followed by the immediate conjugate addition of the appropriate 
sulfonamide 326 or 316 in the presence of catalytic amounts of DABCO.114 Reduction 
of ketone 327/328 was achieved by a modified protocol where higher loadings of 
sodium borohydride and a dual THF/MeOH solvent system were required.183 Key 
sulfonamides 329 and 323 were afforded in good yields and importantly, the acid 
sensitive compounds were isolated by simple aqueous work-up, without the need for 
further purification. 
 
 
 
Scheme 139. Route to Racemic AllylTs & BnTs Secondary Alcohol. 
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4.2.3. EICR Optimisation of Propionate & Phenylacetate N-
Allylsulfonamides 
 
With a rapid and efficient route to multigram quantities of both racemic N-
allylsulfonamide 329 and racemic N-benzylsulfonamide 323 alcohols in hand, 
synthesis of rearrangement substrates was subsequently pursued. Initial investigations 
involved synthesis of the propionate-330 and phenylacetate-allylsulfonamide 331, both 
in excellent yields via the standard esterification protocol using EDCi.  
 
 
 
Scheme 140. Synthesis of Racemic Propionate & Phenylacetate Sulfonamide Substrates. 
 
With the required alkyl and phenylacetate substrates in hand, investigations 
surrounding the EICR of these substrates could now be pursued. Both substrates were 
subjected to optimised rearrangement conditions detailed in Chapter 3 (LiHMDS 1.3 
eq., TMSCl 6 eq.). Subjection of the propionate allylsulfonamide 330 to these 
conditions led to quantitative return of the alcohol precursor 329, presumably resulting 
from instability of enolate or SKA. It is further noted that isolation of methyl 
propionate 332 would be expected, but due to volatility issues this was never 
accomplished. However subjection of phenylacetate 331 to rearrangement conditions 
was mildly successful, generating the rearranged β-amino acid precursor 333 in poor 
yield but excellent diastereoselectivity. Near quantitative mass balance for this 
rearrangement was recovered by isolation of methyl phenylacetate 158. 
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Scheme 141. EICR of Racemic Propionate & Phenylacetate Sulfonamide Substrates. 
 
With encouraging results seen by the rearrangement of the phenylacetate 331, an 
optimisation of rearrangement conditions was performed on this substrate. A possible 
consideration as to why the reaction may produce a poor yield, is that lithiation of the 
N-allyl group and subsequent formation of a sulfonamide co-ordinated 5-membered 
ring may be a competing process.184  
 
 
 
Scheme 142. Possible Formation of 5-membered Ring. 
 
If this were the case then simply increasing the number of equivalents of LiHMDS 
should circumvent this issue. With this in mind a small optimisation involving 
investigations into the equivalents of LiHMDS was pursued, with 2, 2.25, 2.5 and 3 
equivalents all demonstrating increased yields of 333 and reductions in 158. As an 
optimal yield was obtained for use of 2.5 equivalents of LiHMDS (Entry 3, Table 18), 
all future rearrangements of arylacetate sulfonamides were subjected to this condition. 
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Entry 
LiHMDS 
(n eq.) 
Yield 333 
(%) 
Yield 158 
(%)a 
1 2 59 18 
2 2.25 60 31 
3 2.5 67 27 
4 3 60 31 
aYield refers to 333 that 158 would correspond to. 
 
Table 18. Optimisation of Phenylacetate Allylsulfonamide EICR. 
 
With the successful rearrangement of the phenylacetate 331 in hand, efforts were then 
redirected to the rearrangement of the propionate 330. Subjection of 330 to the newly 
optimised rearrangement conditions yielded an intractable mixture of products, 
however analysis of crude 1H-NMR spectra indicated limited signs of 334 with a 
diastereomeric ratio of 1:1.  
 
 
 
Scheme 143. EICR of Racemic Propionate Sulfonamide Substrate. 
 
With the EICR of the propionate 330 still being problematic, the use of Collum’s 
conditions was revisited.173 Subjection of 330 to the standard conditions involving 3 
equivalents of LiHMDS and 30 equivalents of triethylamine led to the formation of 
intractable reaction mixtures. However, following a swift investigation into increasing 
the stoichiometry of the base and co-solvent, clean formation of 334 was only 
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observed with 4.5 equivalents of LiHMDS and 45 equivalents of triethylamine. In an 
attempt to account for mass balance, it is noted that formation of E1cB degradation 
product was not observed, but the presence of methyl propionate 332 signals within the 
crude 1H-NMR alludes to the familiar degradation of enolate. 
. 
 
 
Scheme 144. EICR of Racemic Propionate Allylsulfonamide Using Collum Conditions. 
 
 
4.2.4. EICR of Alkyl & Arylacetate N-Allylsulfonamides 
 
With the optimisation of the phenylacetate 331 and propionate 330 rearrangements 
completed, a number of alkyl- and aryl-substrates were synthesised using the standard 
EDCi coupling conditions in excellent yields. It is noted however, that heteroatom 
substitution (Entry 3 & 4, Table 19) was extremely sensitive and subjection of these 
substrates to EICR conditions was required immediately. Synthesis of an N-
phthalimide substrate (Entry 5, Table 19) was not accomplished as intractable mixtures 
of products resulted post work-up. 
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Entry R Product 
Yield  
(%) 
Entry R Product 
Yield  
(%) 
1 iPr 335 87 7 
 
341 89 
2  336 99 8 
 
342 86 
3 
 
337 87 9 
 
343 86 
4 
 
338 92 10 
Cl
Cl
 
344 82 
5 
 
339 - 11 
 
345 86 
6 
 
340 86 12 
 
346 85 
  
Table 19. Yields for EDCi Couplings. 
 
With several substrates in hand, rearrangement was then pursued using the newly 
optimised conditions. For alkyl derivatives the newly modified Collum conditions 
were utilised and for the aryl derivatives the newly optimised LiHMDS/TMSCl 
conditions were used. The heteroatom substrates, 337 and 338, were subjected to both 
sets of rearrangement conditions. 
 
The rearrangement of the alkyl substrates (Entries 1-3, Table 20) were observed to 
proceed in moderate to good yields and excellent diastereoselectivities, with a 
reduction in diastereoselectivity seen for rearrangement of pentenoicacetate (Entry 3, 
Table 20). The results obtained from the successful rearrangement of these alkylacetate 
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sulfonamide rearrangements are in stark contrast to that observed for the propionate 
oxazolidinone system 256 seen previously. This result presumably signifies the onset 
of a selective enolisation and efficient rearrangement. It is also noted that no E1cB 
degradation product was observed during rearrangement of these alkylsulfonamides. 
Rearrangement of the heteroatom substrates (Entries 4 & 5, Table 20) under these 
conditions provided a different outcome, with complex reaction mixtures resulting. 
Analysis of crude 1H-NMR spectra alluded to no signs of desired rearrangement, 
however careful purification of these reaction mixtures allowed the isolation of the 
familiar E1cB degradation product 353 and 354.  
 
 
Entry R Product 
Yield 
(%) 
d.r.a,b 
(anti:syn) 
By-Product 
Yield 
(%)c 
1 Me 334 51 >25:1 302 0 
2 iPr 347 65 >25:1 351 0 
3  348 70 10:1 352 0 
4 
 
349 0 na 353 41 
5 
 
350 0 na 354 43 
ad.r. measured of crude on 250 MHz 1H NMR bTriplicates have been performed in each case. Measured 
dr is reproducible and reported as an average cYield refers to product that E1cb product corresponds to. 
 
Table 20. Results for Alkyl- & Heteroacetate EICR. 
 
Rearrangement of aryl substrates (Table 21) has also been shown to occur in good 
yield and generally excellent diastereoselectivities. A significant observation is that 
rearrangement of systems that have previously shown poor diastereoselectivity 
Chapter 4  Results & Discussion
   
153 
(Chapter 2) including ortho-substituents and the electron withdrawing para-nitro and 
electron donating para-methoxy now possess excellent diastereoselectivity.  Of 
notable interest is the reduced diastereocontrol observed with the p-CF3 substrate 
(Entry 3, Table 21), which is now less than that obtained for the oxazolidinone variant 
(Chapter 2, 217, d.r. = 21:1). Near quantitative mass balance was returned by isolation 
of the corresponding methyl arylacetates. Attempted rearrangement of the hetereoatom 
substrates 349 and 350 yielded complex intractable reaction mixtures.  
 
 
Entry R Product 
Yield 
(%) 
d.r.a,b 
(anti:syn) 
By-Product 
Yield 
(%)c 
1 
 
355 67 >25:1 362 21 
2 
 
356 73 >25:1 186 18 
3 
 
357 54 12:1 228 18 
4 
 
358 40 20:1 189 15 
5 
Cl
Cl
 
359 68 >25:1 363 22 
6 
 
360 72 20:1 231 15 
7 
 
361 55 >25:1 234 25 
ad.r. measured by acquisition of crude on 250 MHz 1H NMR bDuplicates have been performed in each 
case. Measured dr is reproducible and reported as an average cYield refers to prod that by-prod 
corresponds to. 
Table 21. Results for Arylacetate EICR 
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In order to rationalise the improved diastereoselectivity seen by rearrangement of 
alkyl- and arylsulfonamides compared to the oxazolidinone examples, considerations 
surrounding the electronic nature of these enamide substrates were pursued. Based on 
the observed 13C-NMR resonances it is seen that C1 in the sulfonamides are more 
deshielded than the corresponding carbamates. Whilst resonances are similar for C2 
and C3, subtle differences are observed with C4 and C5 in that the sulfonamides are 
more shielded than the corresponding carbamates. 
 
 
δC 
Entry Substrate NPG2 R 
C1 C2 C3 C4 C5 
1 330 
 
Me 129.5 110.1 69.8 173.5 27.9 
2 256 
 
Me 127.1 110.1 69.5 174.1 28.3 
3 331 
 
Ph 129.9 109.7 70.7 170.8 41.7 
4 154 
 
Ph 127.0 110.1 70.3 171.2 42.0 
 
Table 22. Comparing δC for Sulfonamides & Carbamates. 
 
These differences in δC allude to the degree of nitrogen involvement within these 
substrates. The more deshielded C1 and more shielded C4 of the sulfonamides indicate 
that this N-protection allows a greater degree of electron release into the enamide, 
purporting to more iminium character and an elongated C-Oσ bond 364 as compared 
to the corresponding carbamate. 
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Scheme 145. Structural Depiction of Sulfonamide Substrates. 
 
The increased diastereoselectivity observed with the more electron releasing 
sulfonamide substrates may be an aspect of a faster rearrangement, with issues such as 
Li-enolate and SKA isomerisation, or chair/boat interconversion no longer contributing 
to the diastereochemical outcome. It has been well documented in the related Cope 
rearrangement, that rate accelerations are observed with electron releasing terminal 
allyl substituents.85, 146-148, 185  
 
The successful rearrangement of alkyl sulfonamides under Collum’s protocol is 
markedly improved to that involving propionate oxazolidinone 256, in that a 
diastereoselective rearrangement occurs with no E1cB degradation. This apparent 
resistance may be due to conformational constraints and a steric in-accessibility of 
LiHMDS to the α-H of the rearranged Li-carboxylate.  During rearrangement of the 
sulfonamide and oxazolidinone systems it is envisaged that each Li-carboxylate exists 
as a mixed dimer 365 and 366 respectively. However, steric considerations of the 
sulfonamide may possess another factor hindering post-rearrangement enolisation, 
anticipated to be the formation of the 5-membered lithiated-allylsulfonamide ring 
.  
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Fig. 22. In-Solution Considerations of Rearrangement Li-Carboxylates.  
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4.2.5. Derivatisation of N-Allylsulfonamide  Rearrangement Products 
 
With the successful rearrangement of alkyl- and arylacetate β-amino acid precursors of 
allylsulfonamide in hand, utilisation of the synthetic handles was pursued. Elaboration 
heavily focused on utilising the bis-olefin functionality present within the EICR 
products, with the sole aim of gaining access to heterocyclic β-amino acid precursors 
through means of a simple ring closing metathesis (RCM). In a similar protocol 
reported by Moreno-Mañas involving the RCM of bis-allylic sulfonamides, subjection 
of the sulfonamide EICR products to RCM conditions allowed access to the 
hetereocyclic β-amino acid precursors in high to excellent yield.186 It is noted that 
substrates possessing ortho-substitution required a toluene solvent exchange and 
subjection to mild heating. 
 
 
Entry R Product 
Yield 
(%) 
Entry R Product 
Yield 
(%) 
1 Me 367 71 6 
 
372 91 
2 iPr 368 86 7 
 
373 96 
3 Ph 369 92 8 
Cl
Cl
 
374 83a 
4 
 
370 51a 9 
 
375 90a 
5 
 
371 89 10 
 
376 89 
aConducted in toluene at  65 ˚C 
 
Table 23. Results for Grubbs I RCM of Sulfonamide EICR Products. 
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With a variety of heterocyclic β-amino acid precursors in hand, this opens up possible 
synthetic access to β-proline derivatives and may also allow access to iminosugar 
analogues. With this in mind a variety of transformations on 369 have been pursued, of 
which hydrogenation 377 and saponification 378 have successfully been achieved. 
Brief attempts at sulfonamide deprotection using Mg/MeOH and epoxide formation by 
treatment with mCPBA yielded intractable mixtures of products. 
 
 
 
Scheme 146. Derivitisation of Phenylacetate Heterocyclic β-Amino Acid Precursor. 
 
The synthetic handle presented by ortho-iodo heterocyclic β-amino acid precursor 370 
provides an excellent substrate for the synthesis of an interesting 6,5,5-fused 
heterocyclic β-amino ester 379. Following a protocol reported by Fürstner for 
intramolecular Heck reactions, the synthesis of 379 was accomplished in an excellent 
yield.187 
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Scheme 147. Heck Derivitisation of ortho-Iodo Heterocyclic β-Amino Acid Precursor 370. 
 
4.2.6. EICR of N-Benzylsulfonamides 
 
With the success seen in derivatising N-allylsulfonamide rearrangement products as 
heterocyclic β-amino esters, it was hoped access to carbocyclic β-amino acids such as 
ACPC 21 could be achieved via rearrangement of N-benzyl protected sulfonamides. 
With this in mind esterification of 323 with pentenoic acid yielded 380 in excellent 
yield. 
 
 
 
Scheme 148. Route to Racemic BnTs Secondary Allylic Ester. 
 
Rearrangement of 380 under modified Collum conditions yielded 381 in excellent 
diastereoselectivity but very poor yield, however with no indication of E1cB 
degradation.  
 
 
Scheme 149. EICR of BnTs Secondary Allylic Ester 380. 
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Subsequent attempts at increasing the efficiency of this rearrangement have included 
varying the stoichiometry of the reagents used and performing cold reaction quenches, 
however these attempts have been unsuccessful. Subjection of 380 to LiHMDS and 
TMSCl rearrangement conditions yields similar results, however no diastereoselection 
is obtained in product 381. However, to demonstrate that carbocyclic β-amino acid 
precursors can be accessed from 381 (generated within scheme 149), subjection to 
RCM conditions produced 382 in excellent yield.   
 
 
 
Scheme 150. Generation of Carbocyclic β-Amino Acid Precursor 382. 
 
4.2.7. Chirality Transfer within the EICR of N-Allylsulfonamides 
 
With the success seen in the yield and diastereoselectivities of the EICR of the alkyl- 
and aryl allylsulfonamides, it was decided to pursue an enantiopure synthesis of this 
class of substrate. It was hoped that rearrangement of an enantiopure substrate would 
allow the synthesis of optically active β-amino esters, via the reliable chirality transfer 
apparent in the Ireland-Claisen rearrangement.76 With this in mind, it was decided that 
this study shall focus on the synthesis and rearrangent of the (S)-phenylacetate (S)-331, 
based on an adaptation of Meyer’s reported synthesis.106, 182 
 
 
 
Fig. 23. (S)-Phenylacetate (S)-331. 
 
The synthesis of (S)-331 first involved silyl protection and bromination of alcohol (S)-
149, followed by Ullmann coupling of (S)-383 with allylsulfonamide 326 to afford 
ynamide (S)-384 in good yield. Subsequent TBAF deprotection afforded (S)-385 in 
good yield, however reduction and isolation of (S)-329  proved problematic.  
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Scheme 151. Attempted Synthesis of (S)-329. 
 
Meyer’s synthesis involved the reduction of an anologous N-benzylsulfonamide, with 
purification achieved by an aqueous Rochelle’s salt quench and subsequent column 
chromatography. The reduction of (S)-385 under Meyer’s protocol initially proved 
succesful, however the purification of  (S)-329 presented issues. Superficially the 
aqueous Rochelle’s salt quench appeared to cleanly provide (S)-329 without the need 
for column chromatography. However attempted esterification with phenylacetic acid 
led to unpurifiable mixtures of phenylacetate (S)-331 and unreacted alcohol (S)-329, 
possibly due to the presence of residual aluminium salt impurities. 
 
 
 
Scheme 152. Attempt at Synthesising (S)-Phenylacetate (S)-331. 
 
Attempted purification of (S)-329 via column chromatography using silica or grade V 
alumina unfortunately led to degradation, with spectroscopic analysis aluding to the 
formation of familiar crotonaldehyde 157 and allylsulfonamide 326 dehydration 
products. 
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Scheme 153. Sensitivity of (S)-329 to Purification Conditions. 
 
This difference in stability between the N-benzyl and N-allylsulfonamide alcohols to 
purification is indeed unfortunate. However, to allow clean synthesis of (S)-329 without 
recourse to column chromatography a number of variables were investigated. 
Investigations surrounding the stoichiometry of Red-Al® were initially pursued, where 
reduction to 1.5 equivalents allowed complete conversion to (S)-329, however issues 
with its subsequent esterification were still observed. Similar issues were also observed 
with the use of LiAlH4. In an attempt to solve the purification issues of (S)-329, an 
alternative work-up protocol was pursued. Tomooka noted that the use of a ‘pea crystal’ 
(Na2SO4.10H2O) quench can efficiently remove aluminium hydrides and their by-
products.188 Reduction of (S)-385 following this protocol was found to be succesful and 
subsequent esterification yielded (S)-329 in high yield. 
 
 
 
Scheme 154. Synthesis of (S)-331. 
 
With the desired enantiopure substrate (S)-331 in hand, subjection to rearrangement 
yielded the β-amino acid precursor (2R,3R)-333 in high yield and excellent 
diastereoselectivity. Importantly, excellent levels of enantiocontrol were observed 
within the rearrangement, however efforts at obtaining an absolute value of 
enantiomeric excess have not yet been successful, based on an inability to gain total 
baseline resolution by HPLC. An important observation associated with rearrangement 
of this enantiopure substrate has demonstrated that the minor Z-SKA appears to 
display no chirality transfer, as enantioselection is not observed in formation of the 
syn-product and may be attributed to a non-concerted bimolecular recombination 
reaction. 
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Scheme 154. EICR of (S)-Phenylacetate (S)-331 
 
 
4.3. Conclusions 
 
Although superficial improvements within the diastereoselectivity for rearrangement of 
N-oxazolidinone-propionate 265 were achieved by Collum’s protocol, poor yields 
resulted.173 Subsequent investigation demonstrated that the EICR under these conditions 
was non-selective and 2:1 mixtures of anti:syn diastereomers were generated. The 
superficial appearance of a selective rearrangement was the result of a more facile E1cB 
type elimination of the syn-diastereomer compared to the anti-. 
 
In an attempt to observe successful rearrangement of both alkyl- and arylacetate 
substrates, investigations into the use of alternative N-protected enamides were pursued 
to probe any structure reactivity trends. The use of N-Phthalimide and N-Boc protection 
was non-profitable based on substrate instabilities, however the use of sulfonamide 
protection was observed to allow the successful rearrangement of both alkyl-and aryl-
substrates. Further derivitisation of these N-allylsulfonamide rearrangement products 
was seen within the derivitisation as heterocyclic β-amino acid precursors. Also the 
synthesis of an enantiopure phenylacetate substrate allowed excellent chirality transfer 
within the EICR be demonstrated. 
 
Chapter 5  Conclusions & Future Work 
163 
 
5. Conclusions & Future Work 
 
The initial remit of the enamido Ireland-Claisen rearrangement was to harness the 
synthetic properties associated with the related Ireland-Claisen rearrangement and 
allow access to multi substituted β-amino acids with high levels of stereocontrol. 
Initial efforts focussed on developing the preliminary results involving the 
rearrangement of N-oxazolidinone substrates.109 After a reaction optimisation further 
investigation into the variation of diastereoselectivity based upon the nature of 
electronic perturbation in α-arylacetates was pursued. This study demonstrated a 
conspicuous range of diastereoselectivity whereby a free energy relationship was 
realised for the para-substituted analogues and allowed diastereoselection be examined 
in terms of deconvoluted steric and electronic effects. 
 
 
 
Fig. 24. EICR of Para-Substituted Substrates & Associated Log(d.r.) vs Resonance Parameter R−. 
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As this non-linear Hammett type plot alludes to a change within the rate determining 
step of the mechanism, it was clear that the EICR was sensitive to electronic 
perturbation as reductions in diastereocontrol were observed with increasing electron 
withdrawal and donation.131 In order to evaluate the origins of diastereoselection 
mechanistic studies were undertaken. It was rationalised that 2 key stages within the 
EICR may be responsible for the varied diastereoselectivity, this being from initially 
generated mixtures of E/Z-SKAs which rearrange through a predictable chair transition 
state or from selective formation of the E-SKA which then rearranges through 
competing chair and boat transition states. With these considerations in mind, in-situ 
NMR experimentation was pursued with the aim of being able to monitor the EICR of 
an electron withdrawing, neutral and donating substrate. Initial studies involved the 
1H-NMR monitoring of model α-aryl SKA formation, designed to mimic the 
secondary ester of the enamide substrates. From this study it was shown that SKA 
formation was in fact sensitive to the nature of electronic substitution, with reduced 
geometric control observed for the strongly electron withdrawing and electron 
donating systems.160 These results were indeed important as they demonstrated that 
generation of varied E/Z-SKAs may influence the diastereochemical outcome of the 
associated EICR.  
 
 
 
Scheme 155. Comparing Aryl SKAs to d.r. of EICR 
 
Although varied degrees of geometric control were observed for the in-situ formation 
of the model SKAs, they were shown to be much higher than previous literature 
isolations.149, 156-159 With this in mind a protocol for the formation and isolation of α-
aryl E-SKAs was developed, where (E)-2H1-240 was isolated essentially as a single 
geometric product.160 
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Scheme  156. Isolation of Phenylacetate SKA. 
 
The success observed within the monitoring of SKA formation then led us to follow 
the in-situ reaction monitoring of the EICR. After several attempts at synthesising a 
viable class of substrate, synthesis of 13C-labelled phenyl-, para-methoxy- and para-
trifluoromethylphenylacetates were accomplished. The in-situ reaction monitoring by 
13C-NMR allowed observation of E/Z-SKA formation/consumption and subsequent β-
silylester formation.  
 
 
 
Scheme. 157. EICR Reaction Monitoring by 13C-NMR. 
 
Unfortunately, the inability to detect both the syn- and anti-diastereomers of product 
were plagued by coincident resonances. However the results from this study were 
informative in that the origins of diastereoselection are attributed to- 
 
1) Poor E/Z-SKA control which rearranges through a chair transition state for 
electron donating substitution. 
2) Selective formation of the E-SKA which rearranges through competing chair 
and boat transition states for electron withdrawing substitution. 
 
In addition the results generated from these studies have also allowed a major insight 
into the effects of silyl by-products generated within the reaction. Throughout each in-
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situ reaction, inflections in the return of substrates were observed and this is attributed 
to a facile ‘Internal Proton Return’ mechanism to the enolate and SKA.162,163 
Generation of LiCl is also thought to play a major role within the observed reaction 
profile as it exhibits auto-catalytic effects, speeding up the rate of enolisation and 
reducing that of IPR, resulting in consumption of substrate.165 The formation of 
silanamine within these reactions has also alluded to the observed stalling of the EICR, 
as silylation of LiHMDS becomes more facile compared to enolisation of substrates 
and is attributed to an ever increasing concentration of LiCl exhibiting deleterious 
effects. 
 
In addition to the mechanistic studies, other areas of research have involved 
improvement of the alkylacetate EICR, in which alternative reaction conditions were 
investigated. The most promising conditions for N-oxazolidinone substrates were seen 
to be that offered by Collum, involving a TMSCl-free protocol.173 However, even after 
a comprehensive optimisation the reaction was seen to demonstrate poor 
diastereoselectivity, masked by a pseudo-kinetic resolution involving a preferential 
E1cB degradation of the syn-diastereomer. To allow the successful EICR of 
alkylacetates alternative N-protection was sought. This resulted in the synthesis of N-
allylsulfonamide substrates and encouragingly successful rearrangement of both alkyl- 
and arylacetates was obtained. Utilisation of these rearrangement products has 
subsequently been demonstrated in the synthesis of β-proline analogues. 
 
 
 
Scheme 158. Allylsulfonamide EICR and Subsequent Ring Closing Metathesis. 
 
In addition the successful rearrangement associated with N-allylsulfonamide protection 
has also allowed access to enantiomerically enriched substrates and rearrangement has 
shown high levels of chirality transfer (>88% e.e).  
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 Future Work- This research has created several viable areas for future 
exploration, both within the EICR and external to it. First and foremost the 
mechanistic studies have allowed an interesting insight into the nature of the EICR; 
however they have also demonstrated the complexities associated with it. The inability 
to monitor the formation of both syn- and anti-diastereomers throughout any in-situ 
reaction has been a limiting factor in the discussions surrounding the origins of 
diastereoselectivity. The presence of HMDS and the presumably ever increasing 
concentration of LiCl are envisaged to both play major roles within the EICR and other 
curiosities are observed with the inability to detect LiHMDS and the formation of 
silanamine throughout each reaction. Therefore in order to allow further mechanistic 
rationale other NMR techniques involving isotopically enriched reagents could 
entail:173 
 
1) 7Li-NMR – To allow tracking of total lithium content, including various Li-
incorporated aggregates and build up of LiCl. 
2) 15N-NMR – To allow tracking of total nitrogen content of reagent and reactant, 
including LiHMDS, HMDS, silanamine and also oxazolidinone of substrate. 
3) 29Si-NMR – To allow tracking of total silicon content, with the main aim of 
being able to distinguish E/Z-SKAs and also syn- and anti-β-silylester products. 
 
As further mechanistic studies would allow a greater understanding of the electronic 
effects of substitution within the EICR, we would also gain a further insight into the 
in-situ compatibilities between LiHMDS/TMSCl. These observations could then be 
transposed into other similarly mediated reactions. 
 
In addition to the mechanistic studies, the potential synthetic benefits of the EICR have 
been demonstrated by the successful rearrangement in high diastereo- and 
enantioselectivity of the N-allylsulfonamides. Although further exploitation of these 
synthetic intermediates has only incorporated the synthesis of β-proline analogues, the 
further development of this chemistry may allow a novel route into ACPC 21 derived 
β-foldamers, β-proline organocatalysts 324 and iminosugars 325.20-21 
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Scheme 159. RSA of Potential Target Molecules. 
 
Also, the formation and isolation with high E-SKA purity of phenylacetate derived 
SKAs creates a new topical area of interest. For instance, the involvement in Mannich 
reactions previously inhibited by a non-selective E-SKA formation, or where only the 
selectively formed Z-SKA was used, may now allow selective access into both syn- 
and anti-β-amino acid precursors by utilisation of our selectively formed E-SKA.149,151 
 
 
Scheme. 160. Potential Mannich Reactions for Exploitation with Selective Formation of E-SKA. 
 
The use of our developed synthesis of α-aryl-E-SKAs and their subsequent use within 
various Mannich reactions, may then serve as a back-up route to compliment the 
enamido-Ireland-Claisen rearrangement in the synthesis of β-amino acids. 
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6. Experimental 
 
6.1. General Experimental Information 
Reactions were conducted in flame dried vessels using anhydrous solvents and under an 
inert atmosphere of nitrogen. In all cases, solvents were obtained by passing through 
anhydrous alumina columns using an Innovative Technology Inc. PS-400-7 solvent 
purification system. All reagents were purchased from commercial suppliers: Acros 
Organics, Alfa Aesar, Sigma Aldrich or Novabiochem and used without purification. 
Triethylamine was freshly distilled alone and chlorotrimethylsilane was freshly distilled 
from 10 % quinoline. All distilled materials were stored under nitrogen at 4 oC or less. 
All reactions were monitored by thin layer chromatography (TLC) using pre-coated MN 
Alugram Sil G/UV254 silica gel 60 aluminium backed plates. Plates were developed 
using UV light followed by a chemical dip, usually KMnO4 and gentle heating. Flash 
chromatography was performed on chromatography grade, silica 60Å particle size 35-
70 micron from Fisher Scientific using the solvent system as stated. 
1H and 13C NMR were performed on a Brüker Avance 250 (250 MHz), Brüker Avance 
300 (300 MHz), Brüker Avance 400 (400 MHz) and Brüker Avance 500 (500 MHz) as 
stated. Chemical shifts are reported in parts per million (ppm) relative to 
tetramethylsilane (TMS) (δ = 0.00). Coupling constants are reported in Hertz (Hz) and 
signal multiplicity is denoted as singlet (s), doublet (d), triplet (t), quartet (q), doublet of 
doublets (dd), doublet of triplets (dt), doublet of quartets (dq), quartet of triplets (qt), 
triplet of doublets (td), multiplet (m), quintet (quin) and broad (br). C-H assignments in 
1H-NMR spectra are quoted for compounds that have received 2D-NMR analysis. Mass 
spectroscopy was performed on a Brüker µTOF using electrospray ionisation (ESI) in 
either positive or negative ionisation as stated. Infra-red spectroscopy was carried out 
using a Perkin Elmer Spectrum RX FT-IR system with KBr plates, using a thin film. 
Melting points were determined by recrystallisations of substrates from DCM/petroleum 
ether 60–80° using a Bibby Scientific Melting point apparatus Stuart SMP10 digital. X-
ray data was collected at 150 K on a Nonius KappaCCD area diffractometer using Mo-
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Kα radiation (λ = 0.71073 Å) and all structures were solved by direct methods and 
refined on all F2 data using SHELXL-97 suite of programs, with hydrogen atoms 
included in idealised positions and refined using the riding model. 
 
6.2. General Experimental Procedures 
 
General Procedure 1 –  
Synthesis of Enamido Esters 
 
 
 
To a solution of EDCi (2 eq.) in DCM was added triethylamine (2 eq.), DMAP (0.1 
eq.), and the required carboxylic acid (2 eq.). The resulting solution was cooled to 0 °C 
and the vinylogous enamido alcohol (1 eq.) was added as a solution in DCM. The 
reaction mixture was allowed to stir before slowly warming to room temperature. The 
reaction was quenched by addition of 10 % citric acid (30 ml), washed with further 10 
% citric acid (2 × 30 ml), washed with  NaHCO3 (sat, 3 × 30 ml), washed with brine (30 
ml) and the combined organics were dried over MgSO4, filtered and concentrated in 
vacuo to yield the desired enamido esters. 
 
General Procedure 2 –  
Rearrangement & Esterification of Enamido Esters 
Me
CO2Me
R
N
1) LiHMDS (1.3 eq.),
TMSCl (1.3 eq.),
THF
- 98 °C to RT
2) CH2N2,
Ether, Ethanol
0 °C
N O
Me O
R
O
O
O
O
 
 
To a solution of LiHMDS (1M in THF, 1.3 eq.) and TMSCl (1.3 eq.) at -95 °C was 
added a solution of enamide (1 eq.) in THF by syringe pump (4 ml/h) down the side of 
the reaction vessel. On complete addition the reaction mixture was allowed to warm to 
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RT over 1 hour and was then quenched with HCl (1M)/Brine (1:1, 5 ml). The organics 
were extracted with EtOAc (5 × 15 ml), dried over MgSO4, filtered, concentrated in 
vacuo and the crude acid product was subjected to  esterification with diazomethane 
following general procedure 5, to yield the desired crude methyl esters, of which d.r’s 
were assigned by extended aquistion (100 scans) on the 500 MHz 1H NMR. Each ester 
was then subjected to purification by silica gel chromatography, using gradient elution 
ethyl acetate/petroleum ether 40-60°/triethylamine (20:80:1–40:60:1), to yield pure β-
amino esters. Data is subsequently reported on the major diastereoisomer, unless 
resolution has been achieved. 
 
General Procedure 3 –  
Rearrangement & Esterification of Enesulfonamido Esters 
1) LiHMDS (2.5 eq.),
TMSCl (6 eq.),
THF
- 98 °C to RT
2) CH2N2,
Ether, Ethanol
0 °C
N
Ts
O
Me O
R Me
CO2Me
R
N
Ts
 
 
To a solution of LiHMDS (1M in THF, 2.5 eq.) and TMSCl (6 eq.) at -95 °C was added 
a solution of enamide (1 eq.) in THF by syringe pump (4 ml/h) down the side of 
reaction vessel. On complete addition the reaction mixture was allowed to warm to RT 
over 1 hour and was then quenched with HCl (1M)/Brine (1:1, 5 ml). The organics were 
extracted with Et2O (3 × 15 ml) and the crude acid product was subjected to  
esterification with diazomethane following general procedure 5, to yield the desired 
crude methyl esters, of which d.r’s were assigned by 1H NMR. Each ester was then 
subjected to purification by silica gel chromatography, using gradient elution ethyl 
acetate/petroleum ether 40-60°/triethylamine (20:80:1–40:60:1), to yield pure β-amino 
esters. Data is subsequently reported on the major diastereoisomer. 
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General Procedure 4 -  
Rearrangement & Esterification of Enesulfonamido Esters 
 
 
To a solution of LiHMDS (1M in THF, 4.5 eq.) and TEA (45 eq.) at -95 °C was added a 
solution of enamide (1 eq.) in THF by syringe pump (4 ml/h) down the side of the 
reaction vessel. On complete addition the reaction mixture was allowed to warm to RT 
over 1 hour and was then quenched with HCl (1M)/Brine (1:1, 5 ml). The organics were 
extracted with Et2O (5 × 15 ml) and the crude acid product was subjected to 
esterification with diazomethane following general procedure 5, to yield the desired 
crude methyl esters, of which d.r’s were assigned by 1H NMR. Each ester was then 
subjected to purification by silica gel chromatography, using gradient elution ethyl 
acetate/petroleum ether 40-60°/triethylamine (20:80:1–40:60:1), to yield pure β-amino 
esters. Data is subsequently reported on the major diastereoisomer. 
 
General Procedure 5 –  
Diazomethane Methylation 
Me
CO2Me
R
NR2
CH2N2,
Ether, Ethanol
0 °C
Me
CO2H
R
NR2
 
To a solution of the crude acid in diethylether/ethanol (99:1) at 0 °C was added 
diazomethane generated from N-nitrosomethyl urea (50 mg) and 37% KOH (5 ml). 
Once esterification complete (yellow colour persists), the mix was quenched with 
glacial acetic acid then basified with NaHCO3 (sat). The organics were extracted with 
EtOAc (5 × 15 ml), dried over MgSO4, filtered and concentrated in vacuo. 
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General Procedure 6 – 
RCM of Allyl Sulfonamide β-Amino Esters 
 
 
To a solution of rearranged allyl sulfonamide β-amino ester in DCM was added Grubbs 
I catalyst (5 mol%). The reaction mixture was allowed to stir at room temperature and 
once the reaction was complete by TLC, the reaction mixture was concentrated in vacuo 
and then subjected to purification by silica gel chromatography, using gradient elution 
ethyl acetate/petroleum ether 40-60° (10:90–20:80), to yield pure RCM material.  
 
General Procedure 7 –  
RCM of Allyl Sulfonamide β-Amino Esters 
Grubbs I (5 mol %)
PhMe
60 C
Me
CO2Me
N
N
CO2Me
R1
R2
R1
R2
R1/R2 = I/H, Cl/Cl, OMe/OMe
Ts
Ts
 
 
To a solution of rearranged allyl sulfonamide β-amino ester in toluene was added 
Grubbs I catalyst (5 mol%). The reaction mixture was allowed to stir at 60 ˚C and once 
the reaction was complete by TLC, the reaction mixture was concentrated in vacuo and 
purified by silica gel chromatography, using gradient elution ethyl acetate/petroleum 
ether 40-60° (10:90–20:80), to yield pure RCM material.  
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General Procedure 8 –  
For the in-situ NMR study of SKA Formation & Isomerisation 
 
 
 
To an oven dried Young’s tap NMR tube, inserted into a Dewar at -95 °C and under an 
atmosphere of nitrogen,  was added a solution of M-HMDS (1M in THF, 1.7 eq.) and 
TMSCl (n eq). Thermal equilibration was allowed (5 minutes) and then a solution of 
substrate (50 mg, 1 eq.) was added in THF (0.5 ml). The cooled NMR tube was rapidly 
lowered into the pre-cooled NMR machine at -95 °C. From this point 1H- and 13C-NMR 
spectroscopy were recorded, and the sample was subsequently warned to -50 °C and 25 
°C allowing the sample to equilibrate for five minutes before recording data. 
 
General Procedure 9 –  
For the Synthesis and Isolation of E-selective Phenyl Derived SKA’s 
 
 
 
Method A-To a stirred solution of LiHMDS (1M in THF, 1.7 eq.) and TMSCl (1.7 eq.) 
at -95 °C was added a solution of phenyl ester (1 eq.) in THF by syringe pump at rate of 
4 ml/h.  
Method B- To a stirred solution of LiHMDS (1M in THF, 1.7 eq.) and TMSCl (1.7 eq.) 
at -95 °C was added a solution of phenyl ester (1 eq.) in THF by fast hand addition. 
Method C- To a stirred solution of LiHMDS (1M in THF, 1.7 eq.) and TMSCl (6 eq.) 
at -95 °C was added a solution of phenyl ester (1 eq.) in THF by syringe pump at rate of 
4 ml/h.  
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All three methods were then subjected to a standardised workup protocol- 
Once addition complete the reaction mixture was allowed to stir at room temperature for 
1 hour before rapid vacuum concentration at 4 mbar. The crude SKA was then dissolved 
in CDCl3 (stored over magnesium sulfate and potassium carbonate) and filtered through 
cotton wool into a Young’s tap NMR tube for analysis. Post analysis the product was 
then re-concentrated to constant dryness to allow yield be determined. 
 
6.3. Compound Characterisation 
 
6.3.1. N-Oxazolidinone Substrates 
 
(E)-3-(3-oxobut-1-enyl)oxazolidin-2-one 146 
 
 
 
To a solution of chromium (VI) trioxide (42.8 g, 428 mmol, 1.5 eq.) in 20% H2SO4 (250 
ml) was added dropwise a solution of 3-butyn-2-ol (25.5 ml, 285 mmol, 1 eq.) in 20% 
H2SO4 (250 ml). The reaction mixture was stirred at 0 
°C for 6 hours and a colour 
change from orange to green was observed. The reaction was quenched by addition of 
NaHCO3 (sat.) (200 ml) and the organics were extracted with DCM (3 x 300 ml) and 
dried over MgSO4. The crude butynone was chilled to 0 
°C before 2-oxazolidinone 
(24.84 g, 285.34 mmol, 1 Eq) and DABCO (3.20 g, 28.53 mmol, 0.1 Eq) were added. 
The reaction mixture was allowed to stir for 12 hours whilst slowly warming to room 
temperature and a colour change to a deep maroon was observed. The reaction mixture 
was washed with NaHCO3 (sat, 3 × 200 ml), brine (3 × 200 ml) before the combined 
organics were dried over MgSO4, filtered and concentrated in vacuo to afford (E)-3-(3-
oxobut-1-enyl)oxazolidin-2-one 146 as a cream solid (25.8 g, 58%). M.p. 91–93 oC; 
FTIR (film/cm-1) υmax: 2923 (s), 2853 (s), 1754 (s), 1622 (s); 
1H NMR (250 MHz, 
CDCl3) δ: 2.27 (s, 3H), 3.78 (m, 2H), 4.54 (m, 2H), 5.47 (d, 1H, J = 14.5 Hz), 7.81 (d, 
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1H, J = 14.5 Hz); 13C NMR (62 MHz, CDCl3) δ: 26.8, 42.1, 62.6, 111.0, 137.9, 154.7, 
196.7. HRMS (ESI, +ve) m/z calcd. for C7H10NO3 156.0660,  found 156.0650 (M+H)
+. 
 
3-(3-Oxo-d
1
-d
2
-but-1-enyl)-oxazolidin-2-one 
2
H2-146 
 
 
 
To 2-oxazolidinone (1.28 g, 14.7 mmol, 2.0 eq.) was added D2O (10 ml) and the 
resulting solution was concentrated in vacuo. The resulting N-deuterated 2-
oxazolidinone was redissolved in D2O (20 ml) at 0 ˚C then DABCO (0.08 g, 0.7 mmol, 
0.1 eq.) and but-3-yn-2-one (0.50 g, 7.35 mmol, 1.0 eq.) was added dropwise. The 
reaction mixture was allowed to stir for 3 hours, then DCM (50 ml) and brine (50 ml) 
was added and the organics were extracted with DCM (3 × 50 ml), dried over 
magnesium sulphate and concentrated in vacuo to yield the crude product which was 
further purified by flash column chromatography, using ethyl acetate/petroleum ether 
40-60° (80:20) to yield 3-(3-oxo-d1-d2-but-1-enyl)-oxazolidin-2-one 2H2-146 as a faint 
brown solid (0.14 g, 12 %). M.p. 91–93 °C; FTIR (film/cm-1) υmax:  2992 (w), 2918 (w), 
1762 (s), 1656 (s), 1589 (s), 1572 (s); 1H NMR (250 MHz, CDCl3) δ:  2.20 (s, 3H), 3.72 
(app. t, 2H, J = 7.7 Hz), 4.50 (app. t, 2H, J = 7.7 Hz). 13C NMR (125 MHz, CDCl3) δ: 
26.8, 42.0, 62.6, 110.5 (t, J = 24.3 Hz), 137.6 (t, J = 27.5 Hz), 154.7, 198.7; HRMS 
(ESI, +ve) m/z calcd. for C7H8D2NO3 158.0786,  found 158.0772 (M+H)
+. 
 
(E)-3-(3-Hydroxybut-1-enyl)oxazolidin-2-one 145 
 
 
 
To a solution of (E)-3-(3-oxobut-1-enyl)oxazolidin-2-one 146 (5.00 g, 32.2 mmol, 1 
eq.) in water (250 ml) at 0 °C was slowly added NaBH4 (1.83 g, 48.4 mmol, 1.5 eq.). 
The reaction mixture was allowed to stir for 12 hours whilst slowly warming to room 
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temperature and before quenching with brine (100 ml). The organics were extracted 
with DCM (5 × 50 ml), dried over MgSO4, filtered and concentrated in vacuo to give 
(E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one 145 (5.10 g, 100%) as a yellow oil. FTIR 
(film/cm-1) υmax: 3321 (bs), 2971 (s), 1732 (s), 1668 (s); 
1H NMR (500 MHz, CDCl3) δ: 
1.31 (d, 3H, J = 6.9 Hz), 1.92 (br s, 1H), 3.6–3.72 (m, 2H), 4.32 (app. quin, 1H, J = 6.9 
Hz), 4.44 (app. t, 2H, J = 8.2 Hz), 4.92 (dd, 1H, J = 14.3, 6.9 Hz), 6.84 (d, 1H, J = 14.3 
Hz); 13C NMR (125 MHz, CDCl3) δ: 23.4, 42.5, 62.2, 67.1, 114.9, 124.9, 155.5; HRMS 
(ESI, +ve) m/z calcd. for C7H11NNaO3 180.0636,  found 180.0632 (M+Na)
+. 
 
3-(3-Hydroxy-d
1
-d
2
-d
3
-but-1-enyl)-oxazolidin-2-one 
2
H3-145 
 
 
 
To a solution of 3-(3-hydroxy-d1-d2-d3-but-1-enyl)-oxazolidin-2-one 2H2-146 (0.07 g, 
0.42 mmol, 1 eq.) in D2O (10 ml) at 0 
°C was slowly added NaBD4 (0.03 g, 0.63 mmol, 
1.5 eq.). The reaction mixture was allowed to stir for 12 hours whilst slowly warming to 
room temperature and was then quenched with brine (20 ml). The organics were 
extracted with DCM (5 × 20 ml), dried over MgSO4, filtered and concentrated in vacuo 
to give 3-(3-hydroxy-d1-d2-d3-but-1-enyl)-oxazolidin-2-one 2H3-145 (0.07 g, 99%) as a 
clear oil. FTIR (film/cm-1) υmax:  3422 (br s), 3058 (m), 2973 (m), 2928 (m), 1744 (s), 
1630 (s); 1H NMR (250 MHz, CDCl3) δ:  1.28 (s, 3H), 1.76 (br S, 1H), 3.65 (app. t, 2H, 
J = 7.6 Hz), 4.40 (app. t, 2H, J = 7.6 Hz); 13C NMR (100 MHz, CDCl3) δ: 23.8, 42.2, 
62.3, 66.3 (t, J = 21.0 Hz), 114.5 (t, J = 22.9 Hz), 124.2 (t, J = 24.9 Hz), 155.6; HRMS 
(ESI, +ve) m/z calcd. for C7H8D3NNaO3 183.0825,  found 183.0820 (M+Na)
+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl phenylacetate 154 
 
N O
Me O
O
O
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), phenylacetic acid (0.52 g, 3.81 mmol) and (E)-3-(3-
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hydroxybut-1-enyl)oxazolidin-2-one 145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 
phenylacetate 154 as a white solid (0.46 g, 88%). M.p. 94–96 °C; FTIR (film/cm-1) υmax: 
2981 (s), 1747 (s), 1731 (s), 1672 (s); 1H NMR (300 MHz, CDCl3) δ: 1.30 (d, 3H, J = 
6.7 Hz, CH3CH(CH)O-), 3.60 (s, 2H, -C(O)CH2C6H5), 3.62–3.72 (m, 2H, -N(CH-)CH2-
), 4.40–4.48 (m, 2H, -OCH2-), 4.86 (dd, 1H, J = 14.4, 6.7 Hz, -NCHCH-), 5.43 (app. 
quin, 1H, J = 6.7 Hz, CH3CH(CH-)O-), 6.93 (d, 1H, J = 14.4 Hz, -NCHCH-), 7.21–7.36 
(m, 5H, C6H5-); 
13C NMR (62 MHz, CDCl3) δ: 21.0, 42.0, 42.7, 62.6, 70.3, 110.2, 
127.4, 127.5, 129.0, 129.6, 124.4, 155.7, 171.2; HRMS (ESI, +ve) m/z calcd. for 
C15H17NNaO4  298.1055,  found 298.1050 (M+Na)
+. 
 
Phenyl-acetic acid d
1
-d
2
-d
3
-1-methyl-3-(2-oxo-oxazolidin-3-yl)-allyl ester 
2
H3-154 
 
 
 
EDCi (0.33 g, 1.72 mmol) in DCM (100 ml), triethylamine (0.24 ml, 1.72 mmol), 
DMAP (0.01 g, 0.09 mmol), phenylacetic  acid (0.23 g, 1.72 mmol) and 3-(3-Hydroxy-
d1-d2-d3-but-1-enyl)-oxazolidin-2-one 2H3-145 (0.14 g, 0.86 mmol) in DCM (20 ml) 
were combined according to general procedure 1 (reaction time: 15 hours). Purification 
was achieved by reported procedure to afford phenyl-acetic acid d1-d2-d3-1-methyl-3-(2-
oxo-oxazolidin-3-yl)-allyl ester 2H3-154 as a cream solid (0.38 g, 94%). M.p. 97–100 
°C; FTIR (film/cm-1) υmax:  3054 (m), 2990 (m), 2919 (m), 1740 (s), 1691 (s), 1670 (s), 
1633 (m); 1H NMR (500 MHz, CDCl3) δ:  1.39 (s, 3H), 3.62 (s, 2H), 3.63 (app. t, 2H, J 
= 7.6 Hz), 4.41 (app. t, 2H, J = 7.6 Hz); 13C NMR (125 MHz, CDCl3) δ: 20.4, 41.6, 
42.2, 62.2, 69.4 (t, J = 22.9 Hz), 109.2 (t, J = 22.9 Hz), 126.6 (t, J = 27.0 Hz), 127.0, 
128.5, 129.2, 134.0, 155.2, 170.8; HRMS (ESI, +ve) m/z calcd. for C15H14D3NNaO4 
301.1244,  found 301.1245 (M+Na)+. 
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Phenyl-acetic acid-
13
C2 1-methyl-3-(2-oxo-oxazolidin-3-yl)-allyl ester 
13
C2-154 
 
N O
Me O
O
O
 
 
EDCi (0.69 g, 3.62 mmol) in DCM (100 ml), triethylamine (0.50 ml, 3.62 mmol), 
DMAP (0.02 g, 0.18 mmol), 13C2-phenyl-acetic acid (0.50 g, 3.62 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one  145 (0.28 g, 1.81 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford phenyl-acetic acid-13C2 1-methyl-3-(2-oxo-
oxazolidin-3-yl)-allyl ester 13C2-154 as a white solid (0.48 g, 89%). M.p. 98–101 
oC. 
FTIR (film/cm-1) υmax: 2991 (m), 2918 (m), 1739 (s), 1691 (s), 1669 (s). 
1H NMR (400 
MHz, CDCl3) δ: 1.40 (d, 3H, J = 6.6 Hz), 3.65 (dd, 2H, J = 129.6, 7.8 Hz), 3.74 (app. t, 
2H, J = 7.9 Hz), 4.48 (app. t, 2H, J = 7.9 Hz), 4.91 (dd, 1H, J = 14.3, 7.1 Hz), 5.48 (pd, 
1H, J = 6.6, 3.0 Hz), 6.97 (d, 1H, J = 14.3 Hz), 7.27–7.40 (m, 5H). 13C NMR (100 
MHz, CDCl3) δ: 20.6, 41.6 (d, J 57.4 Hz), 42.3, 62.2, 69.9 (d, J 1.4 Hz), 109.8 (d, J 1.1 
Hz), 127.0, 127.1, 128.5 (d, J 3.5 Hz), 129.3 (t, J 2.3 Hz), 134.0 (dd, J 43.7, 2.95 Hz), 
155.3, 170.8 (d, J 57.4 Hz). HRMS (ESI, +ve) m/z calcd. for C13C
13
2H17NNaO4  
300.1212,  found 300.1115 (M+Na)+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(o-methoxyphenyl)acetate 163 
 
   
  
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), o-methoxyphenylacetic acid (0.63 g, 3.81 mmol) and (E)-
3-(3-hydroxybut-1-enyl)oxazolidin-2-one 145 (0.30 g, 1.91 mmol) in DCM (20 ml) 
were combined according to general procedure 1 (reaction time: 15 hours). Purification 
was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 
2-(o-methoxyphenyl)acetate 163 as an off white solid (0.55 g, 94%). M.p. 92–93  °C; 
FTIR (film/cm-1) υmax: 2925 (s), 2850 (w), 1755 (s), 1676 (s), 1603 (w), 1590 (w); 
1H 
NMR (300 MHz, CDCl3) δ: 1.35 (d, 3H, J = 6.7 Hz), δ 3.59 (s, 2H), 3.63 (app. t, 2H, J 
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= 8.3 Hz), 3.79 (s, 3H), 4.39 (app. t, 2H, J = 8.3 Hz), 4.86 (dd, 1H, J = 14.3, 6.7 Hz), 
5.49 (app. quin, 1H, J = 6.7 Hz), 6.83–6.93 (m, 2H), 7.16 (d, 1H, J = 14.3 Hz), 7.23 (td, 
1H, J = 8.0, 1.6 Hz); 13C NMR (75 MHz, CDCl3) δ:  21.1, 36.7, 42.7, 55.8, 62.6, 69.9, 
110.5, 110.9, 120.8, 123.5, 127.0, 128.9, 131.2, 155.7, 157.9, 171.5; HRMS (ESI, +ve) 
m/z calcd. for C16H19 NNaO5 328.1161,  found 328.1155 (M+Na)
+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(m-methoxyphenyl)acetate 164 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), m-methoxyphenylacetic acid (0.63 g, 3.81 mmol) and (E)-
3-(3-hydroxybut-1-enyl)oxazolidin-2-one 145 (0.30 g, 1.91 mmol) in DCM (20 ml) 
were combined according to general procedure 1 (reaction time: 15 hours). Purification 
was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 
2-(m-methoxyphenyl)acetate 164 as an off white solid (0.44 g, 76%). M.p. 90–91 °C. 
FTIR (film/cm-1) υmax: 3498 (w), 2978 (m), 2933 (m), 1757 (s), 1670 (s), 1601 (s); 
1H 
NMR (250 MHz, CDCl3) δ: 1.34 (d, 3H, J = 6.7 Hz), 3.55 (s, 2H), 3.57–3.68 (m, 2H), 
3.78 (s, 3H), 4.35–4.45 (m, 2H), 4.84 (dd, 1H, J = 14.3, 6.7 Hz), 5.42 (app. quin, 1H, J 
= 6.7 Hz), 6.81–6.90 (m, 3H), 6.90 (d, 1H, J = 14.3 Hz), 7.22 (td, 1H, J = 7.6, 1.2 Hz). 
13C NMR (75 MHz, CDCl3) δ:  19.6, 40.6, 41.3, 54.2, 61.2, 69.0, 108.8, 111.5, 113.8, 
120.6, 126.0, 128.5, 134.4, 154.3, 158.6, 169.7. HRMS (ESI, +ve) m/z calcd. for C16H19 
NNaO5 328.1161,  found 328.1155 (M+Na)
+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-methoxyphenyl)acetate 165 
 
N O
Me O
O
O
OMe
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethyalmine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), para-methoxyphenylacetic acid (0.63 g, 3.81 mmol) and 
(E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 ml) 
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were combined according to general procedure 1 (reaction time: 15 hours). Purification 
was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 
2-(p-methoxyphenyl)acetate 165 as an off white solid (0.53 g, 91%). M.p. 89–91 °C; 
FTIR (film/cm-1) υmax: 2980 (m), 2932 (m), 2838 (w), 1755 (s), 1671 (s), 1613 (m), 
1585 (m), 1514 (s); 1H NMR (300 MHz, CDCl3) δ: 1.34 (d, 3H, J = 6.7 Hz), 3.52 (s, 
2H), 3.61–3.69 (m, 2H), 3.77 (s, 3H), 4.37–4.45 (m, 2H), 4.85 (dd, 1H, J = 14.4, 6.7 
Hz), 5.40 (app. quin, 1H, J = 6.7 Hz), 6.84 (app. d, 2H, J = 8.6 Hz), 6.89 (d, 1H, J = 
14.4 Hz), 7.17 (app. d, 2H, J = 8.6 Hz); 13C NMR (75 MHz, CDCl3) δ:  21.0, 41.1, 42.7, 
55.7, 62.6, 70.2, 110.3, 114.4, 126.5, 127.3, 130.7, 155.7, 159.1, 171.6; HRMS (ESI, 
+ve) m/z calcd. for C16H19 NNaO5 328.1161,  found 328.1155 (M+Na)
+. 
 
13
C1-(4-Methoxyphenyl)acetic acid  (
13
C1-282) 
 
 
 
To a degassed solution of Pd(OAc)2 (0.02 g, 0.07 mmol, 3 mol%), P(
1Nap)3 (0.09 mg, 
0.21 mmol, 9 mol%), and finely ground K3PO4 (2.53 g, 11.90 mmol, 5 eq.) in THF (20 
ml) was added 13C-ethylbromo acetate (0.26 ml, 2.38 mmol, 1.0 eq.). The reaction 
mixture was allowed to stir for 5 minutes and then a solution of 4-methoxyphenyl 
boronic acid (0.36g, 2.38 mmol, 1.0 eq.) and H2O (0.09 ml, 4.76 mmol, 2.0 eq.) in THF 
(10 ml) was added. The reaction mixture was allowed to stir at room temperature over 
16 hours and was then quenched by addition to water and extraction with DCM (3 × 20 
ml), dried over magnesium sulphate and concentrated in vacuo to yield the crude 
product. The crude ester was then saponified by dissolution in 1N NaOH (20 ml) in 
methanol (20 ml) and allowed to stir at room temperature over 12 hours. The target 
compound was isolated by extraction of the organics with 5% NaOH (3 × 20 ml), 
acidifying the aqueous by 6N HCl (30 ml), extracting the organics with DCM (3 × 20 
ml), concentration in-vacuo and subsequent purification by flash column 
chromatography, using ethyl acetate/petroleum ether 40-60° (10:90) to yield 13C1-(4-
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methoxyphenyl)acetic acid  13C1-282 as a white solid (0.12 g, 29 %). M.p. 90–92 
oC; 
FTIR (film/cm-1) υmax: 3006 (m), 3000 (br s), 2915 (m), 2835 (m), 1687 (s), 1614 (s), 
1586 (w), 1512 (s); 1H NMR (400 MHz, CDCl3) δ:  3.64 (d, 2H, J = 129.0 Hz), 3.85 (s, 
3H),  6.93 (app. d, 2H,  J = 8.5 Hz), 7.25 (app. dd, 2H,  J = 8.5, 4.2 Hz), 11.6 (br s, 
1H); 13C NMR (100 MHz, CDCl3) δ: 40.0, 55.3, 114.1 (d, J = 4.3 Hz), 125.4 (d, J = 
44.4 Hz), 130.4 (d, J = 3.3 Hz), 158.9, 178.4 (d, J = 57.1 Hz); HRMS (ESI, +ve) m/z 
calcd. for C8
13C1H10Na2O3 213.0504,  found 213.0411 (M+2Na)
2+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-
13
C1-(4-methoxyphenyl)acetate  
13
C1-165 
 
 
 
EDCi (0.13 g, 0.68 mmol) in DCM (50 ml), triethylamine (0.10 ml, 0.68 mmol), DMAP 
(0.01 g, 0.03 Eq), 13C1-(4-methoxyphenyl)acetic acid  
13
C1-282 (0.11 g, 0.68 mmol) and 
(E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one (0.05 g, 0.34 mmol) in DCM (10 ml) 
were combined according to general procedure 1 (reaction time: 15 hours). Purification 
was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 
2-13C1-(4-methoxyphenyl)acetate 
13
C1-165 as a yellow oil (0.10 g, 100%). FTIR 
(film/cm-1) υmax: 2970 (m), 2991 (m), 2923 (m), 2840 (m), 1745 (s), 1726 (s), 1668 (s), 
1603 (m), 1590 (m); 1H NMR (400 MHz, CDCl3) δ: 1.39 (d, 3H, J = 6.6 Hz), 3.56 (d, 
2H, J = 129.0 Hz), 3.68 (app. t, 2H, J = 7.9 Hz), 3.83 (s, 3H), 4.45 (app. t, 2H, J = 7.9 
Hz), 4.89 (dd, 1H, J = 14.2, 6.9 Hz), 5.45 (app. quin, 1H, J = 6.6 Hz), 6.89 (app. d, 2H, 
J = 8.5 Hz),  6.94 (d, 1H, J = 14.2 Hz),  7.22 (app. dd, 1H, J = 8.5 Hz);  13C NMR (100 
MHz, CDCl3) δ: 20.6, 40.7, 42.3, 55.2, 62.2, 69.8, 109.8, 114.0 (d, J = 4.0 Hz), 126.1 
(d, J = 45.8 Hz), 126.9, 130.3 (d, J = 3.3 Hz), 155.3, 158.6, 171.2 (d, J = 48.9 Hz); 
HRMS (ESI, +ve) m/z calcd. for C15
13C1H19NNaO5  329.1239,  found 329.1177 
(M+Na)+. 
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(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-o-tolylacetate 166 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), o-tolylphenylacetic acid (0.57 g, 3.81 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one 145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
o-tolylacetate 166 as a white solid (0.39 g, 71%). M.p. 83–85 °C; FTIR (film/cm-1) υmax: 
2999 (s), 2924 (s), 1756 (s), 1670 (s); 1H NMR (250 MHz, CDCl3) δ: 1.35 (d, 3H, J = 
6.7 Hz), 2.30 (s, 3H), 3.60 (s, 2H), 3.69–3.77 (m, 2H), 4.46–4.54 (m, 2H), 4.85 (dd, 1H, 
J = 14.6, 6.7 Hz), 5.42 (app quin, 1H, J = 6.7 Hz), 6.90 (d, 1H, J = 14.6 Hz), 7.10–7.20 
(m, 4H); 13C NMR (75 MHz, CDCl3) δ: 20.0, 21.0, 39.9, 42.7, 62.6, 70.3, 110.2, 126.5, 
127.4, 127.7, 130.5, 130.7, 133.2, 137.2, 135.7, 171.1; HRMS (ESI, +ve) m/z calcd. for 
C16H19NNaO4 312.1212,  found 312.1206 (M+Na)
+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-m-tolylacetate 167 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), m-tolylphenylacetic acid (0.57 g, 3.81 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one 145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
m-tolylacetate 167 as a white solid (0.41 g, 74%). M.p. 82–84 °C; FTIR (film/cm-1) 
υmax: 3050 (w), 2980 (s), 2919 (s), 1761 (s), 1670 (s), 1609 (w), 1590 (w); 
1H NMR 
(250 MHz, CDCl3) δ: 1.40 (d, 3H, J = 6.7), 2.33 (s, 3H), 3.55 (s, 2H), 3.55–3.64 (m, 
2H), 4.38–4.48 (m, 2H), 4.86 (dd, 1H, J = 14.2, 6.7 Hz), 5.42 (app. quin, 1H J = 6.7 
Hz), 6.92 (d, 1H, J = 14.2 Hz), 7.03–7.11 (m, 3H), 7.16–7.24 (m, 1 H); 13C NMR (75 
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MHz, CDCl3) δ: 21.0, 21.8, 41.9, 42.7, 62.6, 70.2, 110.2, 126.6, 127.3, 128.2, 128.8, 
130.4, 134.3, 138.6, 155.6, 171.3; HRMS (ESI, +ve) m/z calcd. for C16H19NNaO4 
312.1212,  found 312.1206 (M+Na)+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-p-tolylacetate 168 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), p-tolylphenylacetic acid (0.57 g, 3.81 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one  145  (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
p-tolylacetate 168 as a white solid (0.49 g, 88%). M.p. 86–89 °C; FTIR (film/cm-1) υmax: 
3051 (w), 2981 (s), 2924 (s), 1766 (s), 1670 (s), 1516 (s); 1H NMR (250 MHz, CDCl3) 
δ: 1.35 (d, 3H, J = 7.0 Hz), 2.32 (s, 3H), 3.55 (s, 2H), 3.61–3.71 (m, 2H), 4.38–4.48 (m, 
2H), 4.86 (dd, 1H, J = 14.3, 7.0 Hz), 5.41 (app. quin, 1H, J =  7.0 Hz), δ 6.92 (d, 1H, J 
= 14.3 Hz), δ 7.08–7.19 (m, 4H); 13C NMR (75 MHz, CDCl3) δ: 21.0, 21.5, 41.6, 42.7, 
62.6, 70.3, 110.2, 127.3, 129.5, 129.6, 131.4, 137.0, 155.7, 171.5. HRMS (ESI, +ve) m/z 
calcd. for C16H19NNaO4 312.1212,  found 312.1206 (M+Na)
+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(o-nitrophenyl)acetate 169 
 
   
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), o-nitrophenylacetic acid (0.69 g, 3.81 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one 145  (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
(o-nitrophenyl)acetate 169 as a yellow oil (0.52 g, 85%). FTIR (film/cm-1) υmax: 2982 
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(m), 2928 (m), 1756 (s), 1671 (s), 1613 (m), 1580 (m), 1526 (s); 1H NMR (300 MHz, 
CDCl3) δ: 1.35 (d, 3H, J = 6.7 Hz), 3.68 (app. t, 2H, J = 8.0 Hz), 3.94 (d, 1H, J = 17.1 
Hz), 4.00 (d, 1H, J = 17.1 Hz),4.42 (app. t, 2H J = 8.0 Hz), 4.85 (dd, 1H, J = 14.4, 6.7 
Hz), 5.41 (app. quin, 1H, J = 6.7 Hz), 6.87 (d, 1H, J = 14.4 Hz), 7.33 (dd, 1H, J = 7.8, 
1.2 Hz), 7.45 (td, 1H, J = 7.8, 1.2 Hz), 7.58 (td, 1H, J = 7.8, 1.2 Hz), 8.07 (dd, 1H, J = 
7.8, 1.2 Hz); 13C NMR (75 MHz, CDCl3) δ:  20.8, 40.6, 42.7, 62.7, 71.0, 110.2, 125.7, 
127.5, 129.0, 130.2, 133.8, 134.0, 149.1, 155.7, 169.6; HRMS (ESI, +ve) m/z calcd. for 
C15H16N2NaO6 343.0906,  found 343.0901 (M+Na)
+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(m-nitrophenyl)acetate 170 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), m-nitrophenylacetic acid (0.69 g, 3.81 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one 145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
(m-nitrophenyl)acetate 170 as an orange oil (0.56 g, 92%). FTIR (film/cm-1) υmax: 2983 
(w), 2927 (w), 1755 (s), 1669 (s), 1529 (s); 1H NMR (250 MHz, CDCl3) δ: 1.37 (d, 3H, 
J = 6.9 Hz), 3.64–3.68 (m, 2H), 3.70 (s, 2H), 4.45 (app. t, 2H, J = 8.1 Hz), 4.85 (dd, 1H, 
J = 14.4, 6.9 Hz), 5.44 (app. quin, 1H, J = 6.9 Hz), 6.93 (d, 1H, J = 14.4 Hz), 7.48–7.55 
(m, 1H), 7.58–7.65 (m, 1H), 8.1–8.2 (m, 2H); 13C NMR (75 MHz, CDCl3) δ:  21.0, 
41.4, 42.7, 62.7, 71.1, 109.7, 122.7, 124.6, 127.9, 129.9, 136.0, 136.3, 148.7, 155.7, 
170.0; HRMS (ESI, +ve) m/z calcd. for C15H16N2NaO6 343.0906,  found 343.0901 
(M+Na)+. 
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(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-nitrophenyl)acetate 171 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), p-nitrophenylacetic acid (0.69 g, 3.81 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
(p-nitrophenyl)acetate 171 as a red oil (0.50 g, 85%). FTIR (film/cm-1) υmax: 3081 (w), 
2982 (m), 2928 (m), 1757 (s), 1670 (s), 1606 (m), 1521 (s); 1H NMR (250 MHz, 
CDCl3) δ: 1.35 (d, 3H, J = 6.9 Hz), 3.62–3.71 (m, 2H), 3.70 (s, 2H), 4.44 (app. t, 2H, J 
= 8.1 Hz), 4.83 (dd, 1H, J = 14.4, 6.9 Hz), 5.42 (app. quin, 1H, J = 6.9 Hz), 6.92 (app. 
d, 1H, J = 14.4 Hz), 7.44 (app. d, 2H, J = 8.7 Hz), 8.17 (d, 2H, J = 8.7 Hz); 13C NMR 
(75 MHz, CDCl3) δ:  21.0, 41.7, 42.7, 62.6, 71.1, 109.7, 124.1, 127.8, 130.7, 141.8, 
147.6, 155.6, 169.8; HRMS (ESI, +ve) m/z calcd. for C15H16N2NaO6 343.0906,  found 
343.0901 (M+Na)+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(4-(dimethylamino)phenyl)acetate 202 
 
N O
Me O
O
O
NMe2
 
 
EDCi (0.82 g, 4.28 mmol) in DCM (100 ml), triethylamine (0.60 ml, 4.28 mmol), 
DMAP (0.03 g, 0.21 mmol), p-dimethyl amino phenyl acetic acid (0.77 g, 4.28 mmol) 
and (E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.34 g, 2.14 mmol) in DCM (20 
ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-
yl)but-3-en-2-yl 2-(4-(dimethylamino)phenyl)acetate 202 as a brown solid (0.62 g, 
92%). M.p. 101–103 °C; FTIR (film/cm-1) υmax: 2978.7 (w), 2918.3 (w), 2803.7 (w), 
1764.5 (s), 1731.6 (s), 1670.1 (m), 1615.8 (m), 1523.8 (s). 1H NMR (250 MHz, CDCl3) 
δ: 1.39 (d, 3H, J = 6.8 Hz), 2.93 (s, 6H), 3.49 (s, 2H), 3.62 (app. t, 2H, J = 7.7 Hz), 4.41 
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(app. t, 2H, J = 7.7 Hz), 4.87 (dd, 1H, J = 14.4, 6.8 Hz), 5.41 (app. quin, 1 H, J = 6.8 
Hz), 6.70 (d, 2H, J = 8.8 Hz), 6.92 (d, 1 H, J = 14.4 Hz), 7.14 (d, 2H, J = 8.8 Hz) 13C 
NMR (75 MHz, CDCl3) δ: 19.6, 39.5, 41.3, 52.5, 61.2, 68.6, 109.0, 111.8, 120.8, 125.8, 
128.8, 148.7, 154.3, 170.4. HRMS (ESI, +ve) m/z calcd. For C17H22N2NaO4 341.1477, 
found 341.1472 (M+Na)+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-iodophenyl)acetate 203 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), p-iodophenylacetic acid (1.00 g, 3.81 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one 145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
(p-iodophenyl)acetate 203 as a white solid (0.61 g, 79%). M.p. 97–98 °C; FTIR 
(film/cm-1) υmax: 2979 (w), 2928 (w), 1757 (s), 1670 (s); 
1H NMR (500 MHz, CDCl3) δ: 
1.34 (d, 3H, J = 6.4 Hz), 3.51 (s, 2H), 3.60 (app. t, 2H, J = 6.7 Hz), 4.37–4.44 (m, 2H), 
4.82 (dd, 1H, J = 14.2, 6.4 Hz), 5.40 (app. quin, 1 H, J = 6.4 Hz), 6.89 (d, 1H, J = 14.2 
Hz), 7.01 (app. d, 2H, J = 6.5 Hz), 7.62 (app. d, 2H, J = 6.5 Hz); 13C NMR (125 MHz, 
CDCl3) δ: 20.6, 41.1, 42.3, 62.2, 70.2, 92.6, 109.6, 127.1, 131.3, 133.7, 137.6, 155.3, 
170.2. HRMS (ESI, +ve) m/z calcd. for C15H16INNaO4 424.0022, found 424.0016 
(M+Na)+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-fluorophenyl)acetate 204 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), p-fluorophenylacetic acid (0.59 g, 3.81 mmol) and (E)-3-
(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
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combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
(p-fluorophenyl)acetate 204 as an off white solid (0.43 g, 77%). M.p. 94–96 °C; FTIR 
(film/cm-1) υmax: 2983 (w), 1760 (s), 1670 (s), 1510 (s); 
1H NMR (500 MHz, CDCl3) δ: 
1.32 (d, 3H, J = 6.7 Hz), 3.53 (s, 2H), 3.62 (app. t, 2H, J = 8.1 Hz), 4.38 (app. t, 2H, J = 
8.1 Hz), 4.82 (dd, 1H, J = 14.4, 6.7 Hz), 5.39 (app. quin, 1 H, J = 6.7 Hz), 6.87 (d, 1H, J 
= 14.4 Hz), 6.96 (app t, 2H, J = 8.5 Hz), 7.17–7.23 (m, 2H); 13C NMR (125 MHz, 
CDCl3) δ: 20.6, 40.7, 42.3, 62.3, 70.1, 110.0, 115.3 (d, J = 20.6 Hz), 127.0, 129.8 (d, J = 
3.5 Hz), 130.8, (d, J = 7.3 Hz), 155.3, 161.9 (d, J = 245 Hz), 170.6; HRMS (ESI, +ve) 
m/z calcd. For C15H16FNNaO4 316.0961, found 316.0956 (M+Na)
+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-chlorophenyl)acetate 205 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), p-chlorophenylacetic acid (0.65 g, 3.81 mmol) and (E)-3-
(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
(p-chlorophenyl)acetate 205 as a yellow solid (0.55 g, 93%). M.p. 91–93 °C; FTIR 
(film/cm-1) υmax: 2982 (w), 2928 (w), 1759 (s), 1671 (s), 1599 (w); 
1H NMR (500 MHz, 
CDCl3) δ: 1.34 (d, 3H, J = 6.8 Hz), 3.55 (s, 2H), 3.70 (app. t, 2H, J = 8.0 Hz), 4.42 (app. 
t, 2H, J = 8.0 Hz), 4.83 (dd, 1H, J = 14.4, 6.8 Hz), 5.41 (app. quin, 1 H, J = 6.8 Hz), 
6.91 (d, 1H, J = 14.4 Hz), 7.19 (app. d, 2H, J = 8.4 Hz), 7.28 (app. d, 2H, J = 8.4 Hz); 
13C NMR (125 MHz, CDCl3) δ: 20.6, 40.9, 42.3, 62.2, 70.2, 109.6, 127.1, 128.7, 130.6, 
132.5, 133.0, 155.2, 170.4; HRMS (ESI, +ve) m/z calcd. for C15H16ClNNaO4 332.0660,  
found 332.0653 (M+Na)+. 
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(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-(trifluoromethyl)phenyl)acetate 206 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), p-trifluoromethylphenylacetic acid (0.78 g, 3.81 mmol) 
and (E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 
ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-
yl)but-3-en-2-yl 2-(p-(trifluoromethyl)phenyl)acetate 206 as a yellow oil (0.56 g, 86%). 
FTIR (film/cm-1) υmax: 2984 (w), 1757 (s), 1671 (m), 1619 (w); 
1H NMR (500 MHz, 
CDCl3) δ: 1.34 (d, 3H, J = 7.0 Hz), 3.63 (s, 2H), 3.63 (app. t, 2H, J = 8.1 Hz), 4.40 (app. 
t, 2H, J = 8.1 Hz), 4.83 (dd, 1H, J = 14.4, 7.0 Hz), 5.41 (app. quin, 1 H, J = 7.0 Hz), 
6.90 (d, 1H, J = 14.4 Hz), 7.34 (app. d, 2H, J = 8.0 Hz), 7.55 (app. d, 2H, J = 8.0 Hz); 
13C NMR (125 MHz, CDCl3) δ: 20.6, 41.3, 42.3, 62.2, 70.4, 109.5 124.1 (q, J = 273.0 
Hz), 125.4 (q, J = 3.7 Hz), 127.2, 129.4 (q, J = 32.6 Hz), 129.6, 138.0, 155.3, 170.0; 
HRMS (ESI, +ve) m/z calcd. for C16H16F3NNaO4 366.0929,  found 366.0924 (M+Na)
+. 
 
13
C1-2-(4-(trifluoromethyl)phenyl)acetic acid (
13
C1-283) 
 
 
 
To a degassed solution of Pd(OAc)2 (0.01 g, 0.06 mmol, 3 mol%), P(
1Nap)3 (0.07 mg, 
0.17 mmol, 9 mol%), and finely ground K3PO4 (1.96 g, 9.25 mmol, 5 eq.) in THF (20 
ml) was added 13C-ethylbromo acetate (0.31 mg, 1.85 mmol, 1.0 eq.). The reaction 
mixture was allowed to stir for 5 minutes and then a solution of 4-trifluorophenyl 
boronic acid (0.35 g, 1.85 mmol, 1.0 eq.) and H2O (0.07 ml, 3.70 mmol, 2.0 eq.) in THF 
(10 ml) was added. The reaction mixture was allowed to stir at room temperature over 
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16 hours and was then quenched by addition to water and extraction with DCM (3 × 20 
ml), dried over magnesium sulphate and concentrated in vacuo to yield the crude 
product. The crude ester was subjected to flash column chromatography using ethyl 
acetate/petroleum ether 40-60° (10:90) and was then saponified by dissolution in 1N 
NaOH (20 ml) in methanol (20 ml) and allowed to stir at room temperature over 12 
hours. The target compound was isolated by extraction of the organics with 5% NaOH 
(3 × 20 ml), acidifying the aqueous by 6N HCl (30 ml), extracting the organics with 
DCM (3 × 20 ml), concentration in vacuo and subsequent purification by flash column 
chromatography, using ethyl acetate/petroleum ether 40-60° (10:90) to yield 13C1-2-(4-
(trifluoromethyl)phenyl)acetic acid 13C1-283 as a white solid (0.10 g, 27 %). M.p. 89–
91 oC; FTIR (film/cm-1) υmax: 3018 (m), 2919 (br s), 1694 (s), 1619 (m), 1588 (w); 
1H 
NMR (500 MHz, CDCl3) δ:  3.74 (d, 2H, J = 129.9 Hz), 7.39–7.48 (m, 2H), 7.64 (app. 
d, 2H,  J = 8.5 Hz), 11.77 (br s, 1H); 13C NMR (125 MHz, CDCl3) δ: 40.8, 124.0 (q, J = 
266.3 Hz), 125.6 (quin, J = 125.6 Hz), 129.8 (q, J = 30.8 Hz), 129.8 (d, J = 2.9 Hz), 
137.1 (d, J = 45.2 Hz), 177.4 (d, J = 58.3 Hz); HRMS (ESI, +ve) m/z calcd. for 
C8
13C1H6O2F3 204.0398,  found 204.0343 (M-H)
-. 
 
(E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
13
C1-(4-(trifluoromethyl)phenyl)acetate 
13
C1-206  
 
 
EDCi (0.09 g, 0.49 mmol) in DCM (30 ml), triethylamine (0.07 ml, 0.49 mmol), DMAP 
(2.44 mg, 0.02 eq.), 13C1-2-(4-(trifluoromethyl)phenyl)acetic acid 
13
C1-283 (0.10 g, 0.49 
mmol) and (E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one (0.04 g, 0.24 mmol) in DCM 
(10 ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-
yl)but-3-en-2-yl 2-13C1-(4-(trifluoromethyl)phenyl)acetate 
13
C1-206 as a yellow oil 
(0.06 g, 81%). FTIR (film/cm-1) υmax: 3096 (m), 2978 (m), 2927 (m), 1702 (s), 1664 
(m), 1590 (m), 1561 (m); 1H NMR (500 MHz, CDCl3) δ: 1.37 (d, 3H, J = 6.5 Hz), 3.66 
(d, 2H, J = 130.0 Hz), 3.67 (app. t, 2H, J = 8.1 Hz), 4.45 (app. t, 2H, J = 8.1 Hz), 4.85 
(dd, 1H, J = 14.1, 7.1 Hz), 5.44 (app. quin, 1H, J = 7.1 Hz), 6.94 (d, 2H, J = 14.1 Hz),  
7.34–7.45 (m, 2H), 7.59 (app. d, 2H, J = 7.6 Hz);  13C NMR (125 MHz, CDCl3) δ: 20.6, 
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41.3, 42.3, 62.2, 70.4, 109.5, 123.1 (q, J = 272.4 Hz), 125.5 (quin, J = 4.3 Hz), 127.2, 
129.5 (d, J = 33.3 Hz), 129.7 (d, J = 3.5 Hz), 138.0 (d, J = 46.2 Hz), 155.2, 170.0 (d, J = 
58.2 Hz); HRMS (ESI, +ve) m/z calcd. for C15C
13H16F3NO4  343.1031,  found 343.1002 
(M-H)-. 
 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-cyanophenyl)acetate 207 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), p-cyanophenylacetic acid (0.62 g, 3.81 mmol) and (E)-3-
(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
(p-cyanophenyl)acetate 207 as a yellow oil (0.42 g, 73%). FTIR (film/cm-1) υmax: 2982 
(w), 2929 (w), 2230 (s), 1753 (s), 1670 (s), 1610 (w); 1H NMR (500 MHz, CDCl3) δ: 
1.33 (d, 3H, J = 6.8 Hz), 3.63 (s, 2H), 3.67 (app. t, 2H, J = 8.1 Hz), 4.42 (app. t, 2H, J = 
8.1 Hz), 4.82 (dd, 1H, J = 14.4, 6.8 Hz), 5.40 (app. quin, 1 H, J = 6.8 Hz), 6.89 (d, 1H, J 
= 14.4 Hz), 7.37 (app. d, 2H, J = 7.9 Hz), 7.59 (app. d, 2H, J = 7.9 Hz); 13C NMR (125 
MHz, CDCl3) δ: 20.7, 41.5, 42.3, 62.3, 70.6, 109.4, 111.1, 118.7, 127.3, 130.2, 132.3, 
139.4, 155.3, 169.5; HRMS (ESI, +ve) m/z calcd. For C16H16N2NaO4 323.1008, found 
323.1002 (M+Na)+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(4-(methylsulfonyl)phenyl)acetate 208 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), p-methane sulfunyl phenyl acetic acid (0.81 g, 3.81 mmol) 
and (E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 
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ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford the pure enamido ester 
substrate, but a further toluene trituration was required to yield (E)-4-(2-oxooxazolidin-
3-yl)but-3-en-2-yl 2-(4-(methylsulfonyl)phenyl)acetate 208 as a white solid (0.60 g, 
83%). M.p. 108–110 °C; FTIR (film/cm-1) υmax: 2983.4 (w), 2928.7 (w), 2931.5 (w), 
1756.0 (s), 1670.8 (m), 1600.1 (w). 1H NMR (500 MHz, CDCl3) δ: 1.33 (d, 3H, J = 6.6 
Hz), 3.02 (s, 3H), 3.62 (s, 2H), 3.62 (app. t, 2H, J = 8.2 Hz), 4.41 (app. t, 2H, J = 8.2 
Hz), 4.81 (dd, 1H, J = 14.0, 6.6 Hz), 5.40 (app. quin, 1 H, J = 6.6 Hz), 6.86 (d, 1 H, J = 
14.0 Hz), 7.46 (d, 2 H, J = 8.8 Hz),  7.86 (d, 2 H, J = 8.8 Hz). 13C NMR (125 MHz, 
CDCl3) δ: 20.7, 41.4, 42.3, 44.5, 62.3, 70.6, 109.4, 127.2, 127.6, 130.4, 139.3, 140.3, 
155.3, 169.6. HRMS (ESI, +ve) m/z calcd. for C16H20NO6S 354.1011,  found 354.1025 
(M+H)+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(2,4-dimethoxyphenyl)acetate 209 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), 2,4-dimethoxy phenyl acetic acid (0.74 g, 3.81 mmol) and 
(E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 ml) 
were combined according to general procedure 1 (reaction time: 15 hours). Purification 
was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 
2-(2,4-dimethoxyphenyl)acetate 209 as a clear oil (0.50 g, 79%). FTIR (film/cm-1) υmax: 
2935.8 (w), 1756.9 (s), 1670.5 (m), 1615.0 (w). 1H NMR (300 MHz, CDCl3) δ: 1.63 (d, 
3H, J = 6.6 Hz), 3.53 (s, 2H), 3.62 (app. t, 2H, J = 8.2 Hz),  3.79 (s, 3H), 3.80 (s 3H), 
4.41 (app. t, 2H, J = 8.2 Hz), 4.89 (dd, 1H, J = 14.3, 6.6 Hz), 5.44 (app. quin, 1 H, J = 
6.6 Hz), 6.44 (d, 1 H, J = 7.9 Hz), 6.46 (s, 1 H),  6.90 (d, 1 H, J = 14.3 Hz), 7.07 (d, 1H, 
J = 7.9 Hz). 13C NMR (75 MHz, CDCl3) δ: 21.0, 36.0, 42.8, 55.8, 55.9, 62.6, 69.8, 99.0, 
104.5, 110.6, 115.9, 126.9, 131.5, 155.6, 158.8, 160.6, 171.8. HRMS (ESI, +ve) m/z 
calcd. For C17H21NNaO6 358.1267, found 358.1261 (M+Na)
+. 
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(E)-((E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl) 4-phenylbut-3-enoate 210 
  
 
 
EDCi (0.97 g, 5.06 mmol) in DCM (100 ml), triethylamine (0.70 ml, 5.06 mmol), 
DMAP (0.03 g, 0.25 mmol), E-styryl acetic acid acid (0.82 g, 5.06 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one  145 (0.40 g, 2.53 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-((E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-
yl) 4-phenylbut-3-enoate 210 as a yellow oil (0.76 g, 91%). FTIR (film/cm-1) υmax: 
3027.2 (w), 2980.7 (w), 2928.9 (w), 1756.6 (s), 1670.3 (m), 1619.2 (w). 1H NMR (500 
MHz, CDCl3) δ: 1.38 (d, 3H, J = 6.9 Hz), 3.21 (dd, 2H, J = 7.1, 0.9 Hz), 3.65 (app. t, 
2H, J = 8.1 Hz), 4.40 (app. t, 2H, J = 8.1 Hz), 4.88 (dd, 1H, J = 14.2, 6.9 Hz), 5.45 (app. 
quin, 1 H, J = 6.9 Hz), 6.28 (dt, 1 H, J = 15.5, 7.1 Hz), 6.48 (d, 1 H, J = 15.5 Hz), 6.90 
(d, 1H, J = 14.2 Hz), 7.21 (app. d, 1H, J = 7.3 Hz), 7.29 (app. t, 2H, J = 7.3 Hz), 7.36 
(d, 2H, J = 7.3 Hz). 13C NMR (125 MHz, CDCl3) δ: 20.6, 38.7, 42.3, 62.3, 69.9, 109.8, 
121.7, 126.3, 127.1, 127.6, 128.5, 133.4, 136.9, 155.3, 170.8. HRMS (ESI, +ve) m/z 
calcd. For C17H19NNaO4 324.1212, found 324.1206 (M+Na)
+. 
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(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(1-methyl-1H-indol-3-yl)acetate 211 
 
N O
Me O
O
O
NMe
 
 
Part 1- Synthesis of methyl 2-(1-methyl-1H-indol-3-yl)acetate  
 
N
Me
CO2H
N
H
CO2H
NaH (5 eq.)
MeI (3.3 eq.)
THF
0 C  
 
To stirred suspension of NaH (1.39 g, 57.9 mmol, 5 eq.) in THF (100 ml) at 0 °C was 
added a solution of indole-3-acetic acid (2.00 g, 11.6 mmol, 1 eq.) in THF (50 ml) and 
the reaction mixture was allowed to stir for 30 mins, before the addition of a solution of 
iodomethane (2.41 ml, 38.22 mmol, 3.3 eq.) as a solution in THF (50 ml). The reaction 
mixture was allowed to stir for 15 hours and quenched by the addition of aqueous 
methanol until a clear yellow solution resulted. The resulting mixture was acidified by 
the addition of 6N HCl (100 ml), and the organics were extracted by DCM (3 × 100 ml), 
dried over MgSO4, filtered and concentrated in vacuo to yield methyl 2-(1-methyl-1H-
indol-3-yl)acetate as a brown solid (1.65 g, 76 %). M.p. 128–130 °C; FTIR (film/cm-1) 
υmax: 3433.2 (br s), 1705.3 (s). 
1H NMR (500 MHz, CDCl3) δ: 3.77 (s, 3H), 3.81 (d, 2H, 
J = 0.6 Hz), 7.05 (s, 1H), 7.13 (td, 1H, J = 7.8, 0.9 Hz), 7.22-7.26 (m, 1H), 7.30 (d, 1H, 
J = 7.8 Hz), 7.59 (d, 1H, J = 7.8 Hz), 13C NMR (125 MHz, CDCl3) δ: 31.0, 32.7, 106.1, 
109.4, 119.0, 119.3, 121.9, 127.6, 127.9, 136.9, 178.5. HRMS (ESI, +ve) m/z calcd. For 
C11H11NNaO2 212.0867, found 212.0682 (M+Na)
+. 
 
Part 2- EDCi (0.50 g, 2.61 mmol) in DCM (100 ml), triethylamine (0.36 ml, 2.61 
mmol), DMAP (0.02 g, 0.13 mmol), methyl 2-(1-methyl-1H-indol-3-yl)acetate (0.50 g, 
2.61 mmol) and (E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.20 g, 1.31 mmol) 
in DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(1-methyl-1H-indol-3-yl)acetate 211 as an orange 
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oil (0.42 g, 97%). FTIR (film/cm-1) υmax: 3053.5 (w), 2980.1 (w), 2931.5 (w), 1756.5 
(s), 1670.3 (m), 1616.3 (w), 1552.9 (w). 1H NMR (500 MHz, CDCl3) δ: 1.38 (d, 3H, J = 
6.8 Hz), 3.45 (app. t, 2H, J = 8.1 Hz), 3.71 (s, 3H), 3.75 (s, 2H), 4.27 (app. t, 2H, J = 8.1 
Hz), 4.82 (dd, 1H, J = 14.6, 6.8 Hz), 5.46 (app. quin, 1 H, J = 6.8 Hz), 6.88 (d, 1 H, J = 
14.6 Hz), 7.03 (s, 1 H), 7.11 (td, 1H, J = 7.8, 1.0 Hz), 7.22 (td, 1H, J = 7.8, 1.0 Hz), 
7.28 (d, 1H, J = 7.8 Hz), 7.60 (d, 1H, J = 7.8 Hz). 13C NMR (125 MHz, CDCl3) δ: 20.7, 
31.7, 32.7, 42.2, 62.3, 69.8, 106.8, 109.3, 110.0, 119.0, 119.1, 121.7, 126.8, 127.7, 
127.9, 136.9, 155.4, 171.4. HRMS (ESI, +ve) m/z calcd. For C18H20N2NaO4 351.1321, 
found 351.1315 (M+Na)+. 
 
(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-(benzo[d][1,3]dioxol-5-yl)acetate 212 
 
N O
Me O
O
O
O
O
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), benzodioxole phenyl acetic  acid (0.69 g, 3.81 mmol) and 
(E)-3-(3-hydroxybut-1-enyl)oxazolidin-2-one  145 (0.30 g, 1.91 mmol) in DCM (20 ml) 
were combined according to general procedure 1 (reaction time: 15 hours). Purification 
was achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 
2-(benzo[d][1,3]dioxol-5-yl)acetate 212 as a clear oil (0.52 g, 85%). FTIR (film/cm-1) 
υmax: 2922.9(m), 1750.9(s) 1670.4(s), 1503.6(s). 
1H NMR (250 MHz, CDCl3) δ: 1.34 
(d, 3H, J = 6.9 Hz), 3.49 (s, 2H), 3.66 (app. t, 2H, J = 7.9 Hz),  4.43 (app. t, 2H, J = 7.9 
Hz), 4.85 (dd, 1H, J = 14.4, 6.9), 5.40 (app. quin, 1H, J = 6.9 Hz), 5.93 (s, 2H),  6.66–
6.78 (m, 3H), 6.90 (d, 1H, J = 14.4 Hz). 13C NMR (75 MHz, CDCl3) δ: 21.0, 41.6, 42.7, 
62.6, 70.3, 101.4, 108.7, 110.0, 110.1, 122.8, 127.4, 128.0, 147.1, 148.1, 155.7, 171.4. 
HRMS (ESI, +ve) m/z calcd. For C16H17NNaO6 342.0954, found 342.0948 (M+Na)
+. 
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(E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl propionacetate 265 
 
 
 
EDCi (0.73 g, 3.81 mmol) in DCM (100 ml), triethylamine (0.53 ml, 3.81 mmol), 
DMAP (0.03 g, 0.19 mmol), propionic  acid (0.28 g, 3.81 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one 145 (0.30 g, 1.91 mmol) in DCM (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure to afford (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 
propionacetate 265 as a white solid (0.38 g, 94%). M.p. 89–91 °C. FTIR (film/cm-1) 
υmax: 2977 (s), 2956 (s), 2852 (s), 1747 (s), 1726 (s), 1665 (w), 1479 (w); 
1H NMR (250 
MHz, CDCl3) δ: 1.11 (t, 3H, J = 7.6 Hz, CH3CH2-), 1.35 (d, 3H, J = 6.7 Hz, CH3CH-), 
2.29 (q, 2H, J = 7.6 Hz, CH3CH2-), 3.64–3.73 (m, 2H, -N(CH2-)CH-), 4.39–4.48 (m, 
2H, -OCH2-), 4.87 (dd, 1H, J = 14.4, 6.7 Hz, -NCHCH-), 5.41 (app. quin, 1H, J = 6.7 
Hz, CH3CH(CH-)O-), 6.92 (d, 1H, J = 14.4 Hz, -NCHCH-); 
13C NMR (75 MHz, 
CDCl3) δ: 9.5, 21.1, 28.3, 42.7, 62.6, 69.5, 110.5, 127.1, 155.7, 174.1; HRMS (ESI, 
+ve) m/z calcd. for C1H15NNaO4  236.0898,  found 236.0893 (M+Na)
+. 
 
α,α-
2
H2-Propionic acid 1-methyl-3-(2-oxo-oxazolidin-3-yl)-allyl ester 
2
H2-265 
 
 
 
EDCi (0.60 g, 3.82 mmol) in CD2Cl2 (100 ml), triethylamine (0.53 ml, 3.82 mmol), 
DMAP (0.05 g, 0.19 mmol), α,α-d2-propionic  acid (0.28 g, 3.82 mmol) and (E)-3-(3-
hydroxybut-1-enyl)oxazolidin-2-one (0.30 g, 1.91 mmol) 145 in CD2Cl2 (20 ml) were 
combined according to general procedure 1 (reaction time: 15 hours). Purification was 
achieved by reported procedure, with solutions of citric acid (10%) and sat. sodium 
bicarbonate made as solutions in D2O, to afford α,α-d
2-propionic acid 1-methyl-3-(2-
oxo-oxazolidin-3-yl)-allyl ester 2H2-265 as a cream solid (0.29 g, 71%). M.p. 89–92 ˚C; 
FTIR (film/cm-1) υmax: 2990 (m), 2975 (m), 2937 (m), 1743 (s), 1721 (s), 1662 (s), 1475 
(s); 1H NMR (250 MHz, CDCl3) δ: 1.04 (s, 3H), 1.29 (d, 3H, J = 6.7 Hz), 3.64 (app. t, 
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2H, J = 8.2 Hz), 4.39 (app. t, 3H, J = 8.2 Hz), 4.82 (dd, 1H, J = 14.4, 6.7 Hz), 5.35 (app. 
pent, 1H, J = 6.7 Hz), 6.85 (d, 1H, J = 6.7 Hz); 13C NMR (100 MHz, CDCl3) δ: 8.8, 
20.7, 27.2 (quin, J = 19.8 Hz), 42.3, 62.3, 69.1, 110.1, 126.7, 155.3, 173.6; HRMS (ESI, 
+ve) m/z calcd. for C10H13D2NNaO4  238.1022,  found 238.1020 (M+Na)
+. 
 
6.3.2. N-Oxazolidinone Rearrangement Products 
 
anti-2-Methyl-3-(2-oxo-oxazolidin-3-yl)-hex-4-enoic acid methyl ester 139 
 
 
 
LiHMDS (0.61 ml, 0.61 mmol), TMSCl (0.08 ml, 0.61 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl propionacetate 256 (0.10 g, 0.46 mmol) in THF (1 ml) 
were combined according to general procedure 2 (reaction time : 75 minutes). 
Treatment with diazomethane and purification by flash chromatography afforded anti-2-
methyl-3-(2-oxo-oxazolidin-3-yl)-hex-4-enoic acid methyl ester 139 as a white solid 
(0.06 g, 60%, d.r. 2:1). M.p. 89–90 °C; FTIR (film/cm-1) υmax: 2922 (s), 1754 (s), 1726 
(s) 1658 (m), 1572 (m); 1H NMR (250 MHz, CDCl3) anti δ: 1.12 (d, 3H, J = 7.0 Hz), 
1.65–1.75 (m, 3H), 2.74–2.93 (m, 1H), 3.36–3.63 (m, 2H), 3.66 (s, 3H), 4.15–4.38 (m, 
3H), 5.34−5.54 (m, 1H), 5.64–5.86 (m, 1H, J = 15.3 Hz); syn δ:  1.16 (d, 3H, J = 7.0 
Hz), 1.65–1.75 (m, 3H), 2.74–2.93 (m, 1H), 3.36–3.63 (m, 2H), 3.64 (s, 3H), 4.15–4.38 
(m, 3H), 5.34−5.54 (m, 1H), 5.64–5.86 (m, 1H, J = 15.3 Hz); 13C NMR (62 MHz, 
CDCl3) anti δ: 14.7, 17.9, 41.9, 42.5, 51.9, 59.1, 62.2, 124.9, 131.6, 158.1, 174.8; syn δ: 
14.2, 14.8, 41.4, 42.3, 51.8, 58.1, 62.1, 125.0, 132.4, 157.6, 174.5. HRMS (ESI, +ve) 
m/z calcd. For C11H17NNaO4 250.1055, found 250.1065 (M+Na)
+. 
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(anti-E)-Methyl 3-(2-oxooxazolidin-3-yl)-2-phenylhex-4-enoate 144 
 
 
 
LiHMDS (0.47 ml, 0.47 mmol), TMSCl (0.06 ml, 0.47 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl phenylacetate 154 (0.10 g, 0.36 mmol) in THF (1 ml) 
were combined according to general procedure 2 (reaction time : 75 minutes). 
Treatment with diazomethane and purification by flash chromatography afforded (anti-
E)-methyl 3-(2-oxooxazolidin-3-yl)-2-phenylhex-4-enoate 144 as a white solid (0.08 g, 
72%, d.r. 44:1). M.p. 98–99 °C;  FTIR (film/cm-1) υmax: 3062 (m), 3031 (m), 2952 (m), 
2918 (m), 1738 (s); 1H NMR (500 MHz, CDCl3) δ: 1.49 (dd, 3H, J = 6.5, 1.3 Hz, 
CH3CHCH-), 3.55–3.64 (m, 2H, -N(CH)CH2-), 3.65 (s, 3H, -CO2CH3), 4.14 (d, 1H, J = 
11.4 Hz, -CHCO2CH3), 4.24–4.33 (m, 2H, -OCH2-), 4.69 (dd, 1H, J = 11.4, 7.9 Hz, -
CHCH(C6H5)CO2CH3), 5.29 (ddq, 1H, J = 15.3, 7.9, 1.3 Hz, CH3CHCH-), 5.42 (dqd, 
1H, J = 15.3, 6.5, 0.7 Hz, CH3CHCH-), 7.23–7.34 (m, 5H, C6H5-); 
13C NMR (125 MHz, 
CDCl3) δ:  17.7, 42.7, 52.3, 54.3, 58.7, 62.6, 124.3, 127.9, 128.7, 128.9, 131.5, 135.1, 
157.6, 172.4; HRMS (ESI, +ve) m/z calcd. For C16H20NO4, 290.1392, found 290.1385 
(M+H)+. 
 
(anti-E)-methyl 3-(2- d
2-
oxooxazolidin-3-yl)-2-phenylhex-4- d
4
d
5
-enoate 
2
H3-144 
 
 
 
To an oven dried Young’s tap NMR tube, inserted into a Dewar at -95 °C and under an 
atmosphere of nitrogen,  was added a solution of LiHMDS (1 M in THF, 0.24 ml, 0.23 
mmol, 1.3 eq.),  and TMSCl (0.03 ml, 0.23 mmol, 1.3 eq.). Thermal equilibration was 
allowed (5 minutes) and then a solution of phenyl-acetic acid d1-d2-d3-1-methyl-3-(2-
oxo-oxazolidin-3-yl)-allyl ester 2H3-154 (0.05 g, 0.18 mmol, 1 eq.) in THF (0.5 ml) was 
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added. The cooled NMR tube was rapidly lowered into the pre-cooled NMR machine at 
-95 °C. From this point 1H and 13C NMR spectroscopy were recorded utilising solvent 
suppression techniques, and the sample was subsequently warmed to -50 °C and 25 °C 
allowing the sample to equilibrate for five minutes before recording data. After in-situ 
reaction monitoring the reaction mixture was quenched following general procedure 2 
and treatment with diazomethane and purification by flash column chromatography 
afforded (anti-E)-methyl 3-(2- d2-oxooxazolidin-3-yl)-2-phenylhex-4- d4d5-enoate 2H3-
144 as an amorphous yellow solid (0.03 g, 59%, d.r. 51:1). FTIR (film/cm-1) υmax:  3015 
(m), 3001 (m), 2955 (m), 2919 (m), 1748 (s), 1519 (m); 1H NMR (500 MHz, CDCl3) δ:  
1.51 (s, 3H), 3.57–3.67 (m, 2H), 3.68 (s, 3H), 4.16 (s, 1H),  4.26–4.36 (m, 2H), 7.25–
7.37 (5H, m); 13C NMR (125 MHz, CDCl3) δ: 17.6, 42.6, 52.3, 54.2, 58.3 (t, J = 20.6 
Hz), 62.3, 123.8 (t, J = 23.5 Hz), 127.9, 128.7, 128.9, 131.1 (t, J = 23.5 Hz), 135.1, 
157.5, 172.3 HRMS (ESI, +ve) m/z calcd. for C16H17D3NO4 293.1581,  found 
293.1582(M+H)+. 
 
13
C2-(anti-E)-Methyl 3-(2-oxooxazolidin-3-yl)-2-phenylhex-4-enoate 
13
C2-144 
 
 
 
To an oven dried Young’s tap NMR tube, inserted into a Dewar at -95 °C and under an 
atmosphere of nitrogen,  was added a solution of LiHMDS (1 M in THF, n eq.),  and 
TMSCl (m eq.). Thermal equilibration was allowed (5 minutes) and then a solution of 
13C2-(E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl phenylacetate
 13
C2-154 (0.05 g, 0.17 
mmol, 1 eq.) in THF (0.5 ml) was added. The cooled NMR tube was rapidly lowered 
into the pre-cooled NMR machine at -95 °C. From this point 13C NMR spectroscopy 
was recorded at -95 °C and then the machine was allowed to warm to -65 °C, where it 
was then kept for the rest of the experiment (ca. 12 hours) and 13C data was recorded 
every 5 minutes. After in-situ reaction monitoring the reaction mixture was quenched 
following general procedure 2 and treatment with diazomethane and purification by 
flash chromatography afforded 13C2-(anti-E)-methyl 3-(2-oxooxazolidin-3-yl)-2-
phenylhex-4-enoate 13C2-144 as a white solid.  
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Entry LiHMDS (n eq.) TMSCl (m eq.) 
Yield 13C2-144 
(%) 
d.r. (anti:syn) 
1 1.3 1.3 50 39:1 
2 1.7 1.7 56 38:1 
3 1.3 6 65 56:1 
4 5.2 5.2 33 32:1 
 
Table 24. In-Situ EICR of 13C2-154. 
 
M.p. 98–100 oC; FTIR (film/cm-1) υmax: 3031 (m), 2951 (m), 2920 (m), 1739 (s), 1669 
(s), 1482 (m); 1H NMR (500 MHz, CDCl3) δ: 1.52 (d, 3H, J = 6.3 Hz), 3.58–3.67 (m, 
2H), 3.68 (s, 3H, J = 3.9 Hz), 4.03 (dd, 1H, J = 11.5, 7.1 Hz), 4.25–4.36 (m, 2H), 4.67–
4.75 (m, 1H), 5.31 (dd, 1H, J = 15.2, 7.8 Hz), 5.49 (dq, 1H, J = 15.2, 6.3 Hz), 7.25–7.38 
(m, 5H); 13C NMR (125 MHz, CDCl3) δ:  17.7, 42.6, 52.3, 54.3 (d, J = 61.7 Hz), 58.7 
(d, J = 46.1 Hz),  62.2, 124.3 (d, J = 5.4 Hz),  127.8, 128.6 (d, J = 5.4 Hz),  128.9, 131.4 
(d, J = 2.8 Hz),  135.1 (d, J = 38.9 Hz),  157.5, 172.3 (d, J = 61.7 Hz); HRMS (ESI, 
+ve) m/z calcd. for C14C
13
2H19NNaO4, 314.1368,  found 314.1400 (M+Na)
+. 
 
(anti-E)-Methyl 2-(o-methoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 172 
 
 
 
LiHMDS (0.43 ml, 0.43 mmol), TMSCl (0.06 ml, 0.43 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(o-methoxyphenyl)acetate 163 (0.10 g, 0.33 mmol) 
in THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(o-methoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
172 as a white solid (0.08 g, 79%, d.r. 22:1). M.p. 95–96 °C;  FTIR (film/cm-1) υmax: 
2919 (m), 1747 (s), 1600 (w), 1495 (m); 1H NMR (250 MHz, CDCl3) δ: 1.50 (dd, 3H, J 
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= 6.3, 1.2 Hz), 3.60–3.68 (m, 2H), 3.64 (s, 3H), 3.83 (s, 3H), 4.21–4.37 (m, 2H), 4.67 
(d, 1H, J = 11.0 Hz), 4.78 (dd, 1H, J = 11.0, 7.3 Hz), 5.30 (ddq, 1H, J = 15.3, 7.3, 1.2 
Hz), 5.50 (dq, 1H, J = 15.3, 7.3 Hz), 6.85 (dd, 1H, J = 7.8, 1.0 Hz), 6.93 (td, 1H, J = 
7.8, 1.0 Hz), 7.24 (td, 1H, J = 8.2, 1.6 Hz), 7.42 (dd, 1H, J = 7.8, 1.6 Hz). 13C NMR (75 
MHz, CDCl3) δ:  17.7, 42.2, 45.7, 52.2, 55.6, 57.9, 62.2, 110.7, 120.8, 123.8, 124.8, 
128.8, 129.3, 130.8, 157.1, 157.6, 172.5; HRMS (ESI, +ve) m/z calcd. For C17H22NO5, 
320.1498, found 320.1490 (M+H)+. 
 
(anti-E)-Methyl 2-(m-methoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 173 
 
 
 
LiHMDS (0.43 ml, 0.43 mmol), TMSCl (0.06 ml, 0.43 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(m-methoxyphenyl)acetate 164 (0.10 g, 0.33 mmol) 
in THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(m-methoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
173 as a white solid (0.08 g, 73%, d.r. 19:1). M.p. 98–99 °C; FTIR (film/cm-1) υmax: 
2922 (m), 1746 (s), 1600 (m); 1H NMR (300 MHz, CDCl3) δ: 1.52 (dd, 3H, J = 6.4, 1.2 
Hz), 3.61 (td, 2H, J = 7.9, 2.1 Hz), 3.67 (s, 3H), 3.80 (s, 3H), 4.12 (d, 1H, J = 11.4 Hz) 
4.30 (td, 2H, J = 7.9, 2.1 Hz), 4.68 (dd, 1H, J = 11.4, 7.7 Hz), 5.31 (ddq, 1H, J = 15.3, 
7.7, 1.2 Hz),  5.50 (dqd, 1H, J = 15.3, 6.4, 0.7 Hz), 6.81 (dd, 1H, J = 8.1, 2.4 Hz), 6.87–
6.91 (m, 1H), 6.91–6.94 (m, 1H), 7.22 (t, 1H, J = 8.1 Hz); 13C NMR (75 MHz, CDCl3) 
δ:  16.7, 41.7, 51.3, 53.2, 54.3, 57.6, 61.2, 112.4, 113.5, 120.3, 123.2, 128.6, 130.3, 
135.5, 156.5, 158.7, 171.3; HRMS (ESI, +ve) m/z calcd. for C17H21NNaO5, 342.1317,  
found 342.1304 (M+Na)+. 
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(anti-E)-Methyl 2-(p-methoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 174 
 
 
 
LiHMDS (0.43 ml, 0.43 mmol), TMSCl (0.06 ml, 0.43 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-methoxyphenyl)acetate 165 (0.10 g, 0.33 mmol) 
in THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(p-methoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
174 as a white solid (0.08 g, 77%, d.r. 24:1). M.p. 101–103 °C; FTIR (film/cm-1) υmax: 
2922 (m), 1747 (s), 1611 (w), 1514 (m); 1H NMR (300 MHz, CDCl3) δ: 1.52 (dd, 3H, J 
= 6.4, 1.1 Hz), 3.53–3.66 (m, 2H), 3.66 (s, 3H), 3.79 (s, 3H), 4.08 (d, 1H, J = 11.5 Hz) 
4.23−4.36 (m, 2H), 4.67 (dd, 1H, J = 11.5, 7.7 Hz), 5.23 (ddq, 1H, J = 15.4, 7.7, 1.1 
Hz), 5.49 (dqd, 1H, J = 15.4, 6.4, 0.7 Hz), 6.84 (app. d, 2H, J = 8.8 Hz), 7.25 (app. d, 
2H, J = 8.8 Hz); 13C NMR (75 MHz, CDCl3) δ:  18.2, 42.9, 52.7, 53.9, 55.6, 59.1, 62.7, 
114.4, 124.8, 127.5, 130.4, 131.8, 157.9, 159.6, 173.0; HRMS (ESI, +ve) m/z calcd. for 
C17H21NNaO5, 342.1317,  found 342.1321 (M+Na)
+. 
 
13
C1-(anti-E)-Methyl 2-(4-methoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
13
C1-174 
 
 
To an oven dried Young’s tap NMR tube, inserted into a Dewar at -95 °C and under an 
atmosphere of nitrogen,  was added a solution of LiHMDS (1 M in THF, 0.21 ml, 0.21 
mmol, 1.3 eq.),  and TMSCl (0.03 ml, 0.21 mmol, 1.3 eq.). Thermal equilibration was 
allowed (5 minutes) and then a solution of (E)-4-(2-Oxooxazolidin-3-yl)but-3-en-2-yl 2-
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13C1-(4-methoxyphenyl)acetate 
13
C1-165 (0.05 g, 0.16 mmol, 1.0 eq.) in THF (0.5 ml) 
was added. The cooled NMR tube was rapidly lowered into the pre-cooled NMR 
machine at -95 °C. From this point 13C NMR spectroscopy was recorded at -95 °C and 
then the machine was allowed to warm to -65 °C, where it was then kept for the rest of 
the experiment (ca. 12 hours) and 13C data was recorded every 5 minutes. After in-situ 
reaction monitoring the reaction mixture was quenched following general procedure 2 
and treatment with diazomethane and purification by flash chromatography to afford 
13C1-(anti-E)-methyl 2-(4-methoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
13
C1-
174 as a white solid (0.03 g, 52%, d.r. 25:1). M.p. 103–104 °C; FTIR (film/cm-1) υmax: 
3012 (m), 2985 (m), 2937 (m), 1710 (s), 1671 (m), 1596 (m), 1566 (m); 1H NMR (500 
MHz, CDCl3) δ: 1.53 (d, 3H, J = 6.5 Hz), 3.56–3.65 (m, 2H), 3.67 (s, 3H), 3.80 (s, 3H), 
4.10 (dd, 1H, J = 132.9, 11.3 Hz) 4.26−4.36 (m, 2H),  4.64−4.73 (m, 1H),  5.30 (app. 
dd, 1H, J = 15.1, 8.2 Hz), 5.50 (app. dq, 1H, J = 15.1, 6.5 Hz), 6.86 (app. d, 2H, J = 8.8 
Hz), 7.24 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 17.8, 42.6, 52.3, 53.5, 55.2, 58.7 (d, 
J = 24.9 Hz), 62.2, 114.0 (d, J = 2.6 Hz), 124.4, 127.1 (d, J = 30.0 Hz), 130.0 (d, J = 1.7 
Hz), 131.4 (d, J = 2.6 Hz), 157.6, 159.2, 172.6  (d, J = 39.5 Hz); HRMS (ESI, +ve) m/z 
calcd. for C16
13C1H21NNaO5, 343.1395,  found 343.1377 (M+Na)
+. 
 
(anti-E)-Methyl 3-(2-oxooxazolidin-3-yl)-2-o-tolylhex-4-enoate 175 
 
 
 
LiHMDS (0.45 ml, 0.45 mmol), TMSCl (0.06 ml, 0.45 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-o-tolylacetate 166 (0.10 g, 0.35 mmol) in THF (1 
ml) were combined according to general procedure 2 (reaction time : 75 minutes). 
Treatment with diazomethane and purification by flash chromatography afforded (anti-
E)-methyl 3-(2-oxooxazolidin-3-yl)-2-o-tolylhex-4-enoate 175 as a white solid (0.08 g, 
71%, d.r. 19:1). M.p. 100–102 °C;  FTIR (film/cm-1) υmax: 2923 (w), 1745 (s), 1484 
(m); 1H NMR (250 MHz, CDCl3) δ: 1.48 (d, 3H, J = 5.7 Hz), 2.40 (s, 3H), 3.60–3.71 
(m, 2H), 3.63 (s, 3H), 4.30 (app. t, 2H, J = 7.88 Hz), 4.55–4.69 (m, 2H), 5.30 (dd, 1H, J 
Chapter 6  Experimental
   
204 
=  15.7, 5.7 Hz), 5.41 (dq, 1H, J = 15.7, 5.7 Hz), 7.12–7.21 (m, 3H), 7.34–7.40 (m, 1H); 
13C NMR (75 MHz, CDCl3) δ:  16.7, 19.1, 42.4, 47.6, 51.2, 58.3, 61.2, 122.9, 125.3, 
126.4, 126.5, 129.5, 130.0, 132.8, 136.0, 156.6, 171.8. HRMS (ESI, +ve) m/z calcd. for 
C17H22NO4, 304.1549,  found 304.1546 (M+H)
+. 
 
(anti-E)-Methyl 3-(2-oxooxazolidin-3-yl)-2-m-tolylhex-4-enoate 176 
 
 
 
LiHMDS (0.45 ml, 0.45 mmol), TMSCl (0.06 ml, 0.45 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-m-tolylacetate 167 (0.10 g, 0.35 mmol) in THF (1 
ml) were combined according to general procedure 2 (reaction time : 75 minutes). 
Treatment with diazomethane and purification by flash chromatography afforded (anti-
E)-methyl 3-(2-oxooxazolidin-3-yl)-2-m-tolylhex-4-enoate 176 as an off white solid 
(0.08 g, 74%, d.r. 43:1). M.p. 95–97 °C; FTIR (film/cm-1) υmax: 2919 (m), 1746 (s), 
1607 (m), 1484 (m); 1H NMR (300 MHz, CDCl3) δ: 1.51 (d, 3H, J = 6.4 Hz), 2.33 (s, 
3H), 3.60 (td, 2H, J = 8.0, 3.4 Hz), 3.66 (s, 3H), 4.09 (d, 1H, J = 11.4 Hz), 4.22–4.37 
(m, 2H), 4.71 (dd, 1H, J = 11.4, 7.5 Hz), 5.28 (ddq, 1H, J = 15.4, 7.5, 1.5 Hz), 5.48 (dq, 
1H, J = 15.4, 6.4 Hz), 7.04–7.23 (m, 4H); 13C NMR (75 MHz, CDCl3) δ:  16.7, 20.4, 
41.5, 51.3, 53.2, 57.4, 61.2, 123.3, 124.9, 127.5, 127.6, 128.5, 130.2, 133.9, 137.4, 
156.6, 171.4; HRMS (ESI, +ve) m/z calcd. for C17H22NO4, 304.1549,  found 304.1537 
(M+H)+. 
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(anti-E)-Methyl 3-(2-oxooxazolidin-3-yl)-2-p-tolylhex-4-enoate 177 
 
 
 
LiHMDS (0.45 ml, 0.45 mmol), TMSCl (0.06 ml, 0.45 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-p-tolylacetate 168 (0.10 g, 0.35 mmol) in THF (1 
ml) were combined according to general procedure 2  (reaction time : 75 minutes). 
Treatment with diazomethane and purification by flash chromatography afforded (anti-
E)-methyl 3-(2-oxooxazolidin-3-yl)-2-p-tolylhex-4-enoate 177 as a white solid (0.07 g, 
70%, d.r. 54:1). M.p. 101–102 °C; FTIR (film/cm-1) υmax: 2920 (m), 1746 (s), 1666 (m), 
1612 (m), 1514 (m), 1483 (m); 1H NMR (300 MHz, CDCl3) δ: 1.52 (d, 3H, J = 6.2 Hz), 
2.32 (s, 3H), 3.60 (td, 2H, J = 8.2, 2.0 Hz), 3.65 (s, 3H), 4.09 (d, 1H, J = 11.4 
Hz), 4.21–4.37 (m, 2H), 4.70 (dd, 1H, J = 11.4, 7.7 Hz), 5.29 (ddq, 1H, J = 15.3, 7.7, 
1.4 Hz), 5.50 (dq, 1H, J = 15.3, 6.2 Hz), 7.12 (app. d, 2H, J = 7.9 Hz), 7.22 (app. d, 2H, 
J = 7.9 Hz); 13C NMR (75 MHz, CDCl3) δ:  18.2, 21.5, 42.9, 52.7, 54.4, 58.9, 62.6, 
124.8, 129.2, 129.8, 131.7, 132.4, 138.0, 157.9, 172.9; HRMS (ESI, +ve) m/z calcd. for 
C17H22NO4, 304.1549,  found 304.1538 (M+H)
+. 
 
(anti-E)-Methyl 2-(o-nitrophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate anti-178 
 
 
 
LiHMDS (0.41 ml, 0.41 mmol), TMSCl (0.05 ml, 0.41 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(o-nitrophenyl)acetate 169 (0.10 g, 0.32 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(o-nitrophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 178 
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as a yellow solid (0.06 g, 60%). M.p. 134–135 °C; FTIR (film/cm-1) υmax: 2955 (m), 
2918 (m), 1748 (s), 1529 (m); 1H NMR (500 MHz, CDCl3) δ: 1.45 (dd, 3H, J = 6.6, 1.4 
Hz), 3.66–3.70 (m, 2H), 3.67 (s, 3H), 4.25–4.40 (m, 2H), 4.78 (d, 1H, J = 10.4 Hz), 4.84 
(dd, 1H, J = 10.4, 8.4 Hz), 5.29 (ddq, 1H, J = 15.4, 8.4, 1.4 Hz), 5.48 (dq, 1H, J = 15.4, 
6.6 Hz), 7.42 (td, 1H, J = 8.0, 1.1 Hz), 7.59 (td, 1H, J = 8.0, 1.1 Hz), 7.74 (dd, 1H, J = 
8.0, 1.1 Hz), 7.85 (dd, 1H, J = 8.0, 1.1 Hz); 13C NMR (125 MHz, CDCl3) δ:  17.7, 42.0, 
47.9, 52.6, 58.6, 62.3, 124.0, 124.6, 128.7, 129.9, 131.5, 132.5, 133.1, 149.7, 157.6, 
170.8; HRMS (ESI, +ve) m/z calcd. for C16H18N2NaO6, 357.1063,  found 357.1071 
(M+Na)+. 
 
(syn-E)-Methyl 2-(o-nitrophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate syn-178 
 
 
 
LiHMDS (0.41 ml, 0.41 mmol), TMSCl (0.05 ml, 0.41 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(o-nitrophenyl)acetate 169 (0.10 g, 0.32 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (syn-E)-methyl 2-(o-nitrophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 178 as 
a yellow solid (0.01 g, 12%). M.p. 133–134 °C; FTIR (film/cm-1) υmax: 2954 (m), 2918 
(m), 1747 (s), 1529 (s); 1H NMR (500 MHz, CDCl3) δ: 1.74 (d, 3H, J = 6.4 Hz), 3.34 
(dt, 1H, J = 8.8, 5.0 Hz),  3.47 (q, 1H, J = 8.9 Hz), 3.64 (s, 3H), 3.94 (q, 1H, J = 8.9 
Hz),  4.17 (dt, 1H, J = 8.8, 5.0 Hz), 4.66 (d, 1H, J = 11.4 Hz), 5.17 (dd, 1H, J = 11.4, 
7.8 Hz), 5.53 (ddq, 1H, J = 15.4, 7.8, 1.2 Hz), 5.90 (dq, 1H, J = 15.4, 6.4 Hz), 7.43 (t, 
1H, J = 7.8 Hz), 7.62 (t, 1H, J = 7.8 Hz), 7.76 (d, 1H, J = 7.8 Hz), 7.87 (d, 1H, J = 7.8 
Hz); 13C NMR (125 MHz, CDCl3) δ:  17.9, 40.6, 47.5, 52.6, 56.4, 62.1, 124.2, 124.6, 
128.5, 128.9, 130.6, 132.5, 133.0, 150.5, 157.7, 170.5; HRMS (ESI, +ve) m/z calcd. For 
C16H18N2NaO6, 357.1063, found 357.1069 (M+Na)
+. 
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(anti-E)-Methyl 2-(m-nitrophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 179 
 
 
 
LiHMDS (0.41 ml, 0.41 mmol), TMSCl (0.05 ml, 0.41 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(m-nitrophenyl)acetate 170 (0.10 g, 0.32 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(m-nitrophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 179 
as an orange solid (0.08 g, 75%, d.r. 16:1). M.p. 97–99 °C; FTIR (film/cm-1) υmax: 2953 
(m), 1746 (s), 1531 (s), 1482 (w); 1H NMR (500 MHz, CDCl3) δ: 1.50 (dd, 3H, J = 6.4, 
1.4 Hz), 3.60–3.68 (m, 2H), 3.70 (s, 3H), 4.30–4.35 (m, 2H), 4.35 (d, 1H, J = 11.3 
Hz), 4.64 (dd, 1H, J = 11.3, 8.6 Hz), 5.34 (ddq, 1H, J  = 15.4, 8.7, 1.4 Hz),  5.50 (dqd, 
1H, J = 15.4, 6.4, 0.6 Hz), 7.51 (t, 1H, J = 7.8 Hz), 7.71 (d, 1H, J = 7.8, 1.2 Hz), 8.14 
(d, 1H, J = 7.8 Hz), 8.20 (s, 1H); 13C NMR (75 MHz, CDCl3) δ:  18.1, 43.4, 53.1, 54.1, 
59.6, 62.8, 123.4, 124.2, 124.3, 130.1, 133.3, 135.6, 137.7, 148.8, 157.9, 171.8; HRMS 
(ESI, +ve) m/z calcd. for C16H18N2NaO6, 357.1063,  found 357.1063 (M+Na)
+. 
 
(anti-E)-Methyl 2-(p-nitrophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 180 
 
 
 
LiHMDS (0.41 ml, 0.41 mmol), TMSCl (0.05 ml, 0.41 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-nitrophenyl)acetate 171 (0.10 g, 0.32 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(p-nitrophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate anti-
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180 as a red solid (0.07 g, 69%). M.p. 101–103 °C; FTIR (film/cm-1) υmax: 2954 (m), 
1739 (s), 1607 (w), 1522 (m); 1H NMR (500 MHz, CDCl3) δ: 1.51 (dd, 3H, J = 6.5, 1.2 
Hz), 3.62 (app. t, 2H, J = 8.0 Hz), 3.67 (s, 3H), 4.27–4.34 (m, 2H), 4.35 (d, 1H, J = 11.3 
Hz), 4.62  (dd, 1H, J = 11.3, 8.5 Hz), 5.31 (ddq, 1H, J = 15.3, 8.5, 1.5 Hz),  5.47 (dq, 
1H, J = 15.3, 6.5 Hz), 7.51 (app. d, 2H, J = 8.7 Hz), 8.16 (app. d, 1H, J = 8.7 Hz); 13C 
NMR (125 MHz, CDCl3) δ:  17.7, 43.0, 52.7, 53.8, 59.2, 62.3, 123.7, 123.8, 129.9, 
132.7, 142.5, 147.6, 157.5, 171.3; HRMS (ESI, +ve) m/z calcd. for C16H18N2NaO6, 
357.1063,  found 357.1075 (M+Na)+. (syn-E)-methyl 2-(p-nitrophenyl)-3-(2-
oxooxazolidin-3-yl)hex-4-enoate syn-180 as a red solid (0.01 g, 7%). M.p. 101–102 °C; 
FTIR (film/cm-1) υmax: 2954 (m), 1740 (s), 1607 (w), 1521 (s); 
1H NMR (500 MHz, 
CDCl3) δ: 1.74 (dd, 3H, J = 6.6, 1.3 Hz), 3.31 (app. t, 2H, J = 8.0 Hz), 3.66 (s, 3H), 4.02 
(dt, 1H, J = 8.2, 2.9 Hz), 4.70 (dt, 1H, J = 8.2, 2.9 Hz), 4.27 (d, 1H, J = 11.2 Hz), 4.76  
(dd, 1H, J = 11.2, 8.0 Hz), 5.63 (ddq, 1H, J = 15.3, 8.0, 1.6 Hz),  5.87 (dq, 1H, J = 15.3, 
6.6 Hz), 7.62 (d, 2H, J = 8.7 Hz), 8.12 (d, 1H, J = 8.7 Hz); 13C NMR (125 MHz, CDCl3) 
δ:  17.9, 42.5, 52.6, 53.9, 58.2, 61.9, 123.9, 124.3, 129.5, 132.4, 142.4, 147.7, 157.4, 
170.8; HRMS (ESI, +ve) m/z calcd. for C16H18N2NaO6, 357.1063,  found 357.1058 
(M+Na)+. 
 
(anti-E)-Methyl 2-(4-(dimethylamino)phenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
213 
 
 
LiHMDS (1.02 ml, 1.02 mmol), TMSCl (0.13 ml, 1.02 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(4-(dimethylamino)phenyl)acetate 202 (0.25 g, 0.78 
mmol) in THF (2.5 ml) were combined according to a modified general procedure 2, in 
which LiHMDS was added by syringe pump at 4 ml/h to a solution of (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(4-(dimethylamino)phenyl)acetate 202, TMSCl and 
THF (reaction time : 75 minutes). Treatment with diazomethane and purification by 
flash chromatography afforded (anti-E)-methyl 2-(4-(dimethylamino)phenyl)-3-(2-
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oxooxazolidin-3-yl)hex-4-enoate 213 as a brown solid (0.15 g, 58%, d.r. 6:1); M.p. 
130–132 °C; FTIR (film/cm-1) υmax: 2950 (m), 2916 (m), 2805 (m), 1748 (s), 1612 (w), 
1613 (m), 1523 (m); 1H NMR (500 MHz, CDCl3) Major δ: 1.52 (d, 3H, J = 6.4 Hz), 
2.91 (s, 3H), 3.52–3.60 (m, 2H), 3.67 (s, 3H), 3.97 (d, 1H, J = 11.4 Hz), 4.20–4.32 (m, 
2H), 4.70 (dd, 1H, J = 11.4, 7.4 Hz),  5.27 (ddq, 1H, J = 15.3, 7.4, 0.9 Hz), 5.50 (dqd, 
1H, J = 15.3, 6.4, 0.8 Hz), 6.63 (app. d, 2H, J = 8.9 Hz), 7.19 (app. d, 2H, J = 8.9 Hz). 
Minor δ: 1.69 (d, 3H, J = 6.5 Hz), 2.90 (s, 3H), 3.20–3.32 (m, 2H), 3.59 (s, 3H), 3.84 (d, 
1H, J = 11.4 Hz), 3.88–4.12 (m, 2H), 4.84 (dd, 1H, J = 11.4, 7.6 Hz),  5.57 (ddq, 1H, J 
= 15.3, 7.6, 1.6 Hz), 5.79 (dqd, 1H, J = 15.3, 6.5, 0.6 Hz), 6.63–6.65 (m, 2H), 7.22 (app. 
d, 2H, J = 8.6 Hz); 13C NMR (75 MHz, CDCl3) Major δ: 17.8, 40.3, 42.2, 52.0, 53.4, 
58.2, 62.2, 112.4, 122.3, 124.7, 129.5, 130.8, 150.0, 157.6, 127.8; Minor δ: 17.9, 40.3, 
41.5, 52.0, 53.3, 56.9, 61.9, 112.4, 122.1, 125.6, 128.9, 130.4, 150.1, 157.6, 172.3; 
HRMS (ESI, +ve) m/z calcd. For C18H24NaN2O4 355.1634, found 355.1628 (M+Na)
+. 
 
(anti-E)-Methyl 2-(4-iodophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 214 
 
 
 
LiHMDS (0.32 ml, 0.32 mmol), TMSCl (0.04 ml, 0.32 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-iodophenyl)acetate 203 (0.10 g, 0.25 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(4-iodophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 214 as 
a yellow solid (0.08 g, 77%, d.r. 60:1);  M.p. 108–110 °C; FTIR (film/cm-1) υmax: 2951 
(w), 1745 (s) 1485 (m); 1H NMR (500 MHz, CDCl3) δ: 1.53 (dd, 3H, J = 6.5, 1.4 Hz), 
3.56–3.63 (m, 2H), 3.66 (s, 3H), 4.13 (d, 1H, J = 11.2 Hz),  4.25–4.34 (m, 2H), 4.62  
(dd, 1H, J = 11.2, 8.1 Hz), 5.29 (ddq, 1H, J = 15.3, 8.1, 1.4 Hz),  5.49 (dq, 1H, J = 15.3, 
6.5 Hz), 7.08 (app. d, 2H, J = 8.3 Hz), 7.64 (app. d, 2H, J = 8.3 Hz); 13C NMR (125 
MHz, CDCl3) δ: 17.8, 42.8, 52.4, 53.8, 58.7, 62.3, 93.6, 124.1, 130.8, 132.0, 134.8, 
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137.8, 157.5, 171.9; HRMS (ESI, +ve) m/z calcd. For C16H18INNaO4 438.0178, found 
438.0173 (M+Na)+. 
 
(anti-E)-Methyl 2-(p-fluorophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 215 
 
 
 
LiHMDS (0.42 ml, 0.42 mmol), TMSCl (0.06 ml, 0.42 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-fluorophenyl)acetate 204 (0.10 g, 0.32 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(p-fluorophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 215 
as a yellow solid (0.08 g, 73%, d.r. 23:1). M.p. 95–97 °C; FTIR (film/cm-1) υmax: 2954 
(w), 2918 (w), 1748 (s) 1605 (m), 1510 (s); 1H NMR (500 MHz, CDCl3) δ: 1.51 (dd, 
3H, J = 6.6, 1.3 Hz), 3.53–3.64 (m, 2H), 3.67 (s, 3H), 4.16 (d, 1H, J = 11.4 Hz),  4.25–
4.34 (m, 2H), 4.61  (dd, 1H, J = 11.4, 8.2 Hz), 5.29 (ddq, 1H, J = 15.4, 8.2, 1.3 Hz),  
5.47 (dq, 1H, J = 15.4, 6.6 Hz), 7.00 (app. t, 2H, J = 8.6 Hz), 8.30 (dd, 1H, J = 4.6, 4.2 
Hz); 13C NMR (125 MHz, CDCl3) δ: 17.7, 42.8, 52.4, 53.4, 59.0, 62.2, 115.6 (d, J = 
22.1 Hz), 124.1, 130.5 (d, J = 8.2 Hz), 131.0, 131.9, 157.5, 163.5, 172.3; HRMS (ESI, 
+ve) m/z calcd. for C16H18FNNaO4, 330.1118, found 330.1112 (M+Na)
+. 
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(anti-E)-Methyl 2-(p-chlorophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 216 
 
 
 
LiHMDS (0.42 ml, 0.42 mmol), TMSCl (0.05 ml, 0.42 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-chlorophenyl)acetate 205 (0.10 g, 0.32 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(p-chlorophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 216 
as a yellow solid (0.07 g, 72%, d.r. 46:1). M.p. 107–108 °C; FTIR (film/cm-1) υmax: 
2953 (w), 1746 (s), 1492 (m); 1H NMR (500 MHz, CDCl3) δ: 1.51 (dd, 3H, J = 6.6, 1.4 
Hz), 3.57–3.62 (m, 2H), 3.66 (s, 3H), 4.15 (d, 1H, J = 11.3 Hz),  4.25–4.33 (m, 2H), 
4.61  (dd, 1H, J = 11.3, 8.1 Hz), 5.29 (ddq, 1H, J = 15.4, 8.1, 1.4 Hz),  5.48 (dq, 1H, J = 
15.4, 6.6 Hz), 7.24–7.30 (m, 4H); 13C NMR (125 MHz, CDCl3) δ: 17.7, 42.8, 52.4, 
53.6, 58.9, 62.3, 124.1, 128.9, 130.2, 131.9, 133.6, 133.8, 157.5, 172.0; HRMS (ESI, 
+ve) m/z calcd. for C16H18ClNNaO4, 346.0822, found 346.0832 (M+Na)
+. 
 
(anti-E)-Methyl 3-(2-oxooxazolidin-3-yl)-2-(p-(trifluoromethyl)phenyl)hex-4-enoate 
217 
 
 
LiHMDS (0.36 ml, 0.36 mmol), TMSCl (0.05 ml, 0.36 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-trifluoromethylphenyl)acetate 206 (0.10 g, 0.28 
mmol) in THF (1 ml) were combined according to general procedure 2 (reaction time : 
75 minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 3-(2-oxooxazolidin-3-yl)-2-(p-(trifluoromethyl)phenyl)hex-4-
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enoate 217 as a yellow solid. (0.07 g, 71%, d.r. 21:1); M.p. 103–104 °C; FTIR (film/cm-
1) υmax: 2955 (w), 2917 (w), 2850 (w), 1747 (s), 1671 (w), 1620 (w); 
1H NMR (500 
MHz, CDCl3) δ: 1.51 (dd, 3H, J = 6.6, 1.5 Hz), 3.58–3.65 (m, 2H), 3.68 (s, 3H), 4.26–
4.34 (m, 3H), 4.65 (dd, 1H, J = 11.2, 8.2 Hz), 5.31 (ddq, 1H, J = 15.3, 8.2, 1.5 Hz),  
5.48 (dq, 1H, J = 15.3, 6.6 Hz), 7.46 (app. d, 2H, J = 8.2 Hz), 7.58 (app. d, 2H, J = 8.2 
Hz); 13C NMR (125 MHz, CDCl3) δ: 17.8, 42.9, 52.5, 53.9, 58.9, 62.3, 123.8, 124.0 (q, 
J = 272.1 Hz), 125.6 (q, J = 3.4 Hz), 129.3, 130.1 (q, J = 32.8 Hz), 132.3, 139.2, 157.5, 
171.7;  HRMS (ESI, +ve) m/z calcd. For C17H18F3NNaO4 380.1086, found 380.1080 
(M+Na)+. 
 
13
C1-(anti-E)-methyl 3-(2-oxooxazolidin-3-yl)-2-(4-(trifluoromethyl)phenyl)hex-4-
enoate 
13
C1-217 
 
 
To an oven dried Young’s tap NMR tube, inserted into a Dewar at -95 °C and under an 
atmosphere of nitrogen,  was added a solution of LiHMDS (1 M in THF, 0.23 ml, 0.23 
mmol, 1.3 eq.),  and TMSCl (0.03 ml, 0.23 mmol, 1.3 eq.). Thermal equilibration was 
allowed (5 minutes) and then a solution of (E)-4-(2-oxooxazolidin-3-yl)but-3-en-2-yl 2-
13C1-(4-(trifluoromethyl)phenyl)acetate 
13
C1-206 (0.06 g, 0.18 mmol, 1.0 eq.) in THF 
(0.6 ml) was added. The cooled NMR tube was rapidly lowered into the pre-cooled 
NMR machine at -95 °C. From this point 13C NMR spectroscopy was recorded at -95 
°C and then the machine was allowed to warm to -65 °C, where it was then kept for the 
rest of the experiment (ca. 12 hours) and 13C data was recorded every 5 minutes. After 
in-situ reaction monitoring the reaction mixture was quenched following general 
procedure 2 and treatment with diazomethane and purification by flash chromatography 
to afford 13C1-(anti-E)-methyl 3-(2-oxooxazolidin-3-yl)-2-(4-
(trifluoromethyl)phenyl)hex-4-enoate 13C1-217 as a white solid (0.02 g, 48%, d.r. 
>25:1). M.p. 104–106 °C; FTIR (film/cm-1) υmax: 2998 (m), 2915 (m), 2948 (m), 1737 
(s), 1657 (m);1H NMR (500 MHz, CDCl3) δ: 1.52 (d, 3H, J = 6.6 Hz), 3.60–3.66 (m, 
2H), 3.69 (s, 3H), 4.29 (dd, 1H, J = 135.0, 11.7 Hz) 4.32 (app. dt, 2H, J = 23.5, 8.7 
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Hz),  4.63−4.70 (m, 1H),  5.32 (app. dd, 1H, J = 15.2, 8.3 Hz), 5.49 (app. dq, 1H, J = 
15.2, 6.6 Hz), 7.48 (app. dd, 2H, J = 8.1, 3.5 Hz), 7.59 (app. d, 2H, J = 8.1 Hz); 13C 
NMR (125 MHz, CDCl3) δ: 17.7, 42.9, 52.5, 53.9, 59.0 (d, J = 35.6 Hz), 62.3, 125.6  (q, 
J = 270.6 Hz), 125.0, 125.7 (quin, J = 3.6 Hz), 129.7 (d, J = 2.3 Hz), 130.4 (q, J = 37.9 
Hz), 132.2, 139.2 (d, J = 42.2 Hz), 157.5, 171.7 (d, J = 59.7 Hz); HRMS (ESI, +ve) m/z 
calcd. for C16
13C1H19F3N1O4, 359.1344,  found 359.1311 (M+H)
+. 
 
 
(anti-E)-Methyl 2-(p-cyanophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 218 
 
 
 
LiHMDS (0.43 ml, 0.43 mmol), TMSCl (0.06 ml, 0.43 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(p-cyanophenyl)acetate 207 (0.10 g, 0.33 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(p-cyanophenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 218 
as a cream solid (0.07 g, 63%, d.r. 17:1); M.p. 106–109 °C; FTIR (film/cm-1) υmax: 2954 
(m), 2918 (w), 2851 (w), 1747 (s), 1672 (w), 1608 (w), 1505 (w). 1H NMR (500 MHz, 
CDCl3) δ: 1.50 (dd, 3H, J = 6.4, 1.2 Hz), 3.58–3.63 (m, 2H), 3.67 (s, 3H), 4.26–4.35 (m, 
3H), 4.59 (dd, 1H, J = 11.0, 8.4 Hz), 5.30 (ddq, 1H, J = 15.3, 8.4, 1.2 Hz),  5.46 (dq, 
1H, J = 15.3, 6.4 Hz), 7.45 (app d, 2H, J = 8.3 Hz), 7.61 (app. d, 2H, J = 8.3 Hz); 13C 
NMR (125 MHz, CDCl3) δ: 17.7, 43.0, 52.6, 54.0, 59.2, 62.3, 111.9, 118.4, 123.8, 
129.8, 132.4, 132.6, 140.5, 157.5, 171.4; HRMS (ESI, +ve) m/z calcd. For 
C17H18N2NaO4 337.1164, found 337.1159. (M+Na)
+. 
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(anti-E)-Methyl-2-(4-(methylsulfonyl)phenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
219 
 
 
LiHMDS (0.18 ml, 0.18 mmol), TMSCl (0.02 ml, 0.18 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(4-(methylsulfonyl)phenyl)acetate 208 (0.05 g, 0.47 
mmol) in THF (5 ml) were combined according to general procedure 2 (reaction time : 
75 minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(4-(methylsulfonyl)phenyl)-3-(2-oxooxazolidin-3-yl)hex-4-
enoate 219 as a white solid (0.03 g, 67%, d.r. >25:1); M.p. 138–140 °C; FTIR (film/cm-
1) υmax: 2998 (m), 2954 (m), 2924 (m), 1744 (s), 1598 (m); 
1H NMR (500 MHz, CDCl3) 
δ: 1.50 (d, 3H, J = 6.5 Hz), 3.04 (s, 3H), 3.57–3.64 (m, 2H), 3.68 (s, 3H), 4.25–4.37 (m, 
3H), 4.63 (app. t, 1H, J  = 9.0 Hz), 5.30 (app. dd, 1H, J = 15.5, 9.0 Hz),  5.48 (app. dq, 
1H, J = 15.5, 6.5 Hz), 7.54 (app. d, 2H, J = 8.4 Hz), 7.89 (app. d, 2H, J = 8.4 Hz); 13C 
NMR (125 MHz, CDCl3) δ: 17.7, 43.0, 44.4, 52.6, 53.9, 59.1, 62.3, 123.7, 127.7, 130.0, 
132.7, 140.0, 141.4, 157.5, 171.4; HRMS (ESI, +ve) m/z calcd. For C17H21NaNO6S 
390.0987, found 390.0973 (M+Na)+. 
 
(anti-E)-Methyl 2-(2,4-dimethoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 220 
 
 
LiHMDS (0.39 ml, 0.39 mmol), TMSCl (0.05 ml, 0.39 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(2,4-dimethoxyphenyl)acetate 209 (0.10 g, 0.30 
mmol) in THF (1 ml) were combined according to general procedure 2 (reaction time : 
75 minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 2-(2,4-dimethoxyphenyl)-3-(2-oxooxazolidin-3-yl)hex-4-
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enoate 220 as a clear oil (0.06 g, 57%, d.r. 6:1); FTIR (film/cm-1) υmax: 2951 (m), 2840 
(m), 1747 (s), 1612 (s), 1587 (m), 1508 (m); 1H NMR (500 MHz, CDCl3) δ: 1.51 (dd, 
3H, J = 6.4, 1.0 Hz), 3.58–3.68 (m, 5H), 3.78 (s, 3H), 3.79 (s, 3H), 4.21–4.33 (m, 2H), 
4.55 (d, 1H, J  = 11.1 Hz), 4.74 (dd, 1H, J = 11.1, 7.7 Hz),  5.28 (ddq, 1H, J = 15.4, 7.7, 
1.0 Hz), 5.50 (app. dq, 1H, J = 15.4, 6.4 Hz), 6.41 ( d, 1H, J = 2.4 Hz), 6.46 (dd, 1H, J = 
8.4, 2.3 Hz), 7.31 (d, 1H, J = 8.4 Hz); 13C NMR (125 MHz, CDCl3) δ: 17.7, 42.1, 45.1, 
52.1, 55.2, 55.6, 57.9, 62.1, 98.5, 104.5, 116.1, 124.8, 129.8, 130.7, 157.6, 158.1, 160.1, 
172.6; HRMS (ESI, +ve) m/z calcd. For C18H23NaNO6 372.1423, found 372.1418 
(M+Na)+. 
 
((anti-E)-Methyl 3-(2-oxooxazolidin-3-yl)-2-((E)-styryl)hex-4-enoate 221 
 
 
 
LiHMDS (0.43 ml, 0.43 mmol), TMSCl (0.06 ml, 0.43 mmol) and (E)-((E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl) 4-phenylbut-3-enoate 210 (0.10 g, 0.33 mmol) in 
THF (1 ml) were combined according to general procedure 2 (reaction time : 75 
minutes). Treatment with diazomethane and purification by flash chromatography 
afforded ((anti-E)-methyl 3-(2-oxooxazolidin-3-yl)-2-((E)-styryl)hex-4-enoate 221 as 
an amorphous orange oil (0.07 g, 68%, d.r. >25:1); FTIR (film/cm-1) υmax: 3010 (m), 
2992 (m), 2853 (m), 1745 (s); 1H NMR (500 MHz, CDCl3) δ: 1.78 (d, 3H, J = 6.4 Hz), 
3.52–3.59 (m, 3H), 3.71 (s, 3H), 4.22–4.33 (m, 2H), 4.59 (app. t, 1H, J  = 9.1 Hz), 5.45 
(app. dd, 1H, J = 15.3, 9.1 Hz), 5.75 (app. dq, 1H, J = 15.3, 6.4 Hz), 6.10 (dd, 1H, J = 
15.7, 9.4 Hz), 6.52 (d, 1H, J = 15.7 Hz), 7.23–7.28 (m, 1H), 7.29–7.38 (m, 4H); 13C 
NMR (125 MHz, CDCl3) δ: 17.8, 41.8, 52.2, 52.8, 57.5, 62.2, 123.6, 124.6, 126.4, 
127.9, 128.6, 132.0, 134.6, 136.3, 157.6, 172.0; HRMS (ESI, +ve) m/z calcd. For 
C18H21NNaO4 338.1368, found 338.1368 (M+Na)
+. 
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((anti-E)-Methyl 2-(1-methyl-1H-indol-3-yl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
222 
 
 
LiHMDS (0.40 ml, 0.40 mmol), TMSCl (0.05 ml, 0.40 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(1-methyl-1H-indol-3-yl)acetate 211 (0.10 g, 0.31 
mmol) in THF (1 ml) were combined according to general procedure 2 (reaction time : 
75 minutes). Treatment with diazomethane and purification by flash chromatography 
afforded ((anti-E)-methyl 2-(1-methyl-1H-indol-3-yl)-3-(2-oxooxazolidin-3-yl)hex-4-
enoate 222 as an amorphous brown oil (0.05 g, 50%, d.r. 10:1); FTIR (film/cm-1) υmax: 
3057 (m), 2958 (m), 2917 (m), 2850 (m), 1732 (s), 1667 (s), 1613 (m), 1548 (w); 1H 
NMR (500 MHz, CDCl3) δ: 1.50 (d, 3H, J = 6.4 Hz), 3.52–3.63 (m, 2H), 3.66 (s, 3H), 
3.77 (s, 3H), 4.23 (app. q, 1H, J  = 8.1 Hz), 4.30 (dt, 1H, J  = 8.1, 6.1 Hz),  4.39 (d, 1H, 
J = 10.6 Hz),  4.92 (dd, 1H, J = 10.6, 7.3 Hz), 5.37 (ddq, 1H, J = 15.4, 10.6, 1.6 Hz), 
5.56 (dqd, 1H, J = 15.4, 6.4, 0.9 Hz), 7.12 (s, 1H), 7.13 (t, 1H, J = 7.9 Hz), 7.23 (t, 1H, 
J = 7.9 Hz), 7.29 (t, 1H, J = 7.9 Hz), 7.69 (t, 1H, J = 7.9 Hz); 13C NMR (125 MHz, 
CDCl3) δ: 17.7, 32.9, 41.9, 45.9, 52.1, 57.7, 62.2, 109.1, 109.3, 119.1, 119.4, 121.8, 
124.9, 127.3, 128.2, 130.7, 136.7, 157.7, 172.7; HRMS (ESI, +ve) m/z calcd. For 
C19H23N2O4 343.1657, found 343.1637 (M+H)
+. 
 
(anti-E)-Methyl 2-(benzo[d][1,3]dioxol-5-yl)-3-(2-oxooxazolidin-3-yl)hex-4-enoate 
223 
 
 
LiHMDS (0.39 ml, 0.39 mmol), TMSCl (0.05 ml, 0.39 mmol) and (E)-4-(2-
oxooxazolidin-3-yl)but-3-en-2-yl 2-(benzo[d][1,3]dioxol-5-yl)acetate 212 (0.10 g, 
0.30mmol) in THF (2  ml) were combined according to general procedure 2 (reaction 
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time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (anti-E)-methyl 2-(benzo[d][1,3]dioxol-5-yl)-3-(2-
oxooxazolidin-3-yl)hex-4-enoate 223 as a white solid (0.06 g, 58%, d.r. 32:1); M.p. 
122–125 °C; FTIR (film/cm-1) υmax: 2999 (m), 2917 (m), 1744 (s), 1505 (m); 
1H NMR 
(250 MHz, CDCl3) δ: 1.55 (dd, 3H, J = 6.4, 0.9 Hz), 3.54–3.65 (m, 2H), 3.67 (s, 3H), 
4.06 (d, 1H, J  = 11.3 Hz), 4.22–4.37 (m, 2H), 4.60 (dd, 1H, J = 11.3, 7.7 Hz),  5.30 
(ddq, 1H, J = 15.3, 7.7, 0.9 Hz), 5.52 (app. dq, 1H, J = 15.3, 6.4 Hz), 5.94–5.97 (m, 
2H), 6.71–6.79 (m, 2H), 6.87 ( d, 1H, J = 1.2 Hz); 13C NMR (75 MHz, CDCl3) δ: 18.2, 
43.0, 52.7, 54.2, 59.1, 62.6, 101.5, 108.7, 109.2, 122.9, 124.6, 129.0, 131.9, 147.6, 
148.3, 157.9, 172.8; HRMS (ESI, +ve) m/z calcd. For C17H20NO6 334.1291, found 
334.1292 (M+H)+. 
 
6.3.3. N-Sulfonamide Substrates 
 
N-Allyl-4-methylbenzenesulfonamide 326 
 
 
 
To a solution of p-toluenesulfonyl chloride (18.4 g, 96.3 mmol, 1.1 eq.) and 
triethylamine (13.4 ml, 96.3 mmol, 1.1 eq.) in DCM (70 ml) at 0 oC was added 
allylamine (5.00 g, 87.6 mmol, 1.0 eq.) by dropwise addition. The reaction mixture was 
stirred for 1.5 hours under nitrogen at 0 oC, poured onto brine and washed with brine (3 
× 100 ml), the organics were dried over MgSO4 and concentrated in vacuo to yield a 
white solid which was subjected to flash column chromatography (15% EtOAc/Petrol 
40-60o) to yield N-allyl-4-methylbenzenesulfonamide 326 as a white crystalline solid 
(14.8 g, 80%). M.p. 60–63 °C; 1H NMR (250MHz, CDCl3) δ: 2.42 (s, 3H), 3.57 (app. t, 
2H, J = 6.0 Hz), 4.69 (bt, 1H J = 5.8 Hz), 5.10 (dq, 1H, J = 10.2, 1.1 Hz), 5.19 (dq, 1H, 
J = 17.2, 1.4 Hz), 5.74 (ddt, 1H, J = 17.2, 10.2, 6.0 Hz), 7.31 (app. d, 2H, J = 17.2, 1.4 
Hz), 7.75 (app. d, 2H, J = 17.2, 1.4 Hz); 13C NMR (250MHz, CDCl3) δ 21.5, 45.7, 
117.6, 127.1, 129.7, 133.0, 136.9, 143.5.  All analytical data in accordance with 
commercial sources.  
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(E)-N-Allyl-4-methyl-N-(3-oxobut-1-enyl)benzenesulfonamide 327 
 
0 C to RTMe
OH
Me
O
CrO3 (1.5 eq.)
20% H2SO4 (aq) DABCO (0.1 eq.)
DCM
H
N
N
O
Me
Ts
(1.1 eq.)
0 C to RT
Ts
 
 
To a solution of Cr(VI)O3 (10.3 g, 103 mmol, 1.5 eq.) in 20% H2SO4 (180 ml) at 0 
oC 
under a nitrogen atmosphere was added a solution of 3-butyn-2-ol (5.00 g, 71.3 mmol, 
1.0 eq.) in  20% H2SO4 (180 ml) by dropwise addition. The reaction mixture was stirred 
at 0 oC for 12 hours and a colour change from orange to green was noted, saturated 
aqueous sodium bicarbonate was added and the organics were extracted with DCM (3 × 
450 ml) and dried over MgSO4. The crude butynone was chilled to 0 
oC then N-allyl-4-
methylbenzenesulfonamide  326 (15.0 g, 78.4 mmol, 1.1 eq.) and DABCO (0.80 g, 7.13 
mmol, 0.1 eq.) were added. The reaction mixture was allowed to stir for 12 hours whilst 
slowly warming to room temperature and a colour change from a clear to a deep maroon 
solution was noted. The reaction mixture was washed with 5% NaOH (3 × 500 ml), 
brine and then the organics were dried over MgSO4 and concentrated in vacuo to give a 
red oil which was subjected to flash column chromatography (25% EtOAc/Petrol 40-
60o) to give the desired  (E)-N-allyl-4-methyl-N-(3-oxobut-1-enyl)benzenesulfonamide 
327 (10.5 g, 53%) as well as the –(Z) (0.79 g, 4%) as a brown oil in both cases. 
 
(E)-327 product- FTIR (film/cm-1) υmax: 3082(s), 2980(s), 2879(s), 1682(s), 1586(s); 
1H NMR (250MHz, CDCl3) δ 2.22 (s, 3H), 2.44 (s, 3H), 4.07 (dt, 2H, J = 5.24, 1.59 
Hz), 5.13 (dm, 1H, J = 9.2 Hz), 5.19 (m, 1H), 5.48 (d, 1H, J = 14.3 Hz), 5.56 (ddt, 1H, J 
= 17.2, 10.6, 5.3 Hz), 7.34 (m, 2H), 7.71 (m, 2H), 8.03 (d, 1H, J = 14.3 Hz); 13C NMR 
(250MHz, CDCl3) δ 21.7, 27.6, 48.3, 109.0, 118.9, 127.3, 129.9, 130.2, 135.3, 141.2, 
145.1, 196.6; HRMS (ESI, +ve) m/z calcd. for C14H18NO3S 280.1007,  found 280.0990 
(M+H)+. 
 
(Z)-327 product- FTIR (film/cm-1) υmax: 3100(s), 2925(s), 1679(s), 1595(s); 
1H NMR 
(250MHz, CDCl3) δ 2.03 (s, 3H), 2.33 (s, 3H), 4.41 (dt, 2H, J = 5.7, 1.3 Hz,), 4.86 (dq, 
1H, J = 29.0, 1.5 Hz), 4.91 (dq, 1H, J = 22.3, 1.4 Hz), 5.21 (ddq, 1H, J = 17.9, 10.3, 5.6 
Hz), 5.35 (d, 1H, J = 10.3 Hz), 6.71 (d, 1H, J = 10.4 Hz), 7.23 (m, 2H), 7.62 (m, 2H); 
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13C NMR (250MHz, CDCl3) δ: 21.5, 30.9, 49.67, 108.5, 118.4, 127.2, 130.0, 131.3, 
133.3, 135.6, 144.7, 196.2; HRMS (ESI, +ve) m/z calcd. for C14H18NO3S 280.1007,  
found 280.0990 (M+H)+. Formation of the minor Z-ene-sulfonamide was not observed 
on subsequent  repeats of this reaction and yields in the order of 60% were obtained. 
 
(E)-N-Allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 
 
 
 
To a solution of (E)-N-allyl-4-methyl-N-(3-oxobut-1-enyl)benzenesulfonamide  327 
(1.00 g, 3.58 mmol, 1.0 eq.) in THF:MeOH (20 ml:20 ml) at 0 oC was added NaBH4 
(1.03 g, 27.8 mmol, 7.8 eq.) by portionwise addition. The reaction mixture was allowed 
to stir whilst slowly warming to RT over 12 hours and then was poured onto sat. NaCl 
(100 ml) and extracted  with DCM (3 × 100 ml), dried over MgSO4, filtered and 
concentrated in vacuo to give (E)-N-allyl-N-(3-hydroxybut-1-enyl)-4-
methylbenzenesulfonamide  329 as a colourless oil (1.00 g, 100%). FTIR (film/cm-1) 
υmax: 3392 (bs), 3086 (s), 2971(s), 2925 (s), 2871(s), 1708 (s), 1657 (s), 1597 (s); 
1H 
NMR (250MHz, CDCl3) δ 1.27 (d, 3H), 2.42 (s, 3H), 4.00 (dt, 2H, J = 5.2, 1.6 Hz), 4.32 
(m, 1H), 4.87 (dd, 1H, J = 14.2, 7.5Hz), 5.18 (dm, 2H, J = 9.9Hz), 5.32 (ddt, 1H, J = 
17.4, 10.3, 5.2 Hz), 6.89 (d, 1H, J = 14.2 Hz), 7.30 (m, 2H), 7.67 (m, 2H); 13C NMR 
(250MHz, CDCl3) δ 21.9, 24.4, 48.5, 68.1, 115.3, 118.3, 127.4, 127.5, 130.2, 131.9, 
136.6, 144.3; HRMS (ESI, +ve) m/z calcd. for C14H19NNaO3S 304.0983,  found 
304.0978 (M+Na)+.  
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(S)-(4-Bromobut-3-yn-2-yloxy)(tert-butyl)diphenylsilane  (S)-383 
 
 
 
Part 1 - To a stirred solution of 3-butyn-2-ol (15.0 g, 214 mmol, 1.0 eq.) in THF (200 
ml) was added DMAP (2.61 g, 21.4 mmol, 0.1 eq.), TEA (59.1 ml, 428 mmol, 2.0 eq.) 
and TBDPSCl (64.7 g, 235, 1.1 eq.). The reaction mixture was stirred for 15 hours and 
then poured onto saturated ammonium chloride (200 ml). The organics were extracted 
with heptane (3 × 200 ml), concentrated in vacuo and the crude product was subjected 
to flash column chromatography (0-5% EtOAc/Petrol 40-60o) to give (but-3-yn-2-
yloxy)(tert-butyl)diphenylsilane as a clear oil (66.0 g, 100%). [α]
D
2 0 
= +65 .0 (c 1, DCM); 
Other data as previously reported. 
 
Part 2 - To a stirred solution of but-3-yn-2-yloxy)(tert-butyl)diphenylsilane (66.0 g, 
214 mmol, 1.0 eq.) in acetone (200 ml) was added NBS (41.9 g, 235 mmol, 1.1 eq.) and 
silver nitrate (3.63 g, 21.4 mmol, 0.1 eq.). The reaction mixture was stirred for 15 hours 
and then poured onto saturated sodium chloride (100 ml). The organics were extracted 
with diethyl ether (3 × 200 ml), dried over magnesium sulphate and concentrated in 
vacuo to yield a yellow oil which was triturated with heptane and the insolubilities were 
filtered off and the mother liquir was concentrated in vacuo to yield (4-bromobut-3-yn-
2-yloxy)(tert-butyl)diphenylsilane (S)-383 as an orange oil (65.0 g, 78%). [α]
D
2  0 
= +10.3 
(c 1, DCM); Other data as previously reported. 
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(S)-N-Allyl-N-(3-(tert-butyldiphenylsilyloxy)but-1-ynyl)-4-
methylbenzenesulfonamide   (S)-384 
 
 
 
To a solution of N-allyl-4-methylbenzenesulfonamide   326 (2.46 g, 11.6 mmol, 1.0 eq.) 
in toluene (200 ml) was added (S)-(4-bromobut-3-yn-2-yloxy)(tert-butyl)diphenylsilane 
(S)-383 (5.00 g, 12.9 mmol, 1.1 eq.), CuSO4.5H2O (0.58 g, 2.34 mmol, 0.2 eq.), 1,10-
phenanthroline (0.84 g, 4.68 mmol, 0.4 eq.) and finely ground K3PO4 (4.97 g, 23.2 
mmol, 2 eq.). The reaction mixture was allowed to stir at 65 oC for 48 hours, after which 
was concentrated in vacuo and subjected to flash column chromatography (5-10% 
EtOAc/Petrol 40-60o) to give (S)-N-allyl-N-(3-(tert-butyldiphenylsilyloxy)but-1-ynyl)-
4-methylbenzenesulfonamide   (S)-384 as a colourless oil (5.05 g, 83%). [α]
D
2 0 
= +20.0 (c 
1, DCM); FTIR (film/cm-1) υmax: 3036 (m), 3105 (m), 2961 (m), 2932 (m), 1681 (m), 
1647 (m), 1619 (s), 1582 (s); 1H NMR (500 MHz, CDCl3) δ: 1.06 (s, 9H), 1.41 (d, 3H, J 
= 6.4 Hz), 2.44 (s, 3H), 3.79 (ddt, 1H, J = 14.6, 6.3, 1.3 Hz), 3.85 (ddt, 1H, J = 14.6, 
6.3, 1.3 Hz), 4.61 (app. quin, 1H, J = 6.4 Hz), 5.11–5.17 (m, 2H), 5.62 (ddt, 1H, J = 
17.3, 10.2, 6.3 Hz),  7.28–7.46 (m, 7H),  7.66–7.72 (m, 4H), 7.72–7.77 (m, 2H); 13C 
NMR (100 MHz, CDCl3) δ: 19.1, 21.6, 25.3, 26.5, 26.8, 54.0, 60.1, 73.2, 119.6, 127.4, 
127.6, 127.8, 129.6, 131.0, 133.7, 134.8, 135.7, 135.9, 144.4; HRMS (ESI, +ve) m/z 
calcd. for C30H35NNaO3SSi 540.2005,  found 540.2209 (M+Na)
+. 
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N-Allyl-N-(3-hydroxy-but-1-ynyl)-4-methyl-benzenesulfonamide  (S)-385 
 
 
 
To a solution of N-allyl-N-(3-(tert-butyldiphenylsilyloxy)but-1-ynyl)-4-
methylbenzenesulfonamide   (S)-384 (3.72 g, 7.20 mmol, 1.0 eq.) in THF (200 ml) at 0 
oC was added TBAF (1M soln. in THF, 14.4 ml, 14.4 mmol, 2.0 eq.). The reaction 
mixture was allowed to stir for 2 hours whilst slowly warming to RT, until complete by 
TLC, followed by concentration in vacuo and subjection to flash column 
chromatography (10% EtOAc/Petrol 40-60o) to give N-allyl-N-(3-hydroxy-but-1-ynyl)-
4-methyl-benzenesulfonamide   (S)-385 as a faint yellow oil (1.40 g, 70%). [α]
D
2 0 
= -38.0 
(c 1, DCM); FTIR (film/cm-1) υmax:  2978 (m), 2929 (m), 1697 (m), 1596 (w). 
1H NMR 
(400 MHz, CDCl3) δ: 1.47 (d, 3H, J = 6.6 Hz), 2.03 (d, 1H, J = 5.2 Hz), 2.49 (s, 3H), 
3.93–4.04 (m, 2H), 4.67 (app quin, 1H, J = 6.6 Hz), 5.22–5.31 (m, 4H), 5.71 (ddt, 1H, J 
= 17.1, 10.2, 6.4 Hz),  7.39 (d, 2H, J = 8.3 Hz),  7.83 (d, 2H, J = 8.3 Hz); 13C NMR 
(100 MHz, CDCl3) δ: 21.6, 24.4, 26.5, 54.1, 58.5, 73.1, 120.0, 127.7, 129.7, 130.8, 
134.6, 144.8; HRMS (ESI, +ve) m/z calcd. for C14H18NO3S 280.1007,  found 280.1004 
(M+H)+. 
 
(S)-(E)-N-Allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide   (S)-329 
 
 
 
To a solution of (S)-(E)-N-allyl-4-methyl-N-(3-oxobut-1-enyl)benzenesulfonamide  (S)-
385 (0.10 g, 0.36 mmol, 1.0 eq.) in toluene (5 ml) at 0 oC was added Vitride® (0.11 µl, 
0.53 mmol, 1.5 eq.) by portionwise addition. The reaction mixture was allowed to stir 
whilst slowly warming to RT over 4 hours and then was quenched by the addition of 
Na2SO4.10H2O. After the solution cleared the reaction mixture was filtered through 
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celite and concentrated in vacuo to yield (S)-(E)-N-allyl-N-(3-hydroxybut-1-enyl)-4-
methylbenzenesulfonamide  (S)-329 as a colourless oil (0.07 g, 76%). [α]
D
2 0 
= -11.0 (c 1, 
DCM); Other data as previously reported for racemic compound. 
 
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl propionate 330 
 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), propionic acid (0.22 ml, 2.81 mmol) and (E)-N-allyl-N-(3-
hydroxybut-1-enyl)-4-methylbenzenesulfonamide   329 (0.40 g, 1.41 mmol) in DCM 
(10 ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl propionate 330 as a yellow oil (0.40 g, 84%). 
FTIR (film/cm-1) υmax: 3082 (m), 3039 (m), 2980 (m), 2931 (m), 2861 (m), 1727 (s), 
1656 (s), 1597 (s); 1H NMR (500 MHz, (CD3)2CO) δ: 1.10 (t, 3H, J = 7.6 Hz, CH3CH2-
), 1.29 (d, 3H, J = 6.6 Hz, CH3CH(CH-)O-), 2.25 (q, 2H, J = 7.6 Hz, CH3CH2-), 2.45 (s, 
3H, -C6H4CH3), 3.96 (qd, 2H, J = 15.0, 5.4 Hz, -NCH2CHCH2), 4.80 (dd, 1H, J = 14.2, 
6.6 Hz, -NCHCH-), 5.09–5.17 (m, 2H, CH2CHCH2N-), 5.34 (app. quin, 1H, J = 6.6 Hz, 
CH3CH(CH-)O-), 5.79 (ddt, 1H, J = 17.0, 10.3, 5.4 Hz, -NCH2CHCH2),  6.96 (d, 1H, J 
= 14.2 Hz, -NCHCH-),  7.29 (app. d, 2H, J = 7.6 Hz, ArH Ts), 7.65 (d, 2H, J = 7.6 Hz, 
ArH Ts) ; 13C NMR (125 MHz, (CDCl3) δ: 9.1, 21.0, 21.5, 27.9, 48.0, 69.8, 110.1, 
117.9, 127.0, 129.5, 129.8, 131.3, 136.1, 143.9, 173.6; HRMS (ESI, +ve) m/z calcd. for 
C23H27NNaO4S  436.1558,  found 436.1679 (M+Na)
+. 
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(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-phenylacetate 331 
 
 
 
EDCi (0.68 g, 3.55 mmol) in DCM (100 ml), triethylamine (0.49 ml, 3.55 mmol), 
DMAP (0.02 g, 0.18 mmol), phenylacetic acid (0.48 g, 3.55 mmol) and (E)-N-allyl-N-
(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.50 g, 1.78 mmol) in DCM 
(20 ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 2-phenylacetate 331 as a yellow oil (0.70 g, 
98%). FTIR (film/cm-1) υmax: 3051 (m), 2977 (m), 2922 (m), 1727 (s), 1655 (s), 1597 
(m); 1H NMR (250 MHz, (CD3)2CO) δ: 1.29 (d, 3H, J = 6.5 Hz, CH3CH(CH-)O-), 2.40 
(s, 3H, CH3C6H4-), 3.60 (s, 2H, -CH2C6H5), 3.93–4.10 (m, 2H, -NCH2CHCH2), 4.88 
(dd, 1H, J = 14.2, 6.5 Hz, -NCHCH-), 5.05–5.24 (m, 2H, -NCH2CHCH2), 5.37 (app 
quin, 1H, J = 6.5 Hz, CH3CH(CH-)O-), 5.62 (ddt, 1H, J = 17.3, 10.4, 5.2 Hz, -
NCH2CHCH2),  7.03 (d, 1H, J = 14.2 Hz, -NCHCH-),  7.23–7.37 (m, 5H, CH2C6H5), 
7.39 (app. d, 2H, J = 8.3 Hz, ArH), 7.71 (app. d, 2H, J = 8.3 Hz, ArH); 13C NMR (100 
MHz, CD3Cl) δ: 20.9, 21.5, 41.7, 48.0, 70.7, 109.7, 117.9, 127.0 (x2), 128.5, 129.2, 
129.8 (x2), 131.2, 134.2, 136.1, 143.9, 170.7; HRMS (ESI, +ve) m/z calcd. for 
C22H25NNaO4S1  422.1411,  found 422.1375 (M+Na)
+. 
 
(S,E)-4-(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-phenylacetate (S)-331 
 
 
 
EDCi (0.68 g, 3.55 mmol) in DCM (100 ml), triethylamine (0.49 ml, 3.55 mmol), 
DMAP (0.02 g, 0.18 mmol), phenylacetic acid (0.48 g, 3.55 mmol) and (S)-(E)-N-allyl-
N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide  (S)-329 (0.50 g, 1.78 mmol) in 
DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford (S,E)-4-(N-allyl-4-
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methylphenylsulfonamido)but-3-en-2-yl 2-phenylacetate (S)-331 as a yellow oil (0.53 
g, 74%); [α]
D
2 0 
= -8.0 (c 1, DCM). All data as previously recorded for racemic 
compound.  
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 3-methylbutanoate 335 
 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), isovaleric acid (0.31 ml, 2.81 mmol) and (E)-N-allyl-N-(3-
hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) in DCM (10 
ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 3-methylbutanoate 335 as a yellow oil (0.45 g, 
87%). FTIR (film/cm-1) υmax: 2960 (m), 2931 (m), 1725 (s), 1655 (s), 1597 (m); 
1H 
NMR (500 MHz, CD2Cl2) δ: 0.92–0.96 (m, 6H), 1.32 (d, 3H, J = 6.6 Hz), 2.01–2.10 (m, 
1H), 2.14 (d, 2H, J = 6.7 Hz), 2.44 (s, 3H), 3.94–4.06 (m, 2H), 4.83 (dd, 1H, J = 14.1, 
6.6 Hz), 5.15 (d, 1H, J = 11.0 Hz), 5.18 (d, 1H, J = 17.6 Hz), 5.38 (app. quin, 1H, J = 
6.6 Hz), 5.64 (ddt, 1H, J = 17.6, 11.0, 6.3 Hz),  7.02 (d, 1H, J = 14.1 Hz),  7.35 (app. d, 
2H, J = 7.7 Hz), 7.69 (app. d, 2H, J = 7.7 Hz); 13C NMR (125 MHz, CD2Cl2) δ: 20.8, 
21.2, 22.1, 25.7, 43.6, 47.9, 69.6, 110.2, 117.5, 126.9, 129.6, 129.8, 131.4, 136.0, 144.1, 
172.0; HRMS (ESI, +ve) m/z calcd. for C19H27NNaO4S  388.1558,  found 388.1567 
(M+Na)+. 
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl pent-4-enoate 336 
 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), penteneoic acid (0.28 g, 2.81 mmol) and (E)-N-allyl-N-(3-
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hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) in DCM (20 
ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl pent-4-enoate 336 as a yellow oil (0.51 g, 
99%). FTIR (film/cm-1) υmax: 3054 (m), 2981 (m), 2918 (m), 1718 (s), 1655 (s), 1597 
(m); 1H NMR (500 MHz, (CD3)2CO) δ: 1.28 (d, 3H, J = 6.8 Hz), 2.29–2.37 (m, 4H), 
2.44 (s, 3H), 3.98–4.11 (m, 2H), 4.90 (dd, 1H, J = 14.4, 6.7 Hz), 4.94 (dd, 1H, J = 10.1, 
1.2 Hz), 5.04 (dd, 1H, J = 17.1, 1.4 Hz), 5.13 (dd, 1H, J = 10.1, 1.2 Hz), 5.21 (dd, 1H, J 
= 17.1, 1.2 Hz), 5.35 (app. quin, 1H, J = 6.8 Hz), 5.66 (ddt, 1H, J = 17.1, 10.1, 5.4 Hz),  
5.78–5.92 (m, 1H), 7.01 (d, 1H, J = 14.4 Hz),  7.44 (app. d, 2H, J = 8.2 Hz), 7.74 (app. 
d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, (CD3)2CO) δ: 20.4, 20.5, 33.4, 34.0, 47.6, 
69.7, 110.3, 114.7, 117.1, 127.0, 129.7, 129.8, 131.8, 136.3, 137.0, 144.1, 171.4; HRMS 
(ESI, +ve) m/z calcd. for C19H25NNaO4S  386.1402,  found 386.1480 (M+Na)
+. 
 
Benzyloxy-acetic acid 3-[allyl-(toluene-4-sulfonyl)-amino]-1-methyl-allyl ester 337 
 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), benzyloxyacetic acid (0.41 ml, 2.81 mmol) and (E)-N-
allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) in 
DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford benzyloxy-acetic acid 
3-[allyl-(toluene-4-sulfonyl)-amino]-1-methyl-allyl ester 337 as a yellow oil (0.54 g, 
87%). FTIR (film/cm-1) υmax: 3051 (m), 2971 (m), 2934 (m), 1744 (s), 1655 (s), 1597 
(m); 1H NMR (500 MHz, (CD3)2CO) δ: 1.32 (d, 3H, J = 6.8 Hz), 2.40 (s, 3H), 3.98–
4.15 (m, 4H), 4.60 (s, 2H), 4.93 (dd, 1H, J = 14.3, 6.8 Hz), 4.93 (dq, 1H, J = 10.5, 1.4 
Hz), 5.21 (dq, 1H, J = 17.2, 1.5 Hz), 5.46 (app. quin, 1H, J = 6.8 Hz), 5.65 (ddt, 1H, J = 
17.2, 10.5, 5.2 Hz),  7.08 (d, 1H, J = 14.3 Hz),  7.28–7.43 (m, 7H), 7.74 (app. d, 2H, J 
= 8.1 Hz); 13C NMR (125 MHz, (CD3)2CO) δ: 20.4, 20.5, 47.6, 67.3, 70.5, 72.6, 
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109.9,117.1, 127.0, 127.5, 127.7, 128.2, 129.8, 130.2, 131.7, 136.3, 138.1, 144.1, 169.3; 
HRMS (ESI, +ve) m/z calcd. for C23H27NNaO5S  452.1508,  found 452.1543 (M+Na)
+. 
 
Phenylsulfanyl-acetic acid 3-[allyl-(toluene-4-sulfonyl)-amino]-1-methyl-allyl ester 
338 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), thiophenylacetic acid (0.47 g, 2.81 mmol) and (E)-N-allyl-
N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) in 
DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford phenylsulfanyl-acetic 
acid 3-[allyl-(toluene-4-sulfonyl)-amino]-1-methyl-allyl ester 338 as a yellow oil (0.56 
g, 92%). FTIR (film/cm-1) υmax: 3079 (m), 2980 (m), 2919 (m), 1726 (s), 1655 (s), 1597 
(m); 1H NMR (500 MHz, (CD3)2CO) δ: 1.24 (d, 3H, J = 7.2 Hz), 2.40 (s, 3H), 3.90–
4.07 (m, 2H), 4.83 (dd, 1H, J = 14.3, 7.2 Hz), 5.09 (dq, 1H, J = 10.4, 1.5 Hz), 5.17 (dq, 
1H, J = 17.1, 1.5 Hz), 5.34 (app. quin, 1H, J = 7.2 Hz), 5.62 (ddt, 1H, J = 17.1, 10.4, 
5.2 Hz),  7.03 (d, 1H, J = 14.3 Hz),  7.17–7.24 (m, 1H), 7.25–7.34 (m, 2H),  7.35–7.45 
(m, 4H), 7.71 (app. d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, (CD3)2CO) δ: 25.5, 30.4, 
41.0, 52.8, 72.3, 76.4, 114.7, 122.3, 131.6, 132.1, 134.3, 135.0, 135.4, 136.9, 140.8, 
141.5, 149.3, 173.6; HRMS (ESI, +ve) m/z calcd. for C22H25NNaO4S2  454.1123,  found 
454.1126 (M+Na)+. 
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(2-iodophenyl)acetate 
340 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), 2-Iodo phenylacetic acid (0.74 g, 2.81 mmol) and (E)-N-
allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) in 
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DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 2-(2-iodophenyl)acetate 340 as a yellow oil 
(0.64 g, 86%). FTIR (film/cm-1) υmax: 2978 (m), 2922 (m), 1727 (s), 1655 (s), 1596 (w); 
1H NMR (500 MHz, (CD3)2CO) δ: 1.31 (d, 3H, J = 6.6 Hz), 2.44 (s, 3H), 3.77 (app. d, 
2H), 3.97–4.08 (m, 2H), 4.91 (dd, 1H, J = 14.2, 6.6 Hz), 5.12 (app. dq, 1H, J = 10.4, 1.4 
Hz), 5.20 (app. dq, 1H, J = 17.3, 1.7 Hz), 5.39 (app. quin, 1H, J = 6.6 Hz), 5.65 (ddt, 
1H, J = 17.3, 10.4, 5.0 Hz), 7.00–7.08 (m, 2H), 7.35–7.43 (m, 4H), 7.72 (app. d, 2H, J 
= 8.2 Hz), 7.88 (d, 1H, J = 7.8 Hz); 13C NMR (125 MHz, (CD3)2CO) δ: 20.4, 20.5, 
46.0, 47.6, 70.6, 100.6, 109.9, 117.1, 127.0, 128.4, 128.8, 129.8, 129.9, 131.0, 131.8, 
136.4, 138.5, 139.2, 144.0, 169.0; HRMS (ESI, +ve) m/z calcd. for C22H24INNaO4S  
548.0368,  found 548.0407 (M+Na)+. 
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(4-
methoxyphenyl)acetate 341 
 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), 4-methoxy phenylacetic acid (0.47 g, 2.81 mmol) and (E)-
N-allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) 
in DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 2-(4-methoxyphenyl)acetate 341 as a yellow 
oil (0.54 g, 81%). FTIR (film/cm-1) υmax: 2978 (m), 2943 (m), 1726 (s), 1655 (s), 1613 
(m), 1597 (w); 1H NMR (250 MHz, (CD3)2CO) δ: 1.27 (d, 3H, J = 6.5 Hz), 2.42 (s, 3H), 
3.50 (2H, s), 3.77 (s, 3H), 3.92–4.05 (m, 2H), 4.86 (dd, 1H, J = 14.1, 6.5 Hz), 5.09 (dd, 
1H, J = 10.7, 1.5 Hz), 5.16 (dd, 1H, J = 17.1, 1.5 Hz), 5.37 (app. quin, 1H, J = 6.5 Hz), 
5.59 (ddt, 1H, J = 17.1, 10.7, 5.4 Hz),  6.85 (d, 2H, J = 8.5 Hz),  6.99 (d, 1H, J = 14.1 
Hz), 7.17 (app. d, 2H, J = 8.3 Hz), 7.37 (app. d, 2H, J = 8.2 Hz), 7.68 (d, 2H, J = 8.2 
Hz); 13C NMR (125 MHz, (CD3)2CO) δ: 21.3, 21.4, 41.0, 48.4, 55.4, 71.0, 111.0, 114.5, 
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118.0, 127.4, 127.8, 127.9, 130.7, 131.0, 132.6, 137.2, 144.9, 159.6, 171.3; HRMS 
(ESI, +ve) m/z calcd. for C23H27NNaO5S1  452.1508,  found 452.1463 (M+Na)
+. 
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(4-
(trifluoromethyl)phenyl)acetate 342 
 
N O
Me O
CF3
Ts
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), 4-trifluoro tolyl phenylacetic acid (0.57 g, 2.81 mmol) and 
(E)-N-allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 
mmol) in DCM (20 ml) were combined according to general procedure 1 (reaction time: 
15 hours). Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 2-(4-(trifluoromethyl)phenyl)acetate  342 as a 
yellow oil (0.57 g, 86%). FTIR (film/cm-1) υmax: 3015 (w), 2988 (m), 2937 (m), 1727 
(s), 1699 (s), 1656 (m), 1596 (w); 1H NMR (500 MHz, (CD3)2CO) δ: 1.30 (d, 3H, J = 
6.8 Hz), 2.42 (s, 3H), 3.74 (2H, s), 3.95–4.06 (m, 2H), 4.88 (dd, 1H, J = 14.3, 6.8 Hz), 
5.09 (app. d, 1H, J = 10.7 Hz), 5.17 (app. d, 1H, J = 17.2 Hz), 5.38 (app. quin, 1H, J = 
6.8 Hz), 5.61 (ddt, 1H, J = 17.2, 10.7, 5.1 Hz), 7.03 (d, 1H, J = 14.3 Hz), 7.39 (app. d, 
2H, J = 8.3 Hz), 7.52 (app. d, 2H, J = 8.3 Hz), 7.66 (app. d, 2H, J = 8.3 Hz), 7.71 (app. 
d, 2H, J = 8.3 Hz); 13C NMR (125 MHz, (CD3)2CO) δ: 20.2, 20.4, 40.5, 47.4, 70.6, 
109.6, 116.9, 124.3 (q, J = 271.4 Hz), 124.9 (q, J = 3.6 Hz), 126.8, 128.3 (q, J = 32.0 
Hz), 129.6, 129.8, 129.9, 131.4, 136.1, 139.1, 143.9, 169.3; HRMS (ESI, +ve) m/z 
calcd. for C23H23F3NO4S  466.1299,  found 466.1311 (M+H)
+. 
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(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(4-nitrophenyl)acetate 
343 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), 4-nitro phenylacetic acid (0.51 g, 2.81 mmol) and (E)-N-
allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) in 
DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 2-(4-nitrophenyl)acetate 343 as an orange oil 
(0.54 g, 86%). FTIR (film/cm-1) υmax: 3018 (w), 2988 (m), 2967 (m), 1727 (s), 1698 (s), 
1656 (m), 1599 (w), 1522 (m); 1H NMR (500 MHz, (CD3)2CO) δ: 1.29 (d, 3H, J = 6.7 
Hz), 2.41 (s, 3H), 3.80 (2H, s), 3.95–4.05 (m, 2H), 4.87 (dd, 1H, J = 14.5, 6.7 Hz), 5.08 
(dq, 1H, J = 10.7, 1.95 Hz), 5.15 (dq, 1H, J = 17.2, 1.3 Hz), 5.38 (app. quin, 1H, J = 6.7 
Hz), 5.59 (ddt, 1H, J = 17.2, 10.7, 5.1 Hz), 7.00 (d, 1H, J = 14.5 Hz), 7.38 (app. d, 2H, 
J = 7.9 Hz), 7.57 (app. d, 2H, J = 8.7 Hz), 7.69 (app. d, 2H, J = 7.9 Hz), 8.18 (app. d, 
2H, J = 8.7 Hz); 13C NMR (100 MHz, (CD3)2CO) δ: 20.3, 20.5, 40.6, 47.5, 70.9, 109.6, 
117.1, 123.3, 126.9, 129.8, 130.1, 130.5, 131.6, 136.3, 142.5, 144.1, 147.0, 169.2; 
HRMS (ESI, +ve) m/z calcd. for C44H48N4NaO12S2  911.2613,  found 911.2604 
(2M+Na)+. 
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(2,4-
dichlorophenyl)acetate 344 
 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), 2,4-dichlorophenylacetic acid (0.58 g, 2.81 mmol) and (E)-
N-allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) 
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in DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 2-(2,4-dichlorophenyl)acetate 344 as a yellow 
oil (0.55 g, 82%). FTIR (film/cm-1) υmax: 3091 (m), 2978 (m), 2937 (m), 1729 (s), 1655 
(s), 1614 (s), 1591 (s), 1509 (s); 1H NMR (500 MHz, (CD3)2CO) δ: 1.29 (d, 3H, J = 6.7 
Hz), 2.44 (s, 3H), 3.76 (2H, s), 3.97–4.07 (m, 2H), 4.89 (dd, 1H, J = 14.2, 6.7 Hz), 5.12 
(app d, 1H, J = 10.3 Hz), 5.19 (app d, 1H, J = 17.2 Hz), 5.38 (app. quin, 1H, J = 6.7 
Hz), 5.63 (ddt, 1H, J = 17.2, 10.3, 5.1 Hz), 7.01 (d, 1H, J = 14.2 Hz), 7.32–7.47 (m, 
4H), 7.50 (d, 1H, J = 1.9 Hz), 7.71 (app. d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, 
(CD3)2CO) δ: 20.4, 20.5, 38.4, 47.6, 70.8, 109.7, 117.1, 126.9, 127.2, 128.7, 129.8, 
129.9, 131.7, 132.2, 133.0, 133.1, 135.1, 136.4, 144.0, 168.7; HRMS (ESI, +ve) m/z 
calcd. for C22H23Cl2N1NaO4S1  490.0617,  found 490.0614 (M+Na)
+. 
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(2,4-
dimethoxyphenyl)acetate 345 
 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39 ml, 2.81 mmol), 
DMAP (0.02 g, 0.14 mmol), 2,4-dimethoxyphenylacetic acid (0.56 g, 2.81 mmol) and 
(E)-N-allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 
mmol) in DCM (20 ml) were combined according to general procedure 1 (reaction time: 
15 hours). Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 2-(2,4-dimethoxyphenyl)acetate 345 as a clear 
oil (0.56 g, 86%). FTIR (film/cm-1) υmax: 3061 (w), 2988 (m), 2937 (m), 2838 (m), 1728 
(s), 1656 (s), 1614 (s), 1590 (s), 1509 (s); 1H NMR (500 MHz, (CD3)2CO) δ: 1.27 (d, 
3H, J = 6.6 Hz), 2.43 (s, 3H), 3.47 (2H, s), 3.76 (3H, s), 3.79 (3H, s),  3.94–4.09 (m, 
2H), 4.89 (dd, 1H, J = 14.2, 6.6 Hz), 5.17 (dq, 1H, J = 10.3, 1.4 Hz), 5.21 (dq, 1H, J = 
17.1, 1.4 Hz), 5.34 (app. quin, 1H, J = 6.6 Hz), 5.65 (ddt, 1H, J = 17.1, 10.3, 5.1 Hz), 
6.44–6.49 (m, 1H), 6.51–6.57 (m, 1H), 6.98 (d, 1H, J = 14.2 Hz), 7.07 (d, 1H, J = 8.3 
Hz), 7.39 (app. d, 2H, J = 8.3 Hz), 7.71 (app. d, 2H, J = 8.3 Hz); 13C NMR (125 MHz, 
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(CD3)2CO) δ: 20.5 (x2), 35.0, 47.6, 54.6, 54.9, 69.7, 98.2, 104.2, 110.3, 115.7, 117.1, 
127.0, 129.4, 129.8, 130.9, 131.8, 136.3, 144.0, 158.5, 160.3, 170.5; HRMS (ESI, +ve) 
m/z calcd. for C24H29NNaO6S  482.1613,  found 482.1653 (M+Na)
+. 
 
(E)-4-(N-Allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2- 
(benzo[d][1,3]dioxol-5-yl)acetate 346 
 
 
 
EDCi (0.54 g, 2.81 mmol) in DCM (100 ml), triethylamine (0.39l, 2.81 mmol), DMAP 
(0.02 g, 0.14 mmol), 3,4-methylenedioxyphenylacetic acid (0.51 g, 2.81 mmol) and (E)-
N-allyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 329 (0.40 g, 1.41 mmol) 
in DCM (20 ml) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure to afford (E)-4-(N-allyl-4-
methylphenylsulfonamido)but-3-en-2-yl 2-(benzo[d][1,3]dioxol-5-yl)acetate 346 as a 
yellow oil (0.54 g, 86%). FTIR (film/cm-1) υmax: 3049 (m), 2916 (m), 1729 (s), 1655 (s), 
1503 (s); 1H NMR (500 MHz, CD3Cl) δ: 1.30 (d, 3H, J = 6.6 Hz), 2.41 (s, 3H), 3.46 
(2H, s),  3.89–4.01 (m, 2H), 4.76 (dd, 1H, J = 14.3, 6.6 Hz), 5.10 (app. d, 1H, J = 10.3 
Hz), 5.10 (app. d, 1H, J = 17.0 Hz), 5.32 (app. quin, 1H, J = 6.6 Hz), 5.50 (ddt, 1H, J = 
17.0, 10.3, 5.3 Hz), 5.91 (s, 2H), 6.65–6.75 (m, 3H), 6.97 (d, 1H, J = 14.3 Hz), 7.26 
(app. d, 2H, J = 7.8 Hz), 7.63 (app. d, 2H, J = 7.8 Hz); 13C NMR (125 MHz, CD3Cl) δ: 
20.9, 21.5, 30.9, 41.2, 47.9, 70.6, 100.9, 108.2, 109.6 (x2), 117.8, 122.2, 127.0, 127.1, 
127.7, 129.7, 129.8, 131.2, 136.0, 143.9, 146.6, 147.7, 170.7; HRMS (ESI, +ve) m/z 
calcd. for C23H25NNaO6S  466.1300,  found 466.1295 (M+Na)
+. 
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N-Benzyl-4-methylbenzenesulfonamide 316 
  
 
 
To a solution of p-toluenesulfonyl chloride (6.12 g, 32.1 mmol, 1.1 eq.) and 
triethylamine (4.46 ml, 32.1 mmol, 1.1 eq.) in DCM (70 ml) at 0 oC was added 
benzylamine (5.00 g, 29.2 mmol, 1.0 eq.) by dropwise addition. The reaction mixture 
was stirred for 1.5 hours under nitrogen at 0 oC, poured onto brine and washed with 
brine (3 × 100 ml), the organics were dried over MgSO4 and concentrated in vacuo to 
yield a white solid which was subjected to flash column chromatography (15% 
EtOAc/Petrol 40-60o) to yield N-benzyl-4-methylbenzenesulfonamide 316 as a white 
crystalline solid (6.71 g, 88%). M.p. 111–114 °C; 1H NMR (250 MHz, CDCl3) δ: 2.47 
(s, 3H), 4.15 (s, 2H), 4.81 (br s, 1H), 7.10–7.48 (m, 7H), 7.78 (app. d, 1H, J = 8.3 Hz); 
13C NMR (250 MHz, CDCl3) δ 21.5, 47.8, 127.2, 127.8, 127.9, 128.7, 129.7, 136.3, 
136.8, 143.5. All analytical data in accordance with commercial sources.  
 
(E)-N-Benzyl-4-methyl-N-(3-oxobut-1-enyl)benzenesulfonamide 328 
 
 
 
To a solution of  N-benzyl-4-methylbenzenesulfonamide 316 (6.90 g, 26.4 mmol, 1.0 
eq.), DABCO (0.37 g, 0.26 mmol, 0.1 Eq) in DCM (200 ml) at 0 oC was added butyn-3-
one (2.00 g, 29.41 mmol, 1.1 Eq) and the reaction mixture was stirred for 15 hours 
whilst slowly warming to RT. The reaction mixture was then extracted with 3N HCl (3 
× 200 ml) and then 5% NaOH (3 × 200 ml), dried over MgSO4 and concentrated in 
vacuo to give an amorphous orange oil which was triturated with EtOAc/Petrol 40-60o 
to give (E)-N-benzyl-4-methyl-N-(3-oxobut-1-enyl)benzenesulfonamide 328 as a cream 
solid (total yield after a second trituration of mother liquor = 7.10 g, 72%). M.p. 91–93 
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oC; FTIR (film/cm-1) υmax: 3069 (m), 3039 (m), 2970 (m), 2925 (m); 
1H NMR (500 
MHz, CDCl3) δ: 2.16 (s, 3H), 2.46 (s, 3H), 4.62 (s, 2H), 5.36 (d, 1H, J = 14.9 Hz), 
7.14–7.40 (m, 7H), 7.72 (d, 2H, J = 8.6 Hz), 8.10 (d, 1H, J = 14.9 Hz);  13C NMR (500 
MHz, CDCl3) δ: 21.6, 27.6, 49.7, 109.7, 126.7, 127.2, 127.8, 128.8, 130.2, 133.8, 135.2, 
141.3, 145.0, 196.4; HRMS (ESI, +ve) m/z calcd. for C18H20NO3S 330.1164,  found 
330.1297 (M+H)+.  
 
(E)-N-Benzyl-N-(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide  323 
 
 
 
To a solution of (E)-N-benzyl-4-methyl-N-(3-oxobut-1-enyl)benzenesulfonamide   328 
(2.00 g, 6.07 mmol, 1.0 eq.) in THF:MeOH (50 ml:50 ml) at 0 oC was added NaBH4 
(1.75 g, 47.4 mmol, 7.8 eq.) by portionwise addition. The reaction mixture was allowed 
to stir whilst slowly warming to RT over 12 hours and then was poured onto sat. NaCl 
(200 ml) and extracted  with DCM (3 × 150 ml), dried over MgSO4, filtered and 
concentrated in vacuo to give  (E)-N-benzyl-N-(3-hydroxybut-1-enyl)-4-
methylbenzenesulfonamide   323 as an orange oil (1.97 g, 98%). FTIR (film/cm-1) υmax: 
3375 (b), 3033 (m), 2971 (m), 2924 (m), 1656 (s), 1597 (s), 1542 (w); 1H NMR (500 
MHz, (CD3)2CO) δ: 1.03 (3H, d, J = 6.4 Hz),  2.44 (3H, s), 3.66 (3H, d, J = 4.3 Hz), 
4.14–4.22 (1H, m), 4.49–4.60 (2H, m), 4.87 (1H, dd, J = 14.2, 6.4 Hz), 6.90 (1H, d, J = 
14.2 Hz), 7.21–7.28 (1H, m),  7.28–7.38 (4H, m), 7.44 (2H, d, J = 8.2 Hz), 7.76 (2H, d, 
J = 8.2 Hz);  13C NMR (500 MHz, CDCl3) δ: 21.4, 24.8, 50.0, 66.8, 118.2, 126.7, 127.8 
(x2), 128.0, 129.1, 130.7, 137.2 (x2), 144.8; HRMS (ESI, +ve) m/z calcd. for 
C18H21NNaO3S 354.1140,  found 354.1323 (M+Na)
+.  
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(E)-4-(N-Benzyl-4-methylphenylsulfonamido)but-3-en-2-yl pent-4-enoate 380 
 
 
EDCi (0.46 g, 2.40 mmol) in DCM (100 ml), triethylamine (0.33 ml, 2.81 mmol), 
DMAP (0.02 g, 0.12 mmol), pentenoic acid (0.24 ml, 2.81 mmol) and (E)-N-benzyl-N-
(3-hydroxybut-1-enyl)-4-methylbenzenesulfonamide 323 (0.40 g, 1.20 mmol) in DCM 
(20 ml) were combined according to general procedure 1 (reaction time: 15 hours). 
Purification was achieved by reported procedure to afford (E)-4-(N-benzyl-4-
methylphenylsulfonamido)but-3-en-2-yl pent-4-enoate 380 as a white solid (0.47 g, 
94%). M.p. 100–103 ˚C; FTIR (film/cm-1) υmax: 3082 (m), 3039 (m), 2980 (m), 2931 
(m); 1H NMR (500 MHz, (CD3)2CO) δ: 1.15 (d, 3H, J = 6.6 Hz), 2.17–2.34 (m, 4H), 
2.45 (s, 3H), 4.58 (d, 1H, J = 16.1 Hz), 4.60 (d, 1H, J = 16.1 Hz), 4.80 (app. dd, 1H, J = 
14.2,  6.6 Hz), 4.93 (app. dd, 1H, J = 9.7, 1.7 Hz), 5.01 (app. dd, 1H, J = 17.0, 1.7 Hz), 
5.28 (app. quin, 1H, J = 6.6 Hz), 5.79 (ddt, 1H, J = 17.0, 9.7, 7.1 Hz),  7.05 (d, 1H, J = 
14.2 Hz),  7.23–7.30 (m, 1H), 7.30–7.37 (m, 4H), 7.46 (app. d, 2H, J = 8.2 Hz), 7.78 
(app. d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, CD3Cl) δ: 19.7, 20.5, 27.8, 32.8, 48.3, 
68.7, 109.9, 114.3, 125.8, 126.0, 126.3, 127.4, 128.5, 128.8, 134.0, 134.8, 135.6, 142.9, 
171.0; HRMS (ESI, +ve) m/z calcd. for C23H27NNaO4S  436.1558,  found 436.1679 
(M+Na)+. 
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6.3.4. N-Sulfonamide Rearrangement Products 
 
(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-phenylhex-4-enoate 333 
 
 
 
LiHMDS (1M in toluene, 0.63 ml, 0.63 mmol), TMSCl (0.19 ml, 2.91 mmol) and (E)-4-
(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-phenylacetate 331 (0.10 g, 0.48 
mmol) in THF (1 ml) was combined according to general procedure 3 (reaction time : 
75 minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-phenylhex-4-enoate 
333 as a white solid (0.06 g, 57%, d.r. >25:1). M.p. 103–104 ˚C; FTIR (film/cm-1) υmax: 
3032 (m), 2950 (m), 2855 (m), 1734 (s), 1668 (w), 1598 (m); 1H NMR (500 MHz, 
CD3Cl) δ: 1.28 (d, 3H, J = 4.8 Hz, CH3CH-), 2.33 (s, 3H, CH3C6H4-), 3.55 (s, 3H, -
CO2CH3), 3.62–3.87 (m, 2H, -NCH2CHCH2), 4.19 (d, 1H, J = 11.2 Hz, -CHCO2CH3), 
4.68 (dd, 1H, J = 11.2, 7.4 Hz, -NCH(CH-)CH-), 4.99–5.30 (m, 4H, 
CH2CHCH2N(Ts)CH(CH-)CHCHCH3), 5.63 (ddt, 1H, J = 17.0, 10.3, 6.5 Hz, -
NCH(CH-)CH-), 7.08–7.30 (m, 7H, ArH), 7.65 (app. d, 2H, J = 8.2 Hz, ArH Ts); 13C 
NMR (125 MHz, CD3Cl) δ: 17.6, 21.4, 50.1, 52.0, 55.7, 63.7, 118.1, 125.9, 127.7, 
127.8, 128.5, 128.9, 129.2, 131.8, 134.9, 135.8, 137.8, 143.1, 172.5; HRMS (ESI, +ve) 
m/z calcd. for C23H28NO4S  414.1739,  found  414.1734 (M+H)
+. 
 
 
 
 
 
 
 
 
Chapter 6  Experimental
   
237 
(2R,3R,E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-phenylhex-4-enoate 
(S)-333 
 
 
 
LiHMDS (1M in toluene, 0.63 ml, 0.63 mmol), TMSCl (0.19 ml, 2.91 mmol) and (S,E)-
4-(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-phenylacetate (S)-331 (0.10 g, 
0.48 mmol) in THF (1 ml) was combined according to general procedure 3 (reaction 
time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (2R,3R,E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-
phenylhex-4-enoate (S)-333 as a white solid (0.08 g, 71%, d.r. >25:1). M.p. 105–107 
˚C; [α]
D
2 0 
= -15.0 (c 1, DCM). All other data as previously recorded for racemic 
compound. 
  
(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-methylhex-4-enoate 334 
 
 
 
LiHMDS (1M in toluene, 1.34 ml, 1.34 mmol), triethylamine (1.81 ml, 13.4 mmol) and 
(E)-4-(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl propionate 330 (0.10 g, 0.30 
mmol) in THF (1 ml) was combined according to general procedure 4 (reaction time : 
75 minutes). Treatment with diazomethane and purification by flash chromatography 
afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-methylhex-4-enoate 
334 as a white solid (0.06 g, 55%, d.r. >25:1). M.p. 88–90 ˚C; FTIR (film/cm-1) υmax: 
2966 (m), 2916 (m), 1735 (s), 165s (m); 1H NMR (500 MHz, CD3Cl) δ: 1.06 (d, 3H, J = 
6.9 Hz), 1.51 (dd, 3H, J = 6.4, 1.5 Hz), 2.39 (3H, s), 3.02 (ddt, 2H, J = 10.1, 7.8, 6.9 
Hz), 2.83 (s, 3H), 3.69–3.85 (s, 2H), 4.27 (app. t, 1H, J = 10.1 Hz), 5.07–5.18 (m, 2H), 
5.41 (ddq, 1H, J = 15.1, 10.1, 1.5 Hz), 5.55 (dq, 1H, J = 15.1, 6.4 Hz), 5.71 (ddt, 1H, J 
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= 17.3, 10.2, 6.5 Hz), 7.26 (app. d, 2H, J = 8.2 Hz), 7.69 (app. d, 2H, J = 8.2 Hz); 13C 
NMR (125 MHz, CD3Cl) δ: 15.6, 17.7, 21.4, 43.4, 49.4, 51.7, 64.1, 117.6, 126.2, 127.7, 
129.1, 132.1, 135.3, 137.8, 142.9, 175.0; HRMS (ESI, +ve) m/z calcd. for C18H25NO4S  
352.1582,  found 352.1577 (M+H)+. 
 
(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)- 
2-(4-(trifluoromethyl)phenyl)hex-4-enoate 342 
 
 
 
LiHMDS (1M in toluene, 1.07 ml, 1.07 mmol), TMSCl (0.33 ml, 4.94 mmol) and (I)-4-
(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(4-(trifluoromethyl)phenyl)acetate 
357 (0.20 g, 0.82 mmol) in THF (2 ml) was combined according to general procedure 3 
(reaction time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(4-
(trifluoromethyl)phenyl)hex-4-enoate 342 as a yellow solid (0.11 g, 54%, d.r. 12:1). 
M.p. 104–106 ˚C; FTIR (film/cm-1) υmax: 3034 (w), 2951 (m), 2922 (m), 1735 (s), 1669 
(w), 1598 (m), 1512 (m); 1H NMR (500 MHz, CD3Cl) δ: 1.37 (d, 3H, J = 4.5 Hz), 2.41 
(s, 3H), 3.66 (s, 3H), 3.74–3.89 (m, 2H), 4.39 (d, 1H, J = 11.3 Hz), 4.73 (dd, 1H, J = 
11.3, 8.8 Hz), 5.15 (app. d, 1H, J = 10.1 Hz), 5.22 (app. d, 1H, J = 17.0 Hz), 5.19–5.36 
(m, 2H), 5.70 (ddt, 1H, J = 17.0, 10.1, 6.4 Hz), 7.27 (app. d, 2H, J = 8.1 Hz), 7.44 (app. 
d, 2H, J = 8.1 Hz), 7.54 (app. d, 2H, J = 8.1 Hz), 7.73 (app. d, 2H, J = 8.1 Hz); 13C 
NMR (125 MHz, CD3Cl) δ: 17.5, 21.4, 50.3, 52.2, 55.6, 63.7, 118.4, 124.1 (q, J = 272.0 
Hz), 125.4 (q, J = 3.5 Hz), 125.5, 127.8, 129.3 (x2), 129.9 (q, J = 32.4 Hz), 132.5, 
134.6, 137.6, 139.9, 143.3, 171.9; HRMS (ESI, +ve) m/z calcd. for C24H26F3NO4S  
481.1535,  found  481.1400 (M+H)+. 
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(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)- 
2-isopropylhex-4-enoate 347 
 
 
 
LiHMDS (1M in toluene, 2.47 ml, 2.47 mmol), triethylamine (3.42 ml, 24.7 mmol) and 
(E)-4-(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 3-methylbutanoate 335 (0.20 
g, 0.55 mmol) in THF (2 ml) was combined according to general procedure 4 (reaction 
time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-
isopropylhex-4-enoate 347 as a white solid (0.14 g, 65%, d.r. >25:1). M.p. 105–107 ˚C; 
FTIR (film/cm-1) υmax: 3082 (m), 3021 (m), 2985 (m), 2958 (m), 1730 (s), 1655 (m), 
1615 (m), 1597 (m), 1509 (m); 1H NMR (400 MHz, CD3Cl) δ: 0.90 (d, 3H, J = 6.7 Hz), 
0.99 (d, 3H, J = 6.7 Hz), 1.67 (d, 3H, J = 5.8 Hz), 1.78–1.94 (1H, m), 2.43 (s, 3H), 3.08 
(dd, 2H, J = 11.3, 2.7 Hz), 3.65 (s, 3H), 3.67–3.86 (m, 2H), 4.45 (app. t, 1H, J = 11.3 
Hz), 5.07–5.28 (m, 1H), 5.48–5.80 (m, 1H),  7.27 (app. d, 2H, J = 8.1 Hz), 7.72 (app. d, 
2H, J = 8.1 Hz); 13C NMR (125 MHz, CD3Cl) δ: 16.0, 17.8, 21.4, 21.9, 27.6, 51.1, 54.2, 
61.9, 117.8, 126.9, 127.9, 129.1, 131.5, 135.2, 137.9, 142.9, 172.8; HRMS (ESI, +ve) 
m/z calcd. for C20H30NO4S  380.1895,  found 380.1900 (M+H)
+. 
 
(anti-E)-Methyl 2-allyl-3-(N-allyl-4-methylphenylsulfonamido)hex-4-enoate 348 
 
 
 
LiHMDS (1M in toluene, 2.48 ml, 2.48 mmol), triethylamine (3.43 ml, 24.80 mmol) 
and (E)-4-(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl pent-4-enoate 336 (0.20 g, 
0.55 mmol) in THF (2 ml) was combined according to general procedure 4 (reaction 
time : 75 minutes). Treatment with diazomethane and purification by flash 
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chromatography afforded (anti-E)-methyl 2-allyl-3-(N-allyl-4-
methylphenylsulfonamido)hex-4-enoate 348 as a yellow oil (0.15 g, 70%, d.r. 10:1). 
FTIR (film/cm-1) υmax: 3012 (m), 2983 (m), 2934 (m), 1729 (s), 1655 (s), 1616 9 (s), 
1596 (s), 1509 (m); 1H NMR (400 MHz, CD3Cl) δ: 1.66 (d, 3H, J = 6.3 Hz), 2.12–2.29 
(2H, m), 2.43 (s, 3H), 3.08 (td, 1H, J = 10.6, 4.5 Hz), 3.66 (s, 3H), 3.74 (dd, 1H, J = 
15.8, 6.7 Hz), 3.83 (dd, 1H, J = 16.0, 6.7 Hz), 4.33 (app. t, 1H, J = 10.6 Hz), 4.98–5.22 
(m, 4H), 5.48 (dd, 1H, J = 15.5, 9.9 Hz), 5.60 (dq, 1H, J = 14.2, 6.3 Hz),  5.65–5.77 (m, 
2H), 7.28 (app. d, 2H, J = 8.1 Hz), 7.73 (app. d, 2H, J = 8.1 Hz); 13C NMR (125 MHz, 
CD3Cl) δ: 17.8, 21.4, 34.9, 49.4, 49.5, 51.5, 63.2, 117.1, 117.8, 126.4, 127.8, 129.2, 
132.4, 134.5, 135.1, 137.7, 143.0, 173.6; HRMS (ESI, +ve) m/z calcd. for C20H28NO4S  
378.1739,  found 378.1699 (M+H)+. 
 
(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(2-iodophenyl) 
hex-4-enoate 355 
 
 
 
LiHMDS (1M in toluene, 0.34 ml, 0.34 mmol), TMSCl (0.10 ml, 1.57 mmol) and (E)-4-
(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(2-iodophenyl)acetate 340 (0.07 g, 
0.26 mmol) in THF (0.7 ml) was combined according to general procedure 3 (reaction 
time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(2-
iodophenyl)hex-4-enoate 355 as a white solid (0.05 g, 67%, d.r. >25:1). M.p. 97–99 ˚C; 
FTIR (film/cm-1) υmax: 3179 (w), 2953 (m), 2922 (m), 1734 (s), 1597 (m); 
1H NMR 
(500 MHz, CD3Cl) δ: 1.35 (d, 3H, J = 6.5 Hz), 2.41 (s, 3H), 3.63 (s, 3H), 3.83 (app. d, 
1H, J = 17.3, 6.7 Hz), 3.93 (app. d, 1H, J = 17.3, 6.7 Hz), 4.75 (d, 1H, J = 11.7 Hz), 
4.91 (d, 1H, J = 11.7 Hz), 5.14–5.23 (m, 2H), 5.25–5.37 (m, 2H), 5.79 (ddt, 1H, J = 
17.0, 10.8, 6.7 Hz), 6.92 (app. t, 1H, J = 7.9 Hz), 7.26 (app. d, 2H, J = 8.7 Hz), 7.27–
7.33 (m, 1H),  7.51 (app d, 1H, J = 7.9 Hz), 7.74 (app. d, 2H, J = 8.7 Hz), 7.82 (d, 1H, J 
= 7.9 Hz); 13C NMR (125 MHz, CD3Cl) δ: 17.6, 21.4, 49.2, 52.2, 57.8, 64.2, 118.1, 
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124.7, 127.9, 128.5, 128.9, 129.0, 129.2, 129.3, 132.1, 135.0, 137.7, 138.9, 139.6, 
143.1, 171.8; HRMS (ESI, +ve) m/z calcd. for C25H32NO6S  474.1950,  found  474.1948 
(M+H)+. 
 
(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)- 
2-(4-methoxyphenyl)hex-4-enoate 356 
 
 
 
LiHMDS (1M in toluene, 1.16 ml, 1.16 mmol), TMSCl (0.35 ml, 5.35 mmol) and (E)-4-
(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(4-methoxyphenyl)acetate 341 
(0.20 g, 0.89 mmol) in THF (2 ml) was combined according to general procedure 3 
(reaction time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(4-
methoxyphenyl)hex-4-enoate 356 as a white solid (0.15 g, 73%, d.r. >25:1). M.p. 109–
110 ˚C; FTIR (film/cm-1) υmax: 3039 (w), 2952 (m), 2919 (m), 1734 (s), 1670 (w), 1608 
(m), 1598 (m), 1522 (m), 1512 (m); 1H NMR (500 MHz, CD3Cl) δ: 1.39 (d, 3H, J = 4.5 
Hz), 2.41 (s, 3H), 3.62 (s, 3H), 3.77 (s, 3H), 3.75–3.88 (m, 2H), 4.21 (d, 1H, J = 11.5 
Hz), 4.73 (dd, 1H, J = 11.5, 7.44 Hz), 5.12 (app. d, 1H, J = 10.3 Hz), 5.20 (app d, 1H, J 
= 17.1 Hz), 5.23–5.33 (m, 2H), 5.70 (ddt, 1H, J = 17.1, 10.3, 6.5 Hz), 6.81 (app. d, 2H, 
J = 8.7 Hz), 7.22 (app. d, 2H, J = 8.7 Hz), 7.26 (app. d, 2H, J = 8.4 Hz), 7.73 (app. d, 
2H, J = 8.4 Hz); 13C NMR (125 MHz, CD3Cl) δ: 17.6, 21.4, 50.0, 51.9, 54.9, 55.1, 63.6, 
113.9, 118.0, 126.0, 127.8 (x2), 129.2, 129.9, 131.7, 134.9, 137.9, 143.0, 159.0, 172.8; 
HRMS (ESI, +ve) m/z calcd. for C24H30NO5S  444.1844,  found  444.1857 (M+H)
+. 
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(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(4-nitrophenyl) 
hex-4-enoate 358 
 
 
LiHMDS (1M in toluene, 1.13 ml, 1.13 mmol), TMSCl (0.34 ml, 5.22 mmol) and (E)-4-
(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(4-nitrophenyl)acetate 343 (0.20 
g, 0.87 mmol) in THF (2 ml) was combined according to general procedure 3 (reaction 
time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography, recrystallisation and a two subsequent recrystallisations of the mother 
liquor afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(4-
nitrophenyl)hex-4-enoate 358 as an off white solid (0.10 g, 53%, d.r. 20:1). M.p. 128–
130 ˚C; FTIR (film/cm-1) υmax: 3018 (w), 2988 (m), 2952 (m) 2925 (m), 1736 (s), 1669 
(w), 1598 (m), 1521 (s); 1H NMR (500 MHz, CD3Cl) δ: 1.38 (dd, 3H, J = 6.2, 1.0 Hz), 
2.42 (s, 3H), 3.69 (s, 3H), 3.78 (dd, 1H, J = 16.0, 6.8 Hz), 3.86 (dd, 1H, J = 16.0, 6.8 
Hz), 4.49 (d, 1H, J = 11.2 Hz), 4.69 (app. t, 1H, J = 11.2 Hz), 5.17 (app. d, 1H, J = 10.2 
Hz), 5.23 (app. d, 1H, J = 17.0 Hz), 5.20–5.38 (m, 2H), 5.69 (ddt, 1H, J = 17.0, 10.2, 
6.8 Hz), 7.28 (app. d, 2H, J = 8.2 Hz), 7.51 (app. d, 2H, J = 8.2 Hz), 7.73 (app. d, 2H, J 
= 8.2 Hz), 8.16 (app. d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, CD3Cl) δ: 17.5, 21.4, 
50.5, 52.5, 55.6, 63.8, 118.6, 123.7, 125.4, 127.8, 129.3, 129.9, 132.9, 134.5, 137.5, 
143.2, 143.4, 147.4, 171.5; HRMS (ESI, +ve) m/z calcd. for C23H26N2O6S  481.1409,  
found  481.1715 (M+Na)+. 
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(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(2,4-dichlorophenyl)hex-
4-enoate 359 
 
 
 
LiHMDS (1M in toluene, 1.07 ml, 1.07 mmol), TMSCl (0.33 ml, 4.94 mmol) and (E)-4-
(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(2,4-dichlorophenyl)acetate 344 
(0.20 g, 0.82 mmol) in THF (2 ml) was combined according to general procedure 3 
(reaction time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-
(2,4-dichlorophenyl)hex-4-enoate 359 as a yellow oil (0.14 g, 68%, d.r. >25:1). FTIR 
(film/cm-1) υmax: 3034 (w), 2950 (m), 2919 (m), 1736 (s), 1669 (m), 1598 (m), 1523 
(m), 1512 (m); 1H NMR (500 MHz, CD3Cl) δ: 1.37 (d, 3H, J = 5.8 Hz), 2.41 (s, 3H), 
3.65 (s, 3H), 3.80 (dd, 1H, J = 15.9, 6.9 Hz), 3.92 (dd, 1H, J = 15.9, 6.9 Hz), 4.79 (dd, 
1H, J = 11.5, 8.6 Hz), 4.90 (d, 1H, J = 11.5 Hz), 5.15 (app. d, 1H, J = 10.2 Hz), 5.18–
5.33 (m, 3H), 5.71 (ddt, 1H, J = 16.9, 10.3, 6.9 Hz), 7.21 (dd, 2H, J = 8.3, 2.3 Hz), 7.26 
(app. d, 2H, J = 8.2 Hz), 7.36 (d, 1H, J = 2.3 Hz), 7.51 (d, 1H, J = 8.3 Hz), 7.72 (app. 
d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, CD3Cl) δ: 17.6, 21.4, 49.5, 49.6, 52.3, 63.9, 
118.2, 124.7, 127.4, 127.8, 129.2, 129.3, 130.3, 132.4, 132.5, 133.9, 134.9, 135.2, 
137.6, 143.2, 171.5; HRMS (ESI, +ve) m/z calcd. for C23H26Cl2NO4S  482.0959,  found  
482.0971 (M+H)+. 
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(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(2,4-
dimethoxyphenyl)hex-4-enoate 360 
 
 
 
LiHMDS (1M in toluene, 1.09 ml, 1.09 mmol), TMSCl (0.33 ml, 5.03 mmol) and (E)-4-
(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(2,4-dimethoxyphenyl)acetate 345 
(0.20 g, 0.84 mmol) in THF (2 ml) was combined according to general procedure 3 
(reaction time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-
(2,4-dimethoxyphenyl)hex-4-enoate 360 as a yellow oil (0.15 g, 72%, d.r. 20:1). FTIR 
(film/cm-1) υmax: 3033 (w), 2950 (m), 2919 (m), 1734 (s), 1608 (m), 1522 (m), 1507 
(m); 1H NMR (500 MHz, CD3Cl) δ: 1.35 (d, 3H, J = 4.3 Hz), 2.39 (s, 3H), 3.59 (s, 3H), 
3.77 (s, 3H), 3.78 (s, 3H), 3.77–3.91 (m, 2H), 4.70 (d, 1H, J = 11.0 Hz), 4.77–4.85 (m, 
1H), 5.10 (d, 1H, J = 10.0 Hz), 5.17–5.25 (m, 3H), 5.74 (ddt, 1H, J = 16.9, 10.0, 6.9 
Hz), 6.36–6.40 (m, 1H), 6.40–6.48 (m, 1H), 7.24 (app. d, 2H, J = 8.4 Hz), 7.32 (d, 1H, 
J = 8.5 Hz), 7.72 (app. d, 2H, J = 8.4 Hz); 13C NMR (125 MHz, CD3Cl) δ: 17.6, 21.4, 
45.7, 49.2, 51.8, 55.2, 55.6, 63.5, 98.4, 104.6, 116.8, 117.6, 125.9, 127.9, 129.1, 129.3, 
130.8, 135.3, 138.0, 142.9, 158.0, 160.1, 172.8; HRMS (ESI, +ve) m/z calcd. for 
C25H32NO6S  474.1950,  found  474.1948 (M+H)
+. 
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(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(benzo[d][1,3]dioxol-5-
yl)hex-4-enoate 361 
  
 
 
LiHMDS (1M in toluene, 0.55 ml, 0.55 mmol), TMSCl (0.17 ml, 2.53 mmol) and (E)-4-
(N-allyl-4-methylphenylsulfonamido)but-3-en-2-yl 2-(benzo[d][1,3]dioxol-5-yl)acetate 
340 (0.10 g, 0.42 mmol) in THF (1 ml) was combined according to general procedure 3 
(reaction time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded (anti-E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-
(benzo[d][1,3]dioxol-5-yl)hex-4-enoate 361 as a white solid (0.06 g, 55%, d.r. >25:1). 
M.p. 119–121 ˚C;  FTIR (film/cm-1) υmax: 3020 (w), 2952 (m), 2928 (m), 1733 (s), 1597 
(m), 1504 (s); 1H NMR (500 MHz, CD3Cl) δ: 1.42 (d, 3H, J = 4.8 Hz), 2.41 (s, 3H), 
3.17 (s, 3H), 3.77 (dd, 1H, J = 16.0, 6.9 Hz), 3.84 (dd, 1H, J = 16.0, 6.9 Hz), 4.19 (d, 
1H, J = 11.3 Hz), 4.66 (dd, 1H, J = 11.3 Hz), 5.13 (app. d, 1H, J = 10.1 Hz), 5.20 (app. 
d, 1H, J = 17.1 Hz), 5.27–5.35 (m, 2H), 5.69 (ddt, 1H, J = 17.1, 10.1, 6.9 Hz), 5.92–
5.95 (m, 2H), 6.68–6.77 (m, 2H), 6.85 (d, 1H, J = 1.7 Hz), 7.26 (app. d, 2H, J = 8.3 
Hz), 7.72 (app. d, 2H, J = 8.3 Hz); 13C NMR (125 MHz, CD3Cl) δ: 17.7, 21.4, 50.2, 
52.0, 55.3, 63.6, 101.0, 108.1, 108.8, 118.1, 122.6, 125.9, 127.8, 129.2, 129.5, 131.8, 
134.8, 137.8, 143.1, 147.0, 147.8, 172.6; HRMS (ESI, +ve) m/z calcd. for C24H28NO6S  
458.1637,  found  458.1649 (M+H)+. 
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(anti-E)-Methyl 2-allyl-3-(N-benzyl-4-methylphenylsulfonamido)hex-4-enoate 381 
  
 
 
LiHMDS (1M in toluene, 2.16 ml, 2.16 mmol), triethylamine (3.00 ml, 21.60 mmol) 
and (E)-4-(N-benzyl-4-methylphenylsulfonamido)but-3-en-2-yl pent-4-enoate 380 (0.20 
g, 0.48 mmol) in THF (2 ml) was combined according to general procedure 4 (reaction 
time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography (× 2) afforded (anti-E)-methyl 2-allyl-3-(N-benzyl-4-
methylphenylsulfonamido)hex-4-enoate 381 as a white solid (0.02 g, 10%, d.r. >25:1).  
M.p. 92–94 ˚C; FTIR (film/cm-1) υmax: 3045 (m), 2971 (m), 2934 (m), 1708 (s), 1601 
(m), 1508 (s); 1H NMR (500 MHz, CD3Cl) δ: 1.61 (d, 3H, J = 5.7 Hz), 1.96–2.08 (m, 
1H), 2.10–2.21 (m, 1H), 2.42 (s, 3H), 3.10 (td, 1H, J = 10.7, 4.2 Hz), 3.48 (s, 3H), 4.13–
4.34 (m, 3H), 4.94 (app. d, 1H, J = 12.8 Hz), 5.33–5.49 (m, 2H), 5.55–5.68  (m, 1H), 
7.11–7.18 (m, 2H), 7.20–7.31 (m, 5H), 7.70 (app. d, J = 8.18 Hz); 13C NMR (125 MHz, 
CD3Cl) δ: 17.7, 21.4, 35.1, 48.8, 50.6, 51.4, 63.6, 117.0, 126.6, 127.6, 127.8, 128.1, 
129.2 (x2), 132.0, 134.4, 136.6, 138.0, 143.0, 173.6; HRMS (ESI, +ve) m/z calcd. for 
C24H30NO4S  428.1895,  found  428.1856 (M+H)
+. 
 
6.3.5. Derivatisation of N-Sulfonamide Rearrangement Products 
 
Methyl 2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)propanoate 367 
 
 
 
 anti-(E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-methylhex-4-enoate 334 
(0.02 g, 0.05 mmol), catalytic Grubbs I and DCM (5 ml) were combined according to 
general procedure 6 (reaction time: 6 hours). Purification was achieved by the reported 
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procedure to yield the methyl 2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)propanoate 367 as 
a white solid (0.01 g, 79%).  M.p. 95–97 ˚C; FTIR (film/cm-1) υmax: 2960 (m), 2928 
(m), 2878 (m), 1730 (s), 1597 (m); 1H NMR (500 MHz, CD3Cl) δ: 1.12 (d, 3H, J = 7.1 
Hz), 2.44 (s, 3H), 3.31 (qd, 1H, J = 7.13, 3.96 Hz), 3.72 (s, 3H), 4.06–4.19 (m, 2H), 
4.84–4.89 (m, 1H), 5.55 (app dq, 1H, J = 5.5, 2.2 Hz), 5.72 (app. dq, 1H, J = 5.5, 2.2 
Hz), 7.33 (app. d, 2H, J = 8.1 Hz), 7.74 (app. d, 2H, J = 8.1 Hz); 13C NMR (125 MHz, 
CD3Cl) δ: 10.1, 21.5, 43.9, 51.8, 56.1, 67.9, 126.5, 126.8, 127.4, 129.8, 134.1, 143.6, 
174.5; HRMS (ESI, +ve) m/z calcd. for C15H20NO4S  310.113,  found  310.1108 
(M+H)+. 
 
Methyl 3-methyl-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)butanoate 368 
 
 
 
anti-(E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-isopropylhex-4-enoate 347 
(0.05 g, 0.13 mmol), catalytic Grubbs I and DCM (5 ml) were combined according to 
general procedure 6 (reaction time: 13 hours). Purification was achieved by the reported 
procedure to yield the methyl 3-methyl-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-
yl)butanoate 368 as an amorphous white solid (0.04 g, 86%). FTIR (film/cm-1) υmax: 
2994 (m), 2956 (m), 2878 (m), 1727 (s), 1598 (m); 1H NMR (500 MHz, CD3Cl) δ: 0.86 
(d, 3H, J = 6.0 Hz), 1.10 (d, 3H, J = 6.0 Hz), 1.96–2.06 (m, 1H), 2.42 (s, 3H), 3.03 (app. 
t, 1H, J = 6.0 Hz), 3.72 (s, 3H), 4.08–4.18 (m, 2H), 4.68–4.73 (m, 1H), 5.66 (app. dq, 
1H, J = 6.4, 2.1 Hz), 5.86 (app. dq, 1H, J = 6.4, 2.1 Hz), 7.31 (app. d, 2H, J = 8.1 Hz), 
7.70 (app. d, 2H, J = 8.1 Hz); 13C NMR (125 MHz, CD3Cl) δ: 20.0, 21.5, 22.7, 26.3, 
51.2, 56.0, 67.6, 125.5, 127.5, 128.5, 129.7, 134.0, 143.6, 173.9; HRMS (ESI, +ve) m/z 
calcd. for C17H24NO4S  338.1426,  found  338.1426 (M+H)
+. 
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Methyl 2-phenyl-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 369 
 
 
 
anti-(E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-phenylhex-4-enoate 333 
(0.10 g, 0.24 mmol), catalytic Grubbs I and DCM (10 ml) were combined according to 
general procedure 6 (reaction time: 13 hours). Purification was achieved by the reported 
procedure to yield the methyl 2-phenyl-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 
369 as a white solid (0.08 g, 92%).  M.p. 98–100 ˚C. FTIR (film/cm-1) υmax: 3024 (m), 
2950 (m), 2931 (m), 1730 (s), 1657 (m), 1615 (m), 1596 (m), 1510 (m); 1H NMR (500 
MHz, CD3Cl) δ: 2.43 (s, 3H), 3.39–3.45 (m, 1H), 3.73 (s, 3H), 3.85 (app. dq, 1H, J = 
15.2, 2.1 Hz), 4.48 (d, 1H, J = 4.4 Hz), 5.06–5.06 (m, 1H), 5.43 (app. dq, 1H J = 6.4, 
2.0 Hz), 5.80 (app. dq, 1H J = 6.4, 2.0 Hz), 7.23–7.30 (m, 5H), 7.32 (app. d, 2H, J = 8.2 
Hz), 7.73 (app. d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 52.0, 55.5, 
56.2, 68.3, 129.9, 127.3 (x2), 127.6, 127.8, 129.8, 130.0, 134.0, 134.3, 143.6, 172.9; 
HRMS (ESI, +ve) m/z calcd. for C20H22NO4S  372.1269,  found  372.1238 (M+H)
+. 
  
Methyl 2-(2-iodophenyl)-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 370 
 
 
 
anti-(E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(2-iodophenyl)hex-4-enoate 
355 (0.09 g, 0.17 mmol), catalytic Grubbs I and toluene (5 ml) were combined 
according to general procedure 7 (reaction time : 5 hours). Purification was achieved by 
the reported procedure to yield the methyl 2-(2-iodophenyl)-2-(1-tosyl-2,5-dihydro-1H-
pyrrol-2-yl)acetate 370 as a white solid (0.04 g, 51%).  M.p. 186–188 ˚C; FTIR 
(film/cm-1) υmax: 3026 (m), 2952 (m), 2878 (m), 1728 (s), 1597 (m); 
1H NMR (500 
MHz, CD3Cl) δ: 2.42 (s, 3H), 3.66–3.75 (m, 1H), 3.75 (s, 3H), 3.97 (app. dq, 1H J = 
15.7, 1.9 Hz), 4.78 (d, 1H, J = 5.6 Hz), 5.19–5.24 (m, 1H), 5.50–5.59 (m, 2H), 6.95 
Chapter 6  Experimental
   
249 
(app. t, 1H, J = 7.4 Hz), 7.24–7.34 (m, 4H), 7.73 (app. d, 2H, J = 8.3 Hz), 7.89 (app. d, 
1H, J = 7.4 Hz); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 52.3, 55.5, 59.9, 68.7, 127.5, 
127.6 (x2), 127.7, 129.1, 129.7, 129.9, 134.2, 136.3, 138.0, 140.2, 143.6, 172.2; HRMS 
(ESI, +ve) m/z calcd. for C22H21INO4S  498.0235,  found  498.0259 (M+H)
+. 
 
Methyl 2-(4-methoxyphenyl)-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 371 
 
 
 
anti-(E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(4-methoxyphenyl)hex-4-
enoate 356 (0.05 g, 0.11 mmol), catalytic Grubbs I and DCM (5 ml) were combined 
according to general procedure 6 (reaction time: 13 hours). Purification was achieved by 
the reported procedure to yield the methyl 2-(4-methoxyphenyl)-2-(1-tosyl-2,5-dihydro-
1H-pyrrol-2-yl)acetate 371 as a clear oil (0.04 g, 89%).  FTIR (film/cm-1) υmax: 3035 
(m), 2953 (m), 2884 (m), 1727 (s), 1597 (m), 1512 (m); 1H NMR (500 MHz, CD3Cl) δ: 
2.42 (s, 3H), 3.44 (ddt, 1H, J = 15.0, 5.4, 2.0 Hz), 3.72 (s, 3H), 3.79 (s, 3H), 3.85 (app. 
dq, 1H, J = 15.0, 2.0 Hz), 4.42 (d, 1H, J = 4.3 Hz), 4.97–5.02 (m, 1H), 5.44 (app. dq, 
1H J = 6.4, 2.0 Hz), 5.80 (app. dq, 1H J = 6.4, 2.0 Hz), 6.82 (app. d, 2H, J = 8.6 Hz), 
7.17 (app. d, 2H, J = 8.6 Hz), 7.31 (app. d, 2H, J = 8.6 Hz), 7.72 (app. d, 2H, J = 8.6 
Hz); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 52.0, 55.1, 55.4, 55.5, 68.4, 113.3, 126.0, 
127.0, 127.3, 127.6, 129.8, 131.1, 134.4, 143.6, 158.8, 173.1; HRMS (ESI, +ve) m/z 
calcd. for C21H24NO5S  402.1375,  found  402.1366 (M+H)
+. 
 
Methyl 2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)-2-(4-(trifluoromethyl)phenyl)acetate 
372 
 
 
anti-(E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(4-(trifluoromethyl) phenyl) 
hex-4-enoate 357 (0.05 g, 0.11 mmol), catalytic Grubbs I and DCM (5 ml) were 
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combined according to general procedure 6 (reaction time: 13 hours). Purification was 
achieved by the reported procedure to yield the methyl 2-(1-tosyl-2,5-dihydro-1H-
pyrrol-2-yl)-2-(4-(trifluoromethyl)phenyl)acetate 372 as a yellow solid (0.04 g, 91%).  
M.p. 114–115 ˚C; FTIR (film/cm-1) υmax: 3010 (m), 2948 (m), 2897 (m), 1730 (s), 1597 
(m), 1504 (m); 1H NMR (500 MHz, CD3Cl) δ: 2.44 (s, 3H, CH3C6H4-), 3.38 (ddt, 1H, J 
= 15.1, 5.4, 2.3 Hz, -NCHHCH-), 3.74 (s, 3H, -CO2CH3), 3.84 (app. dq, 1H, J = 15.1, 
2.3 Hz, -NCHHCH-), 4.60 (d, 1H, J = 4.4 Hz, -CHCO2CH3), 5.03–5.07 (m, 1H, -
NCH(CH-)CH-), 5.48 (app. dq, 1H J = 6.5, 2.3 Hz, -NCH2CHCH-), 5.81 (app. dq, 1H J 
= 6.5, 2.3 Hz, -NCH2CHCH-), 7.33 (app. d, 2H, J = 8.2 Hz, ArH Ts), 7.39 (app. d, 2H, 
J = 8.2 Hz, ArH p-CF3), 7.55 (app. d, 2H, J = 8.2 Hz, ArH p-CF3), 7.72 (app. d, 2H, J 
= 8.2 Hz, ArH Ts); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 52.2, 55.5, 55.8, 68.2, 124.1 
(q, J = 272.0 Hz), 124.3 (q, J = 3.6 Hz), 127.0, 127.3, 127.5, 129.6 (q, J = 32.6 Hz), 
129.9, 130.5, 134.0, 138.0, 143.9, 172.1; HRMS (ESI, +ve) m/z calcd. for 
C21H21F3NO4S  440.1143,  found  440.1140 (M+H)
+. 
 
Methyl 2-(4-nitrophenyl)-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 373 
 
 
 
anti-(E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(4-nitrophenyl)hex-4-enoate 
358 (0.03 g, 0.07 mmol), catalytic Grubbs I and DCM (5 ml) were combined according 
to general procedure 6 (reaction time : 13 hours). Purification was achieved by the 
reported procedure to yield the methyl 2-(4-nitrophenyl)-2-(1-tosyl-2,5-dihydro-1H-
pyrrol-2-yl)acetate 373 as an off white solid (0.03 g, 96%).  M.p. 178–180 ˚C; FTIR 
(film/cm-1) υmax: 3030 (m), 2954 (m), 1732 (s), 1599 (s), 1521 (s); 
1H NMR (500 MHz, 
CD3Cl) δ: 2.44 (s, 3H), 3.34–3.42 (m, 1H), 3.76 (s, 3H), 3.84 (app. d, 1H, J = 15.6 Hz), 
4.69 (d, 1H, J = 4.2 Hz), 5.03–5.09 (m, 1H), 5.48–5.54 (m, 1H), 5.80–5.85 (m, 1H), 
7.34 (app. d, 2H, J = 8.1 Hz), 7.45 (app. d, 2H, J = 8.4 Hz), 7.72 (app. d, 2H, J = 8.1 
Hz), 8.16 (app. d, 2H, J = 8.4 Hz); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 52.4, 55.6, 
55.7, 68.2, 122.8, 126.7, 127.4, 127.8, 129.9, 131.2, 133.7, 141.5, 144.0, 147.3, 171.6; 
HRMS (ESI, +ve) m/z calcd. for C20H21N2O6S  417.1120,  found  417.1123 (M+H)
+. 
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Methyl 2-(2,4-dichlorophenyl)-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 374 
 
 
 
anti-(E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(2,4-dichlorophenyl)hex-4-
enoate 359 (0.04 g, 0.08 mmol), catalytic Grubbs I and toluene (5 ml) were combined 
according to general procedure 7 (reaction time : 5 hours). Purification was achieved by 
the reported procedure to yield the methyl 2-(2,4-dichlorophenyl)-2-(1-tosyl-2,5-
dihydro-1H-pyrrol-2-yl)acetate 374 as a white solid (0.03 g, 83%).  M.p. 147–148 ˚C; 
FTIR (film/cm-1) υmax: 3039 (m), 2953 (m), 2931 (m), 2876 (m), 1734 (s), 1589 (m), 
1542 (w), 1524 (w); 1H NMR (500 MHz, CD3Cl) δ: 2.43 (s, 3H), 3.52 (ddt, 1H, J = 
15.4, 5.2, 2.2 Hz), 3.74 (s, 3H), 3.84 (app. dq, 1H, J = 15.4, 2.2 Hz), 4.83 (d, 1H, J = 4.5 
Hz), 5.14–5.23 (m, 1H), 5.50 (app. dq, 1H J = 6.3, 2.2 Hz), 5.79 (app. dq, 1H J = 6.3, 
2.2 Hz), 7.21 (d, 1H, J = 2.1 Hz), 7.29–7.36 (m, 3H), 7.38 (app. d, 1H, J = 2.1 Hz), 
7.72 (app. d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 52.3, 53.2, 55.4, 
68.5, 126.6, 127.0, 127.2, 127.4, 129.7, 129.8, 131.1, 133.4, 133.9, 134.0, 135.7, 143.8, 
171.8; HRMS (ESI, +ve) m/z calcd. for C20H20Cl2NO5S  440.0490,  found  440.0686 
(M+H)+. 
 
Methyl 2-(2,4-dimethoxyphenyl)-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 375 
 
 
 
anti-(E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(2,4-dimethoxyphenyl)hex-
4-enoate 360 (0.07 g, 0.15 mmol), catalytic Grubbs I and toluene (5 ml) were combined 
according to general procedure 7 (reaction time : 5 hours). Purification was achieved by 
the reported procedure to yield the methyl 2-(2,4-dimethoxyphenyl)-2-(1-tosyl-2,5-
dihydro-1H-pyrrol-2-yl)acetate 375 as a clear oil (0.06 g, 90%). FTIR (film/cm-1) υmax: 
3000 (m), 2950 (m), 2867 (m), 2840 (m), 1731 (s), 1611 (s), 1587 (s), 1542 (w), 1508 
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(m); 1H NMR (500 MHz, CD3Cl) δ: 2.42 (s, 3H), 3.41 (ddt, 1H, J = 14.7, 5.4, 2.3 Hz), 
3.68 (s, 3H), 3.70 (s, 3H), 3.80 (s, 3H), 3.76–3.88 (m, 1H), 4.47 (d, 1H, J = 4.1 Hz), 
5.10–5.15 (m, 1H), 5.33 (app. dq, 1H J = 6.4, 2.3 Hz), 5.76 (app. dq, 1H J = 6.4, 2.3 
Hz), 6.38 (d, 1H, J = 2.8 Hz), 6.48 (d, 1H, J = 8.5, 2.8 Hz), 7.27–7.33 (d, 3H), 7.72 
(app. d, 2H, J = 7.9 Hz); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 51.5, 51.7, 55.1, 55.2, 
55.3, 68.5, 98.6, 104.1, 115.5, 124.9, 127.3, 127.8, 129.7. 133.4, 134.5, 143.4, 158.2, 
160.3, 173.4; HRMS (ESI, +ve) m/z calcd. for C22H25NNaO6S  454.1300,  found  
454.1533 (M+Na)+. 
 
Methyl 2-(benzo[d][1,3]dioxol-5-yl)-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 
376 
 
 
anti-(E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-(benzo[d][1,3]dioxol-5-
yl)hex-4-enoate 361 (0.05 g, 0.11 mmol), catalytic Grubbs I and DCM (5 ml) were 
combined according to general procedure 6 (reaction time : 5 hours). Purification was 
achieved by the reported procedure to yield methyl 2-(benzo[d][1,3]dioxol-5-yl)-2-(1-
tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 376 as a white solid (0.04 g, 89%).  M.p. 134–
136 ˚C; FTIR (film/cm-1) υmax: 2994 (m), 2946 (m), 2909 (m), 1728 (s), 1598 (m), 1504 
(s); 1H NMR (500 MHz, CD3Cl) δ: 2.43 (s, 3H), 3.56 (app. ddt, 1H, J = 15.0, 5.3, 2.0 
Hz), 3.73 (s, 3H), 3.89 (app. dq, 1H, J = 15.0, 2.4 Hz), 4.38 (d, 1H, J = 4.4 Hz), 4.95–
4.99 (m, 1H), 5.49 (app. dq, 1H, J = 6.3, 2.1 Hz), 5.77 (app. dq, 1H, J = 6.3, 2.1 Hz), 
5.94 (app. d, 2H, J = 4.7 Hz), 6.70–6.76 (m, 3H), 7.32 (app. d, 2H, J = 8.5 Hz), 7.72 
(app. d, 2H, J = 8.9 Hz); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 52.1, 55.6, 55.8, 68.3, 
101.0, 107.9, 110.1, 123.7, 127.0, 127.3, 127.6 (x2), 129.8, 134.2, 143.7, 146.9, 147.0, 
172.9; HRMS (ESI, +ve) m/z calcd. for C21H22NO6S  416.1167,  found  416.1168 
(M+H)+. 
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(R)-methyl 2-phenyl-2-((R)-1-tosylpyrrolidin-2-yl)acetate 377 
 
 
 
To a solution of methyl 2-phenyl-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 369 
(10.0 mg, 0.03 mmol, 1.0 eq.) in methanol (5 ml) was added Pd/C (1.00 mg, 2.00 × 10-4 
mmol, 1 mol%) and the reaction mixture was allowed to stir at room temperature for 4 
hours. The reaction mixture was filtered through a short pad of silica and concentrated 
in vacuo to yield (R)-methyl 2-phenyl-2-((R)-1-tosylpyrrolidin-2-yl)acetate 377 as an 
amorphous white solid (10.0 mg, 100%). FTIR (film/cm-1) υmax: 3037 (m), 2952 (m), 
2925 (m), 1731 (s), 1598 (m); 1H NMR (500 MHz, CD3Cl) δ: 0.81–0.96 (m, 1H), 1.14–
1.25 (m, 1H), 1.53–1.65 (m, 1H), 1.69–1.80 (m, 1H), 2.45 (s, 3H), 3.00–3.13 (m, 1H), 
3.74 (s, 3H), 4.26 (q, 1H, J = 4.7 Hz), 4.38 (d, 1H, J = 4.7 Hz), 7.28–7.39 (m, 7H), 7.78 
(app. d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 23.6, 28.3, 49.1, 52.0, 
55.4, 61.2, 127.6, 127.7, 128.4, 129.7 (× 2), 134.2, 134.9, 143.6, 173.2; HRMS (ESI, 
+ve) m/z calcd. for C20H24N1O4S1  374.1426,  found  374.1469 (M+H)
+. 
 
anti-methyl 1-tosyl-1,2,8,8a-tetrahydroindeno[2,1-b]pyrrole-8-carboxylate 379 
 
 
 
To a solution of Pd(OAc)2 (3.00 mg, 0.01 mmol, 0.2 eq.), PPh3 (3.67 mg, 0.01 mmol, 
0.2 eq.), Ag2CO3 (29.1 mg, 0.11 mmol, 1.5 eq.) in MeCN was added methyl 2-(2-
iodophenyl)-2-(1-tosyl-2,5-dihydro-1H-pyrrol-2-yl)acetate 370 (35.0 mg, 0.07 mmol, 
1.0 eq.). The reaction mixture was refluxed for 4 hours and then concentrated in vacuo 
and subjected to flash column chromatography using ethyl acetate/petroleum ether 40-
60° (20:80) to yield anti-methyl 1-tosyl-1,2,8,8a-tetrahydroindeno[2,1-b]pyrrole-8-
carboxylate 379 as an amorphous clear solid (22.0 mg, 84%). FTIR (film/cm-1) υmax: 
2958 (m), 2919 (m), 2849 (m), 1734 (s), 1597 (m); 1H NMR (500 MHz, CD3Cl) δ: 2.47 
Chapter 6  Experimental
   
254 
(s, 3H, -C6H4CH3), 3.80 (s, 3H, -CO2CH3), 4.92 (br. d, 1H, J = 9.5 Hz, -NCHHCH-), 
4.63 (br. s, 1H, -CHCO2CH3), 4.90 (dd, 1H, J = 9.5, 2.0 Hz, -NCHHCH-), 5.31 (app. 
dd, 1H, J = 4.1, 2.8 Hz, -NCH(CH-)CH-), 6.36 (app. dd, 1H, J = 4.1, 2.8 Hz, -
NCH2CH-), 7.10–7.15 (m, 1H, ArH), 7.23–7.27 (m, 2H, ArH), 7.36 (app. d, 2H, J = 8.2 
Hz, ArH, Ts), 7.45–7.51 (m, 1H, ArH), 7.75 (app. d, 2H, J = 8.2 Hz, ArH, Ts); 13C 
NMR (125 MHz, CD3Cl) δ: 21.6, 52.5, 54.5, 58.3, 66.1, 112.9, 125.1, 126.1, 127.8, 
127.9, 128.6, 129.9, 130.5, 132.9, 137.8, 142.9, 144.2, 172.3; HRMS (ESI, +ve) m/z 
calcd. for C20H20N1O4S1  370.1148,  found  370.1113 (M+H)
+. 
 
anti-methyl 2-(N-benzyl-4-methylphenylsulfonamido)cyclopent-3-enecarboxylate 
382 
N
CO2Me
Ts
 
 
(anti,E)-methyl 2-allyl-3-(N-benzyl-4-methylphenylsulfonamido)hex-4-enoate 381 
(0.02 g, 0.05 mmol), catalytic Grubbs I and DCM (5 ml) were combined according to 
general procedure 6 (reaction time : 12 hours). Purification was achieved by the 
reported procedure to yield anti-methyl 2-(N-benzyl-4-
methylphenylsulfonamido)cyclopent-3-enecarboxylate 382 as a clear oil (0.02 g, 85%). 
FTIR (film/cm-1) υmax: 3031 (m), 2952 (m), 2925 (m), 1731 (s), 1598 (m); 
1H NMR 
(500 MHz, CD3Cl) δ: 2.34–2.51 (m, 2H, -CH2CH(CH-)CO2Me), 2.45 (s, 3H, -
C6H4CH3), 2.77 (dt, 1H, J = 9.1, 4.9 Hz, -CH2CH(CH-)CO2Me), 3.66 (s, 3H, -
CO2CH3), 4.18 (d, 1H, J = 16.1 Hz, -N(Ts)CHHPh), 4.49 (d, 1H, J = 16.1 Hz, -
N(Ts)CHHPh), 5.19–5.26 (m, 1H, NCH(CHCO2Me)CH-), 5.33–5.39 (m, 1H, 
NCH(CHCO2Me)CH-), 5.75–5.82 (m, 1H, NCH(CHCO2Me)CHCH), 7.22–7.37 (m, 
7H, ArH), 7.73 (app. d, 2H, J = 8.2 Hz, ArH, Ts); 13C NMR (125 MHz, CD3Cl) δ: 21.5, 
35.9, 46.7, 48.2, 52.1, 68.0, 127.3, 127.4, 127.8, 128.3, 128.4, 129.7, 133.9, 137.5, 
138.1, 143.3, 174.9; HRMS (ESI, +ve) m/z calcd. for C12H23N1Na1O4S1  408.1245,  
found  408.1401 (M+Na)+. 
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6.3.6 SKA Precursors & Products 
 
Phenyl-acetic acid methyl ester 158 
 
 
 
EDCi (1.40 g, 7.30 mmol) in DCM (200 ml), triethylamine (1.02 ml, 7.30 mmol), 
DMAP (0.05 g, 0.37 mmol), phenylacetic acid (1.00 g, 7.30 mmol) and methanol (3.02 
ml, 3.65 mmol) in DCM (50 ml) were combined according to general procedure 1 
(reaction time: 15 hours). Purification was achieved by reported procedure and further 
purification by column chromatography using gradient elution ethyl acetate/petroleum 
ether 40-60° (5–15 %) yielded phenyl-acetic acid methyl ester 158 as a pale yellow oil 
(1.10 g, 100%). FTIR (film/cm-1) υmax: 3032 (m), 2953 (s), 1734 (s), 1603 (s); 
1H NMR 
(250 MHz, CDCl3) δ: 3.68 (s, 2H), 3.74 (s, 3H), 7.25–7.49 (m, 5H); 
13C NMR (63 MHz, 
CDCl3) δ: 41.2, 52.0, 127.1, 128.6, 129.2, 134.0, 172.0; HRMS (ESI, +ve) m/z calcd. 
for C9H11O2  151.0759,  found 151.0769 (M+H)
+. 
 
Phenyl-acetic acid isopropyl-2-d1 ester 
2
H1-239 
 
 
 
EDCi (1.24 g, 6.47 mmol) in DCM (200 ml), triethylamine (0.91 ml, 6.47 mmol), 
DMAP (0.04 g, 0.32 mmol), phenyl-acetic acid (0.89 g, 6.47 mmol) and 2-propanol-2-
d1 (0.20 g, 3.23 mmol) as a solution in DCM (30 mL) were combined according to 
general procedure 1 (reaction time: 15 hours). Purification was achieved by reported 
procedure to yield phenyl-acetic acid isopropyl-2-d1 ester 
2
H1-239 as a yellow oil (0.46 
g, 76%). FTIR (film/cm-1) υmax: 3032 (m), 2976 (m), 1731 (s), 1604 (m), 1497 (s); 
1H 
NMR (250 MHz, CDCl3) δ: 1.26 (s, 6H), 3.62 (s, 2H), 7.24–7.42 (m, 5H); 
13C NMR (75 
MHz, CDCl3) δ: 20.3, 41.8, 67.8 (t, J = 24.3 Hz), 127.0, 128.5, 129.2, 134.4, 171.1; 
HRMS (GC-EI, +ve) m/z calcd. for C11H17DO2N1  197.1395,  found 197.1391 
(M+NH4)
+. 
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13
C2-Phenyl-acetic acid isopropyl-D
1
-ester 
2
H1-
13
C2-239 
 
 
 
EDCi (0.28 g, 1.44 mmol) in DCM (100 ml), triethylamine (0.20 ml, 1.44 mmol), 
DMAP (0.01 g, 0.07 mmol),  13C2-phenyl-acetic acid (0.20 g, 1.44 mmol) and d
1-
isopropanol (0.04 ml, 0.72 mmol) were combined according to general procedure 1 
(reaction time: 15 hours). Purification was achieved by reported procedure, with an 
additional chloroform (20 ml) trituration to afford 13C2-phenyl-acetic acid isopropyl-d
1-
ester 2H1-
13
C2-239 as a yellow oil (0.09 g, 34%). FTIR (film/cm
-1) υmax: 2978 (m), 2934 
(m), 1686 (s), 1496 (m); 1H NMR (400 MHz, CDCl3) δ: 1.28 (s, 6H), 3.64 (dd, 2H, J = 
129.8, 7.6 Hz), 7.27–7.42 (m, 5H); 13C NMR (100 MHz, CDCl3) δ: 21.6 (d, J = 2.0 Hz), 
41.8 (d, J = 57.2 Hz), 67.8 (td, J = 23.5, 2.5 Hz), 126.9, 128.5 (d, J = 4.1 Hz), 129.2 (t, J 
= 2.0 Hz), 134.4 (dd, J = 43.9, 3.0 Hz), 171.1 (d, J = 57.2 Hz); HRMS (ESI, +ve) m/z 
calcd. for C11C
13
2H17D1N1O2  223.1556,  found 223.1797 (M+ACN+H)
+. 
 
(1-d1-Isopropoxy-2-phenyl-E-vinyloxy)-trimethyl-silane (E)-
2
H1-240 
 
OTMS
OCD(CH3)2  
 
LiHMDS (0.47 ml, 0.47 mmol, 1M in THF), TMSCl (0.10 ml, 1.68 mol) and phenyl-
acetic acid isopropyl-2-d1 ester 
2
H1-239 (0.05 g, 0.28 mmol) were combined according 
to general procedure 9c and purification was achieved by reported procedure to afford 
(1-d1-isopropoxy-2-phenyl-E-vinyloxy)-trimethyl-silane (E)-
2
H1-240 as a yellow oil 
(0.05 g, 82%, E/Z >100:1). 1H NMR (400 MHz, CDCl3) δ: 0.31 (s, 9H), 1.29 (s, 6H), 
2.29 (s, 3H), 4.72 (s, 1H), 7.04 (app. d, 2H, J = 7.8 Hz), 7.36 (app. d, 2H, J = 7.8 
Hz); 13C NMR (100 MHz, CDCl3) δ: 5.5, 21.0, 22.2, 69.2 (t, J = 22.3 Hz), 88.1, 126.5, 
128.7, 133.1, 134.0, 153.0. IR and HRMS not obtainable. Data in accordance with 
related non-deuterated analogue.152 
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(4-Methoxy-phenyl)-acetic acid isopropyl-2-d1 ester 
2
H1-241 
 
 
 
EDCi (1.24 g, 6.47 mmol) in DCM (200 ml), triethylamine (0.91 ml, 6.47 mmol), 
DMAP (0.04 g, 0.32 mmol), (4-methoxy-phenyl)-acetic acid (1.08 g, 6.47 mmol) and 2-
propanol-2-d1 (0.20 g, 3.23 mmol) as a solution in DCM (30 mL) were combined 
according to general procedure 1 (reaction time: 15 hours). Purification was achieved by 
reported procedure to yield (4-methoxy-phenyl)-acetic acid isopropyl-2-d1 ester 
2
H1-241 
as a yellow oil (0.68 g, 100%). FTIR (film/cm-1) υmax: 2978 (m), 2934 (m), 2837 (m), 
1723 (s), 1613 (w), 1512 (s); 1H NMR (250 MHz, CDCl3) δ: 1.22 (s, 6H), 3.51 (s, 2H), 
3.78 (s, 3H), 6.85 (app. d, 2H, J = 8.8 Hz), 7.19 (app. d, 2H, J = 8.8 Hz); 13C NMR (63 
MHz, CDCl3) δ: 21.7, 40.8, 55.2, 67.7 (t, J = 24.2 Hz), 113.9, 126.4, 130.2, 158.6, 
171.5; HRMS (GC-EI, +ve) m/z calcd. for C12H19D1O3N1  227.1500,  found 227.1499 
(M+NH4)
+. 
 
p-Tolyl-acetic acid isopropyl-2-d1 ester 
2
H1-242 
 
 
 
EDCi (1.24 g, 6.47 mmol) in DCM (200 ml), triethylamine (0.91 ml, 6.47 mmol), 
DMAP (0.04 g, 0.33 mmol), p-tolyl-acetic acid (0.98 g) and 2-propanol-2-d1 (0.20 g, 
3.23 mmol) as a solution in DCM (30 mL) were combined according to general 
procedure 1 (reaction time: 15 hours). Purification was achieved by reported procedure 
to yield p-tolyl-acetic acid isopropyl-2-d1 ester 
2
H1-242 as a yellow oil (0.63 g, 100%). 
FTIR (film/cm-1) υmax: 2979 (m), 2932 (m), 1720 (s), 1516 (m); 
1H NMR (250 MHz, 
CDCl3) δ: 1.23 (s, 6H), 2.34 (s, 3H), 3.55 (s, 2H), 7.07–7.23 (m, 4H); 
13C NMR (75 
MHz, CDCl3) δ: 21.1, 21.7, 41.3, 67.7 (t, J = 23.2 Hz), 129.1, 129.2, 131.3, 136.5, 
171.3; HRMS (GC-EI, +ve) m/z calcd. for C12H19D1O2N1  211.1551,  found 211.1551 
(M+NH4)
+. 
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(4-Trifluoromethyl-phenyl)-acetic acid isopropyl-2-d1 ester 
2
H1-243 
 
 
 
EDCi (1.24 g, 6.47 mmol) in DCM (200 ml), triethylamine (0.91 ml, 6.47 mmol), 
DMAP (0.04 g, 0.32 mmol), (4-trifluoromethyl-phenyl)-acetic acid (1.33 g, 6.47 mmol) 
and 2-propanol-2-d1 (0.20 g, 3.23 mmol) as a solution in DCM (30 mL) were combined 
according to general procedure 1 (reaction time: 15 hours). Purification was achieved by 
reported procedure to yield (4-trifluoromethyl-phenyl)-acetic acid isopropyl-2-d1 ester 
2
H1-243 as a yellow amorphous solid (0.67 g, 83%). FTIR (film/cm
-1) υmax: 2980 (m), 
2937 (m), 1732 (s), 1620 (m); 1H NMR (250 MHz, CDCl3) δ: 1.22 (s, 6H), 3.63 (s, 2H), 
7.39 (app. d, J = 8.0 Hz), 7.52 (app. d, J = 8.0 Hz); 13C NMR (75 MHz, CDCl3) δ: 22.0, 
41.8, 68.7 (t, J = 24.2 Hz), 124.6 (q, J = 272 Hz), 125.8 (q, J = 3.8 Hz), 129.7 (q, J = 
32.0 Hz), 130.0, 138.9, 170.7; HRMS (GC-EI, +ve) m/z calcd. for C12H12D1F3O2  
247.0925,  found 247.0925 (M)+. 
 
(4-Nitro-phenyl)-acetic acid isopropyl-2-d1 ester 
2
H1-244 
 
 
 
EDCi (1.24 g, 6.47 mmol) in DCM (200 ml), triethylamine (0.91 ml, 6.47 mmol), 
DMAP (0.04 g, 0.65 mmol), (4-nitro-phenyl)-acetic acid (1.18 g, 6.47 mmol) and 2-
propanol-2-d1 (0.20 g, 3.23 mmol) as a solution in DCM (30 mL) were combined 
according to general procedure 1 (reaction time: 15 hours). Purification was achieved by 
reported procedure to yield (4-nitro-phenyl)-acetic acid isopropyl-2-d1 ester 
2
H1-244 as 
an orange/red oil (0.73 g, 100%). FTIR (film/cm-1) υmax: 3081 (m), 2979 (m), 2934 (m), 
1726 (s), 1601 (w), 1518 (s); 1H NMR (250 MHz, CDCl3) δ: 1.21 (s, 6H), 3.68 (s, 2H), 
7.44 (app. d, 2H, J = 8.7 Hz), 8.17 (app. d 2H, J = 8.7 Hz); 13C NMR (63 MHz, CDCl3) 
δ: 21.6, 41.4, 68.6 (t, J = 22.4 Hz), 123.7, 130.2, 141.7, 147.2, 169.7; HRMS (GC-EI, -
ve) m/z calcd. for C11H11D1N1O4  223.0835,  found 223.0836 (M-H)
-. 
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tert-Butyl 2-(4-methoxyphenyl)acetate 252 
 
 
 
To a solution of DCC (2.75 g , 13.3 mmol, 2.0 eq.) in DCM (100 ml) at 0 °C was added 
DMAP (0.16 g, 1.33 mmol, 0.2 eq.) and  (4-methoxy-phenyl)-acetic acid (1.11 g, 6.66 
mmol, 1.0 eq.). To the resulting suspension was then added tert-butyl alcohol (33.3 
mmol, 5.0 eq.). The reaction mixture was allowed to stir whilst slowly warming to room 
temperature over 15 hours. The reaction was concentrated in vacuo, washed with ether 
(150 ml), filtered through celite, washed with 1N NaOH (100 ml), washed with 1N HCl 
(100 ml), dried over magnesium sulfate, concentrated in vacuo and subjected to 
purification by preparative HPLC (acetonitrile/water with 3% trifluoroacetic acid) to 
afford tert-butyl 2-(4-methoxyphenyl)acetate 252 as a yellow oil (0.57 g, 42%). FTIR 
(film/cm-1) υmax: 2978 (s), 2934 (m), 2836 (m), 1732 (s), 1613 (s), 1513 (s); 
1H NMR 
(300 MHz, CDCl3) δ: 1.35 (s, 9H), 3.37 (s, 2H), 3.70 (s, 3H), 6.71 (app. d 2H, J = 8.7 
Hz), 7.10 (app. d 2H, J = 8.7 Hz); 13C NMR (63 MHz, CDCl3) δ: 28.0, 41.7, 55.2, 80.7, 
113.9, 126.8, 130.2, 158.5, 171.3; HRMS (GC-EI, +ve) m/z calcd. for C13H22O3N1  
240.1594,  found 240.1594 (M+NH4)
+. 
 
tert-Butyl 2-p-tolylacetate 253 
 
 
 
To a solution of DCC (2.75 g, 13.3 mmol, 2.0 eq.) in DCM (100 ml) at 0 °C was added 
DMAP (0.16 g, 1.33 mmol, 0.2 eq.) and p-tolyl-acetic acid (1.00 g, 6.66 mmol, 1.0 eq.). 
To the resulting suspension was then added tert-butyl alcohol (2.47 g, 33.3 mmol, 5.0 
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eq.). The reaction mixture was allowed to stir whilst slowly warming to room 
temperature over 15 hours. The reaction was concentrated in vacuo, washed with ether 
(150 ml), filtered through celite, washed with 1N NaOH (100 ml), washed with 1N HCl 
(100 ml), dried over magnesium sulfate, concentrated in vacuo and subjected to 
purification by preparative HPLC (acetonitrile/water with 3% trifluoroacetic acid) to 
afford tert-butyl 2-p-tolylacetate 253 as a yellow oil (0.45 g, 33%). FTIR (film/cm-1) 
υmax: 2978(m), 2928 (m), 1734 (s), 1515 (s); 
1H NMR (300 MHz, CDCl3) δ: 1.39 (s, 
9H), 2.26 (s, 3H), 3.41 (s, 2H), 7.00–7.11 (m, 4H); 13C NMR (63 MHz, CDCl3) δ: 21.1, 
28.1, 42.2, 80.7, 129.1, 129.2, 131.7, 136.4, 171.2; HRMS (GC-EI, +ve) m/z calcd. for 
C13H22O2N1  224.1645,  found 224.1644 (M+NH4)
+. 
 
tert-Butyl 2-(4-nitrophenyl)acetate 254 
 
 
 
EDCi (5.17 g, 27.07 mmol) in DCM (400 ml), triethylamine (3.75 ml, 22.07 mmol), 
DMAP (0.08 g, 1.35 mmol), (4-nitro-phenyl)-acetic acid (4.89 g, 27.07 mmol) and tert-
butyl alcohol (1.00 g, 13.54 mmol) as a solution in DCM (30 mL) were combined 
according to general procedure 1 (reaction time: 15 hours). The reaction was 
concentrated in vacuo, washed with ether (150 ml), filtered through celite, washed with 
1N NaOH (100 ml), washed with 1N HCl (100 ml), dried over magnesium sulfate, 
concentrated in vacuo and subjected to purification by preparative HPLC 
(acetonitrile/water with 3% trifluoroacetic acid) to afford tert-butyl 2-(4-
nitrophenyl)acetate 254 as a yellow oil (1.01 g, 31%). FTIR (film/cm-1) υmax: 3084 (w), 
2981 (m), 2932 (m), 1728 (s), 1606 (w), 1519 (s); 1H NMR (250 MHz, CDCl3) δ: 1.43 
(s, 9H), 3.63 (s, 2H), 7.34 (app. d, 2H, J = 8.8 Hz), 8.18 (app. d, 2H, J = 8.8 Hz); 13C 
NMR (63 MHz, CDCl3) δ: 28.2, 42.5, 81.9, 123.8, 130.3, 142.2, 147.2, 169.5; HRMS 
(ESI, -ve) m/z calcd. for C12H14N1O4  236.0928,  found 236.0927 (M-H)
-. 
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tert-Butyl 2-phenylacetate 261 
 
 
 
Utilising a protocol reported by Hofmann.189 To a solution of DCC (8.32 g , 40.4 mmol, 
1.1 eq.) in DCM (200 mL) at 0 °C was added DMAP (3.58 g, 29.4 mmol, 0.8 eq.) and 
phenylacetic acid (5.00 g, 36.8 mmol, 1 eq.). To the resulting suspension was then 
added tert-butyl alcohol (8.20 g, 110 mmol, 3 eq.). The reaction mixture was allowed to 
stir whilst slowly warming to room temperature over 15 hours. The reaction was 
concentrated in vacuo, washed with ether (150 ml), filtered through celite, washed with 
1N NaOH (100 ml), washed with 1N HCl (100 ml), dried over magnesium sulfate, 
concentrated in vacuo and subjected to subjected to column chromatography using 
gradient elution ethyl acetate/petroleum ether 40-60˚ (5–10 %) to yield tert-butyl 2-
phenylacetate 261 as a pale yellow oil (4.90 g, 70%). FTIR (film/cm-1) υmax: 3032 (m), 
2979 (m), 2933 (m), 1729 (s), 1604 (s), 1497 (s); 1H NMR (250 MHz, CDCl3) δ: 1.47 
(s, 9H), 3.56 (s, 3H), 7.23–7.42 (m, 5H); 13C NMR (63 MHz, CDCl3) δ: 28.0, 42.7, 
80.8, 126.8, 128.4, 129.2, 134.7, 170.9; HRMS (ESI, +ve) m/z calcd. for C12H16NaO2  
215.1047,  found 215.1042 (M+Na)+.  
 
(1-Methoxy-2-phenyl-E-vinyloxy)-trimethyl-silane (E)-
2
H1-262 
 
 
 
LHMDS (0.57 ml, 0.57 mmol, 1M in THF), TMSCl (0.25 ml, 2.00  mmol) and phenyl-
acetic acid methyl ester 158 (50 mg, 0.33 mmol) were combined according to general 
procedure 9c and purification was achieved by reported procedure to afford (1-
methoxy-2-phenyl-E-vinyloxy)-trimethyl-silane (E)-2H1-262 as a yellow oil (0.06 g, 
80%, E/Z = 67:1). 1H NMR (400 MHz, CDCl3) δ: 0.38 (s, 9H), 3.76 (s, 3H), 4.74 (s, 
1H), 7.01–7.13 (m), 7.21–7.36 (m, 2H), 7.40–7.51 (m, 2H). 13C NMR (100 MHz, 
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CDCl3) δ: 0.0, 54.2, 86.0, 124.2, 126.9, 128.5, 136.9, 155.0. IR and HRMS not 
obtainable. Spectral data in accordance with literature.190 
 
(1-tert-Butoxy-2-phenyl-E-vinyloxy)-trimethyl-silane (E)-
2
H1-263 
 
 
 
LiHMDS (0.44 ml, 0.44 mmol, 1M in THF), TMSCl (0.20 ml, 1.56 mmol) and tert-
butyl 2-phenylacetate 261 (0.05 g, 0.26 mmol) were combined according to general 
procedure 9c and purification was achieved by reported procedure to afford (1-tert-
butoxy-2-phenyl-E-vinyloxy)-trimethyl-silane (E)-2H1-263 s a yellow oil (0.05 g, 76%, 
E/Z = 34:1). 1H NMR (400 MHz, CDCl3) δ: 0.39 (s, 9H), 1.51 (s, 9H), 4.90 (s, 1H),  
7.09 (app. t 1H,  J = 7.7 Hz), 7.26–7.32 (m, 2H), 7.53 (app. d, 2H, J = 8.1 Hz). 13C 
NMR (100 MHz, CDCl3) δ: 0.1, 29.4, 80.3, 91.7, 124.0, 126.8, 128.0, 137.1, 153.6. IR 
and HRMS not obtainable. Data for E-SKA in accordance with literature, however Z-
SKA is not, see NOE spectral assignments of similar compound in appendix.119 
 
 
6.3.7 Isolated Arylacetate Degradation Products 
 
Methyl 2-(2-methoxyphenyl)acetate 181 
 
 
 
Methyl 2-(2-methoxyphenyl)acetate 181 obtained as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 3.67 (s, 2H), 3.71 (s, 3H), 3.84 (s, 3H), 6.90 (app. d, 1H, J = 7.7 Hz), 6.95 
(app. t, 1H, J = 7.7 Hz), 7.21 (app. td, 1H, J = 7.7 Hz), 7.28 (app. t, 1H, J = 7.7 Hz); 13C 
NMR (125 MHz, CDCl3) δ: 35.7, 51.9, 55.5, 110.5, 120.5, 123.0, 128.6, 130.9, 157.5, 
172.3. All analytical data in accordance with literature values.191 
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Methyl 2-(3-methoxyphenyl)acetate 182 
 
 
 
Methyl 2-(3-methoxyphenyl)acetate 182 obtained as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 3.62 (s, 2H), 3.71 (s, 3H), 3.82 (s, 3H), 6.81–6.91 (m, 3H), 7.25 (t, 1H, J = 
7.5 Hz); 13C NMR (125 MHz, CDCl3) δ: 41.2, 52.0, 55.1, 112.6, 114.9, 121.6, 129.6, 
135.4, 159.7, 171.9. All analytical data in accordance with literature values.192 
 
(4-Methoxy-phenyl)-acetic acid methyl ester 183 
 
 
 
EDCi (1.24 g, 6.47 mmol) in DCM (200 ml), triethylamine (0.91 ml, 6.47 mmol), 
DMAP (0.04 g, 0.32 mmol), (4-methoxy-phenyl)-acetic acid (1.09 g, 6.47 mmol) and 
methanol (0.27 ml, 3.23 mmol) were combined according to general procedure 1 
(reaction time: 15 hours). Purification was achieved by reported procedure and further 
purification by column chromatography using gradient elution ethyl acetate/petroleum 
ether 40-60° (5–15 %) yielded (4-methoxy-phenyl)-acetic acid methyl ester 183 as a 
clear oil (0.50 g, 84%). FTIR (film/cm-1) υmax: 3000 (m), 2953 (m), 2838 (m), 1733 (s), 
1612 (m), 1512 (s); 1H NMR (250 MHz, CDCl3) δ: 3.57 (s, 2H), 3.69 (s, 3H), 3.79 (s, 
3H), 6.86 (app. d, 2H, J = 8.54 Hz), 7.20 (app. d, 2H, J = 8.54 Hz); 13C NMR (63 MHz, 
CDCl3) δ: 40.3, 52.0, 55.3, 114.0, 126.1, 130.3, 158.7, 172.4; HRMS (ESI, +ve) m/z 
calcd. for C10H16O3N1 198.1125,  found 198.1121 (M+NH4)
+. 
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Methyl 2-(o-tolyl)acetate 184 
 
 
 
Methyl 2-(o-tolyl)acetate 184 obtained as a yellow oil. 1H NMR (500 MHz, CDCl3) δ: 
2.34 (s, 3H), 3.67 (s, 2H), 3.71 (s, 3H), 7.14–7.25 (m, 4H); 13C NMR (125 MHz, 
CDCl3) δ: 19.6, 39.0, 52.0, 126.1, 127.4, 130.2, 130.4, 132.7, 136.9, 172.0. All 
analytical data in accordance with literature values.193 
 
Methyl 2-(m-tolyl)acetate 185 
 
 
 
Methyl 2-(m-tolyl)acetate 185 obtained as a yellow oil. 1H NMR (500 MHz, CDCl3) δ: 
2.36 (s, 3H), 3.61 (s, 2H), 3.71 (s, 3H), 7.07–7.13 (m, 3H), 7.23 (app. t, 1H, J = 7.6 
Hz); 13C NMR (125 MHz, CDCl3) δ: 21.4, 41.2, 52.0, 126.3, 127.9, 128.5, 130.0, 133.9, 
138.2, 172.2. All analytical data in accordance with literature values.194 
 
p-Tolyl-acetic acid methyl ester 186 
 
 
 
EDCi (1.24 g, 6.47 mmol) in DCM (200 ml), triethylamine (0.91 ml, 6.47 mmol), 
DMAP (0.04 g, 0.32 mmol), p-tolyl acetic acid (0.98 g, 6.47 mmol) and methanol (0.27 
ml, 3.23 mmol) were combined according to general procedure 1 (reaction time: 15 
hours). Purification was achieved by reported procedure and further purification by 
column chromatography using gradient elution ethyl acetate/petroleum ether 40-60° (5–
15 %) yielded p-tolyl-acetic acid methyl ester 186 as an orange oil (0.43 g, 80%). FTIR 
(film/cm-1) υmax: 3004 (m), 2952 (s), 2924 (m), 1735 (s); 
1H NMR (250 MHz, CDCl3) δ: 
2.35 (s, 3H), 3.60 (s, 2H), 3.70 (s, 3H), 7.11–7.22 (m, 4H); 13C NMR (63 MHz, CDCl3) 
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δ: 21.1, 40.8, 52.0, 129.1, 129.3, 130.9, 136.7, 172.2; HRMS (GC-EI, +ve) m/z calcd. 
for C10H12O2  165.0910,  found 165.0908 (M)
+. 
 
Methyl 2-(2-nitrophenyl)acetate 187 
 
 
 
Methyl 2-(2-nitrophenyl)acetate 187 obtained as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 3.78 (s, 3H), 4.05 (s, 2H), 7.37 (app. d, 1H, J = 7.8 Hz), 7.49 (app. t, 1H, J = 
7.8 Hz), 7.62 (app. t, 1H, J = 7.8 Hz), 8.14 (app. d, 1H, J = 7.8 Hz); 13C NMR (125 
MHz, CDCl3) δ: 39.6, 52.3, 125.3, 128.6, 129.7, 133.3, 133.6, 148.9, 170.4. All 
analytical data in accordance with literature values.195 
 
Methyl 2-(3-nitrophenyl)acetate 188 
 
 
 
Methyl 2-(3-nitrophenyl)acetate 188 obtained as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 3.74 (s, 3H), 3.76 (s, 2H), 7.54 (app. t, 1H, J = 8.0 Hz), 7.64 (app. d, 1H, J = 
8.0 Hz), 8.13–8.20 (m, 2H); 13C NMR (125 MHz, CDCl3) δ: 40.5, 52.4, 122.3, 124.4, 
129.5, 135.6, 135.8, 148.3, 170.8. All analytical data in accordance with literature 
values.196 
 
(4-Nitro-phenyl)-acetic acid methyl ester 189 
 
 
 
EDCi (1.24 g, 6.47 mmol) in DCM (200 ml), triethylamine (0.91 ml, 6.47 mmol), 
DMAP (0.04 g, 0.32 mmol), 4-nitro-phenyl)-acetic acid (1.20 g, 6.47 mmol) and 
methanol (0.27 ml, 3.23 mmol) were combined according to general procedure 1 
(reaction time: 15 hours). Purification was achieved by reported procedure and further 
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purification by column chromatography using gradient elution ethyl acetate/petroleum 
ether 40-60° (5–15 %) yielded (4-nitro-phenyl)-acetic acid methyl ester 189 as an 
amorphous solid (0.53 g, 84%). FTIR (film/cm-1) υmax: 2994 (m), 2955 (m), 1736 (s), 
1607 (m), 1515 (s); 1H NMR (250 MHz, CDCl3) δ: 3.72 (s, 3H), 3.74 (s, 2H), 7.46 
(app.d, 2H, J = 8.79 Hz), 8.19 (app.d, 2H, J = 8.79 Hz); 13C NMR (75 MHz, CDCl3) δ: 
40.9, 52.6, 124.0, 130.7, 141.9, 147.4, 171.0; HRMS (GC-EI, +ve) m/z calcd. for 
C9H9N1O4  195.0526,  found 195.0526 (M)
+. 
 
Methyl 2-(4-(dimethylamino)phenyl)acetate 224 
 
 
 
Methyl 2-(4-(dimethylamino)phenyl)acetate 224 as a brown solid. M.p. 54–57 °C; 1H 
NMR (500 MHz, CDCl3) δ: 2.94 (s, 6H), 3.54 (s, 2H), 3.69 (s, 3H), 6.71 (app.d, 2H, J = 
8.4 Hz), 7.16 (app.d, 2H, J = 8.4 Hz); 13C NMR (125 MHz, CDCl3) δ: 40.2, 40.6, 51.9, 
112.7, 121.8, 129.9, 149.8, 172.7. All analytical data in accordance with literature 
values.197 
 
Methyl 2-(4-iodophenyl)acetate 225 
 
 
 
Methyl 2-(4-iodophenyl)acetate 225 obtained as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 3.58 (s, 2H), 3.71 (s, 3H), 7.04 (app. d, 2H, J = 8.0 Hz), 7.66 (app. d, 1H, J = 
8.0 Hz); 13C NMR (125 MHz, CDCl3) δ: 40.6, 52.2, 92.6, 131.3, 133.6, 137.7, 171.5. 
All analytical data in accordance with literature values.198 
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Methyl 2-(4-fluorophenyl)acetate 226 
 
 
 
Methyl 2-(4-fluorophenyl)acetate 226 obtained as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 3.60 (s, 2H), 3.69 (s, 3H), 6.98–7.04 (m, 2H), 7.21–7.27 (m, 2H); 
13C NMR 
(125 MHz, CDCl3) δ: 40.2, 52.0, 115.4 (d, J = 21.3 Hz), 129.6 (d, J = 3.3 Hz), 130.8 (d, 
J = 7.9 Hz), 161.5 (d, J = 244 Hz), 171.9. All analytical data in accordance with 
literature values.199 
 
Methyl 2-(4-chlorophenyl)acetate 227 
 
 
 
Methyl 2-(4-chlorophenyl)acetate 227 obtained as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 3.61 (s, 2H), 3.71 (s, 3H), 7.22 (app. d, 2H, J = 8.4 Hz), 7.31 (app. d, 1H, J = 
8.4 Hz); 13C NMR (125 MHz, CDCl3) δ: 40.4, 52.1, 128.7, 130.6, 132.4, 133.1, 171.6. 
All analytical data in accordance with literature values.200 
 
Methyl 2-(4-(trifluoromethyl)phenyl)acetate 228 
 
 
 
Methyl 2-(4-(trifluoromethyl)phenyl)acetate 228 obtained as a yellow oil. 1H NMR (500 
MHz, CDCl3) δ: 3.70 (s, 2H), 3.72 (s, 3H), 7.41 (app. d, 2H, J = 8.2 Hz), 7.59 (app. d, 
2H, J = 8.2 Hz); 13C NMR (125 MHz, CDCl3) δ: 40.8, 52.2, 124.2 (q, J = 271.4 Hz), 
125.5 (q, J = 3.8 Hz), 129.5 (q, J = 32.7 Hz), 129.7, 137.9, 171.2. All analytical data in 
accordance with literature values.199 
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Methyl 2-(4-(methylsulfonyl)phenyl)acetate 230 
 
 
 
Methyl 2-(4-(methylsulfonyl)phenyl)acetate 230 obtained as an amorphous white solid. 
FTIR (film/cm-1) υmax: 3003 (m), 2953 (m), 2931 (m), 1735 (s), 1592 (m), 1562 (m);  
1H 
NMR (500 MHz, CDCl3) δ: 3.06 (s, 2H), 3.74 (s, 3H), 3.76 (s, 2H), 7.51 (app. d, 2H, J 
= 8.2 Hz), 7.92 (app. d, 2H, J = 8.2 Hz); 13C NMR (125 MHz, CDCl3) δ: 40.9, 44.5, 
52.4, 127.7, 130.4, 139.5, 140.2, 170.8; HRMS (ESI, +ve) m/z calcd. for C10H12Na1O4S1 
251.0349,  found 251.0347 (M+Na)+. 
 
(2,4-Dimethoxy-phenyl)-acetic acid methyl ester 231 
 
 
 
(2,4-Dimethoxy-phenyl)-acetic acid methyl ester 231 obtained as a clear oil. 1H NMR 
(500 MHz, CDCl3) δ: 3.58 (s, 2H), 3.69 (s, 3H), 3.80 (s, 3H), 3.81 (s, 3H), 6.45–6.49 
(m, 2H), 7.09 (app. d, 1H, J = 7.9 Hz); 13C NMR (125 MHz, CDCl3) δ: 35.1, 51.9, 55.4, 
55.5, 98.7, 104.1, 115.5, 131.1, 158.4, 160.2, 172.6. All analytical data in accordance 
with literature values.Charabarty.201 
 
(E)-Methyl 4-phenylbut-3-enoate 232 
  
 
 
(E)-Methyl 4-phenylbut-3-enoate 232 obtained as a yellow oil. 1H NMR (500 MHz, 
CDCl3) δ: 3.27 (dd, 3H,  J = 7.1, 1.1 Hz), 3.73 (s, 3H), 6.31 (dt, 1H, J = 15.9, 7.1 Hz), 
6.51 (d, 1H, J = 15.9 Hz),7.23–7.27 (m, 1H), 7.32 (app. t, 2H, J = 7.2 Hz), 7.36–7.41 
(m, 2H); 13C NMR (125 MHz, CDCl3) δ: 29.7, 38.2, 116.7, 121.7, 126.3, 126.6, 128.5, 
133.5, 172.0. All analytical data in accordance with literature values.202 
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Methyl 2-(1-methyl-1H-indol-3-yl)acetate 233 
 
 
 
Methyl 2-(1-methyl-1H-indol-3-yl)acetate 233 obtained as a red oil. 1H NMR (500 
MHz, CDCl3) δ: 3.71 (s, 3H), 3.78 (s, 3H), 3.79 (s, 2H), 7.06 (s, 1H), 7.14 (app. t, 1H, J 
= 7.6 Hz), 7.25 (app. d, 1H, J = 7.6 Hz), 7.31 (app. d, 1H, J = 7.6 Hz), 7.61 (app. d, 1H, 
J = 7.6 Hz); 13C NMR (125 MHz, CDCl3) δ: 31.0, 32.7, 51.9, 106.8, 109.3, 118.9, 
119.2, 121.8, 127.6, 127.7, 136.9, 172.7. All analytical data in accordance with 
literature values.203 
 
Benzo[1,3]dioxol-5-yl-acetic acid methyl ester 234 
 
 
 
Benzo[1,3]dioxol-5-yl-acetic acid methyl ester 234 obtained as a yellow oil. 1H NMR 
(500 MHz, CDCl3) δ: 3.52 (s, 2H), 3.67 (s, 3H), 5.91 (s, 2H), 6.66–6.79 (m, 3H); 
13C 
NMR (125 MHz, CDCl3) δ: 40.7, 52.0, 101.0, 108.2, 109.7, 122.4, 127.6, 146.7, 147.8, 
172.1. All analytical data in accordance with literature values.204 
 
(2-Iodo-phenyl)-acetic acid methyl ester 362 
 
 
 
(2-Iodo-phenyl)-acetic acid methyl ester 362 obtained as a yellow oil. 1H NMR (500 
MHz, CDCl3) δ: 3.73 (s, 3H), 3.82 (s, 2H), 6.97 (td, 1H, J = 7.7, 1.6 Hz), 7.26–7.36 (m, 
2H), 7.85 (dd, 1H, J = 7.7, 1.6 Hz); 13C NMR (125 MHz, CDCl3) δ: 46.1, 52.2, 101.0, 
128.5, 128.9, 130.7, 137.7, 139.5, 171.0. All analytical data in accordance with 
literature values.205 
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(2,4-Dichloro-phenyl)-acetic acid methyl ester 363 
 
 
 
(2,4-Dichloro-phenyl)-acetic acid methyl ester 363 obtained as a faint yellow oil. FTIR 
(film/cm-1) υmax: 3009 (w), 2954 (m), 1736 (s), 1592 (m), 1562 (m); 
1H NMR (500 
MHz, CDCl3) δ: 3.70 (s, 3H), 3.73 (s, 2H),  7.16–7.23 (m, 2H), 7.36–7.39 (m, 1H); 
13C 
NMR (125 MHz, CDCl3) δ: 38.3, 52.2, 127.2, 129.3, 131.0, 132.2, 133.8, 135.2, 170.5; 
HRMS (ESI, +ve) m/z calcd. for C9H8Cl2NaO2 240.9794,  found 240.9786 (M+Na)
+. 
 
6.3.8. E1cB Degradation Products 
 
2-Phenyl-hexa-2,4-dienoic acid methyl ester 201 
 
 
 
To a solution of (anti-E)-methyl 3-(2-oxooxazolidin-3-yl)-2-phenylhex-4-enoate 144 
(0.20 g, 0.53 mmol, 1.0 eq.) in THF (2 ml) at –98 °C was added LiHMDS (1 M in THF, 
0.68 ml, 0.68 mmol, 1.3 eq.) by hand addition. On complete addition the reaction 
mixture was allowed to warm to RT over 1 hour and was then quenched with HCl 
(1M)/Brine (1:1, 5 ml). The organics were extracted with EtOAc (5 × 15 ml), dried over 
MgSO4, filtered and then concentrated in vacuo to yield the crude reaction mixture, 
which was purified by flash column chromatography using gradient elution ethyl 
acetate/petroleum ether 40-60°/triethylamine (5:95:1–50:60:1), to yield 2-phenyl-hexa-
2,4-dienoic acid methyl ester 201 as a yellow oil (0.06 g, 57%). FTIR (film/cm-1) υmax: 
2921 (m), 2255 (w), 1705 (s), 1519 (s), 1436 (m); 1H NMR (250 MHz, CDCl3) δ: 1.71 
(d, 3H, J = 6.3 Hz), 3.68 (s, 3H), 5.93–6.24 (m, 2H), 7.17–7.24 (m, 2H), 7.30–7.49 (m, 
4H); 13C NMR (100 MHz, CDCl3) δ: 18.9, 52.1, 127.5, 128.0, 128.2, 130.1, 130.2, 
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135.4, 139.9, 141.2, 168.2; HRMS (ESI, +ve) m/z calcd. for C13H14NaO2, 225.0891,  
found 225.0886 (M+Na)+. 
 
2-Benzyloxy-hexa-2,4-dienoic acid methyl ester 353 
  
 
LiHMDS (1M in toluene, 3.15 ml, 3.15 mmol), triethylamine (4.37 ml, 31.5 mmol) and 
(E)-4-(N-benzyl-4-methylphenylsulfonamido)but-3-en-2-yl pent-4-enoate 337 (0.30 g, 
0.70 mmol) in THF (3 ml) was combined according to general procedure 4 (reaction 
time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded 2-benzyloxy-hexa-2,4-dienoic acid methyl ester 353 as a 
yellow oil (0.16 g, 90%). FTIR (film/cm-1) υmax: 3020 (m), 2961 (m), 1713 (s), 1643 
(m); 1H NMR (500 MHz, CD3Cl) δ: 1.81 (dd, 3H, J = 7.0, 1.4 Hz), 3.81 (s, 3H), 4.90 (s, 
3H), 6.02 (dq, 1H, J = 14.8, 7.0 Hz), 6.40 (ddq, 1H, J = 14.8, 11.4, 1.4 Hz), 6.76 (d, 1H, 
J = 11.4 Hz), 7.31–7.46 (m, 5H); 13C NMR (125 MHz, CD3Cl) δ: 18.8, 51.9, 74.6, 
124.8, 127.4, 128.1, 128.4 (x2), 136.5, 137.0, 141.7, 164.8; HRMS (ESI, +ve) m/z 
calcd. for C14H16NaO3  255. 0997, found 255.0999 (M+Na)
+. 
 
2-Phenylsulfanyl-hexa-2,4-dienoic acid methyl ester 354 
 
CO2MeS
Me  
 
LiHMDS (1M in toluene, 2.61 ml, 2.61 mmol), triethylamine (3.62 ml, 26.1 mmol) and 
(E)-4-(N-benzyl-4-methylphenylsulfonamido)but-3-en-2-yl pent-4-enoate 338 (0.25 g, 
0.58 mmol) in THF (2.5 ml) was combined according to general procedure 4 (reaction 
time : 75 minutes). Treatment with diazomethane and purification by flash 
chromatography afforded 2-phenylsulfanyl-hexa-2,4-dienoic acid methyl ester 354 as a 
yellow oil (0.13 g, 93%). FTIR (film/cm-1) υmax: 3085 (m), 3021 (m), 2982 (m), 2937 
(m), 1730 (s), 1656 (s), 1615 (m), 1596 (m), 1509 (m); 1H NMR (500 MHz, CD3Cl) δ: 
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1.93 (dd, 3H, J = 7.0, 1.1 Hz), 3.70 (s, 3H), 6.39 (dq, 1H, J = 14.8, 7.0 Hz), 6.80–6.90 
(m, 1H), 7.10–7.54 (m, 5H), 7.80 (d, 1H, J = 11.0 Hz); 13C NMR (125 MHz, CD3Cl) δ: 
19.2, 52.6, 121.1, 125.8, 127.6, 128.9, 129.9, 136.2, 143.1, 149.7, 166.5; HRMS (ESI, 
+ve) m/z calcd. for C13H15O2S  235.0792,  found  235.0767 (M+H)
+. 
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7. Appendix 
 
7.1. X-Ray Data for β
2,3
-Amino Acid Precursor 144 
 
Identification code k08dc4 
Empirical formula C16 H19 N O4 
Formula weight 289.32 
Temperature 150(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 15.0780(2)Å α = 90o 
 b = 6.2840(1)Å β = 105.097(1)o 
 c = 16.5130(3)Å γ = 90o 
Volume 1510.61(4) Å3 
Z 4 
Density (calculated) 1.272 Mg/m3 
Absorption coefficient 0.091 mm-1 
F(000) 616 
Crystal size 0.50 x 0.40 x 0.35 mm 
Theta range for data collection 3.63 to 29.13o 
Index ranges -20<=h<=20; -8<=k<=8; -22<=l<=22 
Reflections collected 28323 
Independent reflections 4056 [R(int) = 0.0452] 
Reflections observed (>2σ) 3110 
Data Completeness 0.994 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.96 and 0.90 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4056 / 0 / 193 
Goodness-of-fit on F2 1.018 
Final R indices [I>2σ(I)] R1 = 0.0485   wR2 = 0.1193 
R indices (all data) R1 = 0.0668  wR2 = 0.1327 
Largest diff. peak and hole 0.454 and -0.242 eÅ-3 
 
Table 25. Crystal Data and Structure Refinement for 144. Notes: Potential for C-H···O interactions 
leading to 1-D hydrogen-bonded chains in the lattice. Crystal structure representative of the batch 
according PXRD analysis 
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Atom x y z U(eq) 
O(1) 6104(1) 4741(2) 3039(1) 53(1) 
O(2) 7027(1) 6146(2) 2307(1) 66(1) 
O(3) 6308(1) 3486(2) 391(1) 43(1) 
O(4) 5494(1) 1248(2) 963(1) 38(1) 
N(1) 6977(1) 2554(2) 2539(1) 28(1) 
C(1) 6743(1) 4597(2) 2594(1) 39(1) 
C(2) 5870(1) 2640(3) 3261(1) 49(1) 
C(3) 6533(1) 1140(2) 3007(1) 37(1) 
C(4) 7615(1) 1892(2) 2054(1) 28(1) 
C(5) 7094(1) 623(2) 1268(1) 26(1) 
C(6) 6272(1) 1951(2) 819(1) 27(1) 
C(7) 4691(1) 2534(3) 599(1) 44(1) 
C(8) 8416(1) 644(2) 2579(1) 34(1) 
C(9) 9211(1) 1504(3) 2943(1) 42(1) 
C(10) 10026(1) 349(4) 3483(1) 60(1) 
C(11) 7685(1) 118(2) 677(1) 27(1) 
C(12) 7695(1) -1945(2) 369(1) 33(1) 
C(13) 8182(1) -2386(2) -224(1) 41(1) 
C(14) 8668(1) -809(3) -497(1) 46(1) 
C(15) 8673(1) 1225(3) -184(1) 45(1) 
C(16) 8184(1) 1693(2) 397(1) 37(1) 
Table 26.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) for 
1.U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
 
O(1)-C(1) 1.3589(18) O(1)-C(2) 1.438(2) 
O(2)-C(1) 1.2082(18) O(3)-C(6) 1.2051(16) 
O(4)-C(6) 1.3304(15) O(4)-C(7) 1.4501(16) 
N(1)-C(1) 1.3413(17) N(1)-C(3) 1.4509(16) 
N(1)-C(4) 1.4629(16) C(2)-C(3) 1.510(2) 
C(2)-H(2A) 0.9900 C(2)-H(2B) 0.9900 
C(3)-H(3A) 0.9900 C(3)-H(3B) 0.9900 
C(4)-C(8) 1.5100(18) C(4)-C(5) 1.5502(17) 
C(4)-H(4) 1.0000 C(5)-C(11) 1.5174(17) 
C(5)-C(6) 1.5188(16) C(5)-H(5) 1.0000 
C(7)-H(7A) 0.9800 C(7)-H(7B) 0.9800 
C(7)-H(7C) 0.9800 C(8)-C(9) 1.310(2) 
C(8)-H(8) 0.9500 C(9)-C(10) 1.503(2) 
C(9)-H(9) 0.9500 C(10)-H(10A) 0.9800 
C(10)-H(10B) 0.9800 C(10)-H(10C) 0.9800 
C(11)-C(16) 1.3924(18) C(11)-C(12) 1.3937(18) 
C(12)-C(13) 1.396(2) C(12)-H(12) 0.9500 
C(13)-C(14) 1.376(2) C(13)-H(13) 0.9500 
C(14)-C(15) 1.378(2) C(14)-H(14) 0.9500 
C(15)-C(16) 1.386(2) C(15)-H(15) 0.9500 
C(16)-H(16) 0.9500   
C(1)-O(1)-C(2) 109.39(11) C(6)-O(4)-C(7) 114.89(10) 
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C(1)-N(1)-C(3) 112.59(11) C(1)-N(1)-C(4) 122.09(11) 
C(3)-N(1)-C(4) 125.32(10) O(2)-C(1)-N(1) 128.17(14) 
O(2)-C(1)-O(1) 122.18(13) N(1)-C(1)-O(1) 109.65(12) 
O(1)-C(2)-C(3) 106.20(12) O(1)-C(2)-H(2A) 110.5 
C(3)-C(2)-H(2A) 110.5 O(1)-C(2)-H(2B) 110.5 
C(3)-C(2)-H(2B) 110.5 H(2A)-C(2)-H(2B) 108.7 
N(1)-C(3)-C(2) 101.31(11) N(1)-C(3)-H(3A) 111.5 
C(2)-C(3)-H(3A) 111.5 N(1)-C(3)-H(3B) 111.5 
C(2)-C(3)-H(3B) 111.5 H(3A)-C(3)-H(3B) 109.3 
N(1)-C(4)-C(8) 112.01(10) N(1)-C(4)-C(5) 110.05(10) 
C(8)-C(4)-C(5) 111.59(11) N(1)-C(4)-H(4) 107.7 
C(8)-C(4)-H(4) 107.7 C(5)-C(4)-H(4) 107.7 
C(11)-C(5)-C(6) 110.01(10) C(11)-C(5)-C(4) 113.10(10) 
C(6)-C(5)-C(4) 107.28(10) C(11)-C(5)-H(5) 108.8 
C(6)-C(5)-H(5) 108.8 C(4)-C(5)-H(5) 108.8 
O(3)-C(6)-O(4) 123.17(11) O(3)-C(6)-C(5) 124.74(11) 
O(4)-C(6)-C(5) 112.08(10) O(4)-C(7)-H(7A) 109.5 
O(4)-C(7)-H(7B) 109.5 H(7A)-C(7)-H(7B) 109.5 
O(4)-C(7)-H(7C) 109.5 H(7A)-C(7)-H(7C) 109.5 
H(7B)-C(7)-H(7C) 109.5 C(9)-C(8)-C(4) 123.32(14) 
C(9)-C(8)-H(8) 118.3 C(4)-C(8)-H(8) 118.3 
C(8)-C(9)-C(10) 125.61(17) C(8)-C(9)-H(9) 117.2 
C(10)-C(9)-H(9) 117.2 C(9)-C(10)-H(10A) 109.5 
C(9)-C(10)-H(10B) 109.5 H(10A)-C(10)-H(10B) 109.5 
C(9)-C(10)-H(10C) 109.5 H(10A)-C(10)-H(10C) 109.5 
H(10B)-C(10)-H(10C) 109.5 C(16)-C(11)-C(12) 118.80(12) 
C(16)-C(11)-C(5) 121.54(11) C(12)-C(11)-C(5) 119.57(11) 
C(11)-C(12)-C(13) 119.87(13) C(11)-C(12)-H(12) 120.1 
C(13)-C(12)-H(12) 120.1 C(14)-C(13)-C(12) 120.58(14) 
C(14)-C(13)-H(13) 119.7 C(12)-C(13)-H(13) 119.7 
C(13)-C(14)-C(15) 119.78(14) C(13)-C(14)-H(14) 120.1 
C(15)-C(14)-H(14) 120.1 C(14)-C(15)-C(16) 120.28(15) 
C(14)-C(15)-H(15) 119.9 C(16)-C(15)-H(15) 119.9 
C(15)-C(16)-C(11) 120.67(14) C(15)-C(16)-H(16) 119.7 
C(11)-C(16)-H(16) 119.7   
Table 27.   Bond lengths [Å] and angles [o] for 1. Symmetry transformations used to generate equivalent 
atoms. 
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Atom U11 U22 U33 U23 U13 U12 
O(1) 80(1) 34(1) 57(1) 6(1) 41(1) 17(1) 
O(2) 114(1) 24(1) 77(1) 8(1) 57(1) 7(1) 
O(3) 34(1) 37(1) 59(1) 21(1) 13(1) 4(1) 
O(4) 26(1) 42(1) 47(1) 18(1) 11(1) 6(1) 
N(1) 34(1) 22(1) 30(1) 3(1) 11(1) 1(1) 
C(1) 59(1) 26(1) 37(1) 2(1) 20(1) 7(1) 
C(2) 59(1) 40(1) 58(1) 1(1) 34(1) 4(1) 
C(3) 45(1) 31(1) 40(1) 8(1) 20(1) 3(1) 
C(4) 28(1) 26(1) 30(1) 2(1) 9(1) -1(1) 
C(5) 25(1) 22(1) 30(1) 4(1) 7(1) 0(1) 
C(6) 27(1) 25(1) 28(1) 1(1) 7(1) 1(1) 
C(7) 26(1) 52(1) 54(1) 21(1) 11(1) 10(1) 
C(8) 31(1) 37(1) 32(1) 4(1) 6(1) 2(1) 
C(9) 31(1) 56(1) 37(1) -7(1) 7(1) 0(1) 
C(10) 31(1) 99(2) 44(1) -11(1) 0(1) 13(1) 
C(11) 24(1) 28(1) 29(1) 1(1) 5(1) 2(1) 
C(12) 28(1) 30(1) 39(1) -1(1) 3(1) 1(1) 
C(13) 42(1) 38(1) 40(1) -10(1) 5(1) 9(1) 
C(14) 45(1) 57(1) 39(1) -2(1) 19(1) 11(1) 
C(15) 47(1) 48(1) 49(1) 2(1) 26(1) -2(1) 
C(16) 41(1) 32(1) 42(1) -2(1) 18(1) -4(1) 
Table 28.   Anisotropic displacement parameters (Å2 x 103) for 1. The anisotropic displacement factor 
exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
 
Atom x y z U(eq) 
H(2A) 5230 2285 2960 59 
H(2B) 5933 2545 3872 59 
H(3A) 6980 536 3503 44 
H(3B) 6207 -33 2651 44 
H(4) 7866 3209 1855 33 
H(5) 6869 -742 1455 31 
H(7A) 4802 4002 800 66 
H(7B) 4160 1958 764 66 
H(7C) 4567 2512 -14 66 
H(8) 8339 -840 2648 40 
H(9) 9279 2984 2860 50 
H(10A) 10137 837 4064 89 
H(10B) 10569 641 3279 89 
H(10C) 9904 -1185 3456 89 
H(12) 7372 -3049 563 40 
H(13) 8179 -3787 -441 49 
H(14) 8998 -1121 -900 55 
H(15) 9014 2311 -367 54 
H(16) 8188 3102 606 44 
Table 29.   Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2 x 103). 
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C(3) – N(1) - C(1) - O(2) 176.38(17) 
C(4) – N(1) - C(1) - O(2) -3.6(3) 
C(3) – N(1) - C(1) - O(1) -3.66(18) 
C(4) – N(1) - C(1) - O(1) 176.40(12) 
C(2) – O(1) - C(1) - O(2) 177.21(17) 
C(2) – O(1) - C(1) - N(1) -2.75(19) 
C(1) – O(1) - C(2) - C(3) 7.64(19) 
C(1) – N(1) - C(3) - C(2) 7.94(16) 
C(4) – N(1) - C(3) - C(2) -172.12(12) 
O(1) – C(2) - C(3) - N(1) -9.00(17) 
C(1) – N(1) - C(4) - C(8) 124.51(14) 
C(3) – N(1) - C(4) - C(8) -55.43(16) 
C(1) – N(1) - C(4) - C(5) -110.75(14) 
C(3) – N(1) - C(4) - C(5) 69.32(15) 
N(1) – C(4) - C(5) - C(11) 172.85(10) 
C(8) – C(4) - C(5) - C(11) -62.16(13) 
N(1) – C(4) - C(5) - C(6) 51.36(13) 
C(8) – C(4) - C(5) - C(6) 176.35(10) 
C(7) – O(4) - C(6) - O(3) -3.0(2) 
C(7) – O(4) - C(6) - C(5) 175.93(12) 
C(11) - C(5) - C(6) - O(3) -46.73(17) 
C(4) – C(5) - C(6) - O(3) 76.68(16) 
C(11) - C(5) - C(6) - O(4) 134.35(11) 
C(4) – C(5) - C(6) - O(4) -102.24(12) 
N(1) – C(4) - C(8) - C(9) -95.81(16) 
C(5) – C(4) - C(8) - C(9) 140.31(14) 
C(4) – C(8) - C(9) - C(10) 179.00(14) 
C(6) – C(5) - C(11) - C(16) 68.85(15) 
C(4) – C(5) - C(11) - C(16) -51.09(16) 
C(6) – C(5) - C(11) - C(12) -107.77(13) 
C(4) – C(5) - C(11) - C(12) 132.29(12) 
C(16) - C(11) - C(12) – C(13) -1.51(19) 
C(5) – C(11) - C(12) - C(13) 175.21(12) 
C(11) - C(12) - C(13) – C(14) 1.2(2) 
C(12) - C(13) - C(14) – C(15) -0.1(2) 
C(13) - C(14) - C(15) – C(16) -0.8(2) 
C(14) - C(15) - C(16) – C(11) 0.5(2) 
C(12) - C(11) - C(16) – C(15) 0.7(2) 
C(5) – C(11) - C(16) - C(15) -175.96(13) 
Table 30.   Dihedral angles [o] for 1. Atom1  -  Atom2  -  Atom3  -  Atom4,  Dihedral 
Symmetry Transformations Used to Generate Equivalent Atoms. 
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k08dc4, Single xtal and Bulk
Operations: Background 1.000,1.000 | Import
Y + 50.0 mm - mfmDC - File: mfmDC.RAW - Type: 2Th/Th locked - Start: 4.000 ° - End: 60.000 ° - Step: 0.020 ° - Step time: 2. s - Temp.: 25 °C (Room) - Time Started: 0 s - 2-Theta: 4.000 ° - Theta: 2.000 °
Operations: Displacement 0.505 | Displacement 0.229 | Import
C:\WINNT\Profiles\Administrator\Desktop\k08dc4.x_y - File: k08dc4.RAW - Type: 2Th/Th locked - Start: 3.712 ° - End: 59.751 ° - Step: 0.010 ° - Step time: 1. s - Temp.: 25 °C (Room) - Time Started: 0 s - 2-
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7.2. Hammett Type Plots with Other σ-Values 
Graph 27. Log(d.r.) vs. σ. 
 
 
 
Graph 28. Log(d.r.) vs. σ+. 
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Graph 29. Log(d.r.) vs. σ−. 
 
  
Graph 30. Log(d.r.) vs. Resonance Parameter R. 
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Graph 31. Log(d.r.) vs Resonance Parameter R+. 
 
 
7.3. 1D-NOE Data for Isolated Tolyl Derived SKAs 
 
 
 
Entry R Product (E/Z)a Yield (%) 
1 Me 256 44:1 99 
2 CDMe2 246 68:1 99 
3 CMe3 259 68:1 99 
 
Table 31. Yields & E/Z-Selectivity for 1o, 2o & 3o Derived Tolyl-SKAs. 
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(1-Methoxy-2-p-tolyl-vinyloxy)-trimethyl-silane 256 
 
 
 
LHMDS (0.72 ml, 0.72 mmol, 1M in THF), TMSCl (0.10 ml, 0.72 mmol) and p-tolyl-
acetic acid methyl ester 250 (0.10 g, 0.42 mmol) were combined according to general 
procedure 9a and purification was achieved by reported procedure to afford (1-
methoxy-2-p-tolyl-vinyloxy)-trimethyl-silane 256 as a yellow oil (0.10 g, 99%, E/Z 
44:1).  1H NMR (400 MHz, CDCl3) δ: 0.32 (s, 9H), 2.30 (s, 3H), 3.68 (s, 3H), 4.68 (s, 
1H), 7.06 (app. d, 2H, J = 8.1 Hz), 7.31 (app. d, 2H, J = 8.1 Hz); 13C NMR (100 MHz, 
CDCl3) δ: 5.5, 21.0, 53.9, 86.0, 126.5, 128.8, 133.3, 133.7, 154.4. IR and HRMS not 
obtainable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7  Appendix
   
283 
(1-Methoxy-2-p-tolyl-vinyloxy)-trimethyl-silane 256 
OTMS
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PL12              17.23 dB
PL13              20.00 dB
SFO2        400.1316005 MHz
SI                32768
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 1.00 Hz
GB                    0
PC                 1.40
 
 
 
9 8 7 6 5 4 3 2 1 0 ppm
9
.
4
0
4
3
.
2
3
8
3
.
3
1
9
1
.
0
0
0
2
.
1
1
3
2
.
0
6
9
NAME     Primary tolyl SKA isolation
EXPNO                 1
PROCNO                1
Date_          20091217
Time              15.47
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                   13
DS                    0
SWH            8278.146 Hz
FIDRES         0.126314 Hz
AQ            3.9584243 sec
RG                  128
DW               60.400 usec
DE                 6.00 usec
TE                298.0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                10.75 usec
PL1                0.00 dB
SFO1        400.1324710 MHz
SI                32768
SF          400.1300239 MHz
WDW                  no
SSB                   0
LB                 0.00 Hz
GB                    0
PC                 1.40
4.584.604.624.644.664.684.704.72 ppm
1
.
0
0
0
4
5
.
2
0
2
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(1-d1-Isopropoxy-2-p-tolyl-vinyloxy)-trimethyl-silane 
2
H1-246 
 
 
 
LHMDS (0.64 ml, 642 mmol, 1M in THF), TMSCl (0.09 ml, 642 mmol) and p-tolyl-
acetic acid isopropyl-2-d1 ester 239 (0.10 g, 0.38 mmol) were combined according to 
general procedure 9a and purification was achieved by reported procedure to afford (1-
d1-isopropoxy-2-p-tolyl-vinyloxy)-trimethyl-silane 240 as a yellow oil (0.10 g, 99%, 
E/Z 68:1).  1H NMR (400 MHz, CDCl3) δ: 0.31 (s, 9H), 1.29 (s, 6H), 2.29 (s, 3H), 4.72 
(s, 1H), 7.04 (app. d, 2H, J = 7.8 Hz), 7.36 (app. d, 2H, J = 7.8 Hz); 13C NMR (100 
MHz, CDCl3) δ: 5.5, 21.0, 22.2, 69.2 (t, J = 22.3 Hz), 88.1, 126.5, 128.7, 133.1, 134.0, 
153.0. IR and HRMA not obtainable. 
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4.554.604.654.704.754.804.854.904.95 ppm
1
.
0
0
0
6
1
.
8
0
0
(1-d1-Isopropoxy-2-p-tolyl-vinyloxy)-trimethyl-silane 
2
H1-246 
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NAME     Secondary tolyl SKA isolation
EXPNO                 2
PROCNO                1
Date_          20091221
Time              13.21
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                65536
SOLVENT           CDCl3
NS                  735
DS                    4
SWH           23980.814 Hz
FIDRES         0.365918 Hz
AQ            1.3664756 sec
RG              14596.5
DW               20.850 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 7.30 usec
PL1                0.00 dB
SFO1        100.6228298 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2                0.00 dB
PL12              17.23 dB
PL13              20.00 dB
SFO2        400.1316005 MHz
SI                32768
SF          100.6127690 MHz
WDW                  EM
SSB                   0
LB                 1.00 Hz
GB                    0
PC                 1.40
 
 
 
 
9 8 7 6 5 4 3 2 1 0 ppm
9
.
5
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8
3
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2
.
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5
6
NAME     Sep17-2009-NMR2
EXPNO                90
PROCNO                1
Date_          20090917
Time              16.07
INSTRUM           spect
PROBHD   5 mm CPDCH 13C
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                    8
DS                    2
SWH            8250.825 Hz
FIDRES         0.251795 Hz
AQ            1.9857908 sec
RG                143.7
DW               60.600 usec
DE                10.00 usec
TE                300.0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 9.75 usec
PL1               -4.80 dB
SFO1        400.2326015 MHz
SI                16384
SF          400.2300051 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
Chapter 7  Appendix
   
287 
7 6 5 4 3 2 1 0 ppm
c b d
a
e
f
c
d
c
d
e
f
c
d
e
c
e
f
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1D-NOE of Minor Z-SKA 
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(1-tert-Butoxy-2-p-tolyl-vinyloxy)-trimethyl-silane 259 
 
 
 
LHMDS (0.61 ml, 0.61 mmol, 1M in THF), TMSCl (0.08 ml, 0.61 mmol) and tert-butyl 
2-p-tolylacetate 253 (0.10 g, 0.36 mmol) were combined according to general procedure 
9a and purification was achieved by reported procedure to afford (1-tert-butoxy-2-p-
tolyl-vinyloxy)-trimethyl-silane 259 as a yellow oil (0.10 g, 99%, E/Z 24:1). 1H NMR 
(400 MHz, CDCl3) δ: 0.34 (s, 9H), 1.49 (s, 9H), 2.33 (s, 3H), 4.86 (s, 1H), 7.08 (app. d, 
2H, J = 8.0 Hz), 7.40 (app. d, 2H, J = 8.0 Hz); 13C NMR (100 MHz, THF) δ: 2.9, 20.9, 
29.3, 79.9, 92.9, 127.2, 128.8, 133.4, 134.6, 153.6. IR and HRMS not obtainable. 
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(1-tert-Butoxy-2-p-tolyl-vinyloxy)-trimethyl-silane 259 
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4 NAME           p-Me tBu
EXPNO                 9
PROCNO                1
Date_          20090713
Time              15.29
INSTRUM           spect
PROBHD   5 mm PABBO BB-
PULPROG          zgpg30
TD                65536
SOLVENT             THF
NS                  100
DS                    4
SWH           23980.814 Hz
FIDRES         0.365918 Hz
AQ            1.3664756 sec
RG              11585.2
DW               20.850 usec
DE                 6.00 usec
TE                298.0 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                13C
P1                 7.30 usec
PL1                0.00 dB
SFO1        100.6228298 MHz
======== CHANNEL f2 ========
CPDPRG2         waltz16
NUC2                 1H
PCPD2             80.00 usec
PL2                0.00 dB
PL12              17.23 dB
PL13              20.00 dB
SFO2        400.1316005 MHz
SI                32768
SF          100.6124567 MHz
WDW                  EM
SSB                   0
LB                 1.00 Hz
GB                    0
PC                 1.40
 
 
 
9 8 7 6 5 4 3 2 1 0 ppm
9
.3
3
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.3
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NAME     Sep24-2009-NMR3
EXPNO                20
PROCNO                1
Date_          20090924
Time              15.11
INSTRUM           spect
PROBHD   5 mm SEI 1H/2H
PULPROG            zg30
TD                65536
SOLVENT           CDCl3
NS                    8
DS                    2
SWH            8223.685 Hz
FIDRES         0.125483 Hz
AQ            3.9846387 sec
RG                 22.6
DW               60.800 usec
DE                 8.00 usec
TE                300.0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                 7.60 usec
PL1                0.00 dB
PL1W        11.10253811 W
SFO1        400.1324710 MHz
SI                32768
SF          400.1300000 MHz
WDW                  EM
SSB                   0
LB                 0.30 Hz
GB                    0
PC                 1.00
4.604.654.704.754.804.854.904.955.005.055.105.155.205.25 ppm
1
9
.5
6
1
.0
0
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7.4. HPLC Data 
 
 
(anti-E)-Methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-phenylhex-4-enoate 333 
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VWD: Signal A, 254 nm
Wez_S-Ph98-1
Retention Time
 
 
VWD: Signal 
A, 254 nm 
Results 
    
Retention Time Area Area % Height Height % 
15.693 57182044 49.13 1335586 54.09 
17.417 59210450 50.87 1133646 45.91 
     
Totals     
 116392494 100.00 2469232 100.00 
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(2R,3R,E)-methyl 3-(N-allyl-4-methylphenylsulfonamido)-2-phenylhex-4-enoate 
(S)-333 
 
 
 
Minutes
9 10 11 12 13 14 15 16 17 18 19 20 21
m
A
U
0
20
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m
A
U
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6
7
VWD: Signal A, 250 nm
Wez_S-Pha
Retention Time
 
 
VWD: Signal 
A, 250 nm 
Results 
    
Retention Time Area Area % Height Height % 
14.210 7148487 5.83 316493 6.91 
14.850 4240556 3.46 258057 5.63 
15.260 108865486 88.76 3861193 84.27 
16.067 2399737 1.96 146069 3.19 
     
Totals 122654266 100.00 4581812 100.00 
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